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This dissertation describes the development of cooperative catalyst systems that 
contain an achiral Lewis acid and a chiral Lewis acid that may have overlapping functions 
but play their independent roles to promote enantioselective C−C bond formations. Chapter 
1 provides a summary of recent advances made in the field of enantioselective cooperative 
catalysis that served as intellectual foundations for this dissertation research. As it will be 
discussed in the first chapter, key limitations of cooperative catalysis are: (1) undesirable 
catalyst deactivation which occurs due to acid/base complexation, (2) requirement for base 
sensitive pronucleophiles and acid sensitive electrophiles, and (3) poor reaction efficiency. 
In an effort to overcome these fundamental limitations, we have developed “frustrated” 
Lewis pair (FLP)-based catalyst systems that consist of potent and sterically encumbered 
Lewis acids used in pair with bulky N-containing Lewis bases. To demonstrate the 
potential of the novel FLP catalyst system, we describe our work involving the 
enantioselective Conia-ene-type cyclization (Chapter 2). In the subsequent chapter 
(Chapter 3), we discuss the application of the FLP catalysts for enantioselective β-amino 
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Recent Advances in Enantioselective Transformations Promoted by Cooperative Catalysts 
Introduction 
 Enantioselective cooperative catalysis1-2 involves the use of two or more catalyst units 
(Scheme 1.1) that work in concert to produce chiral organic molecules that cannot be readily 
synthesized using a single acid or base catalyst.3 Cooperative functions of the catalysts allow for 
in situ generation of both nucleophilic and electrophilic partners from otherwise unreactive 
combination of substrates. Such substrate activation strategy has often been accomplished using 
bifunctional catalysts4  (e.g, C4, C5, C8, C11; Scheme 1.1) in which the acidic and/or basic 
moieties are tethered by appropriate linkers. A representative example is the enantioselective  
                                                 
1 For selected reviews on enantioselective cooperative catalysis, see: (a) Yamamoto, H.; Futatsugi, K. Angew. Chem., 
Int. Ed. 2005, 44, 1924−1942. (b) Kobayashi, S.; Mori, Y.; Fossey, J. S.; Salter, M. M. Chem. Rev. 2011, 111, 
2626−2704. (c) Allen, A. E.; MacMillan, D. W. Chem. Sci. 2012, 3, 633−658. (d) Trost, B. M.; Bartlett, M. J. Acc. 
Chem. Res. 2015, 48, 688−701. (e) Shibasaki, M.; Kumagai, N. in Cooperative Catalysis: Designing Efficient 
Catalysts for Synthesis, Peters, R., Eds.; Wiley-VCH: New York, 2015; Chapter 1. (f) Lu, X.; Deng, L. in Cooperative 
Catalysis: Designing Efficient Catalysts for Synthesis, Peters, R., Eds.; Wiley-VCH: New York, 2015; Chapter 5. (g) 
Inamdar, S. M.; Shinde, V. S.; Patil, N. T. Org. Biomol. Chem., 2015, 13, 8116−8162. (h) Wang, M. H.; Scheidt, K. 
A. Angew. Chem., Int. Ed. 2016, 55, 14912−14922. (i) Romiti, F.; del Pozo, J.; Paioti, P. H. S.; Gonsales, S. A.; Li, 
X.; Hartrampf, F. W. W.; Hoveyda, A. H. J. Am. Chem. Soc. 2019, 141, 17952−17961. (j) Sancheti, S. P.; Urvashi, 
Shah, M. P.; Patil, N. T. ACS Catal. 2020, 10, 3462-3489. 
2 For selected reviews on enantioselective non-covalent catalysis, see: (a) Hashimoto, T.; Maruoka, K. Chem. Rev. 
2007, 107, 5656−5682. (b) Ooi, T.; Maruoka, K. Angew. Chem., Int. Ed. 2007, 46, 4222−4266. (c) Adair, G.; 
Mukherjee, S.; List, B. Aldrichimica Acta 2008, 41, 31−39. (d) Zhang, Z.; Schreiner, P. R. Chem. Soc. Rev. 2009, 38, 
1187−1198.  (e) Phipps, R. J.; Hamilton, G. L.; Toste, F. D. Nat. Chem. 2012, 4, 603−614. (f) Brak, K.; Jacobsen, E. 
N. Angew. Chem., Int. Ed. 2013, 52, 534−561. (g) Neel, A. J.; Hilton, M. J.; Sigman, M. S.; Toste, F. D. Nature 2017, 
543, 637−646. 
3  For selected reports on enantioselective cooperative catalysis, see: (a) Yang, T.; Ferrali, A.; Sladojevich, F.; 
Campbell, L.; Dixon, D. J. J. Am. Chem. Soc. 2009, 131, 9140−9141. (b) Burns, N. Z.; Witten, M. R.; Jacobsen, E. N. 
J. Am. Chem. Soc. 2011, 133, 14578−14581. (c) Manville, N.; Alite, H.; Haeffner, F.; Hoveyda, A. H.; Snapper, M. 
L. Nat. Chem. 2013, 5, 768−774. (d) Yin, L.; Brewitz. L.; Kumagai, N.; Shibasakl, M. J. Am. Chem. Soc. 2014, 136, 
17958−17961. (e) Shang, M.; Wang, X.; Koo, S. M.; Youn, J.; Chan, J. Z.; Yao, W.; Hastings, B. T.; Wasa, M. J. Am. 
Chem. Soc. 2017, 139, 95−98. (f) Shang, M.; Cao, M.; Wang, Q.; Wasa, M. Angew. Chem., Int. Ed. 2017, 56, 
13338−13526. (g) Shang, M.; Chan, J. Z.; Cao, M.; Chang, Y.; Wang, Q.; Cook, B.; Torker, S.; Wasa, M. J. Am. 
Chem. Soc. 2018, 140, 10593−10601. (h) Chan, J. Z.; Yesilcimen, A.; Cao, M.; Zhang, Y.; Zhang, B. C.; Wasa, M. J. 
Am. Chem. Soc. 2020, 142, 16493−16505. 
4 (a) Kanai, M.; Kato, N.; Ichikawa, E.; Shibasaki, M. Synlett 2005, 10, 1491−1508. (b) Paull, D. H.; Abraham, C. J.; 
Scerba, M. T.; Alden-Danforth, E.; Lectka, T. Acc. Chem. Res. 2008, 41, 655−633. (c) Dixon, Darren J. Beilstein J. 





Scheme 1.1. Enantioselective Cooperative Catalysts 
 
Mannich-type reaction which occurs in between a 1,3-dicarbonyl compound 1.1 and an aldimine 
1.2 and is promoted by a chiral amino thiourea catalyst C12 (Scheme 1.2).5 As can be seen in this 
example, one distinct advantage of bifunctional catalysis is that catalyst deactivation through 
undesirable acid/base complexation (e.g., between the H-bond donors and tertiary amine unit of  
                                                 





Scheme 1.2. Enantioselective Mannich-Type Reaction Promoted by an Amino-thiourea Catalyst 
 
C12) can be circumvented because the catalyst units are geometrically fixed. Such structural 
rigidity translates to acceleration of the desirable transformation as the catalyst-bound reaction 
partners can be proximately positioned within the catalyst framework (i.e., proximity effect).6 
Despite these notable advantages, bifunctional catalysis has several key shortcomings. Firstly, 
synthesis of the bifunctional catalysts through tethering of the acidic and basic entities is often 
cumbersome, thereby making their evaluation and optimization to be inefficient. Moreover, 
substrates that undergo efficient reactions are typically contrived to those that are small in size 
and/or those that have electronic affinities with the catalyst’s activation site; those that are 
sterically hindered and/or possess functional groups that are electronically repulsive against the 
catalyst are often incompatible. Furthermore, bifunctional catalysts are not immune to 
intermolecular acid/base complexation.4 To avoid such unwanted catalyst deactivation, the 
bifunctional catalysts are typically comprised of weakly acidic and basic catalyst units (e.g., C6, 
C11), and/or the reactions are performed using a large excess of solvent. Consequently, such 
                                                 
6 (a) Page, M. I.; Jencks, W. P. Proc. Natl Acad. Sci. 1971, 68, 1678−1683. (b) Menger, F. M. Acc. Chem. Res. 1993, 
26, 206−212. (c) Bruice, T. C.; Lightstone, F. C. Acc. Chem. Res. 1999, 32, 127−136. (d) Kennan, A. J.; Whitlock, H. 





processes demand highly acid- and/or base-sensitive pronucleophiles and electrophiles (e.g., 1,3-
dicarbonyl compounds and N-Boc-substituted benzaldimines, respectively) that undergo racemic 
background reaction, and suffer from low reaction efficiency. 
 Efficient and enantioselective transformations can also be promoted using Lewis acidic 
and Lewis basic catalysts that are untethered and independently operational (e.g., C1 and C2; 
Scheme 1.1).3 The processes involving this class of catalysts allow for rapid catalyst optimization 
as this can be readily achieved without carrying out the cumbersome tethering processes (vs 
bifunctional catalysis).1-2 Either one or both of the catalysts can be chiral; through the identification 
of a matching catalyst combination, both the reaction efficiency as well as enantio- and diastereo-
selectivies can be improved. A representative method utilizes a combination of [SegPhos–Cu] 
complex C1 and Barton’s base C2 (Scheme 1.3) which was developed by Shibasaki and co-
workers that promote highly enantioselective Mannich-type reactions between 7-
azaindolinylamide 1.4 and N-Boc-substituted benzaldemine 1.5 to afford 1.6 (Scheme 1.3).3d 
Despite such notable advances, highly efficient and enantioselective methods using the untethered 
cooperative catalysts remain underdeveloped.1-2 This is mainly because the untethered acidic and 
basic catalysts can more readily undergo undesired mutual quenching (vs. bifunctional catalysts);1-
2 moreover, the catalysts can also be deactivated by forming stable complexes with the substrates, 
intermediates and products. One strategy to avoid the mutual quenching problem has been to utilize 
the catalyst combinations that have minimal electronic and steric affinities to interact with each 
other (e.g., soft Lewis acid C1 and hard Brønsted base C2, both of them are sterically hindered; 
Scheme 1.3). However, when using mildly acidic catalysts such as the [SegPhos–Cu] complex C1 





Scheme 1.3. Enantioselective Mannich-Type Reaction Promoted by a Chiral Cu-based Catalyst 
and a Brønsted Base Catalyst  
































relatively broader substrate scope
unresolved problems:
mutual quenching is difficult to suppress
demands preactivated substrates




are often confined to those that are highly acid-sensitive (e.g., N-Boc-substituted benzaldemine 
1.5). When more Lewis acidic catalysts that can activate less electrophilic substrates are employed; 
mutual quenching becomes problematic. Furthermore, the processes involving untethered catalysts 
do not benefit from the proximity effect observed in those using bifunctional catalysts, therefore 
resulting in relatively lower reaction efficiency. 
Despite the limitations as described above, there has been key advances made in the 
development of enantioselective methods that rely of the cooperative actions of various untethered, 
independently operational catalysts. As shown in the examples above (Schemes 1.2 and 1.3), the 
cooperative acid/base catalysis has been widely applied in the context of enantioselective 
α-functionalization of carbonyl compounds; these methods often proceed through in situ 
generation of enolate equivalent intermediates by Brønsted base-catalyzed deprotonation of Lewis 
acid-activated carbonyl pronucleophiles.1-2 To highlight both the significance and remaining 
unresolved problems of the state-of-the-art, a review on recent advances in enantioselective 





that served as intellectual foundations of this dissertation research is provided herein. This chapter 
covers topics as listed below. In Chapter 1.1, two selected recent examples of enantioselective 
processes promoted by the cooperative actions of two Lewis acid catalysts are highlighted. Then, 
a review on stereoselective transformations enabled by the use of three catalyst units are provided 
in Chapter 1.2. 
Chapter 1.1: Enantioselective Transformations Promoted by Cooperative Functions of Two 
Lewis Acids 
Chapter 1.2: Enantioselective Transformations Promoted by Cooperative Functions of Three 
Catalyst Units 









1.1. Enantioselective Transformations Promoted by Cooperative Functions of Two Lewis 
Acids 
Enantioselective cooperative acid/acid catalysis involves the use of two independent Lewis 
acids that work in concert to promote a desirable enantioselective transformation. A representative 
example includes the work by Shibata and co-workers, which revealed that a cooperative catalyst 
system consisting of a Zinc-PhBox complex C13 and Yb(OTf)3 promote enantioselective 5-endo-
dig cyclization of 1,3-dicarbonyl compound 1.7 bearing an internal alkyne moiety (Scheme 1.4).7 
With C13 as the only catalyst, the cyclized product 1.8 cannot be generated. When the Lewis acid 
cocatalyst Yb(OTf)3 is incorperated, 5-endo-dig cyclization can proceed to produce 1.8 in 70% 
yield with 95:5 er. The author proposed that the Lewis acidic C13 could activate dicarbonyl moiety 
of 1.7 to generate a nucleophilic zinc−enolate intermedaite while the soft Lewis acid Yb(OTf)3 
activates the electron-rich alkyne moiety (I). The subsequent enantioselective Conia-ene-type 
cyclization between the enolate and electrophilic Yb(OTf)3/alkyne complex would deliver 1.8. 
However, this transformation only occurs with readily enolizable dicarbonyl compounds; less  
Scheme 1.4. Catalytic Enantioselective 5-endo-dig Carbocyclization of β-Ketoesters through 
Cooperative Functions of Chiral Zinc-based Lewis Acid and Yb(OTf)3 
 
                                                 






base-sensitive mono-carbonyl pronucleophiles (ketones, ester, amides and thioesters) are not 
shown to be compatible. This is mainly because the catalyst system comprised of Zn- and Yb-
based complexes is not compatible with Brønsted basic catalysts (e.g., DBU, Barton’s base) that 
may be capable of deprotonating the desirable mono-carbonyl substrates. 
Another representative method utilizes a combination of an achiral organoborane and a 
chiral Mg–PyBOX complex C9 that promotes enantioselective α-amino C−H alkylation of N-
alkylamine 1.9 (Scheme 1.5).3g When only B(C6F5)3 was present in the reaction mixture, the 
desired product 1.11 was obtained in < 5% yield. However, by introducing the chiral Lewis acid 
co-catalyst C9, 1.11 can be generated in up to 88% yield and 98:2 er. The plausible mechanism 
involves abstraction of a hydride from an α-amino C–H unit of N-alkylamine 1.9 by B(C6F5)3 to 
generate a borohydride and an iminium ion (II); at the same time, the Lewis acidic Mg–PyBOX 
complex C9 activates an α,β-unsaturated substrate 1.10 (III); ensuing borohydride reduction of 
PyBOX–Mg-activated 1.10 furnishes a chiral Mg–enolate intermediate (IV). Then, diastereo- and 
enantioselective C–C bond forming reaction between the iminium ion and the enolate affords the 






Scheme 1.5. Direct Enantioselective α-C−H Functionalization of Amines through Cooperative 









1.2. Enantioselective Transformations Promoted by Cooperative Functions of Three 
Catalyst Units 
This section highlights the state-of-the-art of enantioselective α-functionalization of 
carbonyl compounds promoted by cooperative functions of three catalyst units. 8  Carbonyl 
α-functionalization is often achieved through in situ generation of enolate equivalents by 
activation of the pronucleophile’s carbonyl unit by an acidic catalyst, followed by deprotonation 
of α-carbonyl C−H bond by a Brønsted Base (pronucleophile → V, Scheme 1.6a). The subsequent 
reaction between the enolate and an appropriate electrophile can be promoted by the enolate-bound 
Lewis acid (V). Alternatively, another equivalent of the Lewis acid may activate the electrophile 
(VI). Nonetheless, there can be instances when a target reaction cannot proceed because the 
electrophile cannot be sufficiently activated by the Lewis acid used for the activation of the 
carbonyl-based pronucleophiles. Such complication may be remedied through the employment of 
a catalyst system comprised of a Lewis acid catalyst used in pair with a bifunctional catalyst, latter 
of which is comprised of a Brønsted base and an acidic catalyst unit (Scheme 1.6b). Alternatively, 
a catalyst system which constitutes of two acidic catalysts and a Brønsted base catalyst that are 
untethered and independently operational can be employed (Scheme 1.6b). Using these three-
catalyst unit systems, carbonyl-based pronucleophiles may be readily converted into the 
corresponding enolate equivalents by the cooperative actions of their Lewis acidic and Brønsted 
                                                 
8 For selected reports on enantioselective transformations promoted by ternary catalysts, see: (a)Yazaki, R.; Kumagai, 
N.; Shibasaki, M. J. Am. Chem. Soc. 2010, 132, 5522−5531. (b) Yazaki, R.; Kumagai, N.; Shibasaki, M. J. Am. Chem. 
Soc. 2010, 132, 10275−10277. (c) Iwata, M.; Yazaki, R.; Chen, I. H.; Sureshkumar, D.; Kumagai, N.; Shibasaki, M. 
J. Am. Chem. Soc. 2011, 133, 5554−5560. (d) Jiang, G.; List, B. Angew. Chem., Int. Ed. 2011, 50, 9471−9474. (e) 
Capacci, A. G.; Malinowski, J. T.; McAlpine, N. J.; Kuhne, J.; MacMillan, D. W. C. Nat. Chem. 2017, 9, 1073−1077. 
(f) Jiang, X.; Boehm, P.; Hartwig, J. F. J. Am. Chem. Soc. 2018, 140, 1239−1242. (g) Hayashi, Y.; Umekubo, N. 
Angew. Chem., Int. Ed. 2018, 57, 1958−1962. (h) Chen, L.; Luo, M. J.; Zhu, F.; Wen, W.; Guo, Q. X. J. Am. Chem. 
Soc. 2019, 141, 5159−5163. (i) Cao, M.; Yesilcimen, A.; Wasa, M. J. Am. Chem. Soc. 2019, 141, 4199−4203. (j) 





basic catalysts, while the other acidic catalyst can be dedicated for the activation of electrophiles 
(through intermediates VII or VIII, Scheme 1.6b). Through this approach, α-functionalization 
reactions involving a significantly broader range of pronucleophiles and electrophiles may be 
achieved. 












































































One representative example is the enantioselective intramolecular [5+2] cycloaddition 
reaction of racemic pyranone 1.12 to provide chiral 8-oxabicyclo[3.2.1]octane derivatives 1.13  
promoted by cooperative actions of an achiral thiourea C7 and a bifunctional catalyst C8 
consisting of a dual H-bond donor and a Lewis basic primary amine unit (Scheme 1.7).3b When 





was obtained in only 32% yield with 86:14 er. However, by introducing achiral C7, both the yield 
and er could be improved to 72% and 95.5:4.5, respectively. The proposed modes of substrate 
activation involve efficient cleavage of C−OC(=O)Ar bond contained in 1.12 by more acidic C7 
(relative to less acidic C8), and a primary amine unit of C8 undergoes condensation with a 
carbonyl group of 1.12, thereby leading to the formation of pyrylium intermediate IX. Ensuing 
enantioselective [5+2] cycloaddition results in the formation of desired product 1.13. However, 
this reaction demands high catalyst loading, longer reaction time, as well as substrates that possess 
highly acid-sensitive leaving group; these issues likely arise because of the use of weakly acidic 
H-bond donor catalysts. 
Scheme 1.7. A Bifunctional Catalyst and an Achiral Thiourea Promoted Enantioselective 







Recently, our group developed enantioselective α-amination of mono-carbonyl 
compounds catalyzed by a Lewis acidic B(C6F5)3 and a bifunctional catalyst C4, which contains a 
Brønsted basic trialkylamine moiety and a hydrogen bond donor (Scheme 1.8).3e When B(C6F5)3 
and Hünig’s base (which lacks the tethered H-bond donor as seen in C4) were used, rac-1.16 was 
produced at a substantially slower rate. However, with B(C6F5)3 and C4, the reaction proceeds 
more efficiently to generate the enantioenriched α-amino carbonyl compound in 86% yield with 
97:3 er. These results suggest that B(C6F5)3 activates the carbonyl moiety of 1.14, and the 
trialkylamine unit of C4 deprotonates it to afford an intermediate comprised of a boron–enolate 
and C4-derived ammonium ion (1.14 → X). The ammonium ion and the amide units serve as dual 
H-bond donors to activate 1.15, while positioning it in close proximity to the in-situ generated 
boron–enolate, which is ionically bound to the ammonium ion (X). Thus, highly efficient and 
enantioselective α-amination between 1.14 and 1.15 can be achieved to provide 1.16. Despite this 
advance, a key unresolved problem remained to be addressed: the use of weakly acidic dual H- 
Scheme 1.8. Direct Catalytic Enantioselective α-Amination of Carbonyl Compounds Promoted 






bond donors did not allow less pre-activated electrophiles (e.g., N-alkylimine, ketones) to react 
with 1.14. Such limitation leads us to investigate the catalyst systems that incorporate strongly 
Lewis acidic co-catalysts that are to be described in the latter chapters of this dissertation. 
Hayashi and co-workers developed an enantioselective Michael reaction of ketone 1.17 
and α,β-unsaturated aldehyde 1.18 using a cooperative catalyst system consisting of 
diphenylprolinol trimethylsilyl ether C14, pyrrolidine C15, and Brønsted acidic phenol derivative 
C16 (Scheme 1.9).8g With C15 and C16 as the only catalysts, rac- 1.19 was obtained. However, 
by incorporating C14 as the co-catalyst, the reaction can proceed more efficiently and produce 
1.19 in 74% yield, 5:1 dr and 94.5:4.5 er. The authors proposed that ketone 1.17 can be selectively 
activated by C15 and C16 to generate nucleophilic enamine intermediate XI, while α,β-
unsaturated aldehyde 1.18 would be activated by C14 and C16 to deliver the more electrophilic 
iminium ion intermediate XII (vs the iminium ion generated from 1.18 and C15). The subsequent 
enantioselective C−C bond formation between the nucleophilic enamine XI and electrophilic  
Scheme 1.9. Direct Enantioselective Michael Reaction Catalyzed by a Combination of Two 






iminium ion XII followed by Wittig reaction would produce 1.19. Despite the important advances 
described, this method is confined to less hindered and sufficiently electrophilic ketones and 
aldehydes that readily undergo condensation with the secondary amine catalysts. 
In 2011, Shibasaki and co-workers utilized a combination of Cu/(R,R)-Ph-BPE C17, 
LiOAr C18 and a phosphine oxide C19 to promote enantioselective γ-addition of but-3-enenitrile 
1.21 to acetophenone 1.20 producing enantioenriched homoallylic alcohol 1.22 (Scheme 1.10).8a 
While homoallylic alcohol 1.22 can be generated in 83% yield with 97.5:2.5 er using 10 mol% 
C17 and C18 as the only catalysts, by incorporating of Lewis base C19,  the catalyst loading 
significantly lowers to 1.0 mol% (86% yield with >99:1 er). Kinetic studies revealed that 
deprotonation of Lewis acid Ln–Cu-activated 1.21 by C18 was the rate-determining step (XIII).  
Scheme 1.10. Enantioselective Addition of Allyl Cyanide to Ketones Promoted by Soft Lewis 






Thus, C19 enhancing the basicity of C18 through coordination to the Li cation. Then, the ensuing  
enantioselective γ-addition of the in situ generated Cu–nucleophile to the Cu-activated ketone 1.20 
delivers the enantioenriched homoallylic alcohol 1.22 (XIV).  
List and co-workers developed enantioselective α-allylation of aldehyde 1.23 utilizing a 
cooperative catalyst system consisting of a chiral phosphoric acid (S)-TRIP C20, Pd(PPh3)4 and 
N-benzhydryl amine C21 (Scheme 1.11).8d When only C20 and Pd(PPh3)4 were employed, 
allylation product 1.25 was obtained in 55:45 er. In contrast, incorporation of N-benzhydryl amine 
C21 significantly improved the enantioselectivity to 97:3 er. The proposed modes of substrate 
activation involve generation of an enamine intermediate through the reaction of primary amine 
catalyst C21 and aldehyde 1.23; at the same time, Pd(PPh3)4 reacts with allyl alcohol 1.24 to form 
an π-allyl complex XV. Phosphoric acid C20 catalyzes the generation of a Pd/allyl complex while 
bringing the nucleophilic enamine intermediate and electrophilic π-allyl complex in close 







proximity (XV) to facilitate the enantioselective allylation, thereby producing 1.25. However, the 
scope of pronucleophiles is limited to aldehydes that can readily undergo condensation with C21. 
MacMillan and co-workers developed enantioselective α-alkylation of aldehyde 1.26 with 
styrene 1.27 by using a catalyst combination of an Ir(III)-based photocatalyst C22, a chiral amine 
catalyst C23, and a thiol, which serves as a hydrogen atom transfer (HAT) catalyst C24 (Scheme 
1.12).8e With only C22 and C23, the α-alkylated product 1.28 was obtained in <10 % yield. By 
incorporating a HAT catalyst C24, 1.28 could be obtained in 81 % yield with >95:5 er. The authors 
proposed that the process begins with condensation of amine catalyst C23 and 1.26 to provide an 
enamine intermediate, which is then oxidized by C22 to produce an enaminyl radical intermediate 
XVI by single electron transfer. Then, the electrophilic radical XVI would undergo stereoselective 
addition to styrene 1.27 to generate a new C−C bond with a secondary alkyl radical (XVI → XVII).  
Scheme 1.12. Enantioselective α-Alkylation of Aldehyde Using Simple Olefins Promoted by Ir(III) 






Then, hydrogen atom transfer between nucleophilic radical XVII and C24 would deliver the 
desired product 1.28. However, this transformation demands the use of precious Ir-based catalyst 
and the substrate scope is limited to styrene derivatives, thus severely limiting the applicability of 
this method. 
Hartwig and co-workers disclosed a stereodivergent allylation of azaaryl acetamide 1.29 
and acetate 1.30 by synergistic functions of an Ir-based catalyst C25, a copper-based catalyst C26, 
and DBU C27 (Scheme 1.13).8f While allylation product 1.31 could be produced in only 14 % 
yield with 1:1.8 dr using C25 and DBU as the only catalysts, incorporation of Lewis acid C26 
significantly improves both the reaction yield and stereoselectivity (97% yield, >20:1 dr and >99:1 
er). The postulated mechanism is that C25 generates an electrophilic π-allyl complex from 1.30 
(XVIII) while Lewis acidic Cu-based catalyst C26 binds to 1.29 and lowers its pKa so that it can 
be deprotonated by DBU (XIX). The ensuing stereoselective allylation between the in-situ 
generated nucleophilic Cu(I) enolate (XIX) and electrophilic π-allyl complex (XVIII) would 
produce allylation product 1.31. Furthermore, the authors demonstrated that by using different 
combinations of catalyst enantiomers, stereodivergent allylation can be achieved to produce all 
four stereoisomers of 1.31 with excellent diastereoselectivity and enantioselectivity. However, the 
requirement for the use of biscoordination azaaryl acetamide derivatives as the substrates as well 






Scheme 1.13. Stereodivergent Allylation Promoted by Cooperative Functions of an Ir-based 







1.3. Aims of the Dissertation Research 
Despite the advances in the enantioselective transformations that exploit the synergistic 
functions of two and/or more catalyst units as highlighted above, fundamental problems remain to 
be addressed:  
Key problem 1. Catalyst/substrate combination is strictly restricted to those that can circumvent 
undesirable acid–base complexation; Lewis acid- and/or Lewis base-sensitive functional groups 
are poorly tolerated. 
Key problem 2. Weakly to moderately acidic and basic catalysts are often employed. Thus, 
transformations that rely on cooperative catalysis demand the use of highly base sensitive 
pronucleophiles (e.g., 1,3-dicarbonyl compounds, nitroalkanes, cyanoalkanes, aldehyde) and acid 
sensitive electrophiles (e.g., N-Boc-substituted benzaldimines, nitroalkenes). 
Key problem 3. Reaction efficiency is typically poor, thereby requires the use of higher catalyst 
loading and longer reaction time. 
In an effort to overcome the key limitations as listed above, we envisioned the application 
of “frustrated” Lewis pair complexes (i.e., FLP) as enantioselective cooperative catalysts.9 The 
FLPs typically are comprised of a strongly Lewis acidic organoborane and an appropriate Lewis 
base such as a tertiary amine or an organophosphine. These sterically encumbered and 
electronically disparate acids and bases are able to circumvent the undesirable acid–base 
complexation. These FLPs have been shown to activate an array of otherwise unreactive small 
                                                 
9 (a) Welch, G. C.; San Juan, R. R.; Masuda, J. D.; Stephan, D. W. et al. Science 2006, 314, 1124−1126. (b) Momming, 
C. M.; Otten, E.; Kehr, G.; Frolich, R.; Grimme, S.; Stephan, D. W.; Erker, G. Angew. Chem., Int. Ed. 2009, 48, 
6643−6646. (c) Dobrovetsky, R.; Stephan, D. W. J. Am. Chem. Soc. 2013, 135, 4974−4977. (d) Grimme, S.; Stephan, 





molecules such as H2, CO2, CO, SO2 to form the corresponding adducts (Scheme 1.14); notably, 
these small molecules cannot be activated using the preexisting cooperative catalysts that are 
comprised of weaker Lewis acids and/or H-bond donors (e.g., C1/C2, C5/C6, and C7/C8, Scheme 
1.1). Nonetheless, the development of FLP-catalyzed transformations had been confined to 
hydrogenation of unsaturated compounds at the time this dissertation research was started in 2016. 
Scheme 1.14. Stoichiometric Activation of H2 and CO2 by FLP 
 
We envisioned that a catalyst system comprised of B(C6F5)3, a chiral Lewis acid co-catalyst 
and a N-based Brønsted base can promote enantioselective C–C and C–heteroatom bond forming 
reactions between a broad array of pronucleophiles and electrophiles. We thought that the key 
problems 1 and 2 mentioned above can be remedied through the use of the FLP catalysts as they 
are largely immune to acid–base complexation. Moreover, the substrate scope could be broadened 
because the FLP catalysts may not form stable adducts with Lewis acid- and/or base-sensitive 
functional groups. Thus, our FLP-catalyzed transformations may be applicable to synthesis as well 
as late-stage functionalization of structurally complex pharmaceuticals and precursors for natural 





also be addressed through the use of FLP catalysts; less permanent catalyst–substrate, catalyst–
intermediate, and catalyst–product interactions may translate into higher reaction efficiency, and 
therefore lower catalyst loading may be achieved. The enantioselective transformations to be 
described in this dissertation include FLP-catalyzed Conia-ene-type reaction involving alkynyl 
carbonyl compounds (Scheme 1.15a, see Chapter 2), and FLP-catalyzed alkylation of β-amino 
C−H bonds (Scheme 1.15b, see Chapter 3). Through the development of these methods, we aim 
to demonstrate the proof of concept that the FLP catalysts are capable of overcoming the 
aforementioned fundamental limitations of enantioselective cooperative catalysis; specifically, 
poorly acid- and/or base-sensitive substrates that possess an array of different functional groups 
undergo efficient and highly enantioselective C–C bond forming reactions while overcoming the 
undesirable catalyst deactivation due to mutual quenching. 











Enantioselective Conia-Ene-Type Cyclizations of Alkynyl Ketones through Cooperative 
Action of B(C6F5)3, -Alkylamine and a Zn-Based Catalyst 
Introduction 
 Enantioselective α-functionalization of carbonyl compounds represents one of the most 
powerful and widely employed methods for the formations of C−C bonds or C−heteroatom bonds.1 
However, as described in Chapter 1, the processes that employ combinations of weakly acidic and 
basic catalysts demand highly acid- and/or base-sensitive pronucleophiles and electrophiles (e.g., 
1,3-dicarbonyl compounds and nitroalkenes, respectively). Development of enantioselective α-
functionalization reaction involving less base-sensitive mono-carbonyl compounds (e.g., ketones, 
esters, amides, thioesters; pKa = 20-30) and poorly acid-sensitive electrophiles (e.g., electron-rich 
alkynes, CO2, among others) stands as a formidable challenge.2 In this chapter, we describe our 
studies that were aimed at facilitating the α-functionalizations of various mono-carbonyl 
compounds with different electrophiles through the use of FLP catalysts.  
                                                 
1 For selected reviews, see: (a) Evans, D. A. in Asymmetric Synthesis, Vol. 3 (Ed.: Morrison, J. D.), Academic Press, 
Orlando, 1984, 1−10. (b) Enders, D. in Asymmetric Synthesis, Vol. 3, 1st ed. (Ed.: Morrison, J. D.), Academic Press, 
Orlando, 1984, 275−339. (c) Mekelburger, H. B.; Wilcox, C. S.  in Comprehensive Organic Synthesis, Vol. 2 (Eds.: 
Trost, B. M.; Fleming I.), Pergamon, Oxford, 1991, 99−131. (d) Heathcock C. H. in Modern Synthetic Methods, Vol. 
6 (Ed.: Scheffold, R.), Helvetica Chimica Acta, Basel, 1992, 183−213. (e) Rizzacasa, M. A.; Perkins M. in 
Stoichiometric Asymmetric Synthesis, Sheffield Academic Press, Sheffield, 2000. (f) Janey, J. M. Angew. Chem., Int. 
Ed. 2005, 44, 4292-4300. (g) Bellina, F.; Rossi, R. Chem. Rev. 2010, 112, 1082−1146. (h) Smith, A. M. R.; Hill, K. 
K. Chem. Rev. 2011, 113, 1637−1656. (i) Cano, R.; Zakarian, A.; McGlacken, G. P. Angew. Chem., Int. Ed. 2017, 56, 
9278−9290.  
2 For selected reviews on enantioselective cooperative catalysis, see: (a) Yamamoto, H.; Futatsugi, K. Angew. Chem., 
Int. Ed. 2005, 44, 1924−1942. (b) Kobayashi, S.; Mori, Y.; Fossey, J. S.; Salter, M. M. Chem. Rev. 2011, 111, 
2626−2704. (c) Allen, A. E.; MacMillan, D. W. Chem. Sci. 2012, 3, 633−658. (d) Trost, B. M.; Bartlett, M. J. Acc. 
Chem. Res. 2015, 48, 688−701. (e) Shibasaki, M.; Kumagai, N. in Cooperative Catalysis: Designing Efficient 
Catalysts for Synthesis, Peters, R., Eds.; Wiley-VCH: New York, 2015; Chapter 1. (f) Lu, X.; Deng, L. in Cooperative 
Catalysis: Designing Efficient Catalysts for Synthesis, Peters, R., Eds.; Wiley-VCH: New York, 2015; Chapter 5. (g) 
Inamdar, S. M.; Shinde, V. S.; Patil, N. T. Org. Biomol. Chem., 2015, 13, 8116−8162. (h) Wang, M. H.; Scheidt, K. 
A. Angew. Chem., Int. Ed. 2016, 55, 14912−14922. (i) Romiti, F.; del Pozo, J.; Paioti, P. H. S.; Gonsales, S. A.; Li, 
X.; Hartrampf, F. W. W.; Hoveyda, A. H. J. Am. Chem. Soc. 2019, 141, 17952−17961. (j) Sancheti, S. P.; Urvashi, 





2.1. Frustrated Lewis Acid/Brønsted Base Catalysts for α-Functionalization of Carbonyl 
Compounds 
In 2016, our group demonstrated that sterically hindered and electronically disparate 
B(C6F5)3 and a N-based Brønsted base catalyst  can promote direct catalytic Mannich-type reaction 
of ketone, ester or amide pro-nucleophiles (pKa = 20-30) (Scheme 2.1).3 B(C6F5)3 is thought to 
activate the carbonyl compound 2.1 and lower its pKa, thus allowing for DBU to deprotonate its 
acidic α-carbonyl C–H bond to generate an ion pair consisting of a boron–enolate and an 
ammonium ion (I). The latter component may then serve as a Brønsted acid to activate an imine 
substrate 2.2, which would then react with the boron–enolate to afford a β-aminocarbonyl product 
2.3. 
Scheme 2.1. Direct Mannich-Type Reaction Catalyzed by Frustrated Lewis Acid/Brønsted Base 
Complexes 
 
                                                 
3 Chan, J. Z.; Yao, W.; Hastings, B. T.; Lok, C. K.; Wasa, M. Angew. Chem., Int. Ed. 2016, 55, 13877−13881. (b) 
Shang, M.; Wang, X.; Koo, S. M.; Youn, J.; Chan, J. Z.; Yao, W.; Hastings, B. T.; Wasa, M. J. Am. Chem. Soc. 2017, 





In a subsequent work, our group developed enantioselective Mannich-type reaction of 
mono-carbonyl compounds catalyzed by a chiral organoborane C1 and pentamethylpiperidine 
(PMP, Scheme 2.2).4 The cooperative functions of C1 and PMP enables generation of a chiral 
boron–enolate from 2.4, which then reacts with the ammonium ion-activated N-Boc-benzaldimine 
2.5 (II) to afford an enantioenriched β-aminocarbonyl product 2.6.  
Scheme 2.2. Enantioselective Direct Mannich-Type Reaction Catalyzed by Frustrated Lewis 
Acid/Brønsted Base Complexes 
 
In the studies shown above, we revealed that the combination of highly Lewis acidic 
organoboranes and Brønsted basic amines can overcome mutual quenching and promote efficient 
Mannich-type reactions through the conversion of a wide variety of mono-carbonyl compounds 
into the corresponding enolates (III, Scheme 2.3a). As shown in another study (cf., Scheme 1.8, 
Chapter 1),5 organoborane/NR3-catalyzed α-functionalization of carbonyl compounds proceeds 
                                                 
4 Shang, M.; Cao, M.; Wang, Q.; Wasa, M. Angew. Chem., Int. Ed. 2017, 56, 13338−13526. 
5 Shang, M.; Wang, X.; Koo, S. M.; Youn, J.; Chan, J. Z.; Yao, W.; Hastings, B. T.; Wasa, M. J. Am. Chem. Soc. 





through activation of the electrophiles by R3N-derived H-bond donor catalysts (vs, Lewis 
activation by organoboranes; Scheme 1.6a). However, a key limitation of these methods was that 
the compatible electrophile was confined to N-Boc-benzaldemines and diazocompounds that are 
excellent H-bond acceptors and are highly preactivated. With less electrophilic substrates that do 
not possess H-bond acceptor units, the reaction did not proceed. 
We became interested in further expanding the scope of FLP-catalyzed enantioselective α-
functionalization reactions using weakly electrophilic substrates. In particular, we were intrigued 
in investing α-alkenylation of mono-carbonyl compounds 2.7 by electron rich alkyne 2.9 to 
produce various β,γ-unsaturated carbonyl products 2.10. However, with the B(C6F5)3 and a N-
based Brønsted base catalyst, this desirable reaction cannot proceed because the in situ generated 
ammonium ion may not even recognize 2.9 (IV, Scheme 2.3b). For the same reason, the catalyst 
system comprised of B(C6F5)3 and the bifunctional catalyst cannot promote the coupling of 
carbonyl pronucleophiles and alkynes (V, Scheme 2.3c). To overcome this major hurdle, we 
envisioned the incorporation of a chiral π-philic Lewis acid catalyst that is dedicated to activate 
alkyne 2.9 (VI, Scheme 2.3d). Thus, the organoborane and amine catalysts are used to convert 
mono-carbonyl pronuclephiles into the corresponding boron–enolates, which then undergoes 
enantio-determining C–C bond formation with the alkyne bound to the chiral π-philic 
organometallic complex may afford 2,10, To demonstrate the proof of concept that cooperative 
actions of an achiral organoborane, a chiral organometallic complex and an achiral amine promotes 
highly enantioselective union of enolates and otherwise unreactive alkynes, we decided to 
investigate enantioselective Conia-ene-type reactions that involve exo-dig cyclization of alkynyl 






















































































































2.2. Background for Conia-Ene-Type Reaction  
Conia-ene reaction is a class of carbonyl α-functionalization reaction that involves thermal 
intramolecular cyclization of enolizable carbonyl compounds with a tethered alkyne or alkene 
moiety leading to valuable five- or six-membered carbocycles (Scheme 2.4).6 However, the need 
for over 200 ºC reaction temperature in this racemic thermal cyclization restricts its synthetic utility 
because functional groups that are prone to pyrolysis are incompatible under this thermal reaction 
conditions. To overcome this shortcoming, a significant effort has been made to promote Conia-
ene-type cyclization under milder reaction condition by the use of Lewis acidic metal-based 
catalysts, allowing a broader applicability for this unique carbocyclization (Scheme 2.5). 7-8 
Scheme 2.4. Thermal Conia-Ene Reaction 
 
  
                                                 
6 (a) Conia, J. M.; Perchec, P. L. Synthesis 1975, 1, 1−19. (b) Hack, D.; Blümel, M.; Chauhan, P.; Philipps, A. R.; 
Enders, D. Chem. Soc. Rev. 2015, 44, 6059−6093. 
7 For selected reports, see: (a) Ochida, A.; Ito H.; Sawamura, M. J. Am. Chem. Soc. 2006, 128, 16486−16487. (b) Zhou, 
C. Y.; Che, C. M. J. Am. Chem. Soc. 2007, 129, 5828−5829. (c) Gao, Q.; Zheng, B. F.; Li, J. H.; Yang, D. Org. Lett., 
2005, 7, 2185−2188. (d) Kuninobu, Y.; Kawata, A.; Takai, K. Org. Lett., 2005, 7, 4823−4825. (e) Itoh, Y.; Tsuji, H.; 
Yamagata, K.; Endo, K.; Tanaka, I.; Nakamura, M.; Nakamura, E. J. Am. Chem. Soc. 2008, 130, 17161−17167. (d) 
Takahashi, K.; Midori, M.; Kawano, K.; Ishihara, J.; Hatakeyama, S. Angew. Chem., Int. Ed. 2008, 47, 6244−6246. 
(e) Deng, C. L.; Song, R. J.; Liu, Y. L.; Li, J. H. Adv. Synth. Catal., 2009, 351, 3096−3100. (f) Montel, S.; Bouyssi, 
D.; Balme, G. Adv. Synth. Catal., 2010, 352, 2315−2320. 
8 For selected examples on application of Conia-ene-type reaction, see: (a) Staben, S.T.; Kennedy-Smith, J. J.; Huang, 
D.; Corkey, B. K.; LaLonde, R. L.; Toste, F. D. Angew. Chem., Int. Ed. 2006, 45, 5991−5994. (b) Tsuji, H.; Yamagata, 
K. I.; Itoh, Y.; Endo, K.; Nakamura, M.; Nakamura, E. Angew. Chem., Int. Ed. 2007, 46, 8060−8062. (c) Takahashi, 
K.; Midori, M.; Kawano, K.; Ishihara, J.; Hatakeyama, S. Angew. Chem., Int. Ed. 2008, 47, 6244−6246. (d) Liu, X.; 
Lee, C. S. Org. Lett. 2012, 14, 2886−2889. (e) Huwyler, N.; Carreira, E. M. Angew. Chem., Int. Ed. 2012, 51, 
13066−13069. (f) Persich, P.; Llaveria, J.; Lhermet, R.; de Haro, T.; Stade, R.; Kondoh, A.; Fürstner, A. Chem. Eur. 
J. 2013, 19, 13047−13058. (g) Xiong, X.; Li, Y.; Lu, Z.; Wan, M.; Deng, J.; Wu, S.; Shao, H.; Li, A. Chem. 
Commun. 2014, 50, 5294−5297. (h) Hartrampf, F.W.; Furukawa, T.; Trauner, D. Angew. Chem., Int. Ed. 2017, 56, 
893−896. (i) Ye, Q.; Qu, P.; Snyder, S. A. J. Am. Chem. Soc. 2017, 139, 18428−18431. (j) Hartrampf, F. W.; Trauner, 





Scheme 2.5. Application of Conia-Ene-Type Cyclizations in Natural Product Synthesis 
  
However, the direct catalytic stereoselective Conia-ene-type cyclizations are 
underdeveloped.9 In 2005, Toste and coworkers reported the first catalytic enantioselective Conia-
ene-type reaction of β-dicarbonyl compound 2.13 promoted by Pd(II) DTBM-SEGPHOS complex 
C2 (Scheme 2.6).9a By using 20 mol% Yb(OTf)3 with an excess amount acetic acid, the reaction 
rate can be enhanced and the desired product 2.14 can be generated in 86% yield with 95:5 er. The 
author proposed that the Pd-complex C2 is responsible for the generation of nucleophilic  
Scheme 2.6. Catalytic Enantioselective Conia-Ene-Type Reactions Promoted by Cooperative 
Lewis Acid/ Lewis Acid Catalyst System 
 
                                                 
9 For direct catalytic enantioselective Conia-ene-type reaction, see: (a) Corkey, B. K.; Toste, F. D. J. Am. Chem. Soc. 
2005, 127, 17168−17169. (b) Yang, T.; Ferrali, A.; Sladojevich, F.; Campbell, L.; Dixon, D. J. J. Am. Chem. Soc. 
2009, 131, 9140−9141. (c) Matsuzawa, A.; Mashiko, T.; Kumagai, N.; Shibasaki, M. Angew. Chem., Int. Ed. 2011, 
123, 7758−7761. (d) Suzuki, S.; Tokunaga, E.; Reddy, D. S.; Matsumoto, T.; Shiro, M.; Shibata, N. Angew. Chem., 
Int. Ed. 2012, 51, 4131−4135. (e) Shaw, S.; White, J. D. J. Am. Chem. Soc. 2014, 136, 13578−13581. (f) Blümel, M.; 
Hack, D.; Ronkartz, L.; Vermeeren, C.; Enders, D. Chem. Commun. 2017, 53, 3956−3959. (g) Horibe, T.; Sakakibara, 





palladium enolate from the 1,3-dicarbonyl compound 2.13, which then attack Lewis acid-activated 
alkyne (VIII) to afford the cyclized product 2.14. Although they can achieve high level of 
reactivity and enantioselectivity under a mild reaction conditions, this transformation requires the 
use of precious Pd-based catalyst, as well as readily enolizable dicarbonyl compound substrates. 
Dixon and co-workers reported an enantioselective Conia-ene-type cyclization by 
employing a cooperative catalyst system consisting of a Lewis acidic CuOTf and a cinchona-
derived bifunctional catalyst C3 (Scheme 2.7).9b With the cooperative catalyst system consisting 
of 5.0 mol% CuOTf and 20 mol% of C3, enantioselective 5-exo-dig cyclization can afford the 
desired product 2.16 in 98% yield with 96:4 er. Mechanistic study suggests that C3 has two distinct 
roles: (1) serving as a ligand to the Cu(I) Lewis acid catalyst; (2) promoting the enolization and 
subsequent formation of a reactive copper enolate that would undergo syn-carbocupration (IX). 
Although this method does not require the use of precious metal based catalyst, the substrate scope 
still remains limited to the readily enolizable dicarbonyl compound. 
Scheme 2.7. Lewis Acid/Brønsted Base Cooperative Catalysis in the Enantioselective 
Conia-Ene-Type Reaction 
5.0 mol% Cu(OTf) 1/2C6H6
20 mol%





























As discussed in Chapter 1, Shibata and co-workers disclosed the enantioselective 5-endo-
dig cyclization promoted by the cooperative functions of Zn-PhBox complex C4 and Yb(OTf)3 
(Scheme 2.8).9d However, this catalyst system also demands the use of readily enolizable 
dicarbonyl compounds. 
Scheme 2.8. Catalytic Enantioselective 5-endo-dig Carbocyclization of β-Ketoesters through 
Cooperative Functions of Chiral Zinc-based Lewis Acid and Yb(OTf)3 
 
To achieve enantioselective Conia-ene-type cyclization with monocarbonyl compounds, 
Toste and coworkers reported the enantioselective Conia-ene-type cyclization of silyloxy-1,5-
enyne 2.19 promoted by chiral Au complex C5 (Scheme 2.9).10-11 The desired ketone substituted 
cyclopetene derived product 2.20 can be obtained in 75% yield with 97:3 er. The enantioselective 
5-endo-dig cyclization occurs between the nucleophilic silicon enolate and C5-activated alkyne 
(XI). Although monocarbonyl compound derived Conia-ene-type cyclization product can be 
obtained with high yield and enantioselectivity, the requirement for the use of preformed silicon 
enolates that contains sterically hindered gem-substituents to induce Thorpe-Ingold effect severely 
limits the application of this method. Furthermore, this method requires the use of precious Au-
based catalyst. 
 
                                                 
10 Corkey, B. K.; Toste, F. D. J. Am. Chem. Soc. 2007, 129, 2764−2765.  





Scheme 2.9. Enantioselective Cyclizations of Silyloxyenynes Catalyzed by Au Complex 
 
As the aforementioned literature precedents have shown, cooperative catalyst systems that 
promote direct catalytic enantioselective Conia-ene-type processes with mono-carbonyl 
compounds remain unprecedented. This is mainly because these catalyst systems are not 
compatible with Brønsted basic catalysts (e.g., DBU, Barton’s base) that may be capable of 
deprotonating the desirable mono-carbonyl substrates due to the undesirable acid/base 





2.3. Our Approach 
Since we have shown that the combination of borane Lewis acid and N-alkylamine 
Brønsted base can overcome mutual quenching and work cooperatively to activate a wide variety 
of mono-carbonyl compounds to generate boron enolate, we proposed that by incorporating a π-
philic Lewis acid co-catalyst that could selectively activate the alkyne moiety, the direct 
enantioselective Conia-ene-type cyclization between mono-carbonyl and alkyne moieties can then 
be achieved (Scheme 2.10). The basic N-alkylamine could deprotonate B(C6F5)3 activated 
carbonyl compound, generating a boron enolate and an ammonium ion XIII. In the meantime, a 
chiral Lewis acid co-catalyst (M-L*) could activate the alkyne unit. Then the stereoselective C−C 
bond formation between the boron enolate and alkyne would deliver the intermediate XIV. 
Subsequent protonation of alkenyl M-L* bond by the in situ generated ammonium ion would 
afford the desired cyclopentenyl product 2.22.  
One key advantage provided by this untethered cooperative catalyst system is that 
efficiency and stereoselectivity can be optimized through rapid evaluation of readily accessible 
Lewis acids, chiral ligands, and N-alkylamines. However, the two Lewis acids may undergo 
mutual quenching with the Brønsted base catalyst. Furthermore, the two Lewis acid catalysts, 
B(C6F5)3 and M-L*, may have overlapping functions for activation of carbonyl and alkyne 
moieties which may lead to racemic background reaction. Therefore, we need to find the right 
catalyst combination that can overcome these challenges and promote highly enantioselective 














2.4. Results and Discussion 
To begin the initial investigation, the transformation involving the substrate 1-phenylhept-
5-yn-1-one 2.21a was evaluated using B(C6F5)3, 1,2,2,6,6-pentamethylpiperidine (PMP), and 
various Lewis acid co-catalysts4-6, 8, which are known to activate the alkyne moieties, as potential 
catalyst combinations. We found that with 10 mol% B(C6F5)3, 20 mol% PMP, and Au-based Lewis 
acid or Zn-based Lewis acid, the reaction with 2.21a in ClCH2CH2Cl (DCE) at 80 °C would afford 
2.22a in up to >95 % yield (Table 2.1, entry 1-13). However, when the reaction was carried out at 
22 °C, only ZnI2 co-catalyst afforded the desired product 2.22a in quantitative yield (entry 16). 
The use of Zn-based Lewis acid catalyst is more preferable compared to the expensive Au-based 
Lewis acid catalyst. Furthermore, various Zn-based Lewis acid ligand complex catalyzed 
enantioselective transformations have been developed, which can provide us more opportunities 
to achieve the enantioselective Conia-ene-type transformation. With the optimal catalyst 
combination in hand, we carried out control experiments and further optimization studies (Table 
2.2). As the control experiment results show, all three catalysts, B(C6F5)3, PMP and ZnI2 are 
required in order to obtain the desired product (entry 1-4). This suggests the Lewis acid B(C6F5)3, 
Brønsted base   PMP and Lewis acid co-catalyst ZnI2 work cooperatively to promote the Conia-
ene-type cyclization.  After further optimization of reaction condition, the desired product was 
obtained in quantitative yield with 5.0 mol% B(C6F5)3, 10 mol% PMP, and 5.0 mol% ZnI2 in 
CH2Cl2 (entry 5). Since that we have found out the optimal catalyst combination and reaction 
















Table 2.2. Evaluation of Reaction Conditions and Control Experiments 
 
In this Lewis acid, Brønsted base, Lewis acid co-catalyst system, the three catalysts are not 
tethered together, we can easily and independently modify the catalyst structure to achieve highly 
enantioselective reaction.10 The enantioselective transformation can be achieved through either 
using chiral organoboron catalyst, chiral Brønsted base, chiral Lewis acid co-catalyst, or using any 
of these three chiral catalysts in combination (Scheme 2.11).  
Since the chiral boron Lewis acid is forming a covalent bond to the substrate, this could 
promote a better control of enantioselectivity. To test this hypothesis, we first evaluated the chiral 
organoboron catalyst C6, PMP and ZnI2 catalyst system. However, with the substrate 2.21a, the 





reaction efficiency and enantioselectivity is not promising and synthesis and optimization of the 
chiral organoboron structure would be cumbersome. Thus, we decided to investigate the chiral 
Lewis acid co-catalyst approach, which allows us to rapidly evaluate readily available metal ligand 
combinations to achieve the highly enantioselective Conia-ene-type cyclization.12 
Scheme 2.11. Enantioselective Conia-Ene-Type Cyclization  
 
Scheme 2.12. Enantioselective Conia-Ene-Type Cyclization Promoted by Chiral Organoborane, 
N-alkylamine and ZnI2 
 
To identify an optimal metal/ligand combination, we probed the ability of B(C6F5)3, PMP, 
and various chiral Lewis acid/ligand complexes to catalyze the cyclization of 1-phenylhept-5-yn-
1-one 2.21a (CH2Cl2, 12 h, 22 °C), to generate 2.22a. Various representative bisoxazoline ligands 
                                                 
12 Foe selected reviews, see: (a) Wu, X. F.; Neumann, H. Adv. Synth. Catal., 2009, 354, 3141−3160. (b) Łowicki, D.; 
Baś, S.; Mlynarski, J. Tetrahedron 2015, 71, 1339−1394. (c) Baś, S.; Szewczyk, M.; Mlynarski, J. in Chiral Lewis 
Acids in Organic Synthesis, Mlynarski, J., Eds.; Wiley-VCH: 2017; Chapter 5. (d) Trost, B. M.; Hung, C. I.; Mata, 





were evaluated; PhPybox Ligand L3 can give the desired product in highest enantioselectivity 





Table 2.3. Ligand Optimization for the 1-Phenylhept-5-yn-1-one Substrate a,b 
 
However, the enantioselectivity could not be further improved with this substrate. Based 
on the proposed catalytic cycle (Scheme 2.10), we have several hypotheses. First, the desired 
product 2.22a, which still contains an acidic α-proton may undergo racemization. Second, the in 
situ generated boron enolate (XIII) may isomerize to give Z/E mixture. In addition, the methyl 
group in the 2.21a may not be large enough for the catalyst to differentiate between substitutes on 
the alkyne to form a rigid Zn−Alkyne complex (XII). To test these hypotheses, we designed and 
evaluated several substrates. 
Firstly, α-tetralone derived substrate 2.21b was evaluated because it would only afford Z- 
boron enolate (Scheme 2.13). In addition, the desired product 2.22b does not contain α-C−H 





desired product was not obtained. We hypothesized that with the more hindered substrate 2.21b 
that contain tertiary α-C−H bond, the PMP may be too sterically hindered for the deprotonation 
process (Scheme 2.10, XII → XIII). Therefore, less hindered N-alkyl amine Brønsted bases were 
evaluated for this substrate, N-methyl piperidine was found to give the desired product in 27% 
yield with 80:20 er. These results suggest that the racemization of the product and isomerization 
of boron enolate may not be the reason for the low enantioselectivity. 
Scheme 2.13. Enantioselective Conia-Ene-Type Cyclization with Tetralne Derived Substrate 
 
To test the third hypothesis, 1-phenylnon-5-yn-1-one 2.21c was evaluated (Table 2.4). This 
substrate has a more sizable n-Pr substituent and may have better steric interaction with M-L*. 
The combination of 10 mol% ZnI2 and Ph–PyBOX (L3) or Ph–DBFOX (L5) afforded 2.22c in 
20% and 7% yield, and 83:17 and 55:45 er, respectively. With Ph–BOX (L1) as the ligand, the 
desired product was generated in >95% yield and 89:11 er. It seems that steric interaction between 
the Zn/ligand complex and substituent in the alkyne moiety can help improve the 





(6% yield, 71:28 er) were less effective. We proposed that by tuning the bite angle of the Ph–BOX 
ligand, it may have better steric interaction between the substituent and Zn/ligand complex which 
may further improve the enantioselectivity. Therefore, Ph–BOX ligands with varying 2,2’-
substiutents (cyclopropyl (L7), diisopropyl (L8), dicyclopentyl (L9) and dibenzyl (L10)) were  






then evaluated. We found that dibenzyl substituted L10 (large bite angle and better steric 
interaction) is the most effective ligand, providing 2.22c in >95 % yield with 97:3 er. Further 
evaluation of more sterically hindered ligand L11 and L12 does not lead to the further 





We also found that the loading of a bis-oxazoline ligand is essential on reaction efficiency 
and enantioselectivity. In the absence of L10, rac-2.22c can be isolated in >95% yield, when 10 
mol% of ZnI2 and 8.0 mol% of L10 was used, the enantioselectivity of 2.22c decreased to 92:8 er 
which may be due to the racemic background reaction. However, when excess L10 was used (13 
mol%), 2.22c was obtained in <5% yield. This suggests that the Lewis basic oxazoline units of 
L10 can deactivate B(C6F5)3. Therefore, preformed and purified ZnI2/L10 complex was used 
which gave us the desired product in similar yield and enantioselectivity.13-14 
With the optimal ZnI2/ligand combination in hand, we then set out to identify the optimal 
organoborane and Brønsted base catalysts, and optimize the reaction parameters (Table 2.5). With 
Et3N, the desired product 2.22c was obtained in >95% yield and 97:3 er (entry 1); however, with 
DBU as the base, none of the desired product could be detected (entry 2). With less B(C6F5)3 (7.5 
mol%), PMP (15 mol%), and ZnI2/L10 (7.5 mol%), efficiency decreased but enantioselectivity 
remained the same (90% yield, 97:3 er; entry 4). The reaction efficiency improved at 40 °C (entry 
5), allowing catalyst loading to be reduced to 5.0 mol% B(C6F5)3, 10 mol% PMP and 5.0 mol% 
ZnI2/L10; under these conditions, 2.22c was produced in 92% yield and 97:3 er (entry 6). Control 
experiments showed that in the absence of the Brønsted base, the organoborane catalyst, or the 
ZnI2/L10, no desired product was obtained (entries 7–9); when the sterically less hindered 
BF3•OEt2 or the less Lewis acidic BPh3 were used, no desired product was obtained (entries 10–
11). Thus, the appropriately Lewis acidic and sterically hindered B(C6F5)3, PMP, together with 
ZnI2/L10 complex emerged as the most effective combination for this enantioselective Conia-ene-
type cyclization. Furthermore, no racemization was observed when we treated the enantioenriched 
                                                 
13 Thorhauge, J.; Roberson, M.; Hazell, R. G.; Jørgensen, K. A. Chem. Eur. J. 2002, 8, 1888−1898.  





desired product 2.22c with the standard reaction conditions. It is probably because the unfavorable 
streic interaction between the n-Pr and Ph substituents makes 2.22c hard to be deprotonated. 
Table 2.5. Evaluation of Enantioselective Reaction Conditions and Control Experiments a,b,c 
 
Having established the most effective catalyst combination and reaction condition, we have 
demonstrated this synthetic protocol can be applied to a variety of 1-phenyl ketones with different 
alkyne substituents for the enantioselective Conia-ene-type reaction (2.21a–2.21j; Table 2.6). 





was inefficient and moderately enantioselective (10% yield, 70:30 er). In contrast, when 1-
phenylhept-5-yn-1-one was evaluated, which bears an internal alkyne (R = Me), the desired  
























































a Conditions: Alkynl ketone (2.21a-2.21e, 2.21i, 2.21j, 0.2 mmol), B(C6F5)3 (7.5 mol%), 1,2,2,6,6-
pentamethylpiperidine (15 mol%), ZnI2/L10 (7.5 mol%), CH2Cl2 (1.0 mL), under N2, 40 °C, 12 h.
b Yield of isolated
and purified product. The er values were determined by HPLC analysis of the purified product. c Alkynl ketone
(2.21f-2.21h, 0.2 mmol), B(C6F5)3 (10 mol%), 1,2,2,6,6-pentamethylpiperidine (20 mol%), ZnI2/L10 (10 mol%),





product 2.22a can be obtained in 96% yield and 82:18 er. For substrates that carry a larger ethyl, 
n-propyl, n-butyl, and iso-butyl substituent, we are able to obtain the desired products in >95% 
yield and 96:4–97:3 er (2.22c–2.22f). This is in consistent with the hypothesis that the steric 
interaction between the alkyne substituents and M-L* complex could help improve the 
enantioselectivity. Although, with higher reaction temperature, benzyl-substituted substrate 
furnished 2.22g in 82% yield and 98:2 er, phenyl-substituted substrate was less efficient (2.22h, 
50% yield, 91:9 er). These results implied that large steric hindrance of the alkyne substituents 
impeded the reaction efficiency.  We also demonstrated the presence of a carboxylic ester or a 
monosubstituted alkene is tolerated (2.22i and 2.22j). The desired product can be obtained in up 
to 97% yield and 97:3 er. 
Since we have shown various alkyne substituents are compatible for this enantioselective 
transformation, we then investigated reactions with different aryl- and alkyl-substituted ketones 
(Table 2.7). 2-Methoxyphenyl- and 4-bromophenyl-substituted ketones gave 2.22k (95% yield, 
93:7 er) and 2.22l (97% yield, 97:3 er), respectively. The process involving indanone derivative or 
tetralone derivative did not afford desired product when PMP was employed as a Brønsted base 
catalyst. We hypothesize that because it is too hindered for PMP to deprotonate α tertiary C–H 
bond within a B(C6F5)3-activated ketone. After evaluation of various Brønsted base catalyst, less 
sterically hindered 1-methylpiperidine was found to deliver the desired product which contains 
fully substituted stereogenic center. 2.22m was produced in 98% yield and 99:1 er. Tetralone-
derived 2.22n was formed inefficiently (20% yield, 98:2 er) even in 60 °C for 24 hours. Perhaps 
indicating severe steric repulsion between the n-propyl substituent and the tetralone ring. Thus, 
when less steric hindered Me-substituted substrate 2.21b was employed, the desired product can 





substituted substrates are also compatible, which gave us 2.22o (99% yield, 98:2 er) and 2.22p 
(99% yield, 97:3 er). In addition, alkyl substituted ketones were also found to give the desired 
product in similar efficiency as represented by 2.22q (91% yield, 95:5 er) and 2.22r (77% yield, 
96:4 er). However, bicyclic product 2.22s was generated with 1-methylpiperidine as the Brønsted 
base, but in diminished er (82% yield, 80:20 er). 






The method is also readily scalable. Treatment of 1.5 g (7.0 mmol) of 2.21c with 2.5 mol% 
B(C6F5)3, 5.0 mol% PMP, and 2.5 mol% ZnI2/L10 (CH2Cl2, 24 h, 40 °C) afforded 2.22c in 94% 
yield (6.6 mmol, 1.4 g) and 97:3 er (Scheme 2.14). Moreover, this cooperative catalyst system can 
also promote 5-exo-dig cyclization. We discovered that cycloaddition of 1-phenylhept-6-yn-1-one 
2.23a (5-exo-dig) is facilitated by B(C6F5)3, 1-methylpiperidine. and ZnI2/L10 to deliver exo-
methylene-substituted cyclopentane 2.23b in 98% yield but just 68:32 er. The low 
enantioselectivity is probably due to the fact that there is not enough steric interaction between the 
terminal alkyne and ZnI2/L10 complex. In order to further improve enantioselectivity for the 5-
exo-dig cyclization, further optimization of the M-L* combination is still required. 
Scheme 2.14. Scale-up Experiments and 5-exo-dig Cycloaddition 
 
Now that we have demonstrated that we can achieve the direct enantioselective Conia-ene-
type cyclization with broad scope of alkynyl ketones, we then went to investigate the reactivity 
with ester derived substrate 2.25a which is harder to be deprotonated to generate the corresponding 
enolate (Scheme 2.15). Treatment of 2.25a with 10 mol% B(C6F5)3, 20 mol% PMP, and 10 mol% 





reaction conditions leads us to find that for the ester derived substrate 2.25a, the reaction is 
stoichiometric with respect to the loading of ZnI2 and PMP. The desired product can be obtained 
in 42% yield with 10% B(C6F5)3, 50 mol% PMP and 50 mol% ZnI2. Studies are underway to 
further enhance the applicability of this approach. 
Scheme 2.15. Conia-Ene-Type Cyclization with Ester Substrate 
 
Now we have accomplished the direct enantioselective Conia-ene-type cyclization by 
cooperative functions of B(C6F5)3, N-alkylamine, and ZnI2/L complex. However, the exact roles 
of ZnI2/L complex, which could activate either carbonyl and/or alkyne units of 2.21, remained 
undetermined. To shed light on the mechanism of the Conia-ene-type reaction, we investigated 
whether the proposed alkenyl ZnI intermediate XVV derived from 2.21 by 5-endo-dig 
carbocyclization (via 2.21 → XVI → XVII → XVIII; Scheme 2.16) is generated. We 
hypothesized that alkenyl-ZnI intermediate XVIII can undergo transmetallation with an 
appropriate Pd(II)-based complex (XVIII → XIX), which may be formed in situ through oxidative 
addition of Pd(PPh3)4 and an aryl iodide 2.27. The resulting [(Ar)(I)PdII(PPh3)n] XIX can then 
undergo C−Ar bond formation via reductive elimination to afford 1,2,3-substituted cyclopentene 
derivative 2.28. The sequential Conia-ene-type carbocyclization/Negishi coupling reactions could 





Scheme 2.16. Sequential Conia-ene-type Cyclizations/Negishi Coupling Reaction 
 
responsible for activation of alkyne unit in 2.21, thereby generating XVIII.15 Therefore, we need 
to develop a process promoted by B(C6F5)3, N-alkylamine, ZnI2, and Pd(PPh3)4 that play their 
                                                 
15 For selected examples on Negishi cross coupling, see: (a) Negishi, E.; King, A. O.; Okudado, N. J. Org. Chem. 
1977, 42, 1821−1823. (b) Negishi, E.; Valente, L. F.; Kobayashi, M. J. Am. Chem. Soc. 1980, 102, 3298−3299. (c) 
Negishi, E. Acc. Chem. Res. 1982, 15, 340−348. (d) Dai, C.; Fu, G. C. J. Am. Chem. Soc. 2001, 123, 2719−2724. (e) 
Zeng, X.; Quian, M.; Hu Q.; Negishi, E. Angew. Chem., Int. Ed. 2004, 43, 2259−2263. (f) Sase, S.; Jaric, M.; Metzger, 
A.; Malakhov, V.; Knochel, P. J. Org. Chem. 2008, 73, 7380−7382. (g) Son, S.; Fu, G. C. J. Am. Chem. Soc. 2008, 
130, 2756−2757. (h) Han, C.; Buchwald, S. L. J. Am. Chem. Soc. 2009, 131, 7532−7533. (i) Phapale, V. B.; Cardenas, 






independent catalytic roles while overcoming the undesirable acid/base complexation to afford 
1,2,3-substituted cyclopentenes.  
For the initial investigation, we tested the ability of B(C6F5)3, PMP, ZnI2, and Pd(PPh3)4 to 
facilitate the cyclization of 1-phenylnon-5-yn-1-one 2.21a to give the alkenyl ZnI complex XIII, 
followed by Negishi coupling with iodobenzene 2.27a (CH2Cl2, 12 h, 22 °C) to generate 2.28a 
(Table 2.8). With 10 mol% B(C6F5)3, 1.0 equivalent of PMP, 50 mol% ZnI2, and 2.0 mol% 
Pd(PPh3)4, desired product 2.28 can be generated in >95% yield while cyclopentene derivative 
3.22a was obtained in <5% yield (entry 1), which can be formed by protonation of alkenyl ZnI 
intermediate. In the absence of Pd(PPh3)4, only 2.22a was generated in >95% yield (entry 2). 
Control experiments showed that when ZnI2 or PMP was not added, neither 2.28a nor 2.22a were 
produced (entries 3–4). However, PMP, ZnI2, and Pd(PPh3)4 were found to promote the formation 
of 2.28a in 20% yield (entry 5). This observation suggests that alkynyl ketone 2.21a can be 
deprotonated by cooperative functions of the Pd-based complex and PMP.16 This reaction requires 
a stoichiometric amount of PMP because the formation of [PMP–H]+[I]– (XVII → XVIII; Scheme 
2.16) will inhibit the regeneration of PMP; when the loading of PMP was lowered to 50 mol%, 
3.28a was obtained in only 52% (entry 6). With 20 mol% ZnI2, the yield of 3.22a declined to 41% 
(entry 7).17 This sequential cycloaddition/cross-coupling reaction could proceed with a minimal 
amount of Pd(PPh3)4 (1.0 mol%), as 3.22a could be obtained in >95% yield (entry 8).  
                                                 
16 For selected examples of transformations involving palladium enolates, see: (a) Sodeoka, M.; Ohrai, K.; Shibasaki, 
M. J. Org. Chem. 1995, 60, 2648−2649. (b) Sodeoka, M.; Tokunoh, R.; Miyazaki, F.; Hagiwara, E.; Shibasaki, M. 
Synlett 1997, 463−466. (c) Sodeoka, M.; Shibasaki, M. Pure Appl. Chem. 1998, 70, 411−414. (d) Hagiwara, E.; Fujii, 
A.; Sodeoka, M. J. Am. Chem. Soc. 1998, 120, 2474−2475. (e) Fujii, A.; Hagiwara, E.; Sodeoka, M.  J. Am. Chem. 
Soc. 1999, 121, 5450−5458. (f) Hamashima, Y.; Hotta, D.; Sodeoka, M. J. Am. Chem. Soc. 2002, 124, 11240−11241. 
(g) Hayamizu, K.; Terayama, N.; Hashizume, D.; Dodo, K.; Sodeoka, M. Tetrahedron 2015, 71, 6594−6601. 
17 (a) Kálmán, E.; Serke, I.; Pálinkás, G.; Johansson, G.; Kabisch, G.; Maeda, M.; Ohtaki, H. Z. Naturforsch. A. 1983, 
38, 225−230. (b) Wakita, H.; Johansson, G.; Sandström, M.; Goggin, P. L.; Ohtaki, H. J. Solution Chem. 1991, 20, 





Table 2.8. Evaluation of Reaction Parameters for Sequential Conia-ene-type Cyclizations/Negishi 
Coupling Reaction a,b 
 
Various alkynyl ketones and aryl- and heteroaryl-iodides proved to be suitable substrates 
for the sequential Conia-ene-type carbocyclization/Negishi coupling (2.28a–2.28l; Table 2.9). 
Phenyl, naphthalen-2-yl, 2-methoxyphenyl, and furan-2-yl-substituted ketones gave the 
corresponding products (2.28a–2.28e) in 65 to 98% yield. An alkyl substituted ketone was also 
found to be a suitable substrate as 2.28f was obtained in 91% yield. Cyclopentene derivatives with 
1-naphthyl group (2.28g) as well as those containing arenes with electron-donating (2.28h) and 
electron-withdrawing (2.28i–2.28k) groups were obtained in 91 to 95% yield. Heteroaryl 





catalyst system which constitutes of B(C6F5)3, an amine, ZnI2, and Pd(PPh3)4 to promote sequential 
Conia-ene-type cycloaddition/Negishi coupling reactions. Furthermore, the results provide a 
mechanistic insight into that π-philic Zn-based catalyst is responsible for activation of alkyne unit 
in 2.21, while B(C6F5)3 would activate the carbonyl units. 
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a Conditions: Alkynl ketone (2.21, 0.10 mmol), aryl iodide (2.27, 0.12 mmol), B(C6F5)3 (10 mol%), PMP (100 mol%),
ZnI2 (50 mol%), Pd(PPh3)4 (1.0 mol%), CH2Cl2 (0.5 mL), under N2, 22 °C, 12 h.






2.5. Conclusions and Future Outlook 
In summary, we have developed the direct catalytic enantioselective Conia-ene-type 
reaction with mono-carbonyl compound by implementing the cooperative functions of a three-
component catalyst system, which consists of a pair of Lewis acids and a Brønsted basic amine. 
Furthermore, through incorporating Pd(PPh3)4 co-catalyst, the sequential Conia-ene-type 
cycloaddition/Negishi coupling reactions can be accomplished. These two reactions have clearly 
demonstrated that a combination of multiple different catalyst units can work cooperatively to 
promote the union of in situ generated reactive intermediates from poorly acid- and base-sensitive 
starting materials. The principles outlined herein, entailing separate and independently operational 
catalysts, provide a rational framework for the development of novel enantioselective cooperative 






2.6. Expeirimental  
2.6.1 Procedures, Materials and Instrumentation 
General Experimental Procedures. All reactions were performed in standard, oven-dried 
glassware fitted with rubber septa under an inert atmosphere of nitrogen unless otherwise 
described. Stainless steel syringes or cannulas were used to transfer air- and moisture-sensitive 
liquids. Reported concentrations refer to solution volumes at room temperature. Evaporation and 
concentration in vacuo were performed using house vacuum (ca. 40 mm Hg). Column 
chromatography was performed with SiliaFlash® 60 (40–63 micron) silica gel from Silicycle. Thin 
layer chromatography (TLC) was used for reaction monitoring and product detection using pre-
coated glass plates covered with 0.25 mm silica gel with fluorescent indicator; visualization by 
UV light (λex = 254 nm) or KMnO4 stain. 
 
Materials. Reagents were purchased in reagent grade from commercial suppliers and used without 
further purification, unless otherwise described. H2O, in synthetic procedures, refers to distilled 
water. Chiral ligands L1-L12 were prepared according to the procedures previously reported in 
the literature.13-14,18-19 Substrates 2.21, 2.23a, and 2.25a were also synthesized according to the 
literature procedures.20 
                                                 
18 Tse, M. D.; Bhor, S.; Klawonn, M.; Anilkumar, G.; Jiao, H.; Döbler, C.; Spannenberg, A.; Mägerlein, W.; Hugl, H.; 
Beller, M. Chem. Eur. J. 2006, 12, 1855−1874.   
19 Itoh, K.; Sibi, M. P. Org. Biomol. Chem. 2018, 16, 5551−5565.  
20 (a) Kamijo, S.; Dudley, G. B. J. Am. Chem. Soc. 2006, 128, 6499−6507. (b) Wang, L.; Neumann, H.; Beller, M. 
Angew. Chem., Int. Ed. 2018, 57, 6910−6914. (c) Chen, W.; Ma, L.; Paul, A.; Seidel, D. Nat. Chem. 2018, 10, 
165−169. (d) Ramachary, D. B.; Kishor, M. J. Org. Chem. 2007, 72, 5056−5068. (e) Zhao, Y. S.; Tang, X. Q.; Tao, 
J. C.; Tian, P.; Lin, G. Q. Org. Biomol. Chem. 2016, 14, 4400−4404. (f) Wu, X.; Chen, Z.; Bai, Y. B.; Dong, V. M. 
J. Am. Chem. Soc. 2016, 138, 12013−12016. (g) Wu, Y.; Arenas, I.; Broomfield, L. M.; Martin, E.; Shafir, A. Chem. 
Eur. J. 2015, 21, 18779−18784. (h) Meiß, R.; Kumar, K.; Waldmann, H. Chem. Eur. J. 2015, 21, 13526−13530. (i) 
Miesch; L.; Welsch, T.; Rietsch, V.; Miesch, M. Chem. Eur. J. 2009, 15, 4394−4401. (j) Liu, G.; Stahl, S. S. J. Am. 





Instrumentation. Proton nuclear magnetic resonance (1H NMR) spectra and proton-decoupled 
carbon nuclear magnetic resonance (13C {1H} NMR) spectra were recorded at 25°C (unless stated 
otherwise) on Inova 600 (600 MHz) or Varian Unity/Inova 500 (500 MHz) or Oxford AS400 (400 
MHz) spectrometers at the Boston College nuclear magnetic resonance facility. Chemical shifts 
for protons are reported in parts per million downfield from tetramethylsilane and are referenced 
to residual protium in the NMR solvent. Chemical shifts for carbon are reported in parts per million 
downfield from tetramethylsilane and are referenced to the carbon resonances of the solvent. The 
solvent peak was referenced to 0 ppm for 1H for tetramethylsilane and 77.0 ppm for 13C for CDCl3. 
Data are represented as follows: chemical shift, integration, multiplicity (br = broad, s = singlet, d 
= doublet, t = triplet, q = quartet, qn = quintet, sp = septet, m = multiplet), coupling constants in 
Hertz (Hz).  
Optical rotations were measured using a 1 mL cell with a 5 cm path length on a Rudolph 
Research Analytical Autopol IV Polarimeter. Infrared spectra were recorded on a Bruker FT-IR 
Alpha (ATR mode) spectrophotometer. Data are represented as follows: frequency of absorption 
(cm–1). High-resolution mass spectrometry was performed on a JEOL AccuTOF-DART (positive 
mode) or Agilent 6220 TOF-ESI (positive mode) at the Mass Spectrometry Facility, Boston 
College. Chiral HPLC analyses were carried using Agilent 1200 series instruments with Daicel 
CHIRALPAK® columns or Daicel CHIRALCEL® columns (internal diameter 4.6 mm, column 
length 250 mm, particle size 5 µm). 
Abbreviations Used. Bn = benzyl, DART = direct analysis in real time, DCE = 1,2-ichloroethane, 
DCM = dichloromethane, er = enantiomeric ratio, Et2O = diethyl ether, EtOAc = ethyl acetate, 
H2O = water, HPLC = high pressure liquid chromatography, HR = high-resolution, LC = liquid 
chromatography, MS = mass spectrometry, NA = not applicable, PMP = 1,2,2,6,6-












2.6.2 Experimental Section 
2.6.2.1 Substrate Preparation 
General Procedure A: 
 
Preparation of S2: 
To a solution of cyclohexanedione S1 (1.0 equiv.) in dichloromethane (0.2 M), pyridine (2.0 equiv.) 
was added. The mixture was then cooled to –78 °C and trifluoromethane sulfonic anhydride (Tf2O, 
1.2 equiv.) was added slowly at –78 °C. The reaction mixture was allowed to stir for 10 min at –
78 °C and warmed to 0 °C. After the starting material (S1) was consumed (as determined by TLC), 
the mixture was acidified with 1N HCl (aq.) and extracted with dichloromethane (3 x 50 mL). The 
combined organic layers were dried over Na2SO4, and concentrated in vacuo. The resulting residue 
was purified by silica gel column chromatography (pentane:ether = 5:1) to yield S2.20a 
Preparation of 2.21: 
To a solution of S2 (1.0 equiv.) in THF (0.25 M) at −78 °C under N2 atmosphere was added R2–Li 
(0.9 equiv.),20b-20c dropwise. The reaction mixture was allowed to stir at −78 °C for 10 minutes, 
then for 10 minutes at 0 °C, followed by 30 minutes at room temperature. Upon completion of the 
reaction, saturated NH4Cl (aq.) was added to quench the reaction and the mixture was extracted 
with Et2O (3 x 50 mL). The combined organic layers were washed with brine, dried over MgSO4, 
filtered, and concentrated in vacuo. The resulting mixture was purified by silica gel column 






General Procedure B: 
 
Synthesis of S5: 
S5 was prepared from S3 according to the known procedures.20h To a solution of the alkynol S3 
(1.0 equiv.) in dry pyridine (1.25 M) was added p-toluene sulfonyl chloride (1.1 equiv.) and the 
reaction mixture was allowed to stir at 0 °C for 12 h. Upon completion, the reaction mixture was 
poured into water and was subsequently extracted with Et2O (3 x 50 mL). The combined ether 
layers were washed with saturated CuSO4 (aq.) and brine, and then dried over anhydrous MgSO4. 
The solvent was removed in vacuo, and the crude product S4 was used without further purification. 
To a solution of S4 (1.0 equiv.) in acetone (0.4 M) was added sodium iodide (3.0 equiv.). The 
reaction mixture was allowed to heat at reflux for 4 h. Subsequently, the reaction mixture was 
concentrated in vacuo, and the resulting mixture was poured into water and extracted with pentane 
(3 x 50 mL). The combined organic layers were washed with water then brine, and dried over 
anhydrous Na2SO4. The solvent was evaporated under reduced pressure and the resulting mixture 








Synthesis of S7 and S9: 
To a stirred solution of cycloketone S6 or S8 (1.0 equiv.) in benzene (0.6 M) was added N,N-
dimethylhydrazine (1.2 equiv.) and trifluoroacetic acid (10 drops). The mixture was allowed to stir 
at reflux for 15 h with a Dean-Stark apparatus. Benzene was removed by distillation at atmospheric 
pressure. The residue was dissolved in Et2O (30 mL), and ice water (25 mL) was added. After 
extraction with Et2O (3 x 20 mL), the combined organic layers were washed with brine and dried 
over Na2SO4. After filtration and removal of the solvent, the residue was purified by distillation to 
give the desired compound S7 or S9.20i  
 
Synthesis of 1l-1n, 1s: 
To a solution of N,N-dimethylhydrazone S7 or S9 (1.0 equiv.) in THF (0.25 M) was added n-BuLi 
(1.2 equiv.), dropwise at −5 °C. The reaction mixture was allowed to stir for 1 h at −5 °C, 
whereupon a solution of S5 (1.1 equiv.) in THF (1 M) was added dropwise. The reaction mixture 
was allowed to stir at room temperature for 12 h, then 2N HCl (aq., 20 mL) was added to the 
solution. The reaction mixture was allowed to stir at room temperature for 3 h and extracted with 
ethyl acetate (5 x 10 mL). The combined organic layers were successively washed with aqueous 














1-Phenylhept-5-yn-1-one (2.21a)  
1-Phenylhept-5-yn-1-one was prepared following the General Procedure A starting with 10 
mmol of 2-methylcyclohexane-1,3-dione. The product was obtained as a colorless oil (1.7 g, 90% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 9.7 Hz, 2H), 7.56 (t, J = 8.0 Hz, 1H), 7.49 – 
7.44 (m, 2H), 3.10 (t, J = 7.3 Hz, 2H), 2.31 – 2.23 (m, 2H), 1.92 (p, J = 7.0 Hz, 2H), 1.78 (t, J = 
2.6 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 202.50, 139.67, 135.59, 131.19, 130.68, 81.04, 79.06, 
39.98, 26.06, 20.93, 6.11; IR (neat) 2934, 2915, 1681, 1595, 1579, 1446, 1365, 1319, 1228, 1198, 





2-(Pent-3-yn-1-yl)-3,4-dihydronaphthalen-1(2H)-one was prepared following the General 
Procedure B starting with 20 mmol of 3,4 dihydronaphthalen-1(2H)-one. The product was 
obtained as a brown oil (2.8 g, 67% yield). 1H NMR (500 MHz, CDCl3) δ 8.02 (d, J = 8.0 Hz, 
1H), 7.45 (t, J = 7.7 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 3.10 – 2.96 (m, 
2H), 2.70 – 2.62 (m, 1H), 2.44 – 2.32 (m, 1H), 2.32 – 2.16 (m, 3H), 1.93 – 1.82 (m, 1H), 1.76 (s, 





130.04, 129.19, 81.13, 78.85, 48.97, 31.61, 31.26, 30.93, 19.15, 6.13; IR (neat) 2915, 2856, 1678, 




1-Phenylnon-5-yn-1-one (2.21c)  
1-Phenylnon-5-yn-1-one was prepared following the General Procedure A starting with 30 mmol 
of 2-propylcyclohexane-1,3-dione.20d The product was obtained as a pale-yellow oil (5.9 g, 92% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 9.5 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.46 (t, J 
= 7.6 Hz, 2H), 3.11 (t, J = 7.3 Hz, 2H), 2.33 – 2.26 (m, 2H), 2.17 – 2.09 (m, 2H), 1.93 (p, J = 7.0 
Hz, 2H), 1.50 (h, J = 7.3 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 202.55, 
139.68, 135.59, 131.19, 130.69, 83.78, 81.99, 39.97, 26.20, 25.12, 23.40, 20.97, 16.13; IR (neat) 
2958, 2930, 2869, 1682, 1596, 1579, 1447, 1366, 1228, 1000, 745, 689 cm-1; HRMS (DART) m/z 
Calcd for C15H19O (MH+): 215.1430; found: 215.14261. 
 
 
1-Phenyloct-5-yn-1-one (2.21d)  
1-Phenyloct-5-yn-1-one was prepared following the General Procedure A starting with 10 mmol 





1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 8.1 Hz, 2H), 7.56 (t, J = 7.3 Hz, 1H), 7.47 (t, J = 7.6 
Hz, 2H), 3.11 (t, J = 7.3 Hz, 2H), 2.29 (t, J = 6.7 Hz, 2H), 2.16 (q, J = 7.1 Hz, 2H), 1.93 (p, J = 
7.1 Hz, 2H), 1.11 (t, J = 7.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 202.54, 139.68, 135.59, 
131.19, 130.69, 85.31, 81.20, 39.95, 26.16, 20.94, 16.96, 15.05; IR (neat) 2970, 2934, 1681, 1596, 
1579, 1447, 1366, 1318, 1228, 1000, 745, 689 cm-1; HRMS (DART) m/z Calcd for C14H17O 
(MH+): 201.12739; found: 201.12675. 
 
 
1-Phenyldec-5-yn-1-one (2.21e)  
1-Phenyldec-5-yn-1-one was prepared following the General Procedure A starting with 10 mmol 
of 2-butylylcyclohexane-1,3-dione.20d The product was obtained as a colorless oil (1.9 g, 85% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 7.1 Hz, 2H), 7.56 (t, 1H), 7.47 (t, J = 7.9 Hz, 
2H), 3.11 (t, J = 7.3 Hz, 2H), 2.33 – 2.26 (m, 2H), 2.19 – 2.11 (m, 2H), 1.97 – 1.87 (m, 2H), 1.50 
– 1.33 (m, 4H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 202.55, 139.68, 135.58, 
131.19, 130.69, 83.92, 81.81, 39.96, 33.82, 26.18, 24.59, 21.07, 20.97, 16.26; IR (neat) 2953, 2929, 
1683, 1596, 1447, 1366, 1228, 1000, 743, 689 cm-1; HRMS (DART) m/z Calcd for C16H21O 







8-Methyl-1-phenylnon-5-yn-1-one (2.21f)  
8-Methyl-1-phenylnon-5-yn-1-one was prepared following the General Procedure A starting 
with 10 mmol of 2-isobutylcyclohexane-1,3-dione.20e The product was obtained as a colorless oil 
(1.8 g, 78% yield). 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.5 Hz, 2H), 7.56 (t, J = 7.4 Hz, 
1H), 7.46 (t, J = 7.7 Hz, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.33 – 2.28 (m, 2H), 2.07 – 2.02 (m, 2H), 
1.94 (p, J = 7.0 Hz, 2H), 1.81 – 1.71 (m, 1H), 0.96 (d, J = 6.6 Hz, 6H); 13C NMR (151 MHz, 
CDCl3) δ 202.54, 139.67, 135.59, 131.19, 130.68, 82.79, 82.71, 39.99, 30.87, 30.63, 26.24, 24.60, 
20.99; IR (neat) 2953, 2903, 1683, 1595, 1579, 1447, 1366, 1228, 1000, 748, 689 cm-1; HRMS 
(DART) m/z Calcd for C16H21O (MH+): 229.15869; found: 229.15854. 
 
 
1,7-Diphenylhept-5-yn-1-one (2.21g)  
1,7-Diphenylhept-5-yn-1-one was prepared following the General Procedure A starting with 10 
mmol of 2-benzylcyclohexane-1,3-dione.20d The product was obtained as a yellow oil (2.4 g, 90% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 9.6 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.45 (t, J 
= 7.7 Hz, 2H), 7.36 – 7.27 (m, 4H), 7.22 (t, J = 7.2 Hz, 1H), 3.58 (s, 2H), 3.13 (t, J = 7.3 Hz, 2H), 
2.40 – 2.33 (m, 2H), 1.98 (p, J = 7.0 Hz, 2H); 13C NMR (151 MHz, CDCl3) δ 202.45, 140.14, 
139.68, 135.65, 131.25, 131.14, 130.73, 130.53, 129.14, 84.38, 81.43, 39.96, 27.85, 26.07, 21.08; 
IR (neat) 3057, 3019, 1679, 1595, 1156, 1000, 728, 688 cm-1; HRMS (DART) m/z Calcd for 








1,6-Diphenylhex-5-yn-1-one was prepared based on a known procedure with the following 
modifications.20j To a solution of iodobenzene (4.3 g, 21 mmol, 2.1 equiv.), 1-phenylhex-5-yn-1-
one20a (1.7 g, 10 mmol, 1.0 equiv.), triethylamine (20.2 g, 200 mmol, 20 equiv.) in THF (2 M) 
under N2 was added Pd(PPh3)4 (115 mg, 0.1 mmol, 1 mol%) and CuI (38 mg, 0.2 mmol, 2 mol%). 
The reaction mixture was allowed to stir at 22 °C for 12 h. The mixture was filtered through a plug 
of Celite and the filtrate was washed with Et2O, then concentrated under reduced pressure. The 
product was purified by column chromatography (hexanes:ethyl acetate = 20:1) to give the desired 
product as pale-yellow oil (2.4 g, 95% yield). 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.1 Hz, 
2H), 7.56 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 2H), 7.38 (dd, J = 6.5, 3.2 Hz, 2H), 7.31 – 7.26 
(m, 3H), 3.19 (t, J = 7.2 Hz, 2H), 2.56 (t, J = 6.8 Hz, 2H), 2.06 (p, J = 7.0 Hz, 2H); 13C NMR (151 
MHz, CDCl3) δ 202.37, 139.63, 135.68, 134.21, 131.25, 130.87, 130.71, 130.31, 126.43, 91.96, 
84.13, 39.92, 25.81, 21.61; IR (neat) 3055, 2934, 1681, 1595, 1488, 1446, 1228, 755, 689 cm-1; 
HRMS (DART) m/z Calcd for C18H17O (MH+): 249.12739; found: 249.12754. 
 
 





Methyl 9-oxo-9-phenylnon-4-ynoate was prepared following the General Procedure A starting 
with 10 mmol of methyl 3-(2,6-dioxocyclohexyl) propanoate.20f The product was obtained as a 
colorless oil (1.7 g, 65% yield). 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 9.6 Hz, 2H), 7.56 (t, J 
= 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 3.66 (s, 3H), 3.09 (t, J = 7.3 Hz, 2H), 2.52 – 2.44 (m, 4H), 
2.30 – 2.25 (m, 2H), 1.91 (p, J = 7.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 199.80, 172.51, 
136.99, 132.96, 128.55, 128.03, 80.17, 79.09, 51.65, 37.19, 33.79, 23.27, 18.22, 14.74; IR (neat) 
2948, 1735, 1682, 1446, 1365, 1229, 1165, 749, 650 cm-1; HRMS (DART) m/z Calcd for 




1-Phenylnon-8-en-5-yn-1-one was prepared following the General Procedure A starting with 10 
mmol of 2-allylcyclohexane-1,3-dione.20g The product was obtained as a colorless oil (1.8 g, 87% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.3 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.46 (t, J 
= 7.6 Hz, 2H), 5.87 – 5.77 (m, 1H), 5.30 (dd, J = 16.9, 1.8 Hz, 1H), 5.09 (dd, J = 9.9, 1.7 Hz, 1H), 
3.12 (t, J = 7.3 Hz, 2H), 2.97 – 2.91 (m, 2H), 2.38 – 2.30 (m, 2H), 1.96 (p, J = 7.0 Hz, 2H); 13C 
NMR (126 MHz, CDCl3) δ 200.12, 137.34, 133.57, 133.29, 128.89, 128.37, 116.00, 82.17, 77.94, 
37.63, 23.76, 23.45, 18.68; IR (neat) 2935, 2896, 1682, 1596, 1447, 1367, 1199, 990, 914, 750, 







1-(2-Methoxyphenyl)non-5-yn-1-one (2.21k)  
1-(2-Methoxyphenyl)non-5-yn-1-one was prepared following the General Procedure A starting 
with 10 mmol of 2-propylcyclohexane-1,3-dione.20d The product was obtained as a colorless oil 
(1.7 g, 72% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 (dd, J = 7.7, 1.8 Hz, 1H), 7.48 – 7.42 (m, 
1H), 7.03 – 6.94 (m, 2H), 3.90 (s, 3H), 3.09 (t, J = 7.3 Hz, 2H), 2.28 – 2.22 (m, 2H), 2.16 – 2.08 
(m, 2H), 1.91 – 1.84 (m, 2H), 1.49 (h, J = 7.2 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 202.37, 158.44, 133.19, 130.17, 128.58, 120.59, 111.50, 80.66, 79.67, 55.44, 
42.69, 23.81, 22.48, 20.76, 18.43, 13.45; IR (neat) 2958, 2931, 1671, 1595, 1483, 1462, 1435, 





1-(4-Bromophenyl)non-5-yn-1-one was prepared following the General Procedure A starting 
with 10 mmol of 2-propylcyclohexane-1,3-dione.20d The product was obtained as a colorless oil 
(2.2 g, 76% yield). 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 8.5 Hz, 
2H), 3.07 (t, J = 7.3 Hz, 2H), 2.32 – 2.26 (m, 2H), 2.15 – 2.09 (m, 2H), 1.92 (p, J = 7.0 Hz, 2H), 





131.84, 129.57, 128.07, 81.25, 79.18, 37.23, 23.41, 22.46, 20.73, 18.25, 13.48; IR (neat) 2957, 
2930, 1683, 1583, 1394, 1227, 1068, 1009, 991, 809 cm-1; HRMS (DART) m/z Calcd for 




2-(Hept-3-yn-1-yl)-2,3-dihydro-1H-inden-1-one was prepared following the General Procedure 
B starting with 20 mmol of 2,3-dihydro-1H-inden-1-one. The product was obtained as a dark 
brown oil (2.2 g, 50% yield). 1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 
7.4 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 3.43 – 3.33 (m, 1H), 2.91 – 2.81 
(m, 2H), 2.48 – 2.31 (m, 2H), 2.25 – 2.14 (m, 1H), 2.14 – 2.06 (m, 2H), 1.69 – 1.60 (m, 1H), 1.49 
(dt, J = 14.5, 7.2 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 211.14, 156.17, 
139.42, 137.31, 130.01, 129.16, 126.52, 83.94, 81.71, 49.24, 35.35, 33.36, 25.06, 23.39, 19.79, 
16.14; IR (neat) 2957, 2927, 1708, 1607, 1462, 1275, 747 cm-1; HRMS (DART) m/z Calcd for 








2-(Hept-3-yn-1-yl)-3,4-dihydronaphthalen-1(2H)-one was prepared following the General 
Procedure B starting with 20 mmol of 3,4-dihydronaphthalen-1(2H)-one. The product was 
obtained as a brown oil (3.0 g, 62% yield). 1H NMR (500 MHz, CDCl3) δ 8.03 (d, J = 8.9 Hz, 1H), 
7.50 – 7.42 (m, 1H), 7.30 (t, J = 7.8 Hz, 1H), 7.24 (d, J = 7.7 Hz, 1H), 3.07 – 2.99 (m, 2H), 2.73 – 
2.63 (m, 1H), 2.44 – 2.36 (m, 1H), 2.36 – 2.20 (m, 3H), 2.15 – 2.08 (m, 2H), 1.93 – 1.83 (m, 1H), 
1.68 – 1.57 (m, 1H), 1.49 (h, J = 7.3 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 202.65, 146.53, 135.76, 135.21, 131.30, 130.05, 129.20, 83.54, 82.07, 49.05, 31.64, 
31.30, 30.90, 25.12, 23.41, 19.20, 16.13; IR (neat) 2956, 2927, 2863, 2837, 1679, 1598, 1453, 





1-(Thiophen-2-yl)non-5-yn-1-one was prepared following the General Procedure A starting with 
10 mmol of 2-propylcyclohexane-1,3-dione.20d The product was obtained as a pale-yellow oil (1.8 
g, 82% yield). 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 6.0 Hz, 1H), 
7.15 – 7.12 (m, 1H), 3.04 (t, J = 7.3 Hz, 2H), 2.29 (tt, J = 6.8, 2.4 Hz, 2H), 2.13 (tt, J = 7.1, 2.4 
Hz, 2H), 1.93 (p, J = 7.0 Hz, 2H), 1.50 (h, J = 7.3 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR 
(151 MHz, CDCl3) δ 195.44, 147.04, 136.04, 134.41, 130.69, 83.83, 81.84, 40.63, 26.50, 25.09, 
23.36, 20.93, 16.11; IR (neat) 2957, 2930, 1657, 1516, 1412, 1336, 1234, 1067, 718 cm-1; HRMS 







1-(Furan-2-yl)non-5-yn-1-one was prepared following the General Procedure A starting with 10 
mmol of 2-propylcyclohexane-1,3-dione.20d The product was obtained as a pale-yellow oil (1.6 g, 
79% yield). 1H NMR (500 MHz, CDCl3) δ 7.58 (d, J = 0.9 Hz, 1H), 7.20 (d, J = 4.2 Hz, 1H), 6.53 
(dd, J = 3.5, 1.7 Hz, 1H), 2.95 (t, J = 7.4 Hz, 2H), 2.30 – 2.24 (m, 2H), 2.16 – 2.08 (m, 2H), 1.95 
– 1.87 (m, 2H), 1.50 (q, J = 7.2 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 
191.72, 155.41, 148.87, 119.53, 114.74, 83.79, 81.82, 39.86, 26.11, 25.08, 23.36, 20.97, 16.09; IR 
(neat) 2959, 2931, 1675, 1567, 1467, 1393, 1224, 1013, 812, 761 cm-1; HRMS (DART) m/z Calcd 




Undec-7-yn-3-one was prepared following the General Procedure A starting with 10 mmol of 2-
propylcyclohexane-1,3-dione.20d The product was obtained as a colorless oil (1.0 g, 60% yield). 
1H NMR (500 MHz, CDCl3) δ 2.53 (t, J = 6.7 Hz, 2H), 2.44 (qd, J = 7.3, 1.3 Hz, 2H), 2.19 (t, J = 
6.8 Hz, 2H), 2.12 (t, J = 7.6 Hz, 2H), 1.76 (p, J = 7.1 Hz, 2H), 1.50 (h, J = 7.3 Hz, 2H), 1.06 (t, J 





43.81, 38.86, 25.94, 25.33, 23.57, 21.04, 16.30, 10.66; IR (neat) 2958, 2932, 1711, 1456, 1373, 




Tridec-9-yn-5-one was prepared following the General Procedure A starting with 10 mmol of 2-
propylcyclohexane-1,3-dione.20d The product was obtained as a colorless oil (1.40g, 72% yield). 
1H NMR (500 MHz, CDCl3) δ 2.53 (t, J = 7.3 Hz, 2H), 2.41 (t, J = 7.5 Hz, 2H), 2.23 – 2.16 (m, 
2H), 2.16 – 2.10 (m, 2H), 1.75 (p, J = 7.1 Hz, 2H), 1.62 – 1.45 (m, 4H), 1.36 – 1.27 (m, 2H), 0.97 
(t, J = 7.3 Hz, 3H), 0.91 (t, J = 7.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 213.59, 83.58, 81.87, 
45.31, 43.96, 28.63, 25.65, 25.11, 24.98, 23.35, 20.80, 16.47, 16.09; IR (neat) 2956, 2930, 2869, 





2-(Hept-3-yn-1-yl)cyclopentan-1-one was prepared following the General Procedure B starting 
with 20 mmol of cyclopentanone. The product was obtained as a brown oil (2.8 g, 78% yield). 1H 
NMR (500 MHz, CDCl3) δ 2.37–2.17 (m, 5H), 2.17 – 2.07 (m, 3H), 2.07 – 1.91 (m, 2H), 1.79 (d, 





223.66, 83.51, 81.83, 50.87, 40.73, 32.06, 31.77, 25.08, 23.37, 23.35, 19.67, 16.10; IR (neat) 2958, 











2.6.2.2 Preparation Chiral ZnI2/BOX Complexes  
 
Chiral ZnI2/BOX complex (ZnI2/L10) was prepared according to a literature procedure.15,21 To a 
25 mL oven-dried sealed tube was added (4S,4'S)-2,2'-(1,3-diphenylpropane-2,2-diyl)bis(4-
phenyl-4,5-dihydrooxazole) (L10, 973 mg, 2.0 mmol), ZnI2 (766 mg, 2.4 mmol), and CH2Cl2 (10 
mL) under nitrogen atmosphere. The resulting mixture was allowed to stir at 22 °C for 2 h. Upon 
completion, the solution was transferred to a syringe fitted with a 0.22 µm PTFE filter and filtered 
under nitrogen into a Schlenk tube. The solvent was removed in vacuo to deliver ZnI2/L10 
complex as a pale yellow solid (1.5 g, 95% yield).  
1H NMR (500 MHz, CDCl3) δ 7.51 – 7.42 (m, 6H), 7.28 – 7.21 (m, 2H), 7.21 – 7.11 (m, 8H), 6.62 
(d, J = 7.5 Hz, 4H), 5.69 (t, J = 10.5 Hz, 2H), 4.96 (t, J = 9.8 Hz, 2H), 4.22 (t, J = 9.7 Hz, 2H), 
3.91 (d, J = 14.2 Hz, 2H), 3.44 (d, J = 14.2 Hz, 2H).13C NMR (126 MHz, CDCl3) δ 168.43, 135.45, 
133.74, 130.04, 129.21, 128.95, 128.88, 128.39, 128.24, 75.40, 68.43, 51.85, 44.63. 
  
                                                 






2.6.2.3 Experimental Procedure for Optimization Studies 
Experimental Procedure for Optimization of Racemic Conia-Ene-Type Reaction  
(see Tables 2.1 and Tables 2.2) 
To a 7.0 mL oven-dried vial was added Lewis acid Co-catalyst, 1-phenylhept-5-yn-1-one 2.21a 
(37.2 mg, 0.2 mmol), B(C6F5)3, PMP, and solvent (1.0 mL) under nitrogen atmosphere. The 
resulting mixture was allowed to stir at 22 °C or 80 °C for 12 h. Upon completion, the reaction 
mixture was diluted with CH2Cl2, and concentrated in vacuo. The product yield was determined 
by the 1H NMR analysis of the unpurified product mixture using mesitylene as the internal 
standard. 
Experimental Procedure for Optimization of BOX Ligands (See Table 2.3, Table 2.4 and 
Table 2.5) 
To a 7.0 mL oven-dried vial was added ZnI2 (0.02 mmol, 10 mol%), ligand (0.022 mmol, 11 mol%), 
CH2Cl2 (0.5 mL) under nitrogen atmosphere. The mixture was allowed to stir for 30 minutes at 
22 °C. Subsequently, 2.21a or 2.21c (0.20 mmol), B(C6F5)3 (0.02 mmol), PMP (0.04 mmol), and 
CH2Cl2 (0.5 mL) were added to the vial under nitrogen atmosphere, and the resulting mixture was 
allowed to stir at 22 °C for 12 h. Upon completion, the reaction mixture was diluted with CH2Cl2, 
concentrated in vacuo. The product yield was determined by the 1H NMR analysis of the unpurified 
product mixture using mesitylene as the internal standard. The product was purified by preparative 
TLC (hexanes:EtOAc = 10:1). The er values of product 2.22a or 2.22c was determined by HPLC 
analysis of the isolated and purified product. 
Experimental Procedure for Optimization of Reaction Parameters for Sequential Conia-





To a 7.0 mL oven-dried vial was added, 1-phenylhept-5-yn-1-one 2.21a (18.6 mg, 0.10 mmol), 
iodobenzene 2.27a (24.5 mg, 0.12 mmol), B(C6F5)3, PMP, ZnI2, Pd(PPh3)4 and CH2Cl2 (0.5 mL) 
under nitrogen atmosphere. The resulting mixture was allowed to stir at 22 °C for 12 h. Upon 
completion, the reaction mixture was diluted with CH2Cl2, and concentrated in vacuo. The product 
yield was determined by the 1H NMR analysis of the unpurified product mixture using mesitylene 











2.6.2.4 General Procedures for the Enantioselective Conia-Ene-Type Reaction (See Table 2.6 
and Table 2.7) 
General Procedure C  
 
To a 7.0 mL oven-dried vial was added substrate 2.21 (0.2 mmol), ZnI2/L10 (7.5 mol%), B(C6F5)3 
(7.5 mol%), PMP or N-methylpiperidine (15 mol%), and CH2Cl2 (1.0 mL) under nitrogen 
atmosphere. The resulting mixture was allowed to stir at 40 °C for 12 h. Upon completion, the 
reaction mixture was diluted with CH2Cl2, concentrated in vacuo and purified by silica gel column 
chromatography. 
General Procedure D  
 
To a 7.0 mL oven-dried vial was added substrate 2.21 (0.2 mmol), ZnI2/L10 (10 mol%), B(C6F5)3 
(10 mol%), PMP or N-methylpiperidine (20 mol%), and DCE (1.0 mL) under nitrogen atmosphere. 
The resulting mixture was allowed to stir at 60 °C for 24 h. Upon completion, the reaction mixture 






2.6.2.5 General Procedures for Sequential Conia-Ene-Type Cyclizations/Negishi Coupling 
Reaction (see Tables 2.9) 
General Procedure E 
  
To a 7.0 mL oven-dried vial was added substrate 2.21 (0.10 mmol), aryl iodide 2.27 (0.12 mmol), 
B(C6F5)3 (10 mol%), PMP (100 mol%), ZnI2 (50 mol%), Pd(PPh3)4 (1.0 mol%) and CH2Cl2 (0.5 
mL) under nitrogen atmosphere. The resulting mixture was allowed to stir at 22 °C for 12 h. Upon 
completion, the reaction mixture was diluted with CH2Cl2, concentrated in vacuo and purified by 







2.6.2.6 Procedure for Large Scale Reaction 
To a 25 mL oven-dried sealed tube was added substrate 1-phenylnon-5-yn-1-one 2.21c (1.5 
g, 7 mmol), ZnI2/L10 (141 mg, 0.175 mmol, 2.5 mol%), B(C6F5)3 (179 mg, 0.350 mmol, 5.0 
mol%), PMP (109 mg, 0.700 mmol, 10 mol%), and CH2Cl2 (10 mL) under nitrogen atmosphere. 
The resulting mixture was allowed to stir at 40 °C for 24 h. Upon completion, the solvent was 
removed in vacuo and purification by silica gel column chromatography gave the product as a pale 
yellow oil (1.4 g, 94% yield, 97:3 er). The er value was determined by HPLC analysis of the 






2.6.3 Analytical Data 
 
(S)-(2-Methylcyclopent-2-en-1-yl)(phenyl)methanone (2.22a) 
According to the General Procedure C, 1-phenylhept-5-yn-1-one 2.21a (37.2 mg, 0.2 mmol) was 
subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22a (35.7 
mg, 96%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.01 (d, J = 8.1 Hz, 2H), 7.56 (t, J = 
7.9 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 5.67 – 5.56 (m, 1H), 4.37 (t, J = 7.3 Hz, 1H), 2.53 – 2.43 (m, 
1H), 2.43 – 2.30 (m, 2H), 2.14 – 2.05 (m, 1H), 1.70 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 205.48, 
141.63, 140.32, 136.09, 131.93, 131.75, 131.70, 59.32, 34.93, 32.87, 18.98; IR (neat) 3057, 2928, 
1704, 1674, 1578, 1345, 1175, 1111, 1000, 775, 697 cm-1; HRMS (DART) m/z Calcd for C13H15O 
(MH+): 187.1117; found: 187.1114; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 
mL/min; tr = 11.5 min (major), 13.6 min (minor); 82:18 er); [α]25 D = −36.7° (c = 1.0, CH2Cl2). 



























According to the General Procedure D, 2-(pent-3-yn-1-yl)-3,4-dihydronaphthalen-1(2H)-one 
2.21b (42.5 mg, 0.2 mmol) was subjected to the Conia-ene-type reaction using N-methylpiperidine 
as the Brønsted base catalyst. The product was purified by silica gel column chromatography (1.0 
% EtOAc in hexanes) to give 2.22b (31.0 mg, 73%) as a pale yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 8.05 (d, J = 7.8 Hz, 1H), 7.45 (t, J = 7.4 Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.23 (d, J = 
7.6 Hz, 1H), 5.65 – 5.60 (m, 1H), 3.19 – 3.09 (m, 1H), 2.96 – 2.87 (m, 1H), 2.40 – 2.34 (m, 1H), 
2.34 – 2.29 (m, 1H), 2.11 – 1.99 (m, 2H), 1.91 – 1.80 (m, 1H), 1.65 (s, 3H); 13C NMR (151 MHz, 
CDCl3) δ 203.14, 146.36, 144.77, 135.78, 134.64, 131.19, 130.64, 130.56, 129.27, 63.82, 36.31, 
34.72, 32.34, 28.96, 16.11; IR (neat) 2848, 2765, 1674, 1597, 1375, 1216, 1021, 900, 830, 738, 
486 cm-1; HRMS (DART) Calcd for C15H15O (MH+): 213.12739; found: 213.12669; HPLC 
(Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 14.0 min (major), 18.7 min 
(minor); 91:9 er); [α]25 D = −21.1° (c = 1.0, CH2Cl2). The absolute configuration for this product 





























According to the General Procedure C, 1-phenylnon-5-yn-1-one 2.21c (42.9 mg, 0.2 mmol) was 
subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22c (42.0 
mg, 98%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.1 Hz, 2H), 7.56 (t, J = 
7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 5.71 – 5.58 (m, 1H), 4.42 (t, J = 7.6 Hz, 1H), 2.55 – 2.44 (m, 
1H), 2.44 – 2.37 (m, 1H), 2.37 – 2.26 (m, 1H), 2.12 – 2.00 (m, 2H), 2.00 – 1.89 (m, 1H), 1.52 – 
1.35 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 202.56, 143.21, 137.18, 
132.88, 128.57, 128.48, 127.29, 54.88, 32.12, 31.65, 29.68, 20.89, 13.98; IR (neat) 2956, 2929, 
2869, 1707, 1676, 1447, 1314, 1258, 1069, 710, 699 cm-1; HRMS (DART) m/z Calcd for C15H19O 
(MH+): 215.1430; found: 215.1427; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 
mL/min; tr = 9.8 min (major), 10.9 min (minor); 97:3 er). [α]25 D = −19.6° (c = 1.0, CH2Cl2). For 





























According to the General Procedure C, 1-phenyloct-5-yn-1-one 2.21d (40.0 mg, 0.2 mmol) was 
subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22d (38.0 
mg, 95%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.2 Hz, 2H), 7.56 (t, J = 
7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 5.64 (q, J = 1.8 Hz, 1H), 4.43 (t, J = 7.8 Hz, 1H), 2.57 – 2.45 
(m, 1H), 2.44 – 2.26 (m, 2H), 2.16 – 2.03 (m, 2H), 2.01 – 1.88 (m, 1H), 1.03 (t, J = 7.4 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 202.57, 144.90, 137.21, 132.88, 128.57, 128.49, 126.31, 55.04, 
31.62, 29.66, 23.10, 12.20; IR (neat) 2933, 2876, 2850, 1706, 1675, 1446, 1272, 1023, 1001, 700, 
647 cm-1; HRMS (DART) m/z Calcd for C14H17O (MH+): 201.1274; found: 201.1264; HPLC 
(Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 10.3 min (major), 12.4 min 
(minor); 96:4 er); [α]25 D = −23.1° (c = 1.0, CH2Cl2). The absolute configuration for this product 





























According to the General Procedure C, 1-phenyldec-5-yn-1-one 2.21e (45.7 mg, 0.2 mmol) was 
subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22e (45.2 
mg, 99%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.1 Hz, 2H), 7.56 (t, J = 
7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 5.64 (d, J = 1.6 Hz, 1H), 4.42 (t, J = 7.9 Hz, 1H), 2.54 – 2.44 
(m, 1H), 2.44 – 2.28 (m, 2H), 2.15 – 2.01 (m, 2H), 1.99 – 1.89 (m, 1H), 1.45 – 1.35 (m, 2H), 1.33 
– 1.18 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 202.57, 143.40, 137.20, 
132.87, 128.56, 128.49, 127.14, 54.94, 31.64, 29.88, 29.66, 22.52, 13.89; IR (neat) 2953, 2927, 
2857, 1707, 1676, 1342, 1109, 931, 859, 699, 669 cm-1; HRMS (DART) m/z Calcd for C16H21O 
(MH+): 229.1587; found: 229.1582; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 
mL/min; tr = 9.7 min (major), 10.3 min (minor); 97:3 er); [α]25 D = −31.4° (c = 1.0, CH2Cl2). The 


























According to the General Procedure D, 8-methyl-1-phenylnon-5-yn-1-one 2.21f (45.7 mg, 0.2 
mmol) was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The 
product was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22f 
(44.4 mg, 97%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 7.1 Hz, 2H), 7.56 (t, 
J = 7.4 Hz, 1H), 7.47 (t, J = 7.8 Hz, 2H), 5.86 – 5.45 (m, 1H), 4.40 (t, J = 7.5 Hz, 1H), 2.56 – 2.44 
(m, 1H), 2.44 – 2.27 (m, 2H), 2.10 – 1.99 (m, 1H), 1.96 – 1.89 (m, 2H), 1.74 – 1.62 (m, 1H), 0.97 
– 0.70 (m, 6H); 13C NMR (126 MHz, CDCl3) δ 202.55, 142.17, 137.20, 132.87, 128.67, 128.57, 
128.48, 54.68, 39.35, 31.61, 29.75, 26.42, 23.14, 22.06; IR (neat) 2949, 2924, 2864, 1676, 1461, 
1445, 1364, 1205, 958, 849, 779 cm-1; HRMS (DART) m/z Calcd for C16H21O (MH+): 229.1587; 
found: 229.1576; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 9.2 
min (major), 9.9 min (minor); 96:4 er); [α]25 D = −24.9° (c = 1.0, CH2Cl2). The absolute 

























According to the General Procedure D, 1,7-diphenylhept-5-yn-1-one 2.21g (52.5 mg, 0.2 mmol) 
was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22g (43.2 
mg, 80%) as a colorless oil.  1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 7.4 Hz, 2H), 7.54 (t, J = 
7.4 Hz, 1H), 7.42 (t, J = 7.7 Hz, 2H), 7.23 (dd, J = 13.4, 6.3 Hz, 2H), 7.16 (t, J = 7.3 Hz, 1H), 7.09 
(d, J = 7.2 Hz, 2H), 5.62 (s, 1H), 4.38 – 4.25 (m, 1H), 3.56 (d, J = 15.5 Hz, 1H), 3.23 (d, J = 15.4 
Hz, 1H), 2.56 – 2.44 (m, 1H), 2.44 – 2.27 (m, 2H), 2.10 – 2.01 (m, 1H); 13C NMR (126 MHz, 
CDCl3) δ 202.41, 142.36, 139.41, 137.03, 132.92, 129.75, 128.98, 128.53, 128.51, 128.29, 126.03, 
53.91, 36.64, 31.59, 29.79; IR (neat) 3058, 3024, 2931, 1674, 1594, 1447, 1211, 1072, 1025, 758, 
700 cm-1; HRMS (DART) m/z Calcd for C19H19O (MH+): 263.1430; found: 263.1431; HPLC 
(Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 12.1 min (minor) , 13.2 min 
(major); 98:2 er); [α]25 D = −14.1° (c = 1.0, CH2Cl2). The absolute configuration for this product 





























According to the General Procedure D, 1,6-diphenylhex-5-yn-1-one 2.21h (49.6 mg, 0.2 mmol) 
was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % Et2O in hexanes) to give 2.22h (24.8 
mg, 50%) as a colorless solid. 1H NMR (600 MHz, CDCl3) δ 8.06 (d, J = 7.6 Hz, 2H), 7.59 (t, J = 
7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.29 (d, J = 7.5 Hz, 2H), 7.22 (t, J = 7.7 Hz, 2H), 7.16 (t, J 
= 7.3 Hz, 1H), 6.49 – 6.44 (m, 1H), 4.95 (d, J = 11.7 Hz, 1H), 2.73 – 2.50 (m, 3H), 2.17 – 2.10 (m, 
1H); 13C NMR (126 MHz, CDCl3) δ 201.11, 141.64, 136.52, 135.57, 133.05, 130.12, 128.69, 
128.65, 128.37, 127.07, 125.78, 53.48, 32.39, 30.06; IR (neat) 3052, 3025, 2937, 2843, 1678, 1577, 
1445, 1207, 980, 752, 690 cm-1; HRMS (DART) m/z Calcd for C18H17O (MH+): 249.12739; found: 
249.12799; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 20.6 min 
(minor), 26.6 min (major); 91:9 er); [α]25 D = −34.6° (c = 1.0, CH2Cl2). The absolute configuration 






























Methyl (S)-3-(5-benzoylcyclopent-1-en-1-yl)propanoate (2.22i) 
According to the General Procedure C, methyl 9-oxo-9-phenylnon-4-ynoate 2.21i (51.7 mg, 0.2 
mmol) was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The 
product was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22i 
(50.1 mg, 97%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ 8.00 (d, J = 8.0 Hz, 2H), 7.57 (t, 
J = 7.4 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 5.66 (s, 1H), 4.45 (d, J = 7.1 Hz, 1H), 3.63 (s, 3H), 2.54 
– 2.44 (m, 3H), 2.44 – 2.35 (m, 3H), 2.34 – 2.27 (m, 1H), 2.13 – 1.96 (m, 1H); 13C NMR (151 
MHz, CDCl3) δ 204.66, 176.22, 144.01, 139.51, 135.69, 131.29, 131.18, 130.66, 57.68, 54.19, 
35.13, 34.31, 32.34, 27.85; IR (neat) 2920, 2849, 1734, 1676, 1445, 1342, 1208, 1162, 1000, 701, 
670 cm-1; HRMS (DART) m/z Calcd for C16H19O3 (MH+): 259.1329; found: 259.1335; HPLC 
(Chiralcel OD-H; 5%/ 95% isopropanol/ hexanes, 1.0 mL/min; tr = 10.3 min (minor), 24.6 min 
(major); 94:6 er); [α]25 D = +1.7° (c = 1.0, CH2Cl2). The absolute configuration for this product 




























(S)-(2-Allylcyclopent-2-en-1-yl)(phenyl)methanone (2.22j)  
According to the General Procedure C, 1-phenylnon-8-en-5-yn-1-one 2.21j (42.5 mg, 0.2 mmol) 
was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % Et2O in hexanes) to give 2.22j (40.0 mg, 
94%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 8.7 Hz, 2H), 7.56 (t, J = 7.4 
Hz, 1H), 7.47 (t, J = 7.7 Hz, 2H), 5.87 – 5.74 (m, 1H), 5.72 – 5.64 (m, 1H), 5.02 – 4.89 (m, 2H), 
4.44 (t, J = 7.5 Hz, 1H), 2.91 (dd, J = 16.3, 6.0 Hz, 1H), 2.70 (dd, J = 16.2, 7.5 Hz, 1H), 2.55 – 
2.45 (m, 1H), 2.44 – 2.30 (m, 2H), 2.11 – 2.00 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 202.29, 
141.28, 137.10, 135.78, 132.95, 128.80, 128.57, 128.52, 116.14, 54.42, 34.61, 31.68, 29.68; IR 
(neat) 3059, 2936, 1711, 1674, 1578, 1407, 1211, 1177, 1000, 861, 700 cm-1; HRMS (DART) m/z 
Calcd for C15H17O (MH+): 213.12739; found: 213.12726; HPLC (Chiralcel OD-H; 0.3%/ 99.7% 
isopropanol/ hexanes, 0.5 mL/min; tr = 30.4 min (major), 32.2 min (minor); 97:3 er); [α]25 D = 
−1.5° (c = 1.0, CH2Cl2). The absolute configuration for this product was assigned in analogy to 





























According to the General Procedure C, 1-(2-methoxyphenyl)non-5-yn-1-one 2.21k (48.9 mg, 0.2 
mmol) was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The 
product was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22k 
(46.4 mg, 95%) as a colorless oil. 1H NMR (600 MHz, CDCl3) δ 7.55 (d, J = 9.1 Hz, 1H), 7.44 (t, 
J = 7.0 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 5.62 – 5.55 (m, 1H), 4.48 – 4.36 
(m, 1H), 3.89 (s, 3H), 2.48 – 2.38 (m, 1H), 2.35 – 2.27 (m, 1H), 2.26 – 2.19 (m, 1H), 2.09 – 2.00 
(m, 2H), 1.97 – 1.89 (m, 1H), 1.48 – 1.35 (m, 2H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 206.35, 158.03, 143.88, 132.81, 129.91, 129.87, 127.03, 120.67, 111.44, 59.09, 55.48, 
32.16, 31.37, 29.38, 20.84, 14.02; IR (neat) 2954, 2928, 2867, 2847, 1671, 1595, 1483, 1462, 1435, 
1281, 1243, 1021, 999, 754 cm-1; HRMS (DART) m/z Calcd for C16H21O2 (MH+): 245.15361; 
found: 245.15409; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 14.6 
min (major), 16.4 min (minor); 93:7 er); [α]25 D = −45.0° (c = 1.0, CH2Cl2). The absolute 



























According to the General Procedure C, 1-(2-methoxyphenyl)non-5-yn-1-one 2.21l (58.6 mg, 0.2 
mmol) was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The 
product was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22l 
(56.8 mg, 97%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 8.6 Hz, 2H), 7.61 (d, 
J = 8.7 Hz, 2H), 5.67 – 5.59 (m, 1H), 4.41 – 4.25 (m, 1H), 2.53 – 2.45 (m, 1H), 2.43 – 2.26 (m, 
2H), 2.09 – 1.98 (m, 2H), 1.97 – 1.87 (m, 1H), 1.51 – 1.35 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) δ 201.52, 142.93, 135.83, 131.89, 130.03, 128.08, 127.52, 55.00, 32.10, 
31.64, 29.55, 20.87, 13.96; IR (neat) 2956, 2928, 2869, 1706, 1675, 1581, 1208, 1102, 1068, 839, 
756 cm-1; HRMS (DART) m/z Calcd for C15H18OBr (MH+): 293.05355; found: 293.05226; 
HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 8.7 min (major), 9.4 
min (minor); 97:3 er); [α]25 D = −27.2° (c = 1.0, CH2Cl2). The absolute configuration for this 




























According to the General Procedure C, 2-(hept-3-yn-1-yl)-2,3-dihydro-1H-inden-1-one 2.21m 
(45.3 mg, 0.2 mmol) was subjected to the Conia-ene-type reaction using N-methylpiperidine as 
the Brønsted base catalyst. The product was purified by silica gel column chromatography (1.0 % 
EtOAc in hexanes) to give 2.22m (44.4 mg, 98%) as a pale yellow oil. 1H NMR (600 MHz, CDCl3) 
δ 7.77 (d, J = 7.7 Hz, 1H), 7.60 (t, J = 7.4 Hz, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.38 (t, J = 7.4 Hz, 
1H), 5.70 – 5.63 (m, 1H), 3.24 (d, J = 17.4 Hz, 1H), 3.08 (d, J = 17.4 Hz, 1H), 2.58 – 2.50 (m, 1H), 
2.50 – 2.35 (m, 2H), 1.95 – 1.85 (m, 1H), 1.73 – 1.64 (m, 2H), 1.51 – 1.32 (m, 2H), 0.82 (t, J = 
7.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 213.24, 155.99, 148.63, 139.37, 137.47, 130.05, 
129.49, 129.00, 126.73, 67.30, 42.38, 40.60, 33.51, 32.29, 23.50, 16.72; IR (neat) 2953, 2926, 
2868, 2847, 1704, 1604, 1462, 1275, 909, 780, 729 cm-1; HRMS (DART) m/z Calcd for C16H19O 
(MH+): 227.1430; found: 227.1429; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 
mL/min; tr = 10.7 min (minor), 11.5 min (major); 99:1 er); [α]25 D = −131.7° (c = 1.0, CH2Cl2). 





























According to the General Procedure D, 2-(hept-3-yn-1-yl)-3,4-dihydronaphthalen-1(2H)-one 
2.21n (48.1 mg, 0.2 mmol) was subjected to the Conia-ene-type reaction using N-methylpiperidine 
as the Brønsted base catalyst. The product was purified by silica gel column chromatography (1.0 
% EtOAc in hexanes) to give 2.22n (9.6 mg, 20%) as a pale yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 8.06 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.4 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.23 (d, J = 
7.6 Hz, 1H), 5.65 (s, 1H), 3.24 – 3.08 (m, 1H), 2.98 – 2.86 (m, 1H), 2.45 – 2.36 (m, 1H), 2.35 (dd, 
J = 4.4, 2.4 Hz, 2H), 2.05 (t, J = 6.9 Hz, 2H), 1.96 – 1.81 (m, 3H), 1.61 – 1.45 (m, 2H), 0.92 (t, J 
= 7.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 203.22, 149.39, 146.32, 135.73, 134.68, 131.15, 
130.64, 129.28, 128.58, 64.11, 36.59, 35.00, 32.80, 32.37, 29.02, 23.72, 16.92; IR (neat) 2952, 
2924, 2867, 2848, 1674, 1597, 1431, 1215, 904, 831, 789 cm-1; HRMS (DART) m/z Calcd for 
C17H21O (MH+): 241.15869; found: 241.15884; HPLC (Chiralcel OD-H; 1%/ 99% isopropanol/ 
hexanes, 0.5 mL/min; tr = 10.0 min (major), 15.7 min (minor); 98:2 er); [α]25 D = −12.3° (c = 1.0, 
CH2Cl2). The absolute configuration for this product was assigned in analogy to that determined 































According to the General Procedure C, 1-(thiophen-2-yl)non-5-yn-1-one 2.21o (44.1 mg, 0.2 
mmol) was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The 
product was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22o 
(43.7 mg, 99%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.78 (dd, J = 3.8, 1.1 Hz, 1H), 
7.64 (dd, J = 4.9, 1.1 Hz, 1H), 7.14 (dd, J = 4.9, 3.8 Hz, 1H), 5.64 (d, J = 1.6 Hz, 1H), 4.24 (t, J = 
6.8 Hz, 1H), 2.58 – 2.47 (m, 1H), 2.45 – 2.36 (m, 1H), 2.36 – 2.27 (m, 1H), 2.18 – 2.09 (m, 1H), 
2.09 – 2.00 (m, 1H), 2.00 – 1.91 (m, 1H), 1.54 – 1.36 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ 195.69, 144.56, 143.01, 133.68, 131.99, 128.11, 127.68, 56.75, 32.04, 31.79, 
29.77, 20.87, 13.96; IR (neat) 2953, 2926, 2866, 1652, 1410, 1231,1207, 1060, 892, 860, 720 cm-
1; HRMS (DART) m/z Calcd for C13H17OS (MH+): 221.0995; found: 221.0998; HPLC (Chiralcel 
OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 12.8 min (major), 14.8 min (minor); 98:2 
er); [α]25D = −89.5° (c = 1.0, CH2Cl2). The absolute configuration for this product was assigned in 






























According to the General Procedure C, 1-(furan-2-yl)non-5-yn-1-one 2.21p (40.9 mg, 0.2 mmol) 
was subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % EtOAc in hexanes) to give 2.22p (40.5 
mg, 99%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.61 (dd, J = 1.7, 0.8 Hz, 1H), 7.23 
(dd, J = 3.5, 0.8 Hz, 1H), 6.55 (dd, J = 3.6, 1.7 Hz, 1H), 5.63 (d, J = 1.7 Hz, 1H), 4.26 – 4.18 (m, 
1H), 2.57 – 2.46 (m, 1H), 2.43 – 2.34 (m, 1H), 2.33 – 2.22 (m, 1H), 2.16 – 2.07 (m, 1H), 2.07 – 
1.98 (m, 1H), 1.98 – 1.88 (m, 1H), 1.53 – 1.35 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 191.79, 152.78, 146.52, 142.82, 127.68, 117.54, 112.16, 55.47, 31.98, 31.72, 29.18, 
20.83, 13.93; IR (neat) 2955, 2928, 1662, 1564, 1462, 1390, 1289, 1013, 811, 918, 593 cm-1; 
HRMS (DART) m/z Calcd for C13H17O2 (MH+): 205.1223; found: 205.1218; HPLC (Chiralcel 
OD-H; 1%/ 99% isopropanol/ hexanes, 0.5 mL/min; tr = 12.3 min (major), 15.7 min (minor); 97:3 
er); [α]25 D = −103.8° (c = 1.0, CH2Cl2). The absolute configuration for this product was assigned 




























According to the General Procedure C, undec-7-yn-3-one 2.21q (33.2 mg, 0.2 mmol) was 
subjected to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product 
was purified by silica gel column chromatography (1.0 % Et2O in pentane) to give 2.22q (30.2 mg, 
91%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 5.58 (s, 1H), 3.51 (t, J = 9.0 Hz, 1H), 2.45 
(q, J = 7.1 Hz, 3H), 2.41 – 2.30 (m, 1H), 2.20 – 2.10 (m, 1H), 2.04 – 1.87 (m, 3H), 1.54 – 1.36 (m, 
2H), 1.05 (t, J = 7.3 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 216.66, 
145.66, 130.17, 63.15, 36.08, 34.70, 34.43, 30.72, 23.45, 16.61, 10.52; IR (neat) 2955, 2924,2869, 
2850, 1704, 1457, 1376, 1181, 1111, 798 cm-1; HRMS (DART) m/z Calcd for C11H19O (MH+): 
167.14304; found: 167.14224; HPLC (Chiralcel OD-H; 0.3%/ 99.7% isopropanol/ hexanes, 0.5 
mL/min; tr = 13.9 min (major), 14.7 min (minor); 95:5 er); [α]25 D = −189.3° (c = 1.0, CH2Cl2). 































According to the General Procedure C, tridec-9-yn-5-one 2.21r (38.9 mg, 0.2 mmol) was subjected 
to the Conia-ene-type reaction using PMP as the Brønsted base catalyst. The product was purified 
by silica gel column chromatography (1.0 % Et2O in pentane) to give 2.22r (30.3 mg, 78%) as a 
colorless oil. 1H NMR (600 MHz, CDCl3) δ 5.61 – 5.55 (m, 1H), 3.49 (d, J = 5.8 Hz, 1H), 2.51 – 
2.40 (m, 3H), 2.40 – 2.32 (m, 1H), 2.19 – 2.09 (m, 1H), 2.04 – 1.87 (m, 3H), 1.58 – 1.52 (m, 2H), 
1.52 – 1.37 (m, 2H), 1.30 (h, J = 7.4 Hz, 2H), 0.95 – 0.84 (m, 6H); 13C NMR (151 MHz, CDCl3) 
δ 216.22, 145.64, 130.19, 63.33, 42.69, 34.69, 34.43, 30.61, 28.47, 25.06, 23.45, 16.61, 16.54; IR 
(neat) 2954, 2928, 2869, 1703, 1461, 1405, 1377, 1125, 1060 cm-1; HRMS (DART) m/z Calcd 
for C13H23O (MH+): 195.17434; found: 195.17326; HPLC (Chiralcel OD-H; 0.3%/ 99.7% 
isopropanol/ hexanes, 0.5 mL/min; tr = 14.4 min (major), 16.1 min (minor); 96:4 er); [α]25 D = 
−136.9° (c = 1.0, CH2Cl2). The absolute configuration for this product was assigned in analogy to 






























According to the General Procedure C, 2-(hept-3-yn-1-yl)cyclopentan-1-one 2.21s (35.7 mg, 0.2 
mmol) was subjected to the Conia-ene-type reaction using N-methylpiperidine as the Brønsted 
base catalyst. The product was purified by silica gel column chromatography (1.0 % Et2O in 
pentane) to give 2.22s (28.4 mg, 82%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 5.65 – 
5.59 (m, 1H), 2.45 – 2.26 (m, 3H), 2.23 – 2.10 (m, 1H), 2.10 – 2.00 (m, 3H), 1.91 – 1.78 (m, 4H), 
1.78 – 1.71 (m, 1H), 1.58 – 1.38 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
δ 222.72, 145.09, 126.90, 64.61, 38.05, 36.91, 34.51, 30.14, 20.93, 20.06, 14.15; IR (neat) 2953, 
2924, 2867, 1730, 1449, 1121, 1092, 959, 890, 817, 790 cm-1; HRMS (DART) m/z Calcd for 
C12H19O (MH+): 179.14304; found: 179.14233; HPLC (Chiralcel OJ-H; 0.5%/ 99.5% isopropanol/ 
hexanes, 0.5 mL/min; tr = 9.2 min (major), 9.7 min (minor); 80:20 er); [α]25 D = −42.5° (c = 1.0, 
CH2Cl2). The absolute configuration for this product was assigned in analogy to that determined 




























According to the General Procedure C, 2-(pent-4-yn-1-yl)-3,4-dihydronaphthalen-1(2H)-one20i 
2.23a (42.5 mg, 0.2 mmol) was subjected to the Conia-ene-type reaction using N-methylpiperidine 
as the Brønsted base catalyst. The product was purified by silica gel column chromatography (1.0 
% EtOAc in hexanes) to give 2.24a (41.6 mg, 98%) as a pale yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 8.04 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.3 Hz, 1H), 7.29 (t, J = 7.4 Hz, 1H), 7.22 (d, J = 
7.6 Hz, 1H), 5.01 (s, 1H), 4.65 (s, 1H), 3.12 – 3.01 (m, 1H), 3.01 – 2.91 (m, 1H), 2.67 – 2.54 (m, 
1H), 2.53 – 2.43 (m, 1H), 2.41 – 2.29 (m, 1H), 2.29 – 2.18 (m, 1H), 2.04 – 1.90 (m, 1H), 1.87 – 
1.76 (m, 1H), 1.76 – 1.65 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 203.13, 157.96, 146.40, 135.75, 
134.78, 131.32, 130.73, 129.27, 109.75, 59.45, 39.27, 36.77, 36.63, 28.87, 25.51; IR (neat) 2829, 
2874, 1677, 1598, 1452, 1430, 1317, 1218, 889, 740 cm-1; HRMS (DART) Calcd for C15H17O 
(MH+): 213.12739; found: 213.12739; HPLC (Chiralcel OJ-H; 1%/ 99% isopropanol/ hexanes, 
0.5 mL/min; tr = 15.6 min (major), 17.6 min (minor); 68:32 er); [α]25 D = +4.0° (c = 1.0, CH2Cl2). 


































According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.10 mmol) 
reacted with iodobenzene 2.27a (24.5 mg, 0.12 mmol) following the general procedure. After 
purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28a was obtained as a 
colorless liquid (24.9 mg, 95%). 1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 7.4 Hz, 2H), 7.57 (t, 
J = 7.3 Hz, 1H), 7.49 (t, J = 7.7 Hz, 2H), 7.40 – 7.32 (m, 4H), 7.28 – 7.21 (m, 1H), 4.63 – 4.56 (m, 
1H), 2.86 (t, J = 6.4 Hz, 2H), 2.45 – 2.33 (m, 1H), 2.16 – 2.03 (m, 1H), 1.80 (s, 3H); 13C NMR 
(126 MHz, CDCl3) 202.2, 139.1, 137.9, 137.2, 133.1, 133.0, 128.7, 128.6, 128.1, 127.9, 126.7, 
77.3, 77.0, 76.8, 58.9, 36.4, 27.7, 14.9; IR (neat) 1717, 1674, 1176, 1157, 850, 760, 695 cm-1; 




According to the General Procedure E, 1-phenyloct-5-yn-1-one 2.21d (20.0 mg, 0.10 mmol) 
reacted with iodobenzene 2.27a (24.5 mg, 0.12 mmol) following the general procedure. After 
purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28b was obtained as a 
colorless liquid (27.5 mg, 98%). 1H NMR (500 MHz, CDCl3) δ 8.00 – 7.92 (m, 2H), 7.49 (t, J = 
6.7 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 7.31 – 7.21 (m, 4H), 7.16 (t, J = 6.9 Hz, 1H), 4.67 – 4.58 (m, 
1H), 2.85 – 2.77 (m, 1H), 2.71 (dd, J = 16.7, 7.2 Hz, 1H), 2.43 – 2.23 (m, 3H), 2.09 – 1.90 (m, 





137.07, 132.94, 128.64, 128.45, 128.06, 127.82, 126.65, 55.45, 36.73, 28.12, 21.21, 12.87; IR 
(neat) 2961, 1677, 1595, 1208, 1177, 761, 698 cm-1; HRMS (DART) m/z Calcd for C20H21O 




According to the General Procedure E, 1-(naphthalen-2-yl)hept-5-yn-1-one 2.21u (23.6 mg, 0.10 
mmol) reacted with iodobenzene 2.27a (24.5 mg, 0.12 mmol)  following the general procedure. 
After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28c was obtained 
as a yellow solid (28.5 mg, 91%). 1H NMR (400 MHz, CDCl3) δ 8.49 (s, 1H), 8.02 (d, J = 8.6 Hz, 
1H), 7.90 (d, J = 8.0 Hz, 1H), 7.82 (dd, J = 13.2, 8.4 Hz, 2H), 7.50 (dt, J = 19.7, 7.0 Hz, 2H), 7.28 
(d, J = 4.4 Hz, 4H), 7.17 (dd, J = 7.8, 3.5 Hz, 1H), 4.68 (t, J = 7.6 Hz, 1H), 2.90 – 2.72 (m, 2H), 
2.47 – 2.28 (m, 1H), 2.10 (dq, J = 13.6, 6.9 Hz, 1H), 1.75 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 
202.2, 139.1, 137.8, 135.5, 134.5, 133.2, 132.6, 130.2, 129.6, 128.5, 128.4, 128.1, 127.9, 127.7, 
126.7, 126.6, 124.3, 58.9, 36.4, 27.8, 14.9; IR (neat) 1669, 1624, 1461, 1438, 1274, 697, 647 cm-




According to the General Procedure E, 1-(2-methoxyphenyl)dec-5-yn-1-one 2.21v (25.8 mg, 0.10 





After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28d was obtained 
as a white solid (25.1 mg, 75%). 1H NMR (600 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 1H), 7.44 (t, 
J = 8.5 Hz, 1H), 7.31 (dt, J = 14.0, 7.3 Hz, 4H), 7.22 (t, J = 7.0 Hz, 1H), 7.07 – 6.89 (m, 2H), 4.76 
– 4.61 (m, 1H), 3.90 (s, 3H), 2.87 – 2.75 (m, 1H), 2.75 – 2.62 (m, 1H), 2.42 – 2.16 (m, 2H), 2.09 
(dd, J = 13.3, 8.5 Hz, 2H), 1.44 – 1.05 (m, 4H), 0.76 (t, J = 7.2 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 205.96, 157.91, 139.21, 138.39, 138.38, 132.78, 129.88, 129.78, 127.96, 127.86, 126.42, 
120.67, 111.40, 59.94, 55.46, 36.55, 30.25, 27.87, 27.62, 22.69, 13.81; IR (neat) 2953, 1670, 1193, 





According to the General Procedure E, 1-(furan-2-yl)non-5-yn-1-one 2.21q (20.4 mg, 0.10 mmol) 
reacted with iodobenzene 2.27a (24.5 mg, 0.12 mmol) following the general procedure. After 
purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28e was obtained as a 
colorless liquid (18.3 mg, 65%). 1H NMR (600 MHz, CDCl3) δ 7.62 (s, 1H), 7.35 (t, J = 7.6 Hz, 
2H), 7.29 (d, J = 8.0 Hz, 2H), 7.28 – 7.21 (m, 2H), 6.56 (s, 1H), 4.48 (dd, J = 9.1, 6.5 Hz, 1H), 
2.95 – 2.85 (m, 1H), 2.85 – 2.76 (m, 1H), 2.37 – 2.26 (m, 2H), 2.17 – 2.08 (m, 1H), 2.02 (t, J = 
9.4 Hz, 1H), 1.53 – 1.37 (m, 1H), 1.34 – 1.21 (m, 1H), 0.79 (t, J = 7.3 Hz, 3H); 13C NMR (151 
MHz, CDCl3) δ 191.6, 152.7, 146.5, 140.1, 138.1, 137.2, 128.1, 127.8, 126.7, 117.5, 112.2, 56.5, 
37.0, 30.1, 27.7, 21.4, 14.1; IR (neat) 3118, 1970, 1718, 1491, 1463, 1084, 834, 802 cm-1; HRMS 







According to the General Procedure E, undec-9-yn-5-one 2.21x (16.6 mg, 0.10 mmol) reacted with 
iodobenzene 2.27a (24.5 mg, 0.12 mmol) following the general procedure. After purification by 
column chromatography (Hexane:Ethyl acetate = 40:1), 2.28f was obtained as a colorless liquid 
(22.1 mg, 91%). 1H NMR (500 MHz, CDCl3) 7.35 (t, J = 7.6 Hz, 2H), 7.30 (d, J = 7.0 Hz, 2H), 
7.25 (d, J = 7.1 Hz, 1H), 3.72 – 3.59 (m, 1H), 2.91 – 2.72 (m, 2H), 2.47 (td, J = 17.0, 16.4, 7.5 Hz, 
2H), 2.22 (dd, J = 13.3, 6.3 Hz, 1H), 1.99 (dd, J = 13.4, 8.5 Hz, 1H), 1.78 (s, 3H), 1.59 (p, J = 7.2 
Hz, 2H), 1.32 (h, J = 7.3 Hz, 2H), 0.92 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) 213.1, 
139.4, 137.7, 132.7, 128.1, 127.8, 126.8, 64.7, 40.2, 36.5, 26.0, 25.8, 22.4, 14.6, 13.9; IR (neat) 







According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.10 mmol) 
reacted with 1-iodonaphthalene 2.27b (30.5 mg, 0.12 mmol) following the general procedure. 
After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28g was obtained 
as a bright yellow solid (28.8 mg, 92%). 1H NMR (600 MHz, CDCl3) δ 8.1 (d, J = 8.2 Hz, 3H), 





= 6.8 Hz, 1H), 4.7 (dd, J = 10.3, 5.1 Hz, 1H), 2.9 (d, J = 9.0 Hz, 1H), 2.8 (s, 1H), 2.6 – 2.5 (m, 
1H), 2.3 (dd, J = 8.8, 4.7 Hz, 1H), 1.5 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 202.2, 139.1, 137.1, 
136.6, 134.9, 133.7, 133.0, 131.4, 128.7, 128.6, 128.2, 127.1, 126.1, 126.0, 125.7, 125.6, 125.4, 
57.7, 38.6, 28.4, 14.4; IR (neat) 2921, 1676, 1594, 1320, 1252, 801, 777 cm-1; HRMS (DART) 




According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.10 mmol) 
reacted with 1-iodo-4-methoxybenzene 2.27c (28.1 mg, 0.12 mmol) following the general 
procedure. After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28h 
was obtained as a yellow solid (27.8 mg, 95%). 1H NMR (600 MHz, CDCl3) δ 8.03 (d, J = 8.0 Hz, 
2H), 7.57 (t, J = 7.4 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 
2H), 4.62 – 4.52 (m, 1H), 3.81 (s, 3H), 2.83 (t, J = 7.3 Hz, 2H), 2.44 – 2.29 (m, 1H), 2.14 – 2.01 
(m, 1H), 1.79 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 202.3, 158.2, 138.4, 137.1, 132.9, 131.7, 
130.3, 129.0, 128.6, 128.5, 113.5, 58.9, 55.2, 36.4, 27.6, 14.9; IR (neat) 2929, 1675, 1508, 1243, 








According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.10 mmol) 
reacted with 1-chloro-4-iodobenzene 2.27d (28.6 mg, 0.12 mmol) following the general procedure. 
After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28i was obtained 
as a colorless liquid (27.6 mg, 93%). 1H NMR (500 MHz, CDCl3) δ 8.03 (d, J = 8.3 Hz, 2H), 7.59 
(t, J = 7.9 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.9 Hz, 2H), 4.59 
(d, J = 15.7 Hz, 1H), 2.82 (t, J = 7.2 Hz, 2H), 2.47 – 2.31 (m, 1H), 2.10 (dq, J = 13.1, 6.3 Hz, 1H), 
1.78 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 202.0, 138.0, 137.0, 136.2, 133.9, 133.1, 132.3, 129.2, 
128.7, 128.5, 128.2, 58.7, 36.3, 27.7, 14.9; IR (neat) 2933, 1675, 1445, 1341, 1208, 1091, 826 cm-




According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.10 mmol) 
reacted with 1-iodo-4-(trifluoromethyl)benzene 2.27e (32.7 mg, 0.12 mmol) following the general 
procedure. After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28j was 





2H), 7.60 (t, J = 7.9 Hz, 3H), 7.50 (t, J = 7.8 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 4.68 – 4.57 (m, 
1H), 2.95 – 2.76 (m, 2H), 2.48 – 2.36 (m, 1H), 2.17 – 2.05 (m, 1H), 1.81 (s, 3H); 13C NMR (101 
MHz, CDCl3 δ 201.77, 141.47, 141.46, 137.97, 136.94, 135.35, 133.15, 128.71, 128.55, 124.31 (q, 
J = 272.7 Hz), 125.06 (q, J = 3.8 Hz), 124.95, 58.71, 36.23, 27.74, 14.88; 19F NMR (564 MHz, 
CDCl3) δ −62.44; IR (neat) 1677, 1322, 1163, 1067, 886, 697 cm-1; HRMS (DART) m/z Calcd 




According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.1 mmol) 
reacted with 1-chloro-3-iodobenzene 2.27f (28.6 mg, 0.12 mmol) following the general procedure. 
After purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28k was obtained 
as a colorless liquid (27.3 mg, 92%). 1H NMR (500 MHz, CDCl3) δ 8.0 (d, J = 8.0 Hz, 2H), 7.6 
(t, J = 6.9 Hz, 1H), 7.5 (t, J = 7.7 Hz, 2H), 7.3 (s, 1H), 7.3 – 7.2 (m, 1H), 7.2 (d, J = 9.2 Hz, 2H), 
4.7 – 4.5 (m, 1H), 2.8 (dd, J = 4.2, 2.2 Hz, 2H), 2.4 – 2.3 (m, 1H), 2.2 – 2.0 (m, 1H), 1.8 (s, 3H); 
13C NMR (101 MHz, CDCl3) δ 201.8, 139.6, 137.8, 137.0, 134.5, 133.9, 133.1, 129.3, 128.7, 
128.5, 127.9, 126.7, 126.0, 58.7, 36.2, 27.7, 14.8; IR (neat) 1672, 1577, 1211, 1177, 786, 750, 711, 








According to the General Procedure E, 1-phenylnon-5-yn-1-one 2.21a (18.6 mg, 0.1 mmol) 
reacted with 2-iodothiophene 2.27g (25.2 mg, 0.12 mmol) following the general procedure. After 
purification by column chromatography (Hexane:Ethyl acetate = 40:1), 2.28l was obtained as a 
white solid (22.8 mg, 85%). 1H NMR (400 MHz, CDCl3) δ 8.1 – 8.0 (m, 2H), 7.6 (t, J = 7.4 Hz, 
1H), 7.5 (t, J = 7.6 Hz, 2H), 7.3 – 7.2 (m, 1H), 7.0 (d, J = 4.5 Hz, 2H), 4.7 – 4.5 (m, 1H), 3.1 – 2.8 
(m, 2H), 2.5 – 2.3 (m, 1H), 2.2 – 2.0 (m, 1H), 2.0 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 201.8, 
140.0, 136.9, 133.0, 132.8, 132.1, 128.6, 128.5, 126.7, 125.0, 124.4, 59.4, 36.2, 27.6, 15.6; IR 
(neat) 1674, 1594, 1374, 1338, 1177, 1158, 694 cm-1; HRMS (DART) m/z Calcd for C17H17O1S 














2.6.4 Determination of Absolute Configuration 
To determine the absolute configuration of 2.22c, it was first transformed to 2.30c according 
to a literature procedure.22 2.30c was then recrystallized and its X-ray crystallographic analysis 
was carried out as described below. 
 
(S)-Phenyl((S)-2-propylcyclopent-2-en-1-yl)methanol (2.29c–major) 
To a solution of (S)-phenyl(2-propylcyclopent-2-en-1-yl)methanone 2.22c (642 mg, 3.0 mmol 1.0 
equiv.) in CH2Cl2 (0.1 M) was added DIBAL-H (1.7 g, 12 mmol, 4.0 equiv.), dropwise at −78 °C. 
The reaction mixture was allowed to stir for 2 h at −78 °C. Then, 1N HCl (30 mL) was added to 
the solution. The reaction mixture was extracted with CH2Cl2 (3 x 30 mL). The combined organic 
layers were washed with brine (2 x 50 mL) and dried over Na2SO4. After filtration and removal of 
the solvent, 1H NMR analysis of the crude material revealed that 2.29c-major and 2.29c-minor 
were obtained in the ratio of 1.2:1.0. The crude material was purified by silica gel column 
chromatography (1.0 % Et2O in hexanes) to give compound 2.29c-major (314 mg, 48%) as a 
colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.28 (m, 4H), 7.26 – 7.21 (m, 1H), 5.45 (s, 
1H), 4.73 (t, J = 5.1 Hz, 1H), 3.07 – 3.01 (m, 1H), 2.19 – 1.95 (m, 3H), 1.94 – 1.79 (m, 3H), 1.72 
(ddd, J = 12.7, 8.6, 4.3 Hz, 1H), 1.52 – 1.33 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H).  
  
                                                 
22 (a) Wadamoto, M.; Phillips, E. M.; Reynolds, T. E.; Scheidt, K. A. J. Am. Chem. Soc. 2007, 129, 10098−10099. (b) 





(S)-Phenyl((S)-2-propylcyclopent-2-en-1-yl)methyl (4-bromophenyl)carbamate (2.30c) 
To a solution of 2.29c-major (151 mg, 0.70 mmol, 1.0 equiv.) in toluene (0.035 M) were added p-
bromophenyl isocyanate (416 mg, 2.1 mmol, 3.0 equiv.) and pyridine (277 mg, 3.5 mmol, 5.0 
equiv.). The resulting heterogeneous solution was allowed to stir at 100 °C for 1 h. The solution 
was then cooled and filtered through a short plug of Celite using CH2Cl2. The filtrate was 
concentrated and the residue was purified by silica gel column chromatography (10 % EtOAc in 
hexanes) to give compound 2.30c (261 mg, 90%) as a white solid. 2.30c was recrystallized using 
the vapor-vapor diffusion method, using EtOH to dissolve the product in an inner vial, and pentane 
as the precipitant placed in the outer vial in order for slow diffusion to occur into the inner vial. 
The solution was placed at 0 °C, whereupon a crystal was obtained for X-ray crystallographic 
analysis which revealed that the absolute configuration of 2.30c is (S,S); see 2.6.7 for X-ray 
crystallographic data.  
1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.6 Hz, 2H), 7.31 (d, J = 5.5 Hz, 4H), 7.30 – 7.24 (m, 
4H), 6.64 (s, 1H), 5.74 (d, J = 6.6 Hz, 1H), 5.43 (s, 1H), 3.19 – 3.10 (m, 1H), 2.23 – 2.07 (m, 2H), 
2.07 – 1.96 (m, 1H), 1.84 – 1.73 (m, 2H), 1.73 – 1.63 (m, 1H), 1.63 – 1.53 (m, 1H), 1.53 – 1.43 
(m, 1H), 0.91 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 152.55, 144.32, 138.95, 136.99, 
131.93, 127.99, 127.71, 127.48, 126.82, 120.21, 115.91, 79.11, 51.32, 32.57, 30.45, 26.88, 21.06, 
14.10; IR (neat) 3313, 2953, 2926, 1697, 1592, 1530, 1488, 1396, 1305, 1217, 1073, 1045, 822, 
698 cm-1; HRMS (DART) Calcd for C22H25NO2Br (MH+): 414.10632; found: 414.10436; HPLC 
(Chiralcel OD-H; 5%/ 95% isopropanol/ hexanes, 1.0 mL/min; tr = 13.8 min (major), 7.0 min 




























































































































































































































































































































































2.6.6 X-Ray Crystallography Data of 2.30c 
 
Table S1.  Crystal data and structure refinement for C22H24BrNO2. 
Identification code  C22H24BrNO2 
Empirical formula  C22 H24 Br N O2 
Formula weight  414.33 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 





 b = 21.213(3) Å β= 97.186(3)°. 
 c = 17.838(2) Å γ = 90°. 
Volume 1942.2(4) Å3 
Z 4 
Density (calculated) 1.417 Mg/m3 
Absorption coefficient 3.002 mm-1 
F(000) 856 
Crystal size 0.600 x 0.320 x 0.250 mm3 
Theta range for data collection 2.496 to 66.756°. 
Index ranges -6<=h<=6, -25<=k<=25, -20<=l<=21 
Reflections collected 30083 
Independent reflections 6781 [R(int) = 0.0411] 
Completeness to theta = 66.756° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.4524 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6781 / 3 / 478 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0220, wR2 = 0.0569 
R indices (all data) R1 = 0.0221, wR2 = 0.0570 
Absolute structure parameter 0.021(12) 
Extinction coefficient n/a 





Table S2.   Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for C22H24BrNO2.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
___________________________________________________________________________ 
Br(1) 5552(1) 4272(1) 373(1) 27(1) 
Br(2) 8026(1) 5755(1) 4587(1) 28(1) 
N(1) 8293(4) 4037(1) 3778(1) 18(1) 
N(2) 6281(4) 5943(1) 1162(1) 17(1) 
O(1) 4149(4) 4070(1) 4106(1) 22(1) 
O(2) 7713(4) 3972(1) 4984(1) 17(1) 
O(3) 1851(4) 5883(1) 877(1) 21(1) 
O(4) 4533(4) 6040(1) -23(1) 17(1) 
C(1) 6504(6) 4167(1) 1432(2) 19(1) 
C(2) 4892(6) 3817(1) 1835(2) 22(1) 
C(3) 5475(6) 3765(1) 2614(2) 21(1) 
C(4) 7673(5) 4067(1) 2983(2) 16(1) 
C(5) 9320(5) 4393(1) 2562(2) 19(1) 
C(6) 8750(6) 4445(1) 1784(2) 21(1) 
C(7) 6491(5) 4034(1) 4275(2) 17(1) 
C(8) 6067(5) 3935(1) 5595(2) 18(1) 
C(9) 6056(5) 4574(1) 5963(2) 18(1) 





C(11) 8145(6) 5384(2) 6781(2) 27(1) 
C(12) 6055(6) 5782(2) 6582(2) 26(1) 
C(13) 3961(6) 5578(2) 6083(2) 27(1) 
C(14) 3957(6) 4974(1) 5778(2) 23(1) 
C(15) 7162(5) 3395(1) 6112(2) 20(1) 
C(16) 6529(6) 2736(1) 5786(2) 24(1) 
C(17) 5701(7) 2367(2) 6299(2) 31(1) 
C(18) 5627(8) 2681(2) 7049(2) 38(1) 
C(19) 5897(6) 3381(2) 6853(2) 26(1) 
C(20) 6859(6) 2541(2) 4996(2) 26(1) 
C(21) 9695(6) 2526(2) 4827(2) 29(1) 
C(22) 9871(7) 2342(2) 4009(2) 36(1) 
C(23) 7432(5) 5826(1) 3517(2) 18(1) 
C(24) 5238(6) 5543(1) 3130(2) 20(1) 
C(25) 4809(5) 5585(1) 2349(2) 19(1) 
C(26) 6541(5) 5909(1) 1959(2) 16(1) 
C(27) 8711(5) 6201(1) 2359(2) 20(1) 
C(28) 9153(6) 6160(1) 3142(2) 22(1) 
C(29) 4005(5) 5944(1) 689(2) 17(1) 
C(30) 2302(5) 6083(1) -624(2) 18(1) 
C(31) 2150(5) 5466(1) -1050(2) 18(1) 
C(32) 341(6) 5017(2) -893(2) 23(1) 





C(34) 1896(6) 4309(2) -1788(2) 25(1) 
C(35) 3688(6) 4754(2) -1950(2) 26(1) 
C(36) 3833(6) 5330(1) -1578(2) 23(1) 
C(37) 2767(5) 6672(1) -1085(2) 20(1) 
C(38) 830(6) 6705(1) -1822(2) 26(1) 
C(39) 161(8) 7410(2) -1942(2) 36(1) 
C(40) 850(6) 7676(2) -1166(2) 28(1) 
C(41) 2246(5) 7290(1) -694(2) 22(1) 
C(42) 3279(6) 7452(1) 107(2) 23(1) 
C(43) 6244(6) 7513(2) 256(2) 25(1) 






 Table S3. Bond lengths [Å] and angles [°] for C22H24BrNO2. 
_____________________________________________________  
Br(1)-C(1)  1.904(3) 
Br(2)-C(23)  1.901(3) 
N(1)-C(7)  1.364(4) 
N(1)-C(4)  1.417(4) 
N(1)-H(1N)  0.89(2) 
N(2)-C(29)  1.360(4) 
N(2)-C(26)  1.414(4) 
N(2)-H(2N)  0.86(2) 
O(1)-C(7)  1.214(4) 
O(2)-C(7)  1.347(3) 
O(2)-C(8)  1.468(3) 
O(3)-C(29)  1.210(3) 
O(4)-C(29)  1.348(3) 
O(4)-C(30)  1.476(3) 
C(1)-C(6)  1.382(4) 
C(1)-C(2)  1.384(4) 
C(2)-C(3)  1.389(4) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.395(4) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.389(4) 





C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(8)-C(9)  1.506(4) 
C(8)-C(15)  1.534(4) 
C(8)-H(8)  1.0000 
C(9)-C(14)  1.385(4) 
C(9)-C(10)  1.397(4) 
C(10)-C(11)  1.388(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.384(5) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.383(5) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.392(4) 
C(13)-H(13)  0.9500 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.532(4) 
C(15)-C(19)  1.548(4) 
C(15)-H(15)  1.0000 
C(16)-C(17)  1.317(5) 
C(16)-C(20)  1.499(4) 
C(17)-C(18)  1.498(5) 





C(18)-C(19)  1.535(5) 
C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(20)-C(21)  1.535(4) 
C(20)-H(20A)  0.9900 
C(20)-H(20B)  0.9900 
C(21)-C(22)  1.524(5) 
C(21)-H(21A)  0.9900 
C(21)-H(21B)  0.9900 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 
C(23)-C(28)  1.375(4) 
C(23)-C(24)  1.389(4) 
C(24)-C(25)  1.387(4) 
C(24)-H(24)  0.9500 
C(25)-C(26)  1.383(4) 
C(25)-H(25)  0.9500 
C(26)-C(27)  1.397(4) 
C(27)-C(28)  1.388(4) 





C(28)-H(28)  0.9500 
C(30)-C(31)  1.511(4) 
C(30)-C(37)  1.532(4) 
C(30)-H(30)  1.0000 
C(31)-C(32)  1.387(4) 
C(31)-C(36)  1.391(4) 
C(32)-C(33)  1.391(5) 
C(32)-H(32)  0.9500 
C(33)-C(34)  1.384(5) 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.378(5) 
C(34)-H(34)  0.9500 
C(35)-C(36)  1.388(4) 
C(35)-H(35)  0.9500 
C(36)-H(36)  0.9500 
C(37)-C(41)  1.525(4) 
C(37)-C(38)  1.551(4) 
C(37)-H(37)  1.0000 
C(38)-C(39)  1.544(4) 
C(38)-H(38A)  0.9900 
C(38)-H(38B)  0.9900 
C(39)-C(40)  1.494(5) 





C(39)-H(39B)  0.9900 
C(40)-C(41)  1.322(4) 
C(40)-H(40)  0.9500 
C(41)-C(42)  1.502(4) 
C(42)-C(43)  1.529(4) 
C(42)-H(42A)  0.9900 
C(42)-H(42B)  0.9900 
C(43)-C(44)  1.521(4) 
C(43)-H(43A)  0.9900 
C(43)-H(43B)  0.9900 
C(44)-H(44A)  0.9800 
C(44)-H(44B)  0.9800 































































































































































































































 Table S4.    Anisotropic displacement parameters  (Å2x 103) for C22H24BrNO2.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_________________________________________________________________ 
Br(1) 37(1)  24(1) 18(1)  1(1) -3(1)  -1(1) 
Br(2) 39(1)  26(1) 16(1)  2(1) -2(1)  -2(1) 
N(1) 15(1)  20(1) 18(1)  -1(1) 1(1)  -1(1) 
N(2) 15(1)  21(1) 16(1)  1(1) 4(1)  -1(1) 
O(1) 16(1)  29(1) 21(1)  1(1) 1(1)  1(1) 
O(2) 16(1)  18(1) 16(1)  1(1) 2(1)  -1(1) 
O(3) 16(1)  31(1) 18(1)  2(1) 3(1)  0(1) 
O(4) 16(1)  20(1) 14(1)  1(1) 0(1)  -1(1) 
C(1) 25(1)  15(1) 17(1)  -2(1) 1(1)  5(1) 
C(2) 19(1)  23(2) 21(1)  -2(1) -2(1)  0(1) 
C(3) 20(1)  19(1) 23(2)  -2(1) 5(1)  -2(1) 
C(4) 17(1)  12(1) 18(1)  -1(1) 0(1)  4(1) 
C(5) 17(1)  18(2) 22(1)  -2(1) 2(1)  -1(1) 
C(6) 24(1)  17(1) 21(1)  1(1) 4(1)  -2(1) 
C(7) 19(1)  11(1) 19(1)  0(1) 1(1)  0(1) 
C(8) 18(1)  21(1) 17(1)  1(1) 4(1)  1(1) 
C(9) 20(1)  19(1) 16(1)  2(1) 4(1)  -2(1) 





C(11) 28(2)  26(2) 27(2)  -6(1) 2(1)  -6(1) 
C(12) 35(2)  19(1) 27(2)  -4(1) 10(1)  -3(1) 
C(13) 29(2)  22(2) 29(2)  0(1) 6(1)  6(1) 
C(14) 23(1)  22(2) 24(2)  -1(1) 2(1)  1(1) 
C(15) 22(1)  17(1) 20(1)  2(1) 2(1)  0(1) 
C(16) 23(1)  18(1) 30(2)  2(1) 1(1)  1(1) 
C(17) 33(2)  19(2) 39(2)  6(1) 3(1)  -2(1) 
C(18) 51(2)  31(2) 33(2)  11(2) 11(2)  -2(2) 
C(19) 32(2)  26(2) 21(2)  4(1) 6(1)  -1(1) 
C(20) 29(2)  16(1) 29(2)  -2(1) -2(1)  0(1) 
C(21) 29(2)  23(2) 34(2)  -1(1) 2(1)  6(1) 
C(22) 40(2)  30(2) 39(2)  -7(2) 9(2)  2(2) 
C(23) 24(1)  16(1) 15(1)  -2(1) -1(1)  6(1) 
C(24) 21(1)  16(1) 23(2)  3(1) 4(1)  0(1) 
C(25) 19(1)  16(1) 21(1)  0(1) -1(1)  -2(1) 
C(26) 17(1)  13(1) 18(1)  -1(1) 2(1)  3(1) 
C(27) 19(1)  19(1) 21(1)  -1(1) 2(1)  -2(1) 
C(28) 18(1)  22(2) 24(2)  -4(1) 0(1)  -1(1) 
C(29) 20(1)  13(1) 17(1)  0(1) 2(1)  1(1) 
C(30) 16(1)  22(2) 15(1)  2(1) 1(1)  1(1) 
C(31) 20(1)  17(1) 16(1)  2(1) -2(1)  3(1) 
C(32) 23(1)  25(2) 22(2)  3(1) 3(1)  2(1) 





C(34) 34(2)  17(1) 23(1)  -2(1) -5(1)  4(1) 
C(35) 28(2)  25(2) 25(2)  -3(1) 3(1)  6(1) 
C(36) 22(1)  23(2) 23(2)  -1(1) 3(1)  0(1) 
C(37) 22(1)  18(1) 20(1)  2(1) 2(1)  1(1) 
C(38) 32(2)  22(2) 22(2)  3(1) -2(1)  -1(1) 
C(39) 48(2)  24(2) 32(2)  9(1) -10(2)  -1(2) 
C(40) 27(2)  19(2) 35(2)  3(1) 0(1)  0(1) 
C(41) 19(1)  19(1) 27(2)  2(1) 5(1)  -3(1) 
C(42) 28(2)  16(1) 24(2)  -1(1) 6(1)  2(1) 
C(43) 29(2)  20(2) 26(2)  -1(1) 5(1)  -2(1) 






 Table S5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 
C22H24BrNO2. 
___________________________________________________________________________ 
 x  y  z  U(eq) 
___________________________________________________________________________ 
H(1N) 9980(50) 4058(16) 3953(18) 21 
H(2N) 7700(50) 5998(17) 970(19) 21 
H(2) 3396 3613 1581 26 
H(3) 4380 3526 2895 25 
H(5) 10855 4584 2811 23 
H(6) 9885 4667 1498 25 
H(8) 4249 3827 5374 22 
H(10) 9600 4512 6608 27 
H(11) 9574 5521 7129 33 
H(12) 6059 6195 6787 32 
H(13) 2521 5851 5948 32 
H(14) 2503 4835 5440 27 
H(15) 9092 3443 6232 24 
H(17) 5197 1941 6204 37 
H(18A) 7088 2539 7422 45 
H(18B) 3960 2598 7249 45 
H(19A) 7014 3602 7263 32 





H(20A) 5866 2837 4639 31 
H(20B) 6092 2117 4902 31 
H(21A) 10491 2946 4928 35 
H(21B) 10691 2219 5168 35 
H(22A) 9085 1925 3908 54 
H(22B) 11703 2329 3922 54 
H(22C) 8936 2653 3671 54 
H(24) 4045 5323 3398 24 
H(25) 3318 5391 2080 23 
H(27) 9892 6428 2094 24 
H(28) 10625 6360 3414 26 
H(30) 667 6141 -386 21 
H(32) -821 5107 -534 28 
H(33) -1003 4129 -1147 32 
H(34) 1807 3914 -2040 30 
H(35) 4826 4666 -2315 31 
H(36) 5087 5634 -1686 27 
H(37) 4594 6670 -1214 24 
H(38A) 1641 6536 -2254 31 
H(38B) -761 6458 -1769 31 
H(39A) 1215 7605 -2306 43 
H(39B) -1711 7470 -2122 43 





H(42A) 2716 7122 444 27 
H(42B) 2490 7855 241 27 
H(43A) 7056 7114 119 30 
H(43B) 6826 7852 -67 30 
H(44A) 6292 8053 1221 50 
H(44B) 9031 7721 1155 50 





























































































































Table S7.   Hydrogen bonds for C22H24BrNO2 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________ 
 N(1)-H(1N)...O(1)#1 0.89(2) 2.14(2) 3.013(3) 167(3) 
 N(2)-H(2N)...O(3)#1 0.86(2) 2.19(3) 2.990(3) 156(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  






Enantioselective Synthesis of N-Alkylamines through β-Amino C−H Functionalization 
Promoted by Cooperative Actions of B(C6F5)3 and a Chiral Lewis Acid Co-Catalyst 
Introduction 
 Synthesis of enantioenriched N-alkylamines through enantioselective transformations of α, 
β, γ, and/or δ-amino C−H bonds has emerged as an enabling approach to produce N-containing 
natural products and bioactive compounds (Scheme 3.1).1-2 However, despite significant advances 
made in the development of C−H functionalization reactions,  methods that allow for regio- and 
stereoselective late-stage C−H functionalization of bioactive amines that contain an array of Lewis 
acid and/or Lewis base-sensitive functional groups are rare. 3-4 This is mainly due to the paucity of 
catalyst systems that can cleave the otherwise unreactive amino C−H bonds while overcoming the 
undesirable acid–base complexation. To overcome this fundamental issue, previously reported 
amino C−H functionalization methods have typically been confined to structurally simple  
                                                 
1 (a) Vardanyan, R. in Piperidine-Based Drug Discovery; Vardanyan, R., Ed.; Elsevier: 2017, p 147. (b) McGrath, N. 
A.; Brichacek, M.; Njardarson, J. T. J. Chem. Educ. 2010, 87, 1348−1349. (c) Campos, K. R.; Coleman, P. J.; Alvarez, 
J. C.; Dreher, S. D.; Garbaccio, R. M.; Terrett, N. K.; Tillyer, R. D.; Truppo, M. D.; Parmee, E. R. Science 2019, 363, 
eaat0805. 
2 For reviews on enantioselective amine synthesis, see: (a) Chiral Amine Synthesis: Methods, Developments and 
Applications; Nugent, T. C., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2010. (b) Weiner, B.; 
Szymański, W.; Janssen, D. B.; Minnaard, A. J.; Feringa, B. L. Chem. Soc. Rev. 2010, 39, 1656−1691. 
3 For selected reviews on transformations of C(sp3)−H bonds, see: (a) Dick, A. R.; Sanford, M. S. Tetrahedron 2006, 
62, 2439−2463. (b) Davies, H. M.; Manning, J. R. Nature 2008, 451, 417−424. (c) Baudoin, O. Chem. Soc. Rev. 2011 
40, 4902−4911. (d) Haibach, M. C.; Seidel, D. Angew. Chem., Int. Ed. 2014, 53, 5010−5036. (e) Girard, S. A.; Knauber, 
T.; Li, C.-J. Angew. Chem., Int. Ed. 2014, 53, 74−100. (f) Daugulis, O.; Roane, J.; Tran, L. D. Acc. Chem. Res. 2015, 
48, 1053−1064. (g) He, J.; Wasa, M.; Chan, K. S. L.; Shao, Q; Yu, J.-Q. Chem. Rev. 2017, 117, 8754−8786. (h) Chu, 
J. C. K.; Rovis, T. Angew. Chem., Int. Ed. 2018, 57, 62−101. (i) Davies, H. M.; Liao, K. Nat. Rev. Chem. 2019, 3, 
347−360. 
4 For selected reviews on transformations of amino C(sp3)−H bonds, see: (a) Campos, K. R. Chem. Soc. Rev. 2007, 
36, 1069−1084. (b) Mitchell, E. A.; Peschiulli, A.; Lefevre, N.; Meerpoel, L.; Maes, B. U. W. Chem. Eur. J. 2012, 18, 
10092−10142. (c) He, C.; Whitehurst, W. G.; Gaunt, M. J. Chem 2019, 5, 1031−1058. (d) Trowbridge, A.; Walton, S. 





Scheme 3.1. Regioselective Amino C−H Functionalization of Bioactive Compounds 
 
N-alkylamine substrates that have minimal steric and electronic affinities with the catalysts (see 
Schemes 3.2 and 3.3). 
Homolytic or heterolytic cleavage of α-amino C−H bonds generate α-amino radical 
intermediates5  or iminium ions6  that are stabilized by hyperconjugation with the neighboring 
nitrogen atom and serve as versatile intermediates for achieving α-amino C−H functionalization. 
                                                 
5 For advances in α-amino C−H functionalization via α-amino radical intermediates, see: (a) Noble, A.; MacMillan, 
D. W. J. Am. Chem. Soc. 2014, 136, 11602−11605. (b) Osberger, T. J.; Rogness, D. C.; Kohrt, J. T.; Stepan, A. F.; 
White, M. C. Nature 2016, 537, 214−219.  (c) Le, C.; Liang, Y.; Evans, R. W.; Li, X.; MacMillan, D. W. C. Nature 
2017, 547, 79−83. (d) McManus, J. B.; Onuska, N. P. R.; Nicewicz, D. A. J. Am. Chem. Soc. 2018, 140, 9056−9060. 
(e) Ye, J.; Kalvet, I.; Schoenebeck, F.; Rovis, T. Nat. Chem. 2018, 10, 1037−1041. 
6 For advances in enantioselective α-amino C−H functionalization via iminium ion, see: (a) Li, Z.; Li, C.-J. Org. Lett. 
2004, 6, 4997−4999. (b) Murarka, S.; Deb, I.; Zhang, C.; Seidel, D. J. Am. Chem. Soc. 2009, 131, 13226−13227. (c) 
Mori, K.; Ehara, K.; Kurihara, K.; Akiyama, T. J. Am. Chem. Soc. 2011, 133, 6166−6169. (d) DiRocco, D. A.; Rovis, 
T. J. Am. Chem. Soc. 2012, 134, 8094−8097. (e) Shang, M.; Chan, J. Z.; Cao, M.; Chang, Y.; Wang, Q.; Cook, B.; 
Torker, S.; Wasa, M. J. Am. Chem. Soc. 2018, 140, 10593−10601. (f) Chan, J. Z.; Yesilcimen, A.; Cao, M.; Zhang, 





Transformations of α-amino C−H bonds can also be achieved through metal–carbenoid insertion,7 
and heteroatom-directed metalation (Scheme 3.2).8-9 Conversion of γ-amino C−H bonds into C−C  
and C−heteroatom bonds has been performed by N-directed LnPd-catalyzed cyclometalation 
(Scheme 3.3). 10  Despite these notable advances in α- and γ-amino C−H functionalizations, 
catalytic strategies to functionalize β-amino C−H bonds remain underdeveloped, particularly in an 
enantioselective manner. This is mainly due to the fact that radical or cationic intermediates 
generated by β-amino C−H activation are not readily accessible (vs. α-amino radical and iminium 
ions generated by α-amino C−H activation). Moreover, N-directed LnPd-catalyzed β-amino C−H 
activation must proceed through the formation of strained four-membered palladacycle. 
Consequently, development of a broadly applicable catalyst system for regio- and enantio-
selective transformations of β-amino C−H bonds that are applicable to late-stage functionalization 
of structurally complex bioactive amines represents a compelling research objective. 
  
                                                 
7 (a) Davies, H. M.; Venkataramani, C.; Hansen, T.; Hopper, D. W. J. Am. Chem. Soc. 2003, 125, 6462−6468. (b) Liu, 
W.; Babl, T.; Röther, A.; Reiser, O.; Davies, H. M. Chem. Eur. J. 2020, 26, 4236−4241. 
8 (a) Campos, K. R.; Klapars, A.; Waldman, J. H.; Dormer, P. G.; Chen, C. Y. J. Am. Chem. Soc. 2006, 128, 3538−3539. 
(b) Cordier, C. J.; Lundgren, R. J.; Fu, G. C. J. Am. Chem. Soc. 2013, 135, 10946−10949. 
9 Jain, P.; Verma, P.; Xia, G.; Yu, J. Q. Nat. Chem. 2017, 9, 140−144. 
10 (a) Chan, K. S.; Fu, H. Y.; Yu, J. Q. J. Am. Chem. Soc. 2015, 137, 2042−2046. (b) Rodrigalvarez, J.; Nappi, M.; 
Azuma, H.; Floden, N. J.; Burns, M. E.; Gaunt, M. J. Nat. Chem. 2020, 12, 76−81. (c) Zhuang, Z.; Yu, J. Q. J. Am. 





Scheme 3.2. Key Intermediates of Enantioselective α-Amino C−H Bond Functionalization 
 







Despite the challenges associated with β-amino C−H functionalization, there are several 
reported methods for the synthesis of enantiomerically enriched β-substituted amines through 
activation of a β-amino C−H bond. 11  Gaunt and coworkers reported a Pd-catalyzed 
enantioselective C−H amination to afford aziridines using chiral phosphoric acid as an anionic 
ligand (Scheme 3.4).11b In the presence of 10 mol% Pd(OAc)2, 20 mol% (R)-TRIP, and 
stoichiometric oxidant, the desired aziridine product 3.2 can be generated in 70% yield with 97:3 
er through desymmetrization of gem-dimethyl groups in tetramethyl-morpholinone 3.1. The 
authors proposed that (R)-TRIP/Pd(OAc)2 complex could coordinate to the secondary amine of 
3.1, thereby allowing stereoselective C−H activation to take place to afford a four-membered 
cyclopalladation complex (VI). Although they have demonstrated they are able to achieve 
selective β-amino C−H activation, this method requires the sterically hindered amine substrates 
such as tetramethyl-morpholinone or piperazinone scaffold to overcome the undesired acid/base 
complexation. Furthermore, functional groups that readily react with AgOAc, I2, and/or IOAc are 
problematic. Therefore, this method cannot be easily applied to the late stage functionalization of  
Scheme 3.4. Palladium-Catalzyed Enantioselective C−H Activation of Aliphatic Amines 
 
                                                 
11 (a) He, J.; Li, S.; Deng, Y.; Fu, H.; Laforteza, B. N.; Spangler, J. E.; Homs, A.; Yu, J.-Q. Science 2014, 343, 
1216−1220. (b) Smalley, A. P.; Cuthbertson, J. D.; Gaunt, M, J. J. Am. Chem. Soc. 2017, 139, 1412−1415. (c) Su, B.; 
Lee, T.; Hartwig, J. F. J. Am. Chem. Soc. 2018, 140, 18032−18038. (d) Lin, W.; Zhang, K.-F.; Baudoin, O. Nat. Catal. 





N-containing drug molecules. 
In 2018, Hartwig and coworkers developed a method for β-selective C(sp3)−H silylation 
of aliphatic amine 3.3 to form silapyrrolidine 3.4 promoted by an Ir-based catalyst (Scheme 3.5).11c 
The reaction of (silylmethyl)amine 3.3 with 2.0 mol% Ir-based complex can generate 
silapyrrolidine 3.4 in 80% yield with 91.5:8.5 er. They proposed that the norbornene served as 
hydrogen acceptor for this transformation. However, this method requires the use of precious Ir-
based catalyst and long reaction time. What’s more, the use of silapyrrolidine substrate with Ir-
based catalyst would be problematic with a wide variety of functional groups that may undergo 
reduction. 
Scheme 3.5. Iridium-Catalzyed β-Selective C(sp3)−H Silylation of Aliphatic Amines 
 
In 2019, Baudoin and coworkers disclosed a regiodivergent enantioselective C−H 
functionalization of Boc-1,3-oxazinane 3.6 (Scheme 3.6).11d This one-pot reaction proceeds 
through sparteine-mediated enantioselective lithiation of Boc-1,3-oxazinane 3.5 to deliver an 
enantioenriched organozinc intermediate 3.6. Without the isolation or purification of the 
organozinc species, Negishi coupling with phenyl bromide can give β-phenyl-substituted amine 
3.7 in 72% yield in 96.5:3.5 er. However, the use of stoichiometric amounts of s-BuLi and (+)-
sparteine could be problematic with various functional groups. Moreover, this enantioselective 





Scheme 3.6. Regiodivergent Enantioselective C−H Functionalization of Boc-1,3-oxazinanes  
 
As the aforementioned literatures have shown, all three enantioselective methods demand 
the use of precious Ir- or Pd-based catalysts. In addition, strong oxidant (AgOAc, I2, and/or IOAc) 
or base (s-BuLi) are also required which would be problematic with substrates that contain 
function groups that react with these reactive compounds. Consequently, these methods cannot be 
applied to the late stage functionalization of N-containing drug molecules that typically contain an 
array of acid, base and/or oxidant-sensitive functional groups (Scheme 3.7a). Considering the 
limitations of the state-of-the-art, we became intrigued in developing a sustainable element-based, 
highly functional group tolerant and enantioselective catalyst system that is applicable to the late 
stage β-amino C−H functionalization of N-containing drug molecules under redox-neutral 
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3.2. Our Approach 
Nonstereoselective β-amino C−H functionalization can be achieved through in situ 
generation of enamine from N-alkylamines.12-13 In 2002, Santini and coworkers reported that 
B(C6F5)3 could abstract hydride from the amine to give a borohydride/iminium complex (3.8 → 
3.9) (Scheme 3.8).12a  When diethyl aniline 3.10 were treated with B(C6F5)3, ion pairs 3.11 and  
Scheme 3.8. Reaction of B(C6F5)3 and N-alkylamines 
 
                                                 
12 For transformations that proceed through (F5C6)3B-catalyzed hydride abstraction from N-alkylamines, see: (a) 
Millot, N.; Santini, C. C.; Fenet, B.; Basset, J. M. Eur. J. Inorg. Chem. 2002, 2002, 3328−3335. (b) Schwendemann, 
S.; Fröhlich, R.; Kehr, G.; Erker, G. Chem. Sci. 2011, 2, 1842−1849. (c) Maier, A. F. G.; Tussing, S.; Schneider, T.; 
Flörke, U.; Qu, Z.-W.; Grimme, S.; Paradies, J. Angew. Chem., Int. Ed. 2016, 55, 12219−12223. (d) Kojima, M.; 
Kanai, M. Angew. Chem., Int. Ed. 2016, 55, 12224−12227. (e) Maier, A. F. G.; Tussing, S.; Zhu, H.; Wicker, G.; 
Tzvetkova, P.; Flörke, U.; Daniliuc, C. G.; Grimme, S.; Paradies, J. Chem. Eur. J. 2018, 24, 16287–16291. (f) Zhang, 
J.; Park, S.; Chang, S. J. Am. Chem. Soc. 2018, 140, 13209−13213. (g) Chan, J. Z.; Chang, Y.; Wasa, M. Org. Lett. 
2019, 21, 984−988. (h) Chang, Y.; Yesilcimen, A.; Cao, M.; Zhang, Y.; Zhang, B.; Chan, J. Z.; Wasa, M. J. Am. Chem. 
Soc. 2019, 141, 14570−14575. (h) Zhang, J.; Chang, S. J. Am. Chem. Soc. 2020, 142, 12585−12590.  
13 For β-amino C−H functionalization promoted by organometallic complexes through the formation of enamine 
intermediates, see: (a) Xia, X.-F.; Shu, X.-Z.; Ji, K.-G.; Yang, Y.-F.; Shaukat, A.; Liu, X.-Y.; Liang, Y.-M. J. Org. 
Chem. 2010, 75, 2893−2902. (b) Sundararaju, B.; Tang, Z.; Achard, M.; Sharma, G. V. M.; Toupet, L.; Bruneau, C. 
Adv. Synth. Catal. 2010, 352, 3141−3146. (c) Sundararaju, B.; Achard, M.; Sharma, G. V. M.; Bruneau, C. J. Am. 
Chem. Soc. 2011, 133, 10340−10343. (d) Yuan, K.; Jiang, F.; Sahli, Z.; Achard, M.; Roisnel, T.; Bruneau, C. Angew. 





3.12 were observed by 1H and 11B NMR spectroscopy. They hypothesized that N-alkylamine 3.10 
would undergo hydride abstraction to afford the intermediate VIII, which would then be 
deprotonated to yield an enamine intermediate IX consisting of a nucleophilic enamine and ion 
pair 3.12. The nucleophilic enamine could attack the Lewis acid B(C6F5)3 to give the complex 
3.11. This literature precedence has shown that sterically hindered B(C6F5)3 could abstract hydride 
from N-alkylamines to generate electrophilic iminium ion. Further, when the N-alkylamines 
contain β-amino C−H, the iminium ion could undergo further deprotonation to give nucleophilic 
enamine intermediates.  
Inspired by this pioneering work, our group have achieved enantioselective α-amino C−H 
functionalization through cooperative functions of B(C6F5)3 and a chiral Lewis acid co-catalysts.14 
In 2018, we developed a method for enantioselective union of N-alkylamines 3.13 and α,β-
unsaturated compounds 3.14 to produce β-amino carbonyl compounds 3.15 promoted by B(C6F5)3 
and a Mg-based catalyst (Scheme 3.9).14a For the catalytic enantioselective transformation, we 
have demonstrated sterically hindered B(C6F5)3 could overcome mutual quenching with Lewis 
basic N-alkylamines and abstract hydride from a wide variety of N-alkylamines in a catalytic 
manner to generate iminium ion intermediate (X). The iminium ion intermediate can then react 
with in situ generated chiral Mg-enolate which is formed through boronhydride reduction to 
deliver the desired α-amino functionalized product 3.15 in 88% yield with up to 98:2 er. 
Since we have shown that B(C6F5)3 could abstract hydride in a catalytic manner, we then 
went to investigate whether B(C6F5)3 and N-alkylamines could generate enamine intermediate in a 
                                                 
14 (a) Shang, M.; Chan, J. Z.; Cao, M.; Chang, Y.; Wang, Q.; Cook, B.; Torker, S.; Wasa, M. J. Am. Chem. Soc. 
2018, 140, 10593−10601. (b) Chan, J. Z.; Yesilcimen, A.; Cao, M.; Zhang, Y.; Zhang, B. C.; Wasa, M. J. Am. 





Scheme 3.9. Direct Enantioselective α-C−H Functionalization of Amines through Cooperative 
Action of B(C6F5)3 and Chiral Mg-based Catalyst. 
 
catalytic manner. In 2019, we disclosed a method for B(C6F5)3-catalyzed hydrogen isotope 
exchange involving β-amino C–H bonds of various bioactive molecules (Scheme 3.10).12h 
Treatment of the O-TBS raloxifene 3.16 with only 10 mol% B(C6F5)3 and acetone-d6 3.17 (6.8 
equiv.), the desired product 3.18 can be obtained in >95% yield; 97% of cyclic β-amino C−H 
bonds were converted to C–D bonds while 27% of acyclic β-amino C−H bonds were converted to 
C–D bonds. We proposed that through the sequential hydride abstraction and deprotonation the 
enamine intermediate can be generated (3.16 → XI → XII). At the same time, N-alkylamine could 
dedeuterate B(C6F5)3-activated acetone-d6 3.17, generating a boron enolate and a deuterated 
ammonium ion (3.17 → XIII). Ensuing deuteration (XIV) of the enamine XII by XIII gives an 
iminium ion; subsequent borohydride reduction would afford β-deuterated product 3.18. Here, we 
have developed a powerful catalyst system for selectively β-amino C–H deuteration of various 





Scheme 3.10. Catalytic Deuterium Incorporation within Metabolically Stable β-Amino C−H 
Bonds of Drug Molecules 
 
The principles outlined herein, entailing conversion of amine containing drugs into 
nucleophilic enamine and its reaction with in situ generated electrophilic partner, provide a new 
rational framework for enantioselective β-amino C−H functionalization of bioactive amine 
molecules. In contemplating ways to develop a protocol for catalytic enantioselective β-amino 





consisting of B(C6F5)3, a Brønsted base catalyst, and a chiral Lewis acid co-catalyst (M–L*) 
(Scheme 3.11).12,15-16 We proposed that  B(C6F5)3 could abstract hydride from N-alkylamine 3.19 
to give a borohydride/iminium complex (XV). Then a Brønsted base catalyst would deprotonate 
XV to furnish enamine XVI. An stereoselective C–C bond formation between enamine XVI and 
the chiral Lewis acid co-catalyst  activated α,β-unsaturated compound (XVII), would deliver 
zwitterionic XVIII. Ensuing protonation and reduction of XVII would produce β-alkylation 
product 3.21. 
The key advantage provided by the untethered and independently operational catalyst 
system is that both the efficiency and stereoselectivity can be easily optimized by evaluation of 
readily accessible Lewis acids, Brønsted base and chiral ligands. However, the fundamental 
challenge of cooperative catalyst system is that Lewis acidic and basic units among catalysts, 
substrates and products need to overcome mutual quenching. In addition, B(C6F5)3 may have 
overlapping functions with the chiral Lewis acid co-catalyst (M–L*) for the activation of α,β-
unsaturated compound, which would lead to racemic background reaction. Therefore, we need to 
develop potent cooperative catalyst system that can overcome these challenges and promote the 
catalytic enantioselective β-amino C−H functionalization of N-alkylamine. 
  
                                                 
15 (a) Phipps, R. J.; Hamilton, G. L.; Toste, F. D. Nat. Chem. 2012, 4, 603−614. (b) Brak, K.; Jacobsen, E. N. Angew. 
Chem., Int. Ed. 2013, 52, 534−561. 
16 For reviews on frustrated Lewis pair chemistry, see: (a) Frustrated Lewis Pairs I: Uncovering and Understanding; 
Stephan, D. W.; Erker, G. Eds.; Springer: Berlin, 2013; Vol. 332. (b) Frustrated Lewis Pairs II: Expanding the Scope; 
Erker, G.; Stephan, D. W. Eds.; Springer: Berlin, 2013; Vol. 334. (c) Ashley, A. E.; O'Hare, D. Top. Curr. Chem. 
2013, 334, 191−218. (d) Feng, X.; Du, H. Tetrahedron Lett. 2014, 55, 6959−6964. (e) Stephan, D. W.; Erker, G. 
Angew. Chem., Int. Ed. 2015, 54, 6400−6441. (f) Stephan, D. W. J. Am. Chem. Soc. 2015, 137, 10018−10032. (g) 





Scheme 3.11. Direct Enantioselective β-C−H Functionalization of Amines through Cooperative 







3.3. Results and Discussion 
To begin the investigation, we set out to study whether B(C6F5)3 can activate both N,N-
dibenzylethanamine (3.19a) and diisopropyl fumarate (3.20a), generating 3.21a (Table 3.1). When 
we treated 3.19a and 3.20a with 10 mol% B(C6F5)3 and various Brønsted base catalysts, the desired 
product 3.21a can be obtained in up to 50% yield (entries 1–3). Other than the desired product 
3.21a, over alkylation product 3.22a can be generated (entries 1–6), which probably was formed 
through the conjugated addition of a boron enolate (XVIII) to the 3.20a followed by the 
intramolecular cyclization. Control experiments showed that in the absence of Brønsted base  
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5d B(C6F5)3 none 5543
a Conditions: N,N-dibenzylethanamine (3.19a, 0.20 mmol), diisopropyl fumarate (3.20a, 0.30 mmol), Lewis acid,
Brønsted base, C6H6 (0.20 mL), under N2, 50 °C.
b Yield was determined by the 1H NMR analysis of unpurified
reaction mixtures with m-xylene as the internal standard. c The structure and relative configuration of 3.22a were





catalyst, the desired product 3.21a can be obtained in 73% yield with over alkylation product 3.22a 
in 25% yield. This implies that N-alkylamine substrate 3.19a, product 3.21a or 3.22a can serve as 
the Brønsted base to deprotonate an iminium to deliver an enamine (XV→ XVI, Scheme 3.11). 
With more diluted reaction condition, the over alkylation product 3.22a can be suppressed (entries 
4–5).  Further optimization leads us to obtain the desired product 3.21a in 91% yield with 10 mol% 
B(C6F5)3 in benzene for 12 hours (entry 6). Furthermore, without B(C6F5)3 or with less hindered 
BCl3 or less acidic BPh3 as Lewis acid catalyst, the desired product cannot be obtained (entries 7–
9). These results indicate that the potent sterically hindered Lewis acid B(C6F5)3 with the sterically 
demanding and electron rich N-alkylamines represent the most effective combination for the β-
amino C−H functionalization. 
A variety of N-benzyl-substituted acyclic and cyclic amines may be used in the reaction 
with diisopropyl fumarate (3.20a) to generate the corresponding β-substituted amines (3a–3f, 
Table 3.2). Reaction with N,N-dibenzylethanamine 3.19a and 3.20a afforded 3.21a in 88% yield. 
However, when N,N-dibenzylpropan-1-amine was used, product 3.21b and 3.21c can be generated 
in 58% and 33% yield, respectively. Compound 3.21c is likely the result of intramolecular 
Mannich-type reaction between an iminium ion and enolate (XVIII, Scheme 3.11). With the more 
sizeable N,N-dibenzyl-2-methylpropan-1-amine, 3.21d was obtained as the only product (69% 
yield), which is probably due to acceleration of the intramolecular cyclization by the Thorpe-
Ingold effect. When cyclic amine, N-benzyl-4-(((tert-butyldimethylsilyl)oxy)methyl)piperidine 
3.19d was used, saturated product 3.21e and enamine product 3.21f can be generated in 74% and 
26% yield, respectively. A series of aniline derived amines also reacted efficiently with 3.20a to 
afford 3.21g–3.21j (87–97% yield). When acyclic amine substrates were used, the desired product 































































































3.21h, 87% yield 3.21i, 89% yieldc,e
1.3:1 dr
3.21j, 93% yieldf













a Conditions: N-alkylamine (3.19, 0.20 mmol), diisopropyl fumarate (3.20a, 0.30 0.40 mmol), B(C6F5)3 (10 mol %),
C6H6, under N2, 50 °C.
b Yield of isolated and purified product. The dr values were determined by the 1H NMR
analysis of the unpurified reaction mixtures. c The structure and relative configuration of 3.21b and 3.21e were
established by X-ray crystallographic analysis. The stereochemistry of 3.21f, 3.21i, 3.21l, and 3.21m were
assigned in analogy. d The structure and relative configuration of 3.21d were established by NOESY studies. The
stereochemistry of 3.21c was assigned in analogy. e 5.0 mol% of B(C6F5)3 was used.
f DCM was used as solvent.







cyclic amine 3.19g furnished 3.21i as the only product in 89% yield. However, with the more 
sterically hindered 4,4-dimethyl-substituted piperidine substrate 3.19h, enamine 3.21j was 
obtained in 93% yield. In addition, N-benzhydryl-substituted secondary amines 1.19i, 1.19j and 
1.19k were suitable substrates. The corresponding β-substituted amine products can be generated 
in up to 93% yield. 
Next, we investigated reactions with different commercially available chiral N-alkylamines 
and drug molecules (Table 3.3). As a result, the employed chiral acyclic N-alkylamines gave 
product 3.21n and 3.21o in 69% yield (1.5:1 dr) and 90% yield (1.4:1 dr), respectively. In addition, 
these diastereomers are chromatographically separable, allowing us to obtain enantiomerically 
pure amino ester. Chiral pyrrolidines substrates can also be compatible. The protocol is also 
applicable to late-stage modification of N-containing drug molecules17 that possess an array of 
Lewis acid-sensitive functional groups (3.19p-3.19r). In addition to the Lewis basic N-alkylamine 
moieties, a ketone, a benzothiophene, an ether, a pyrimidinone and a benzoisoxazole were tolerated. 
The reaction with N-benzyl paroxetine 3.19p and 3.20a afforded 3.21r and 3.21s in 39% and 14% 
yield, respectively. Silyl-protected raloxifene 3.19q reacted efficiently with 3.20a to afford 3.21t 
in 80% yield and 2.5:1 dr. Risperidone 3.19r, possessing more sterically hindered β-amino C−H 
bonds (vs. 3.19q), was reacted with 3.20a, furnishing enamine product 3.21u (32% yield); minimal 
amounts (<5%) of the product derived from alkylation of acyclic β-amino C−H bond could be 
observed (1H NMR analysis). For N-containing drug molecules such as paroxetine and raloxifene, 
although this method demands the installment of protecting groups in order to obtain high 
reactivity, the remove of those protecting groups can be easily achieved.    
                                                 





Table 3.3. Derivatization of Chiral Amines and Drugs 
a Conditions: N-alkylamine (3.19, 0.20 mmol), dialkyl fumarate (3.20, 0.30 0.40 mmol), B(C6F5)3 (10 mol %),
C6H6, under N2, 50 °C.
b Yield of isolated and purified product. The dr values were determined by the 1H NMR
analysis of the unpurified reaction mixtures. . c The structure and relative configuration of 3.21t and 3.21u were
assigned in analogy. The stereochemistry of 3.21r and 3.21s was assigned in analogy and also by the NOESY
studies. d The absolute configuration of 3.21o was determined based on the specific rotation of the derivative. e
The structure and absolute configuration of 3.21q was established by the X-ray crystallographic analysis. The































































































Although enantiomerically pure β-substituted amine product can be obtained, we can only 
obtain the desired product in up to 2.5:1 dr. We proposed through the use of enantiomerically pure 
electrophile, diastereoselectivity can be further improved.  For the initial investigation, we choseto 
utilize the prolinol derivative 3.19o and α,β-unsaturated oxazolidinone 3.23 as model substrate 
(Table 3.4). Indeed, with B(C6F5)3 as the only catalyst, reaction with 3.19o and (S,E)-4-phenyl-3 -
(4,4,4-trifluorobut-2-enoyl)oxazolidin-2-one 3.23a can deliver the desired product 3.24a in 26% 
yield (7.0:1 dr, entry1). To further improve the reaction yield and diastereoselectivity, various 
representative Lewis acid co-catalysts were then evaluated, the latter of which may activate 3.23a  






(entries 2–5); with 10 mol% ZnI2 co-catalyst, the desired product 3.24a can be obtained in 64% 
yield (8.0:1 dr). Furthermore, the addition of 70 mol% HBPin to the reaction was found to enhance 
the diastereoselectivity (18:1 dr, entry 6). When the opposite enantiomer (S,E)-4-phenyl-3-(4,4,4-
trifluorobut-2-enoyl)oxazolidin-2-one 3.23b was used, the desired product 3.24b can be generated 
in 85% yield and as a single diastereomer (>20:1 dr, entries 7–8). Further optimization of the 
oxazolidinone structure does not lead to higher diastereoselectivity (entries 9–11). With 10 mol% 
B(C6F5)3 and ZnI2, 3.24b-(R,R,R,S) can be isolated in 82% yield and as a single diastereomer 





Scheme 3.12. Direct Diastereoselective β-C−H Functionalization of Chiral Amines through 
Cooperative Actions of B(C6F5)3 and ZnI2 Co-catalyst. 
 
Having established this high diastereoselective process, we also explored the suitability of 
developing an enantioselective β-amino C−H alkylation reaction between achiral substrates 3.19s 
and 3.23c, promoted by a combination of B(C6F5)3 and an enantiomerically pure organometallic 
co-catalyst (Table 3.5). We discovered that the combination of Mg(ClO4)2 and PhPybox (L1) or 
BnPybox (L2), afforded 3.24c in 70% and 72% yield, and 82:18 and 85:15 er, respectively. With 
more sterically hindered L3 and L4, the enantioselectivity cannot be further enhanced. However, 
when using the L5 which contains longer alkyl chain, the enantioselectivity can be further 
improved to 90:10 er. With even longer alkyl chain L6, the enantioselectivity decreased to 80:20 
er. What’s more, with this substrate combination, neither efficiency nor the enantioselectivity 
could be improved by further catalyst optimization. 






C6H6, 22 °C, 12 h

















































































a Conditions: 1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine (3.19s, 0.10 mmol), (E)-3-(4,4,4-trifluorobut-2-
enoyl)oxazolidin-2-one (3.23c, 0.15 mmol), B(C6F5)3 (10 mol%), Mg(ClO4)2 (10 mol%), ligand (11 mol%), C6H6
(0.6 mL), under N2, 22 °C, 12 h.
b Yield and dr were determined by 1H NMR analysis of unpurified reaction
mixtures with mesitylene as the internal standard. The er values were determined by HPLC analysis of the purified
product.  
To improve enantioselectivity, we investigated the transformations involving a number of  





































































































CH2Cl2, 60 °C, 1 h































a Conditions: 1-(4-methoxyphenyl)pyrrolidine (3.19t, 0.20 mmol), ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-
oxopyrazolidin-1-yl)-4-oxobut-2-enoate (3.25a, 0.30 mmol), B(C6F5)3 (10 mol%), Sc(OTf)3 (5.0 mol%), ligand (6.0
mol%), CH2Cl2 (1.0 mL), under N2, 60 °C, 1 h.
b Yield and dr were determined by 1H NMR analysis of unpurified
reaction mixtures with mesitylene as the internal standard. The er values were determined by HPLC analysis of





chiral Lewis acid co-catalysts and α,β-unsaturated compounds bearing different auxiliaries.18 We 
found that 1-(4-methoxyphenyl)pyrrolidine 3.19t reacts efficiently with 2-acryloylpyrazolidinone 
derivative 3.25a in the presence of 10 mol % of B(C6F5)3 together with Sc(OTf)3 and various chiral 
bisoxazoline ligands (Table 3.6). We then found that reactions with Ph-substituted bisoxazoline 
ligand (e.g., L1, L7, L8) are hardly enantioselective (58:42–50:50 er). When the alkyl-substituted 
PyBOX ligands were employed (e.g., L2–L3, L9–L10), the enantioselectivity was enhanced and 
in the presence of (S)-i-Bu–PyBOX (L10), 3.26a was formed in 72% yield, 2.7:1 dr and up to 98:2 
er. Reaction efficiency can be further improved (85% yield) when L11 and its diastereomer L12 
were used. 
The stereochemical course of 3.19t-derived enamine addition to [L12–Sc(OTf)3]-activated 
3.25a can be rationalized by the models presented in Figure 3.1.19 Models XIX and XX represent  
Figure 3.1. Stereochemical Rationale for Enamine Addition to α,β-Unsaturated Compounds 













































XIX, favored XX, disfavored  
                                                 
18 (a) Evans, D. A.; Chapman, K. T.; Bisaha, J. J. Am. Chem. Soc. 1988, 110, 1238−1256. (b) Sibi, M. P.; Ji, J. J. Org. 
Chem. 1997, 62, 3800−3801. (c) Adachi, S.; Takeda, N.; Sibi, M. P. Org. Lett. 2014, 16, 6440−6443. (d) Espelt, L. 
R.; McPherson, I. S.; Wiensch, E. M.; Yoon, T. P. J. Am. Chem. Soc. 2015, 137, 2452−2455. 
19 (a) Evans, D. A.; Masse, C. E.; Wu, J. Org. Lett. 2002, 4, 3375−3378. (b) Evans, D. A.; Fandrick, K. R.; Song, H-
J.; Scheidt, K. A.; Xu, R. J. Am. Chem. Soc. 2007, 129, 10029−10041. (c) Sibi, M. P.; Itoh, K.; Jasperse, C. P. J. Am. 





the energetically minimized structures of [L12–Sc(OTf)3] docked with 3.25a, respectively. As 
shown in model XIX, the high level of enantioselectivity observed in the formation of 3.26a-(R,S) 
can be explained by selective 1,4-addition of the enamine to the re-face of [L12–Sc(OTf)3]-bound 
3.25a; as depicted in model XX, the si-face is effectively shielded by a sec-butyl group of the 
PyBOX ligand. 
Enantioselective reactions between an array of N-alkylamines and α,β-unsaturated 
compounds were carried out in the presence of B(C6F5)3 and a L−Sc(OTf)3 complex (Table 3.7). 
Various α,β-unsaturated compounds (3.25a–3.25d) bearing ester, ketone, or CF3 groups can react 
with 1-(4-methoxyphenyl)pyrrolidine (3.19t) to afford the β-functionalized product in 62–83% 
yield, 2.0:1–6.7:1 dr and 95:5–98:2 er. The reaction of 3.19t with 3.25a (R5 = Et) and 3.25b (R5 = 
Bn) gave 3.26a (2.0:1 dr, up to 98:2 er) and 3.26b (3.0:1, up to 95:5 er), respectively. These results 
indicate that N-substituents of the pyrazolidinone unit could have influence over both diastereo- 
and enantioselectivity. The reaction between acyclic N-ethyl-4-methoxy-N,2,6-trimethylaniline 
3.19e and 3.25d would deliver the N-arylpiperidine derivative 3.26e in 67% yield (>20:1 dr, 95:5 
er) (Scheme 3.13a). We proposed that the generation of 3.26e probably entails β-amino C–H 
alkylation of 3.19e by 3.25d to afford a zwitterionic intermediate containing an iminium and an 
enolate (XXI), followed by isomerization of the iminium to give XXI; then intramolecular 
cyclization between the iminium and the enolate gives 3.26e. Furthermore, various N-aryl 
substituted cyclic amines (3.19g-3.19h, 3.19u) were found to be compatible with this 
enantioselective β-alkylation to generate enamines 3.26f–3.26h in 74–95% yield and 94:6–96:4 er. 
The reaction of N-arylpiperidine-3,3,5,5-d4 3.19g-d (0.10 mmol) and 3.25d (0.20 mmol) delivered 





Table 3.7. Evaluation of Chiral Ligands for Enantioselective β-Alkylation of Amines 
 
3.26f-d and 3.27d-d revealed that there is deuterium incorporation at their enolizable α-carbonyl 
units, and that there is D/H exchange at C5 of 3.26f-d (>95% in 3.19g-d → 81% in 3.26f-d).12h 





3.27d-d to regenerate B(C6F5)3 (vs by releasing H–D). We were able to employ this method for 
the β-C−H functionalization of bioactive trialkylamines, including cloperastine (cough 
suppressant) 3.19v and raloxifene (estrogen modulator) 3.19q, to generate enamines 3.26i and 
3.26j in 53% yield (90:10 er) and 57% yield (95:5 er), respectively. 
Scheme 3.13. Additional Data Interpretation 
 
The catalytic method is scalable. Treatment of 4.0 mmol of N-arylpiperidine 3.19g and 
3.25d with 10 mol % B(C6F5)3, and 10 mol % L12–Sc(OTf)3, (CH2Cl2, 12 h, 60 °C) generated 
3.26f in 95% yield (1.9 g; Scheme 3.14a). Treatment of 3.26d-(R,S) with LiSEt followed by 
reduction of the resulting thioester with LiAlH4 afforded alcohol 3.28d-(R,S) in 95% overall yield 
(Scheme 3.14b). Compound 3.28d-(R,S) was subsequently converted to its derived carbamate 
3.29d-(R,S) which was subjected to the X-ray crystallographic analysis for determination of 
absolute configuration (see the Supporting Information for details). Enamines obtained by 
enantioselective β-alkylation were found to be versatile intermediates (Scheme 3.14c). 





dr,20a and treatment of 3.26f with NFSI and TMSCN gave fluorocyanation product 3.31f in 88%  
yield and 4.0:1 dr.20b 
Scheme 3.14. Modification of Products and Scalability 
 
  
                                                 
20 (a) Hou, G. H.; Xie, J. H.; Yan, P. C.; Zhou, Q. L. J. Am. Chem. Soc. 2009, 131, 1366−1367. (b) Dilman, A. D.; 






3.4. Mechanistic Investigations 
To gain insight regarding the mechanistic nuances of the catalytic process, we designed 
and performed mechanistic studies. These studies included determining reaction orders, kinetic 
isotope effects, and Hammett ρ values (Figure 3.2, Schemes 3.15 and 3.18, respectively). 
Additionally, these investigations led to revised pathways for catalytic β-C–H alkylation reaction 
(Schemes 3.16–3.17).  
We first performed the kinetic experiments for the reaction of N-arylpyrrolidine 3.19t with 
α,β-unsaturated compound 3.25e to determine the order of each component of this reaction. The 
kinetic experiments suggest the following rate equation: second-order dependence on B(C6F5)3 
concentration (Figure 3.2a), zero order dependence on the concentration of L9–Sc(OTf)3 complex 
(Figure 3.2b), first-order dependence on amine concentration of 3.19t (Figure 3.2c), and reverse 
first-order dependence on the concentration of electrophile 3.25e (Figure 3.2d). The independence 
of the reaction rate on the initial concentration of L9–Sc(OTf)3 suggests that enantioselective C–
C bond forming event between in situ generated enamine and [L9–Sc(OTf)3]-activated 3.25e 
(Scheme 3.11, XVI → XVIII) occurs after the turnover-limiting step. Additionally, this suggests 
that either the hydride abstraction step (3.19 → XV) or the deprotonation step (XV → XVI) is 
likely the turnover-limiting step.  
In order to figure out whether hydride abstraction step or the deprotonation step is the 
turnover-limiting step, we designed and performed independent kinetic isotope effect experiments 
to see whether α-C−H or β-C−H bond cleavage is involved in the turnover-limiting step. 21 
However, independent rate measurements involving 3.19t and 3.19tα-d (Scheme 3.15a) were 
                                                 
21 (a) Simmons, E. M.; Hartwig, J. F. Angew. Chem., Int. Ed. 2012, 51, 3066−3072. (b) Blackmond, D. G. J. Am. 





found to have kH/kD = 1.28 ± 0.07. These results suggest that B(C6F5)3 catalyzed hydride 
abstraction step is not the turnover-limiting step. We then carried out independent kinetic isotope 
effect experiments at the β-position. Comparison of the reaction rate between 3.19t and 3.19tβ-d 
(Scheme 3.15b) revealed that 3.19t reacts 2.5 times faster than 3.19tβ-d (kH/kD = 2.50 ± 0.13). 
These KIE experiments support the notion that the turnover-limiting step is the deprotonation step 
(Scheme 3.11, XV → XVI) which entails the cleavage of α-imino C−H or C−D bonds. 
Figure 3.2. Determination of Reaction Orders 

































Scheme 3.15. Kinetic Isotope Effect Studies 
(b) Independent rate measurements with amine isotopologues
(a) Independent rate measurements with amine isotopologues
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The negative first-order dependence on the concentration of 3.25e implies that the resting 
state consists of 3.25e and the Lewis acid. Spectroscopic analysis of the reaction mixture (19F 
NMR) supports the proposal in regard to formation of [3.25e–B(C6F5)3] (XXIII, Scheme 3.16).22  
                                                 















































































































































































































Since we also observe the reaction rate has a second-order dependence on B(C6F5)3 concentration, 
this suggests there are two B(C6F5)3 involved in the turnover-limiting step. If that is the case, the 
reaction rate should be reverse second-order dependence on the concentration of electrophile 





turnover-limiting step. Furthermore, since the reaction rate is first-order dependence on amine 
concentration of 3.19t, amine 3.19t is not responsible for the deprotonation of the iminium ion. 
Thus, it is likely that β-C−H alkylation proceeds through the release of free B(C6F5)3 from XXIII, 
which then abstracts a hydride from 3.19 to form an iminium/borohydride complex (XXIV). 
Borohydride reduction of (F5C6)3B-activated 3.25 delivers a [(F5C6)3B–enolate]–[iminium]+ 
complex (XXIV → XXV).6e, 23 Subsequent isomerization of the iminium into an enammonium 
(XXV → XXVI) is likely the turnover-limiting step (see the Hammett studies, as well as the 
section 3.6.6).24 Protonolysis of [(F5C6)3B–enolate]– in XXVI releases B(C6F5)3, 3.27, and an 
enamine (XXVII). Then, enantioselective C−C bond forming reaction between the enamine and 
[L–Sc(OTf)3]-activated electrophile 3.25 leads to a zwitterionic intermediate that bears an iminium 
and an enolate moiety (XXVII → XXVIII). Finally, proton transfer within XXVIII produces 
3.26-enamine and regenerates L–Sc(OTf)3, thus closing the cycle. Alternatively, borohydride 
reduction of the iminium and protonation of the resulting enolate in XXVIII produces an N-
alkylamine product (3.26-alkylamine), as illustrated by the studies described below. 
β-Amino C–H alkylation products (Tables 3.2, 3.3 and 3.7) were obtained either as an 
enamine, an N-alkylamine, or a mixture of the two (e.g., 3.21r and 3.21s, Table 3.3). We proposed 
that N-alkylamine products were formed by transfer hydrogenation of XXVIII (XXVIII → 3.26-
alkylamine, Scheme 3.17a), or reduction of enamines (3.26-enamine → 3.26-alkylamine). To 
identify each product’s origins, we studied the progress of (F5C6)3B-catalyzed reaction between 
N-arylpiperidine 3.19g and 3.20a (Scheme 3.17a), which gives a mixture of N-alkylamine 3.21i 
                                                 
23 Chen, G. Q.; Kehr, G.; Daniliuc, C. G.; Bursch, M.; Grimme, S.; Erker, G. Chem. Eur. J. 2017, 23, 4723−4729. 
24 (a) Sorgi, K. L.; Maryanoff, C. A.; McComsey, D. F.; Graden, D. W.; Maryanoff, B. E. J. Am. Chem. Soc. 1990, 
112, 3567−3579. (b) Han, J.; Lu, Z.; Flach, A. L.; Paton, R. S.; Hammond, G. B.; Xu, B. Chem. Eur. J. 2015, 21, 





(57% yield) and enamine 3.21v (29% yield) using 0.4 mL of C6D6 (vs the process involving 1.6 
mL of C6H6 which selectively gives 3.21i; Tables 3.2). We found that there is minimal conversion 
of 3.21i into 3.21v as evidenced by the mostly unchanged concentration of 3.21v once the β-
alkylation reaction completed (2 h; Scheme 3.17b). These results are consistent with the scenario 
that 3.26-alkylamine (Scheme 3.16b) is formed by transfer hydrogenation of XXVIII without the 
intermediacy of 3.26-enamine. Nonetheless, the hydride and proton source of transfer 
hydrogenation remained to be identified. 
Scheme 3.17. Origin of Enamine and N-Alkylamine Products 
  
To probe further if, and under precisely what conditions 3.21v can be converted to 3.21i, 
we investigated the transformation of 3.21v (isolated and purified by flash silica gel 
chromatography) in the presence of 20 mol% B(C6F5)3 (C6H6, 12 h; Scheme 3.17c). There was 





Treatment of 3.21v with N-arylpiperidine-3,3,5,5-d4 3.19g-d furnished 3.21i-d in 50% yield, and 
not only was there significant deuterium incorporation at C3 and C5 positions of 3.21i-d (71% and 
67%, respectively), recovered 3.19g-d had also undergone D/H exchange. These data suggest that 
B(C6F5)3 can catalyze transfer hydrogenation of 3.21v in the presence of another molecule of 3.21v 
and/or 3.19g-d serving as sources of H+ (or D+) and hydride (Scheme 3.17c). Nevertheless, under 
the standard conditions for (F5C6)3B-catalyzed β-C–H alkylation reaction (Schemes 3.16 and 3.17), 
in situ generated [(F5C6)3B–H]–[Base–H]+ (derived from the reaction of B(C6F5)3 and N-
alkylamine 3.19) appears to react with either a highly reactive zwitterionic intermediate (XXVIII 
→ 3.26-alkylamine) or (F5C6)3B-activated α,β-unsaturated compounds  (XXIV → XXV → 
XXVI → 3.27). As a consequence, hydrogenation of the relatively unreactive enamine 3.21v to 
give 3.21i may be outcompeted by these more facile processes. 
Hammett studies revealed a strong dependence of the reaction rate on the electronic 
properties of the N-alkylamines, with N-arylpyrrolidine derivatives (3.19) bearing electron-
donating substituents reacting more rapidly (ρ = –4.9, Schemes 3.18a and 3.18c). The large 
negative ρ value obtained supports the proposed mechanism (Scheme 3.16) in which B(C6F5)3 
abstracts a hydride from N-arylpyrrolidine 3.19 into a N-aryl iminium cation (3.19 → XXIV), and 
its isomerization into an enammonium species (XXIV → XXV → XXVI); these processes take 
place at or prior to the turnover-limiting step. While the reaction rate was found to be less 
dependent of the electronic properties of α,β-unsaturated compounds 3.25, those involving more 
electron-withdrawing groups reacted with higher efficiency (ρ = 0.92, Schemes 3.18b and 3.18d).  
This latter outcome is consistent with the hypothesis that 3.25 reacts with in situ generated 
[(F5C6)3B–H]– to afford a boron–enolate intermediate (Scheme 3.16; XXIV → XXV), and that 















3.5. Conclusions and Future Outlook 
In summary, we have developed a cooperative catalyst system consisting of B(C6F5)3 and 
a chiral Sc-based complex for enantioselective β-amino C–H functionalization to generate 
enantioenriched δ-amino carbonyl compounds. We found that the cooperative funtions of B(C6F5)3 
and a chiral Sc-based complex can convert an N-alkylamine into a nucleophilic enamine and then 
promote its enantio- and diastereo-selective reaction with an α,β-unsaturated compound. 
Furthermore, this method is applicable to late-stage modification of bioactive trialkylamine 
molecules that contain various acid-sensitive function groups. Mechanistic investigations reveal 
that the turnover-limiting step is likely the isomerization of N-alkylamine-derived iminium ion 
into an enammonium intermediate.  
The principles outlined above demonstrated that the use of an achiral Lewis acid and a 
chiral Lewis acid that may possess overlapping functions enables the chemo- and enantioselective 
β-amino C–H alkylation. It provides a rational basis for future development of processes for late-






3.6. Expeirimental  
3.6.1. Procedures, Materials and Instrumentation 
General Experimental Procedures. All reactions were performed in standard, oven-dried 
glassware fitted with rubber septa under an inert atmosphere of nitrogen unless otherwise 
described. Stainless steel syringes or cannulas were used to transfer air- and moisture-sensitive 
liquids. Reported concentrations refer to solution volumes at room temperature. Evaporation and 
concentration in vacuo were performed using house vacuum (ca. 40 mm Hg). Column 
chromatography was performed with SiliaFlash® 60 (40–63 micron) silica gel from Silicycle. Thin 
layer chromatography (TLC) was used for reaction monitoring and product detection using pre-
coated glass plates covered with 0.25 mm silica gel with fluorescent indicator; visualization by 
UV light (λex = 254 nm) or KMnO4 stain. 
 
Materials. Reagents were purchased in reagent grade from commercial suppliers and used without 
further purification, unless otherwise described. Tris(pentafluorophenyl)borane was purchased 
from TCI and used without further purification. H2O, in synthetic procedures, refers to distilled 
water. Chiral ligands L1-L12 were prepared according to the procedures previously reported in 
the literature. 25  Amines and α, β-unsaturated compounds were prepared according to the 
procedures reported previously.6e, 6f, 12g, 12h, 26  
                                                 
25 (a) Thorhauge, J.; Roberson, M.; Hazell, R. G.; Jørgensen, K. A. Chem. Eur. J. 2002, 8, 1888−1898. (b) Tse, M. D.; 
Bhor, S.; Klawonn, M.; Anilkumar, G.; Jiao, H.; Döbler, C.; Spannenberg, A.; Mägerlein, W.; Hugl, H.; Beller, M. 
Chem. Eur. J. 2006, 12, 1855−1874. (c) Desimoni, G.; Faita, G.; Jørgensen, K. A. Chem. Rev. 2011, 111, 284−437. 
(d) Itoh, K.; Sibi, M. P. Org. Biomol. Chem. 2018, 16, 5551−5565. 
26 (a) Takasu, N.; Oisaki, K.; Kanai, M. Org. Lett. 2013, 15, 1918−1921. (b) Kawamoto, K.; Zhong, M.; Wang, R.; 
Olsen, B. D.; Johnson, J. A. Macromolecules 2015, 48, 8980–8988. (c) Schmidt, W.; Vögtle, F.; Poetsch, E. Liebigs 
Ann. 1995, 1319–1326. (d) Jiang, X.; Wei, X.; Lin, F.; Zhang, Z.; Yao, G.; Yang, S.; Zhao, W.; Zhao, C.; Xu, H. Eur. 
J. Org. Chem. 2020, 3997–4003. (e) Sibi, M. P.; Ma, Z.; Jasperse, C. P. J. Am. Chem. Soc. 2004, 126, 718–719. (f) 





Instrumentation. Proton nuclear magnetic resonance (1H NMR) spectra and proton-decoupled 
carbon nuclear magnetic resonance (13C {1H} NMR) spectra were recorded at 25 °C (unless stated 
otherwise) on Inova 600 (600 MHz), Varian Unity/Inova 500 (500 MHz) or Oxford AS400 (400 
MHz) spectrometers at the Boston College nuclear magnetic resonance facility. Chemical shifts 
for protons are reported in parts per million downfield from tetramethylsilane and are referenced 
to 0 ppm. Chemical shifts for carbon are reported in parts per million downfield from 
tetramethylsilane and are referenced to the carbon resonances of the solvent. The peak positions 
are quoted to one decimal place unless they are indistinguishable. The solvent peak was referenced 
to 77.2 ppm for 13C for CDCl3. Benzotrifluoride was used as an external standard for 19F NMR 
and referenced to −63.7 ppm. Data are represented as follows: chemical shift, integration, 
multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling 
constants in Hertz (Hz). Infrared spectra were recorded on a Bruker FT-IR Alpha (ATR mode) 
spectrophotometer. Data are represented as follows: frequency of absorption (cm–1). High-
resolution mass spectrometry was performed on a JEOL AccuTOF-DART (positive mode) at the 
Mass Spectrometry Facility, Boston College. 
Abbreviations used. Bn = benzyl, Boc = tert-butoxycarbonyl, COD = 1,5-cyclooctadiene, COSY 
= correlation spectroscopy, DART = direct analysis in real time, DCM = dichloromethane, DMAP 
= 4-dimethylaminopyridine, DMF = N,N-dimethylformamide, er = enantiomeric ratio, HPLC = 
high pressure liquid chromatography, Et3N = trimethylamine, EtOAc = ethyl acetate, HR = high-
resolution, HSQC = heteronuclear single quantum coherence, LC = liquid chromatography, MS = 
mass spectrometry, NOESY = nuclear Overhauser effect spectroscopy, OTf = triflate, PMP = p-
methoxyphenyl, PTLC = preparatory thin-layer chromatography, TBAF = tetra-n-butylammonium 





TLC = thin-layer chromatography, TMS = trimethylsilyl, TOF = time-of-flight. 
3.6.2. Experimental Section 
3.6.2.1 Substrate Preparation 
3.6.2.1.1 Preparation of Amine Substrates (Table S1) 
Substrates 3.19 were prepared according to the literature procedures. 6e, 6f, 12g, 12h, 25 Methods used 
to prepare the newly synthesized amines (3.19d, 3.19f, 3.19g-d, 3.19h, 3.19l, 3.19m, 3.19o, 
3.19tα-d and 3.19tβ-d) and their spectroscopic data are provided below. 
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1-Benzyl-4-(((tert-butyldimethylsilyl)oxy)methyl)piperidine (3.19d)  
1-Benzyl-4-(((tert-butyldimethylsilyl)oxy)methyl)piperidine was prepared following the General 
Procedure for the TBS Protection of Alcohols using (1-benzylpiperidin-4-yl)methanol (10 mmol) 
as the alcohol. The unpurified product was subjected to silica gel column chromatography (ethyl 
ether:hexanes = 1:4) to afford 3.19d as a colorless liquid (3.0 g, 94%). 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 4H), 7.26 (s, 1H), 3.49 (s, 2H), 3.43 (d, J = 6.5 Hz, 
2H), 2.88 (dt, J = 11.6, 3.3 Hz, 2H), 1.93 (td, J = 11.7, 2.5 Hz, 2H), 1.73 – 1.63 (m, 2H), 1.46 (ddd, 
J = 11.4, 7.5, 4.5 Hz, 1H), 1.28 – 1.16 (m, 2H), 0.88 (s, 9H), 0.03 (s, 6H). 
 
 
N-Benzyl-N-ethyl-4-methoxy-2,6-dimethylaniline (3.19f)  
N-Benzyl-N-ethyl-4-methoxy-2,6-dimethylaniline was prepared following the General Procedure 
for the Alkylation of Amines using N-ethyl-4-methoxy-2,6-dimethylaniline2 (0.9 g, 5.0 mmol), 
benzyl bromide (1.5 equiv.) and K2CO3 (2.0 equiv.). The unpurified product was subjected to silica 
gel column chromatography (ethyl ether:hexanes = 1:19) to afford 3.19f as a colorless liquid (1.2 
g, 88%).  
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.26 (m, 4H), 7.26 – 7.18 (m, 1H), 6.55 (s, 2H), 4.13 (s, 






1-(4-Methoxy-2,6-dimethylphenyl)piperidine-3,3,5,5-d4 (3.19g-d)  
3.19g-d was prepared following the previously reported literature,12h using 1-(4-Methoxy-2,6-
dimethylphenyl)piperidine (877 mg, 4.0 mmol), acetone-d6 (2.0 mL, 28 mmol) and B(C6F5)3 (102 
mg, 0.20 mmol). The crude reaction mixture was subjected to silica gel chromatography (ethyl 
ether:hexanes = 1:20) to give the product 3.19g-d as a yellow liquid with 88% d-incorporation at 
the β-amino position. This compound was resubjected to the aforementioned reaction conditions 
and after flash silica gel column chromatography (ethyl ether:hexanes = 1:20), 3.19g-d was 
obtained with >95% d-incorporation level at the β-amino position. (0.63 g, 70%). 1H NMR (500 
MHz, CDCl3): δ 6.69 – 6.35 (m, 2H), 3.77 – 3.71 (m, 3H), 3.15 – 2.74 (m, 4H), 2.43 – 2.15 (m, 
6H), 1.63 – 1.57 (m, 0.19H, >95%D), 1.56 – 1.47 (m, 2H). 
 
Synthesis of 1,5-Dibromo-3,3-dimethylpentane (S3) 
 
1,5-Dibromo-3,3-dimethylpentane (S3) was prepared following the literature previously 
reported.26d 
3,3-Dimethylpentane-1,5-diol (S2) 
To a solution of 3,3-dimethylpentanedioic acid S1 (3.0 g, 18.7 mmol) in THF, LiAlH4 was added 





12 hours. Upon completion of the reaction (monitored by TLC), the mixture was quenched with 
1.0 M NaOH (aq.) at 0 °C and extracted with EtOAc (3 x 50 mL). The organic layer was dried 
over MgSO4, filtered, and concentrated in vacuo. The unpurified product was subjected to flash 
silica gel column chromatography (EtOAc:hexanes = 1:1) to give 3,3-dimethylpentane-1,5-diol S2 
as a colorless liquid (1.8 g, 73%). 1H NMR (600 MHz, CDCl3): δ 3.74 (t, J = 7.1 Hz, 4H), 1.58 
(t, J = 7.0 Hz, 4H), 0.95 (s, 6H). 
 
1,5-Dibromo-3,3-dimethylpentane (S3) 
To a solution of 3,3-dimethylpentane-1,5-diol S2 (1.2 g, 9.4 mmol) in 47% HBr (aq.), H2SO4 was 
added dropwise at 0 °C. The reaction mixture was slowly heated to 100 °C and was allowed to stir 
for 12 hours. Upon completion of the reaction (monitored by TLC), the mixture was quenched 
with NaHCO3 (aq.) and extracted with ethyl ether (3 x 20 mL). The combined organic layers were 
washed with brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The unpurified 
product was then subjected to flash silica gel column chromatography (100% hexanes) to afford 
1,5-dibromo-3,3-dimethylpentane S3 as a colorless liquid (1.8 g, 75%). 1H NMR (400 MHz, 
CDCl3): δ 3.41 – 3.33 (m, 4H), 1.90 – 1.82 (m, 4H), 0.94 (s, 6H). 
 
 
1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpiperidine (3.19h)  
3.19h was prepared through the reaction of 4-methoxy-2,6-dimethylaniline (0.7 g, 4.7 mmol), 1,5-
dibromo-3,3-dimethylpentane (1.5 equiv.) and K2CO3 (4.0 equiv.) in MeCN. The reaction mixture 





completion (monitored by TLC), the solution was cooled to 22 °C. H2O was then added and the 
organic material was extracted with EtOAc. The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The unpurified product mixture was subjected to flash silica 
gel column chromatography (ethyl ether:hexanes = 1:49) to afford 3.19h as a colorless liquid (0.7 
g, 61%). 1H NMR (500 MHz, CDCl3): δ 6.53 (s, 2H), 3.74 (s, 3H), 3.01 – 2.94 (m, 4H), 2.30 (s, 




(R)-2-((tert-Butyldimethylsilyl)oxy)-1-phenylethan-1-amine was prepared from (R)-2-amino-2-
phenylethan-1-ol S4 following the General Procedure for the TBS Protection of Alcohols on a 21.8 
mmol scale. The unpurified product was subjected to silica gel column chromatography 
(EtOAc:hexanes = 1:9) to afford S5 as a yellow liquid (3.2 g, 58%). 
1H NMR (600 MHz, CDCl3) δ 7.37 (d, J = 7.5 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 7.26 (d, J = 6.4 
Hz, 2H), 4.07 (dd, J = 8.4, 4.0 Hz, 1H), 3.72 (dd, J = 9.8, 4.0 Hz, 1H), 3.52 (dd, J = 9.8, 8.4 Hz, 
1H), 1.81 (br, 2H), 0.90 (s, 9H), 0.02 (s, 6H). 
 
(R)-N-Benzyl-2-((tert-butyldimethylsilyl)oxy)-1-phenylethan-1-amine (S6) 
(R)-N-Benzyl-2-((tert-butyldimethylsilyl)oxy)-1-phenylethan-1-amine was prepared following 
the General Procedure for the Alkylation of Amines using (R)-2-((tert-butyldimethylsilyl)oxy)-1-
phenylethan-1-amine (12.5 g, 49.7 mmol), (bromomethyl)benzene (0.9 equiv.) and K2CO3 (1.5 





ether:hexanes = 1:9) to afford S6 as a colorless liquid (13.8 g, 81%).  
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 6.8 Hz, 2H), 7.37 – 7.26 (m, 7H), 7.25 – 7.20 (m, 1H), 
3.81 (dd, J = 9.1, 4.0 Hz, 1H), 3.75 (d, J = 13.6 Hz, 1H), 3.66 (dd, J = 9.9, 4.0 Hz, 1H), 3.61 – 
3.52 (m, 2H), 0.88 (s, 9H), 0.01 (s, 3H), -0.00 (s, 3H). 
 
(R)-N-Benzyl-2-((tert-butyldimethylsilyl)oxy)-N-ethyl-1-phenylethan-1-amine (3.19l)  
(R)-N-Benzyl-2-((tert-butyldimethylsilyl)oxy)-N-ethyl-1-phenylethan-1-amine was prepared 
following the General Procedure for the Alkylation of Amines using (R)-N-benzyl-2-((tert-
butyldimethylsilyl)oxy)-1-phenylethan-1-amine (5.5 g, 16.1 mmol), iodoethane (1.5 equiv.) and 
K2CO3 (2.0 equiv.). The unpurified product was subjected to silica gel column chromatography 
(ethyl ether:hexanes = 1:19) to afford 3.19l as a colorless liquid (4.3 g, 72%).  
1H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 7.4 Hz, 4H), 7.30 (dt, J = 11.2, 7.5 Hz, 4H), 7.21 (dt, 
J = 14.5, 7.3 Hz, 2H), 4.05 (dd, J = 10.1, 5.7 Hz, 1H), 3.95 – 3.83 (m, 2H), 3.76 (d, J = 14.3 Hz, 
1H), 3.57 (d, J = 14.3 Hz, 1H), 2.71 (dq, J = 14.0, 7.1 Hz, 1H), 2.48 (dq, J = 13.9, 7.0 Hz, 1H), 




(R)-N-Ethyl-1-phenyl-N-((R)-1-phenylethyl)ethan-1-amine (3.19m)  
3.19m was prepared through the reaction of (R)-bis((R)-1-phenylethyl)amine (2.7 g, 11.8 mmol), 
iodoethane (1.5 equiv.) and K2CO3 (2.0 equiv.) in MeCN. The reaction mixture in pressure vessel 





(monitored by TLC), the solution was allowed to cool to 22 °C. H2O was then added and the 
organic material was extracted with EtOAc. The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The unpurified product mixture was subjected to flash silica 
gel column chromatography (ethyl ether:hexanes = 1:19) to afford 1g as a colorless liquid (2.1 g, 
70%). 1H NMR (500 MHz, CDCl3): δ 7.38 (d, J = 7.6 Hz, 4H), 7.29 (t, J = 7.6 Hz, 4H), 7.20 (t, 
J = 7.2 Hz, 2H), 4.01 (q, J = 6.8 Hz, 2H), 2.67 (dq, J = 14.1, 7.0 Hz, 1H), 2.48 (dq, J = 14.2, 7.1 




(R)-2-(((tert-Butyldimethylsilyl)oxy)diphenylmethyl)pyrrolidine (S8)  
S8 was prepared through the TBS protection of (R)-diphenyl(pyrrolidin-2-yl)methanol (S7).  
To a solution of S7 (20 mmol) in DCM at 0 °C, Et3N (1.3 equiv.) was added, followed by the 
dropwise addition of TBSOTf (1.3 equiv.). After the addition, the reaction mixture was allowed to 
warm to 22 °C and stirred for 12 hours. Upon completion (monitored by TLC), H2O was added 
and the organic material was then extracted with DCM. The combined organic layers were dried 
over MgSO4, filtered, and concentrated in vacuo. The unpurified product mixture was subjected 
to flash silica gel column chromatography (ethyl ether:hexanes = 1:9) to afford S8 as a colorless 
liquid (4.1 g, 56%). 1H NMR (500 MHz, CDCl3): δ 7.52 (d, J = 7.6 Hz, 2H), 7.36 (d, J = 8.2 Hz, 
2H), 7.32 – 7.17 (m, 6H), 4.01 (t, J = 7.3 Hz, 1H), 2.88 – 2.76 (m, 1H), 2.76 – 2.64 (m, 1H), 1.59 






(R)-1-Benzyl-2-(((tert-butyldimethylsilyl)oxy)diphenylmethyl)pyrrolidine (3.19o)  
3.19o was prepared through the reaction of S8 (1.5 g, 4.1 mmol), benzyl bromide (1.1 equiv.) and 
K2CO3 (4.0 equiv.) in MeCN. The reaction mixture in pressure vessel was placed in an oil bath at 
100 °C and was allowed to stir for 12 hours. Upon completion (monitored by TLC), the solution 
was cooled to 22 °C. H2O was then added and the organic material was extracted with EtOAc. The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
unpurified product mixture was subjected to flash silica gel column chromatography (ethyl 
ether:hexanes = 1:19) to afford 3.19o as a colorless liquid (1.45 g, 78%). 1H NMR (500 MHz, 
CDCl3): δ 7.64 (dd, J = 7.6, 2.2 Hz, 2H), 7.55 (dd, J = 8.0, 1.8 Hz, 2H), 7.32 – 7.25 (m, 6H), 7.25 
– 7.19 (m, 2H), 7.17 (d, J = 7.2 Hz, 1H), 7.11 (d, J = 7.4 Hz, 2H), 4.36 (d, J = 13.3 Hz, 1H), 4.00 
(dd, J = 9.4, 4.1 Hz, 1H), 3.45 (d, J = 13.3 Hz, 1H), 2.30 (td, J = 6.5, 3.4 Hz, 1H), 2.12 (td, J = 9.2, 
6.6 Hz, 1H), 1.99 (dd, J = 13.4, 8.9 Hz, 1H), 1.87 (dd, J = 8.6, 4.3 Hz, 1H), 1.39 – 1.26 (m, 1H), 
0.90 (s, 9H), 0.64 – 0.54 (m, 1H), -0.39 (s, 3H), -0.43 (s, 3H).  
 
Synthesis of 1-(4-Methoxyphenyl)pyrrolidine-2,2,3,3,4,4,5,5-d8 (S11) 
 
1,4-Dibromobutane-1,1,2,2,3,3,4,4-d8 (S10) was prepared following the literature previously 
reported.26b S11 was prepared through the reaction of 4-methoxyaniline (1.2 g, 10 mmol), S10 (2.0 
g, 0.9 mmol) and K2CO3 (4.1 g, 30 mmol) in MeCN. The reaction mixture in pressure vessel was 
placed in an oil bath at 120 °C and was allowed to stir for 12 hours. Upon completion (monitored 





with EtOAc. The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The unpurified product mixture was subjected to flash silica gel column chromatography 
(ethyl ether:hexanes = 1:20) to give the product S11 as a white solid (1.1 g, 82%). 1H NMR (400 
MHz, CDCl3): δ 6.84 (d, J = 8.9 Hz, 2H), 6.53 (d, J = 9.0 Hz, 2H), 3.76 (s, 3H), 3.22 – 3.18 (m, 
0.02H, >95%D), 1.96 – 1.91 (m, 0.03H, >95%D). 
 
 
1-(4-Methoxyphenyl)pyrrolidine-2,2,5,5-d4 (3.19tα-d)  
3.19tα-d was prepared following a method previously reported in the literature12h using S11 (556 
mg, 3.0 mmol), acetone (1.5 mL, 20.4 mmol) and B(C6F5)3 (154 mg, 0.30 mmol). The crude 
reaction mixture was subjected to silica gel chromatography (ethyl ether:hexanes = 1:20) to give 
the product 3.19tα-d as a yellow liquid with >95% and 40% d-incorporation at the α- and β-amino 
position, respectively. This compound was resubjected to the aforementioned reaction conditions 
and after flash silica gel column chromatography (ethyl ether:hexanes = 1:20), 3.19tα-d was 
obtained with >95% and <5% d-incorporation level at the α- and β-amino position. (501 mg, 80%). 
1H NMR (600 MHz, CDCl3): δ 6.90 – 6.78 (m, 2H), 6.60 – 6.46 (m, 2H), 3.76 (s, 3H), 3.23 – 







1-(4-Methoxyphenyl-2,6-d2)pyrrolidine-3,3,4,4-d4 (3.19tβ-d)  
3.19tβ-d was prepared following a method previously reported in the literature12h using 1-(4-
methoxyphenyl)pyrrolidine (886 mg, 5.0 mmol), acetone-d6 (2.5 mL, 35 mmol) and B(C6F5)3 (128 
mg, 0.25 mmol). The crude reaction mixture was subjected to silica gel chromatography (ethyl 
ether:hexanes = 1:20) to give the product 3.19tβ-d as a yellow liquid with 70% d-incorporation at 
the β-amino position. This compound was resubjected to the aforementioned reaction conditions 
and after flash silica gel column chromatography (ethyl ether:hexanes = 1:20), 3.19tβ-d was 
obtained with >95% d-incorporation level at the β-amino position. (686 mg, 74%). 1H NMR (400 
MHz, CDCl3): δ 6.84 (s, 2H), 6.56 – 6.51 (m, 0.02H, >95%D), 3.76 (s, 3H), 3.33 – 3.12 (m, 4H), 






3.6.2.1.2. Preparation of α,β-Unsaturated Compounds 
α,β-Unsaturated compounds were prepared following the methods reported in the literature26d-26f 
and as described below. 
Table S2. List of α,β-Unsaturated Compounds 
 
 
Preparation of Diisopropyl Fumarate (3.20a) 
 
Diisopropyl fumarate was prepared according to a procedure reported previously in the literature. 





benzene (25.0 mL) was heated at 80 °C and was allowed to stir for 12 hours. The reaction mixture 
was quenched with NaHCO3 (aq.) at 0 °C and extracted with ethyl ether (3 x 25 mL). The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. The 
unpurified product mixture was distilled (75 °C, 40 mmHg) to give diisopropyl fumarate 3.20a as 
a colorless liquid (24.0 g, 60%). 1H NMR (500 MHz, CDCl3): δ 6.81 (s, 2H), 5.11 (hept, J = 6.2 
Hz, 2H), 1.29 (d, J = 6.3 Hz, 12H). 
 
Preparation of Dibenzyl Fumarate (3.20b) 
 
Dibenzyl fumarate was prepared according to a procedure reported previously in the literature.26d 
To a solution of fumaric acid (6.0 g, 51.7 mmol) in DMF (6 mL), Et3N (2.0 equiv) and 
(bromomethyl)benzene (1.9 equiv.) were added dropwise. The reaction mixture was allowed to 
stir at 100 °C for 12 hours. Upon completion, the reaction mixture was poured into cold water and 
then filtered to give a brown solid. The unpurified product was then subjected to silica gel column 
chromatography (EtOAc:hexanes = 3:17) and was further purified by recrystallization 
(EtOAc:hexanes = 1:20) to give dibenzyl fumarate 3.20b as a white solid (8.2 g, 56%). 1H NMR 







General Procedure A for Preparation of 2-Acryloylpyrazolidinone Derivatives 
 
Corresponding carboxylic acid (1.0 eq.), pyrazolidinone26e (1.0 eq.) and 4-dimethylaminopyridine 
(0.1 eq) were dissolved in DCM at 22 °C. After N,N'-dicyclohexylcarbodiimide (1.1 eq) was added 
to the solution, it was allowed to stir overnight to afford the corresponding α,β-unsaturated 
compound. Upon completion, reaction mixture was filtered through Celite using DCM as solvent. 
The unpurified product mixture was subjected to flash silica gel column chromatography. 
 
General Procedure B for Preparation of 2-Acryloylpyrazolidinone Derivatives 
 
n-BuLi (1.1 eq.) was added to the appropriate pyrazolidinone in dry THF at –78 °C, and the mixture 
(Mixture A) was allowed to stir at –78 °C. Oxalyl chloride (3.0 eq.) was added dropwise into 
corresponding carboxylic acid (1.0 eq.) in DCM solution at 0 °C. 2 drops of DMF was added, and 
the mixture was allowed to stir for 1 hour. The solvent was removed under reduced pressure, and 
the residue was added into Mixture A. The mixture was stirred at –78 °C for 2-3 hours until the 
reaction was complete. The reaction was quenched with saturated aqueous ammonium chloride 
and THF was removed under reduced pressure. The residue was dissolved in DCM and washed 





concentrated under reduced pressure. The unpurified product mixture was subjected to flash silica 
gel column chromatography. 
 
 
Ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-oxopyrazolidin-1-yl)-4-oxobut-2-enoate (3.25a)  
6c was prepared following General Procedure B for Preparation of 2-Acryloylpyrazolidinone 
Derivatives using (E)-4-ethoxy-4-oxobut-2-enoic acid (3.60 g, 25.0 mmol), 1-ethyl-5,5-
dimethylpyrazolidin-3-one (3.60 g, 25.0 mmol), oxalyl chloride (9.52 g, 75 mmol) and n-BuLi 
(27.5 mmol). The unpurified product was subjected to flash silica gel column chromatography 
(EtOAc:hexanes = 1:3) to afford 3.25a as a yellow liquid (4.5 g, 67%). 1H NMR (500 MHz, 
CDCl3): δ 7.93 (d, J = 15.6 Hz, 1H), 6.96 (d, J = 15.6 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.01 (q, 
J = 7.1 Hz, 2H), 2.60 (s, 2H), 1.35 – 1.31 (m, 9H), 1.08 (t, J = 7.2 Hz, 3H). 
 
 
Ethyl (E)-4-(2-benzyl-3,3-dimethyl-5-oxopyrazolidin-1-yl)-4-oxobut-2-enoate (3.25b)  
3.25b was prepared following General Procedure B for Preparation of 2-
Acryloylpyrazolidinone Derivatives using (E)-4-ethoxy-4-oxobut-2-enoic acid (5.04 g, 35.0 
mmol), 1-benzyl-5,5-dimethylpyrazolidin-3-one (6.79 g, 35.0 mmol), oxalyl chloride (13.33 g, 
105 mmol) and n-BuLi (38.5 mmol). The unpurified product was subjected to flash silica gel 





NMR (400 MHz, CDCl3): δ 7.44 (d, J = 15.5 Hz, 1H), 7.29 (d, J = 5.0 Hz, 2H), 7.26 – 7.22 (m, 
3H), 6.49 (d, J = 15.5 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 4.00 (s, 2H), 2.61 (s, 2H), 1.34 (s, 6H), 
1.30 (t, J = 7.1 Hz, 3H). 
 
 
(E)-1-(2-Benzyl-3,3-dimethyl-5-oxopyrazolidin-1-yl)-4-phenylbut-2-ene-1,4-dione (3.25c)  
3.25c was prepared following General Procedure A for Preparation of 2-
Acryloylpyrazolidinone Derivatives using (E)-4-oxo-4-phenylbut-2-enoic acid (2.64 g, 15.0 
mmol), 1-benzyl-5,5-dimethylpyrazolidin-3-one (3.06 g, 15.0 mmol), N,N'-
dicyclohexylcarbodiimide (3.30g, 16.5 mmol) and dimethylaminopyridine (0.18 g, 1.5 mmol). The 
unpurified product was subjected to flash silica gel column chromatography (Et3N:EtOAc:hexanes 
= 1:30:90) to afford 3.25c as a yellow solid (1.5 g, 26%). 1H NMR (400 MHz, CDCl3): δ 7.92 (d, 
J = 7.8 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.6 Hz, 3H), 7.30 (d, J = 7.6 Hz, 2H), 7.25 
(s, 1H), 7.19 (t, J = 7.5 Hz, 2H), 7.11 (t, J = 7.3 Hz, 1H), 4.01 (s, 2H), 2.64 (s, 2H), 1.37 (s, 6H). 
 
 
(E)-1-Ethyl-5,5-dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one (3.25d)  
3.25d was prepared following General Procedure A for Preparation of 2-
Acryloylpyrazolidinone Derivatives using (E)-4,4,4-trifluorobut-2-enoic acid (2.52 g, 18.0 





dicyclohexylcarbodiimide (4.10 g, 20 mmol) and dimethylaminopyridine (0.24 g, 2.0 mmol). The 
unpurified product was subjected to flash silica gel column chromatography (EtOAc:hexanes = 
1:3) to afford 3.25d as a yellow liquid (3.1 g, 65%). 1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 
15.6 Hz, 1H), 6.88 (dq, J = 13.8, 6.7 Hz, 1H), 3.01 (q, J = 7.1 Hz, 2H), 2.60 (s, 2H), 1.33 (s, 6H), 
1.07 (t, J = 7.1 Hz, 3H); 19F NMR (376 MHz, CDCl3): δ -65.20 (d, J = 6.8 Hz). 
 
 
1-Benzyl-2-cinnamoyl-5,5-dimethylpyrazolidin-3-one (3.25e)  
3.25e was prepared following General Procedure A for Preparation of 2-
Acryloylpyrazolidinone Derivatives using cinnamic acid (2.67 g, 15.0 mmol), 1-benzyl-5,5-
dimethylpyrazolidin-3-one (3.05 g, 15.0 mmol), N,N'-dicyclohexylcarbodiimide (3.30 g, 16.5 
mmol) and dimethylaminopyridine (0.18 g, 1.5 mmol). The unpurified product was subjected to 
flash silica gel column chromatography (EtOAc:hexanes = 1:3) to afford 3.25e as a yellow solid 
(3.0 g, 60%). 1H NMR (500 MHz, CDCl3): δ 7.65 (d, J = 15.7 Hz, 1H), 7.52 (dd, J = 6.6, 2.9 Hz, 










3.25f was prepared following General Procedure A for Preparation of 2-
Acryloylpyrazolidinone Derivatives using (E)-3-(4-(trifluoromethyl)phenyl)acrylic acid (3.24 g, 
15.0 mmol), 1-benzyl-5,5-dimethylpyrazolidin-3-one (3.05 g, 15.0 mmol), N,N'-
dicyclohexylcarbodiimide (3.30 g, 16.5 mmol) and dimethylaminopyridine (0.18 g, 1.5 mmol). 
The unpurified product was subjected to flash silica gel column chromatography (EtOAc:hexanes 
= 1:3) to afford 3.25f as a yellow solid (2.7 g, 45%). 1H NMR (500 MHz, CDCl3): δ 7.66 – 7.54 
(m, 5H), 7.50 – 7.42 (m, 1H), 7.40 (m, 2H), 7.28 – 7.23 (m, 2H), 7.20 (t, J = 7.3 Hz, 1H), 4.11 (s, 










(E)-1-Benzyl-2-(3-(4-bromophenyl)acryloyl)-5,5-dimethylpyrazolidin-3-one (3.25g)  
3.25g was prepared following General Procedure A for Preparation of 2-
Acryloylpyrazolidinone Derivatives using (E)-3-(4-bromophenyl)acrylic acid (3.39 g, 15.0 
mmol), 1-benzyl-5,5-dimethylpyrazolidin-3-one (3.05 g, 15.0 mmol), N,N'-
dicyclohexylcarbodiimide (3.30 g, 16.5 mmol) and dimethylaminopyridine (0.18 g, 1.5 mmol). 
The unpurified product was subjected to flash silica gel column chromatography (EtOAc:hexanes 
= 1:3) to afford 3.25g as a yellow solid (1.8 g, 29%). 1H NMR (500 MHz, CDCl3): δ 7.57 – 7.46 








(E)-1-Benzyl-2-(3-(4-methoxyphenyl)acryloyl)-5,5-dimethylpyrazolidin-3-one (3.25h)  
3.25h was prepared following General Procedure A for Preparation of 2-
Acryloylpyrazolidinone Derivatives using (E)-3-(4-methoxyphenyl)acrylic acid (2.67 g, 15.0 
mmol), 1-benzyl-5,5-dimethylpyrazolidin-3-one (3.05 g, 15.0 mmol), N,N'-
dicyclohexylcarbodiimide (3.30 g, 16.5 mmol) and dimethylaminopyridine (0.18 g, 1.5 mmol). 
The unpurified product was subjected to flash silica gel column chromatography (EtOAc:hexanes 
= 1:3) to afford 3.25h as a yellow solid (2.1 g, 38%). 1H NMR (500 MHz, CDCl3): δ 7.63 (d, J = 
15.7 Hz, 1H), 7.50 – 7.46 (m, 2H), 7.43 – 7.39 (m, 2H), 7.35 (d, J = 15.7 Hz, 1H), 7.28 – 7.24 (m, 









3.6.2.2. Optimization Studies for (F5C6)3B-Catalyzed β-Alkylation involving N-Alkylamines 
3.6.2.2.1. Evaluation of Reaction Conditions for (F5C6)3B-Catalyzed β-Alkylation involving 
N-Alkylamines 
Experimental Procedure for the Evaluation of Solvents (Table S3) 
To a 15 mL oven-dried pressure vessel was added N,N-dibenzylethanamine 3.19a (0.20 mmol), 
B(C6F5)3 (10 mol%), diisopropyl fumarate 3.20a (0.30 mmol), and solvent (0.20 mL) under a 
nitrogen atmosphere. The reaction mixture was placed in an oil bath at 50 °C and was allowed to 
stir for 3 hours. After the solution was cooled to 22 °C, it was concentrated in vacuo. The product 
yield was determined by the 1H NMR analysis of the unpurified product mixtures using m-xylene 
as the internal standard. 






3.6.2.2.2. Effect of Concentration of Solution to Chemoselectivity of (F5C6)3B-Catalyzed β-
Alkylation involving Cyclic N-Alkylamines 
For piperidine substrates (e.g., N-arylpiperidine 3.19g, Table S4) that react with 3.20a to give a 
mixture of products in the forms of N-alkylamines (e.g., 3.21i) and enamines (e.g., 3.21v), we 
carried out a series of optimization studies that were aimed to selectively prepare 3.21i (Table S4). 
Specifically, to a 15 mL oven-dried pressure vessel were added amine 3.19g (0.20 mmol), B(C6F5)3 
(10 mol%), diisopropyl fumarate 3.25a (0.30 mmol), and benzene (0.20 mL or 0.80 mL) under a 
nitrogen atmosphere. The reaction mixture was placed in an oil bath at 50 °C and was allowed to 
stir for 12 hours. Upon completion, the solution was cooled down to room temperature and was 
concentrated in vacuo. The yield values for 3.21i and 3.21v were determined by the 1H NMR 
analysis of the unpurified product mixtures using m-xylene as the internal standard.  
As shown in Table S4, it was found that, when the reaction was run in more dilute conditions (0.80 
mL, 0.25 M in benzene) than the standard reaction conditions (0.20 mL, 1.0 M in benzene), the N-
alkylamine product 3.21i can be obtained more preferably over enamine 3.21v. 
Furthermore, when the enamine product (e.g., 3.21v) is generated, the formation of diisopropyl 
succinate (3.32a) was observed. This is likely due to the hydrogenation of 3.20a by in situ 
generated borohydride and ammonium ion to regenerate the Lewis acid and Brønsted base 
catalysts. We hypothesized that if a larger quantity of 3.20a is present in the reaction mixture to 
serve as a sacrificial H+/H- acceptor, the formation of enamine product would be favored.  
To a 15 mL oven-dried pressure vessel was added 1-(4-methoxy-2,6-dimethylphenyl)-4,4-
dimethylpiperidine 3.19h (0.2 mmol), B(C6F5)3 (10 mol%), diisopropyl fumarate 3.20a (0.3 mmol, 
1.5 equiv.) and DCM (0.1 mL) under a nitrogen atmosphere (Scheme S1). The reaction mixture 





Table S4. Evaluation of Solvent Concentration involving Amine 3.19g 
 








































2.20a, 0.3 mmol 3.21j, 50% yield 3.21w, 25% yield
C6H6 (0.2 mL)
































cooled to 22 °C, diisopropyl fumarate 2.20a (0.2 mmol, 1.0 equiv.) and DCM (0.05 mL) were 
added under a nitrogen atmosphere. Then the reaction mixture was placed again in an oil bath at 
50 °C and was allowed to stir for 12 hours. Upon completion, the solution was cooled to 22 °C 
and was concentrated in vacuo. The product yield was determined by the 1H NMR analysis of the 
unpurified product mixtures using m-xylene as the internal standard. It was found that adding 2.5 
equiv. of 2.20a in a batchwise manner improves the product yield as well as the chemoselectivity 






3.6.2.3. Optimization Studies for Diastereoselective β-Alkylation 
Experimental Procedure for the Optimization of Diastereoselective Reaction (Table 3.4) 
To a 15 mL oven-dried pressure vessel were added (R)-1-benzyl-2-(((tert-
butyldimethylsilyl)oxy)diphenylmethyl)pyrrolidine 3.19o (0.10 mmol), 3.23 (0.15 mmol), 
B(C6F5)3 (10 mol%), Lewis acid co-catalyst (10 mol%), HBPin (0 mol% or 70 mol%), and benzene 
(0.60 mL) under a nitrogen atmosphere. The reaction mixture was placed in an oil bath at 60 °C 
and was allowed to stir for 24 or 36 hours. Upon completion, the solution was cooled to 22 °C and 
concentrated in vacuo. The product yield and dr were determined by the 1H NMR and 19F NMR 
analyses of the unpurified product mixtures using mesitylene (for 1H NMR analysis) and 







3.6.2.4. Studies for Enantioselective β-Alkylation with a Chiral Boron Lewis Acid Catalyst 
Based on the hypothesis that B(C6F5)3 is responsible for the activation of both the N-alkylamine 
and α,β-unsaturated compounds, we envisioned the use of chiral boron Lewis acid catalyst to 
achieve the enantioselective β-alkylation reaction.  
N,N-dibenzylpropan-1-amine (3.19b) and benzyl acrylate (3.20c) were used as model substrates 
which afforded β-alkylated product 3.21x in 75% yield (Scheme S2). We first examined the ability 
of a chiral borane catalyst to promote the C−C bond forming reaction in an enantioselective manner. 
No desired product was observed using less Lewis acidic Du’s catalyst (Scheme S3A).22 When 
Du’s catalyst was used in combination with B(C6F5)3, the product was obtained in 70% yield and 
50:50 er (Scheme S3B).  
Scheme S2. β-Amino C−H Alkylation Involving 3.19b and 3.20c 
 
Benzyl 5-(dibenzylamino)-4-methylpentanoate (3.21x)  
1H NMR (600 MHz, CDCl3) δ 7.34 (d, J = 5.4 Hz, 9H), 7.28 (t, J = 7.5 Hz, 4H), 7.20 (t, J = 7.3 
Hz, 2H), 5.10 (s, 2H), 3.48 (s, 4H), 2.33 – 2.25 (m, 2H), 2.23 (dd, J = 12.4, 7.3 Hz, 1H), 2.14 (dd, 
J = 12.5, 7.3 Hz, 1H), 1.86 – 1.79 (m, 1H), 1.79 – 1.71 (m, 1H), 1.40 – 1.31 (m, 1H), 0.84 (d, J = 
6.6 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.8, 139.8, 136.1, 128.9, 128.5, 128.2, 128.14, 
128.10, 126.7, 66.1, 60.3, 58.8, 31.7, 30.4, 29.7, 17.8; IR (neat) ν 2951, 2926, 1733, 1493, 1452, 










Scheme S3. Evaluation of Du’s Catalyst 
 
 
Experimental Procedure for the Evaluation of Du’s Catalyst 





(S)-3,3'-diphenyl-2,2'-divinyl-1,1'-binaphthalene (0.005 mmol), HB(C6F5)2 (0.01 mmol), and 
toluene (0.2 mL) under nitrogen atmosphere.22 This reaction mixture was allowed to stir for 20 
minutes at 22 °C to generate the chiral organoborane catalyst. To this mixture were added 3.19b 
(0.10 mmol), 3.20c27 (0.15 mmol), B(C6F5)3 (0.005 mmol), and toluene (0.2 mL). The reaction 
mixture was placed in an oil bath at 50 °C and was allowed to stir for 12 hours. Upon completion, 
the reaction mixture was concentrated in vacuo. The product yield was determined by the 1H NMR 
analysis of the unpurified product mixtures using mesitylene as the internal standard. The product 
was isolated and purified using preparatory TLC. The er was determined by HPLC analysis of the 
isolated and purified product. HPLC (Chiralcel OD-H; 1.5%/ 98.5% isopropanol/ hexanes, 0.3 




                                                 





3.6.2.5. Evaluation of Various Auxiliaries and Chiral Lewis Acid Co-Catalysts for 
Enantioselective β-Amino C−H Alkylation  
To achieve highly enantioselective β-alkylation of N-alkylamines, various combinations of chiral 
Lewis acid co-catalysts and electrophiles containing different auxiliaries were evaluated (Scheme 
S4).  
Using achiral substrates N-arylpyrrolidine 3.19s and oxazolidinone-substituted 3.23c, we 
evaluated various chiral organometallic complexes to find that Mg(ClO4)2/L5 give 3.24c with 67% 
yield in up to 90:10 er. In comparison, when a chiral Zn-BOX complex was used, 3.24c was 
produced in 10 % yield (10:1 dr, 50:50 er; Scheme S4A). 
In order to identify the optimal auxiliary, we evaluated substrates 3.24d, 3.24e and 3.24f in the 
presence of various chiral organometallic co-catalysts. However, the desired products were 
obtained in 0–30% yield and up to 69:31 er (Schemes S4B−D). 















3.6.2.6. Optimization Studies for Enantioselective β-Alkylation Involving 3.23c with Chiral 
Mg-based Complexes 
Experimental Procedure for the Optimization of Ligand (Table 3.5) 
To a 15 mL oven-dried pressure vessel was added Mg(ClO4)2 (0.010 mmol, 10 mol%), ligand 
(0.010 mmol, 10 mol%), benzene (0.3 mL) under nitrogen atmosphere. The mixture was allowed 
to stir for 20 minutes at 22 °C. Subsequently, 1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine 3.19s 
(0.10 mmol), (E)-3-(4,4,4-trifluorobut-2-enoyl)oxazolidin-2-one 3.23c (0.15 mmol), and benzene 
(0.30 mL) were added to the vial under nitrogen atmosphere, and the resulting mixture was allowed 
to stir at 22 °C for 12 h. Upon completion, the reaction mixture was concentrated in vacuo. The 
product yield and dr were determined by the 1H NMR and 19F NMR analyses of the unpurified 
product mixtures using mesitylene (for 1H NMR analysis) and perfluorobenzene (for 19F NMR 
analysis) as the internal standard. The product was purified by preparative TLC (EtOAc:hexanes 







3.6.2.7. Optimization Studies for Enantioselective β-Alkylation Involving 3.25a with Chiral 
Lewis Acid Co-Catalysts 
Experimental Procedure for the Optimization of Lewis Acid Co-Catalyst (Table S5) 
To a 15 mL oven-dried pressure vessel was added Lewis Acid (0.010 mmol, 10 mol%), 2,6-bis((S)-
4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine L9 (0.012 mmol, 12 mol%), and DCM (0.50 mL) 
under nitrogen atmosphere. The mixture was allowed to stir for 20 min at 22 °C. Subsequently, 
(E)-1-benzyl-5,5-dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25i (0.15 mmol), 1-
(4-methoxy-2,6-dimethylphenyl)pyrrolidine 3.19s (0.10 mmol), B(C6F5)3 (0.010 mmol, 10 mol%) 
and DCM (0.50 mL) were added to the reaction vessel, and the resulting mixture was allowed to 
stir at 22 °C for 12 hours. Upon completion, the solution was concentrated in vacuo. The product 
yield and dr were determined by the 1H NMR and 19F NMR analyses of the unpurified product 
mixtures using mesitylene (for 1H NMR analysis) and perfluorobenzene (for 19F NMR analysis) 
as the internal standard. The product was purified by preparative TLC (EtOAc:hexanes = 1:3). The 
er values of product 3.26l was determined by HPLC analysis of the isolated and purified product. 
Experiments for Evaluation of N-Aryl Substituents 
We evaluated N-arylpyrrolidine with different substituents on the aromatic ring (e.g., 3.16s, 3.19t) 
in the presence of B(C6F5)3 and L12−Sc(OTf)3 (Scheme S5). The reaction between 3.19s and 3.25d 
gave 3.26m in 45% yield (6.5:1 dr, 96:4 er). When less sterically hindered p-methoxyphenyl 
(PMP)-substituted 3.19t unit was reacted with 3.25d, 3.26d could be produced in 62% yield, 6.7:1 







Table S5. Optimization of Chiral Lewis Acid Co-Catalyst 
 









3.6.2.8. Optimization Studies for Enantioselective β-Alkylation Involving 6c with Chiral Sc-
based Complexes 
3.6.2.8.1. Evaluation of Reaction Parameters (Table S6) 
To a 15 mL oven-dried pressure vessel was added Sc(OTf)3 (0.020 mmol, 10 mol%), 2,6-bis((S)-
4-((S)-sec-butyl)-4,5-dihydrooxazol-2-yl)pyridine L12 (0.024 mmol, 12 mol%), and DCM (1.0 
mL) under nitrogen atmosphere. The mixture was allowed to stir for 20 min at 22 °C. Subsequently, 
ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-oxopyrazolidin-1-yl)-4-oxobut-2-enoate 3.25a (0.30 mmol), 
1-(4-methoxyphenyl)pyrrolidine 3.19t (0.20 mmol), B(C6F5)3 (0.020 mmol, 10 mol%) and DCM 
(1.0 mL) were added to the reaction vessel, and the resulting mixture was placed in an oil bath at 
60 °C and was allowed to stir for 1 hour or 3 hours. Upon completion, the solution was cooled to 
22 °C and concentrated in vacuo. The product yield and dr were determined by the 1H NMR 
analyses of the unpurified product mixtures using as the internal standard. The product was 
purified by preparative TLC (EtOAc:hexanes = 1:1). The er values of product 3.26a was 













3.6.2.8.2. General Reaction Procedure for Evaluation of Chiral Ligands (See Table 3.6) 
To a 15 mL oven-dried pressure vessel was added Sc(OTf)3 (0.010 mmol, 5.0 mol%), Ligand 
(0.012 mmol, 6.0 mol%), and DCM (1.0 mL) under nitrogen atmosphere. The mixture was allowed 
to stir for 20 min at 22 °C. Subsequently, ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-oxopyrazolidin-1-
yl)-4-oxobut-2-enoate 3.25a (0.30 mmol), 1-(4-methoxyphenyl)pyrrolidine 3.19t (0.20 mmol), 
B(C6F5)3 (0.020 mmol, 10 mol%) and DCM (1.0 mL) were added to the reaction vessel, and the 
resulting mixture was placed in an oil bath at 60 °C and was allowed to stir for 1 hour. Upon 
completion, the solution was cooled to 22 °C and concentrated in vacuo. The product yield and dr 
were determined by the 1H NMR analyses of the unpurified product mixtures using mesitylene as 
the internal standard. The product was purified by preparative TLC (EtOAc:hexanes = 1:1). The 






3.6.2.9. Evaluation of Acyclic Amine Substrates for Enantioselective β-Alkylation with 
Chiral Sc-based Complexes 
We have evaluated several acyclic amines (3.19) for enantioselective β-amino C−H alkylation; 
however, the current conditions were found to be incompatible with this class of substrate (Scheme 
S6). 







3.6.2.10. General Procedures for β-Alkylation of N-Alkylamines 
General Procedure C for the β-Alkylation of N-Alkylamines (See Tables 3.1-3.3 in the 
Manuscript)  
 
To a 15 mL oven-dried pressure vessel was added amine (0.20 mmol), B(C6F5)3 (5.0 or 10 mol%), 
α,β-unsaturated compound (0.30 mmol, 1.5 equiv.) and benzene under a nitrogen atmosphere. The 
reaction mixture was placed in an oil bath at 50 °C and was allowed to stir for 12 hours. Upon 
completion, the solution was cooled to 22 °C and concentrated in vacuo followed by flash silica 
gel column chromatography.  
 




To a 15 mL oven-dried pressure vessel was added amine (0.20 mmol), B(C6F5)3 (5.0 or 10 mol%), 
α,β-unsaturated compound (0.30 mmol, 1.5 equiv.) and benzene (0.30 mL) under a nitrogen 
atmosphere. The reaction mixture was placed in an oil bath at 50 °C and was allowed to stir for 12 





and benzene (0.10 mL) were added under a nitrogen atmosphere and the reaction mixture was 
again placed in an oil bath at 50 °C and was allowed to stir for 12 hours.  Upon completion, the 
solution was cooled to 22 °C and concentrated in vacuo followed by flash silica gel column 
chromatography. 
General Procedure E for the Enantioselective β-Alkylation of N-Alkylamines (See Tables 3.6-
3.7 in the Manuscript) 
 
 
To a 15 mL oven-dried pressure vessel was added Sc(OTf)3 (5.0 or 10 mol%), ligand (6.0 or 12 
mol%), and DCM (0.50 mL) under nitrogen atmosphere. The mixture was allowed to stir for 20 
min at 22 °C. Subsequently, α,β-unsaturated compound 3.25 (0.15 or 0.20 mmol), amine 3.19 
(0.10 mmol), B(C6F5)3 (10 or 20 mol%) and DCM (0.50 mL) were added to the reaction vessel, 
and the resulting mixture was placed in an oil bath at 60 °C or 80 °C and was allowed to stir for 
1−36 hours. Upon completion, the solution was cooled to 22 °C and concentrated in vacuo 
followed by flash silica gel column chromatography. 
 






To a 25 mL oven-dried sealed tube was added Sc(OTf)3 (10 mol%), 2,6-bis((S)-4-((S)-sec-butyl)-
4,5-dihydrooxazol-2-yl)pyridine L12 (12 mol%), and DCM (5.0 mL) under nitrogen atmosphere. 
The mixture was allowed to stir for 2 hours at 22 °C. Subsequently, (E)-1-ethyl-5,5-dimethyl-2-
(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d (8.0 mmol), 1-(4-methoxy-2,6-
dimethylphenyl)piperidine 3.19g (4.0 mmol), B(C6F5)3 (10 mol%) and DCM (1.0 mL) were added 
to the reaction vessel, and the resulting mixture was placed in an oil bath at 60 °C and was allowed 
to stir for 12 hours. Upon completion, the solvent was cooled to 22 °C and concentrated in vacuo 
followed by purification through flash silica gel column chromatography to afford the product as 
a light yellow oil (1.93 g, 95% yield, 95:5 er). The er value was determined by HPLC analysis of 






3.6.3. Determination of Relative Configuration  
3.6.3.1. Determination of the Relative Configuration of 3.21e-Major 
The relative configurations of 3.21e-major was determined by the X-ray crystallographic analysis 













3.19d, 0.20 mmol 3.20a, 0.30 mmol
C6H6 (0.80 mL)
















1-Benzyl-4-(((tert-butyldimethylsilyl)oxy)methyl)piperidine 3.19d was reacted with diisopropyl 
fumarate 3.20a following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst and benzene (0.80 mL) as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 1.1:1. After purification by flash silica gel column 
chromatography (ethyl ether:hexanes = 1:4), 3.21e was obtained as a mixture of diastereomers 
(77.0 mg, 74%). Further purification was carried out by PTLC using ethyl ether:DCM = 1:6 as the 
eluent to separate 3.21e-major and 3.21e-minor. The relative configuration for 3.21e-major and 
3.21e-minor were assigned based on X-ray crystallography data of 3.34e-major and 3.34e-minor, 
respectively (see Section 3.6.10). 
 
3.21e-Major. 1H NMR (600 MHz, CDCl3): δ 7.27 (dp, J = 22.0, 7.5 Hz, 5H), 4.98 (dp, J = 16.3, 
6.4 Hz, 2H), 3.71 (dd, J = 10.0, 2.6 Hz, 1H), 3.65 (dd, J = 10.1, 5.1 Hz, 1H), 3.52 (d, J = 13.4 Hz, 
1H), 3.41 (d, J = 13.4 Hz, 1H), 3.09 (dt, J = 11.2, 3.4 Hz, 1H), 2.82 (tt, J = 16.1, 10.8 Hz, 3H), 





2H), 1.46 (pt, J = 11.9, 6.7 Hz, 2H), 1.21 (dt, J = 12.1, 6.0 Hz, 12H), 0.87 (d, J = 3.2 Hz, 9H), 0.03 
(d, J = 2.9 Hz, 6H); 13C NMR (151 MHz, CDCl3): δ 172.7, 171.6, 138.2, 129.1, 129.0, 128.2, 
128.1, 126.9, 67.91, 67.86, 64.6, 63.3, 55.4, 53.3, 40.7, 40.4, 40.0, 35.3, 29.3, 26.0, 25.9, 21.9, 
21.82, 21.80, 21.75, 18.3, -5.4, -5.5; IR (neat): ν 2950, 2854, 1727, 1466, 1372, 1254, 1173, 1104, 
834, 775 cm-1; HRMS (DART): Calcd for C29H50NO5Si (MH+): 520.3453; found: 520.3454. 




3.34e-Major was synthesized by the following procedure. To a solution of 3.21e-major (386 mg, 
0.75 mmol) in THF (10 mL) was added Et3N(HF)3 (0.50 mL) in a dropwise manner. The reaction 
was allowed to stir at 22 °C for 12 hours. The reaction mixture was concentrated and filtered 
through a plug of Celite using DCM as solvent. The unpurified product was then subjected to flash 
silica gel column chromatography (EtOAc:hexanes = 9:1) to afford diisopropyl 2-(1-benzyl-4-
(hydroxymethyl)piperidin-3-yl)succinate 3.34e-major-int as a colorless oil (295 mg, 97%).  





11.5, 4.1 Hz, 1H), 3.64 (dd, J = 11.5, 3.2 Hz, 1H), 3.55 (d, J = 13.2 Hz, 1H), 3.43 (d, J = 13.2 Hz, 
1H), 3.18 (td, J = 6.3, 3.3 Hz, 1H), 2.98 – 2.83 (m, 2H), 2.76 (dd, J = 17.3, 8.2 Hz, 1H), 2.37 (dd, 
J = 17.3, 6.3 Hz, 1H), 2.23 (s, 1H), 1.94 – 1.82 (m, 2H), 1.72 (t, J = 11.1 Hz, 1H), 1.63 (dd, J = 
10.2, 3.9 Hz, 2H), 1.60 – 1.46 (m, 2H), 1.30 – 1.18 (m, 14H). 
 
3.34e-Major-int was then diluted in ethyl ether (0.10 mL) and 2.0 M HCl in ethyl ether was added 
dropwise to the solution until a white precipitate was formed. The solid was allowed to precipitate 
out of solution, whereupon the solvent was removed in vacuo to afford 3.34e-major as a white 
solid.  
3.34e-Major was recrystallized using the vapor-vapor diffusion method, using i-PrOH to dissolve 
the product in an inner vial, and ethyl ether as the precipitant placed in the outer vial in order for 
slow diffusion to occur into the inner vial. The solution was cooled to 0 °C, whereupon a crystal 
was obtained for X-ray crystallography. The X-ray crystallographic analysis revealed that the 
relative configuration of 3.34e-major is (R,R,R) or (S,S,S). The relative configuration of products 







3.6.3.2. Determination of the Relative Configuration of 3.21e-Minor  
The relative configurations of 3.21e-Minor was determined by the X-ray crystallographic analysis 













3.19d, 0.20 mmol 3.20a, 0.30 mmol
C6H6 (0.80 mL)














3.21e-Minor. 1H NMR (500 MHz, CDCl3): δ 7.31 – 7.23 (m, 4H), 7.23 – 7.17 (m, 1H), 5.03 – 
4.93 (m, 1H), 4.93 – 4.84 (m, 1H), 3.61 (dd, J = 10.3, 4.1 Hz, 1H), 3.55 (t, J = 5.2 Hz, 1H), 3.50 
(d, J = 13.2 Hz, 1H), 3.36 (d, J = 13.2 Hz, 1H), 3.19 (dt, J = 12.2, 3.6 Hz, 1H), 2.86 (d, J = 11.2 
Hz, 1H), 2.67 – 2.50 (m, 2H), 2.35 – 2.24 (m, 1H), 2.09 (d, J = 11.0 Hz, 1H), 1.95 (t, J = 11.5 Hz, 
1H), 1.78 – 1.65 (m, 2H), 1.54 (tt, J = 14.2, 7.1 Hz, 1H), 1.33 (dq, J = 11.0, 5.3 Hz, 1H), 1.20 (dd, 
J = 10.0, 6.3 Hz, 6H), 1.13 (d, J = 6.3 Hz, 3H), 1.03 (d, J = 6.3 Hz, 3H), 0.89 (s, 9H), 0.04 (d, J = 
5.8 Hz, 6H); 13C NMR (151 MHz, CDCl3): δ 173.7, 172.0, 138.3, 129.0, 128.1, 126.9, 125.5, 
67.9, 67.8, 65.0, 63.3, 54.4, 53.9, 41.3, 39.8, 39.3, 31.0, 29.0, 25.95, 25.94, 21.8, 21.74, 21.70, 












3.34e-Minor was synthesized by the following procedure. To a solution of 3.21e-minor (150 mg, 
0.3 mmol) in THF (10 mL) was added Et3N(HF)3 (0.3 mL), dropwise. The reaction was allowed 
to stir at 22 °C for 12 hours. The reaction mixture was concentrated and filtered through a plug of 
Celite using DCM as solvent. The unpurified product was then subjected to flash silica gel column 
chromatography (EtOAc:hexanes = 9:1) to afford diisopropyl 2-(1-benzyl-4-
(hydroxymethyl)piperidin-3-yl)succinate 3.34e-minor-int as a colorless oil (116 mg, 95%).  
1H NMR (500 MHz, CDCl3): δ 7.27 (d, J = 4.5 Hz, 4H), 7.21 (q, J = 4.5 Hz, 1H), 4.98 (p, J = 6.3 
Hz, 1H), 4.90 (p, J = 6.2 Hz, 1H), 3.73 (dd, J = 10.9, 4.4 Hz, 1H), 3.59 (dd, J = 10.9, 5.9 Hz, 1H), 





11.2 Hz, 1H), 2.68 – 2.48 (m, 2H), 2.32 (dd, J = 16.6, 3.3 Hz, 1H), 2.10 – 2.03 (m, 1H), 1.99 (t, J 
= 11.3 Hz, 1H), 1.79 (dt, J = 27.4, 12.1 Hz, 2H), 1.61 – 1.46 (m, 1H), 1.45 – 1.36 (m, 1H), 1.26 (t, 
J = 7.6 Hz, 1H), 1.21 (t, J = 6.3 Hz, 6H), 1.14 (d, J = 6.2 Hz, 3H), 1.04 (d, J = 6.2 Hz, 3H). 
3.34e-Minor-int was then diluted in ethyl ether (0.10 mL) and 2.0 M HCl in ethyl ether was added 
dropwise to the solution until a white precipitate was formed. The solid was allowed to precipitate 
out of solution, whereupon the solvent was removed in vacuo to afford 3.34e-minor as a white 
solid. 3.34e-Minor was recrystallized using the vapor-vapor diffusion method, using i-PrOH to 
dissolve the product in an inner vial, and ethyl ether as the precipitant placed in the outer vial in 
order for slow diffusion to occur into the inner vial. The solution was cooled to 0 °C, whereupon 
a crystal was obtained for X-ray crystallography. The X-ray crystallographic analysis revealed that 
the relative configuration of 3.34e-minor is (R,R,S) or (S,S,R). The relative configuration of 






3.6.3.3. Determination of the Relative Configuration of 3.21b-Major 
The relative configuration of 3.21b-major was determined by the X-ray crystallographic analysis 
of 3.34b-major. 
 
To a 15 mL oven-dried pressure vessel was added dibenzylpropanamine 3.19b (0.40 mmol), 
B(C6F5)3 (10 mol%), dimethylfumarate 3.20d (0.60 mmol) and benzene (0.40 mL) under a 
nitrogen atmosphere. The reaction mixture was placed in an oil bath at 50 °C and was allowed to 
stir for 12 hours. Upon completion, the solution was cooled to 22 °C and concentrated in vacuo. 
The 1H NMR analysis of the unpurified product mixture revealed that 3.34b was obtained as a 
mixture of diastereomers in 2.6:1 ratio. After purification by flash silica gel column 
chromatography (ethyl ether:hexanes = 1:19), 3.34b was obtained as a mixture of diastereomers 
(66 mg, 43%). Further purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the 
eluent to separate 3.34b-major and 3.34b-minor. The major diastereomer was isolated as a white 
solid (45 mg, 29% yield).  
 
Dimethyl 2-(1-(dibenzylamino)propan-2-yl)succinate (3.34b-major) 
1H NMR (600 MHz, CDCl3): δ 7.34 (d, J = 6.7 Hz, 4H), 7.29 (t, J = 7.5 Hz, 4H), 7.22 (t, J = 7.1 
Hz, 2H), 3.78 (d, J = 13.2 Hz, 2H), 3.67 (s, 6H), 3.38 (d, J = 11.9 Hz, 1H), 3.26 (d, J = 13.3 Hz, 
2H), 2.37 (dd, J = 16.8, 11.5 Hz, 2H), 2.24 (t, J = 11.5 Hz, 1H), 2.14 (dd, J = 13.0, 5.5 Hz, 1H), 






The major diastereomer was then recrystallized using DCM:hexanes = 1:10 to afford a crystal for 
the X-ray analysis. The X-ray crystallographic analysis revealed that the relative configuration of 
3.34b-major is (R,R) or (S,S). The relative configuration of 3.21b-major was assigned in analogy. 
 






3.6.3.4. Determination of the Relative Configuration of 3.22a 
The relative configuration for 3.22a was determined by NOESY experiments. The following are 
the NOE spectrum and assignments (Figure S2). 
 






3.6.3.5. Determination of the Relative Configuration of 3.21p-Major 
The relative configuration for 3.21p-major was determined by NOESY experiments. The 
following are the NOE spectrum and assignments (Figure S3). 
 
Figure S3. 2D NOESY spectra of 3.21p-major 





3.6.4. Determination of Absolute Configuration 
3.6.4.1 Determination of the Absolute Configuration of Product 3.21o-(R,R,R). 
We carried out the following studies in order to determine the absolute configuration of product 
3.21o.  
 
The derivatization of the major diastereomer of 3.21o was performed based on a method previously 
reported in the literature.28 3.21o-Major (79 mg, 0.14 mmol) was dissolved in a solution of 4.4% 
formic acid in MeOH (3.0 mL), whereupon Pd/C (10%, 7.9 mg) was added. The reaction mixture 
was placed in an oil bath at 40 °C and was allowed to stir for 12 hours. After the solution was 
cooled down to 22 °C, the suspension was filtered through a pad of Celite using DCM as solvent 
and the mixture was concentrated to remove the solvent and volatile side products to obtain the 
product 3.34o-major-int as a colorless oil (23 mg, >95% yield).  
2-(2-Aminoethyl)succinic acid 3.34o-major-int was then dissolved in DCM, whereupon Et3N (20 
µL, 0.15 mmol) and di-tert-butyl dicarbonate (30 µL, 0.15 mmol) were added, dropwise. The 
reaction mixture was allowed to stir at 22 °C for 12 hours. Upon completion, the unpurified 
mixture was concentrated to remove the solvent and volatile side products to obtain the product 
3.34o-major as a colorless oil (25 mg, 88% yield). [α]25D = + 27.6° (c = 1.0, acetone). Based on 
the observed optical rotation value, the absolute configuration of the major diastereomer was 
assigned in analogy as 3.21o-(R,R,R).28 
                                                 






3.6.4.2. Determination of the Absolute Configuration of 3.21q-(R,R,R) 
The absolute configuration of 3.21q-(R,R,R) was determined by the X-ray crystallographic 
analysis of 3.34q-major (Scheme S9). 
Scheme S9. Derivatization of 3.21q-Major and Crystal Structure of 3.34q-Major 
 
(2R,4R)-1-Benzyl-2-(((tert-butyldimethylsilyl)oxy)diphenylmethyl)-4-((R)-1,4-diisopropoxy-
1,4-dioxobutan-2-yl)pyrrolidin-1-ium chloride (3.34q-major) 
11i-major was synthesized by the following procedure. 3.21q-(R,R,R) was diluted in ethyl ether 
(0.2 mL) and 2.0 M HCl in ethyl ether was added dropwise to the solution until a white precipitate 
was formed. The solid was allowed to precipitate out of solution, whereupon the solvent was 
removed in vacuo to afford 3.34q-major as a white solid. 3.34q-Major was then recrystallized 











3.6.4.3. Determination of the Absolute Configuration of 3.21r-(S,S,R,S) 
The absolute configuration of 3.21r-(S,S,R,S) was determined through 2D NMR studies. The 
following are the spectra and assignments (Figures S4−6). 
 








Figure S5. 2D COSY spectra of 3.21r-major 
 





The absolute configuration of 3.21r-major was assigned to be (S,S,R,S) by the 2D NMR analyses 





3.6.4.4. Determination of the Absolute Configuration of 3.24b-(R,R,R,S) 
The absolute configuration of 3.24b-(R,R,R,S) was determined by the X-ray crystallographic 
analysis of 3.35b (Scheme S10). 




11a was synthesized by the following procedure. To a solution of 3.24b (371 mg, 0.50 mmol) in 
THF (5.0 mL) was added TBAF (2.0 M, 2.5 mL), dropwise. The reaction was placed in an oil bath 
at 60 °C and was allowed to stir for 12 hours. After the reaction mixture was cooled down to 22 
°C, it was quenched with NaHCO3 (aq.) and extracted with DCM (3 x 25 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The unpurified product was 
then subjected to flash silica gel column chromatography (EtOAc:hexanes = 1:4) to afford 3.35b 
as a white solid (120 mg, 40%). 
1H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 7.3 Hz, 2H), 7.51 (d, J = 7.0 Hz, 2H), 7.32 (t, J = 7.5 
Hz, 2H), 7.29 – 7.23 (m, 5H), 7.23 – 7.07 (m, 7H), 6.97 (d, J = 6.2 Hz, 2H), 6.27 (d, J = 6.9 Hz, 
1H), 4.90 (dt, J = 6.7, 4.8 Hz, 1H), 3.99 (dd, J = 10.3, 3.1 Hz, 1H), 3.77 (d, J = 4.9 Hz, 2H), 3.11 
(d, J = 12.5 Hz, 1H), 3.06 (br, 1H), 2.95 (d, J = 12.6 Hz, 1H), 2.77 – 2.65 (m, 1H), 2.26 – 2.14 (m, 
3H), 2.10 (dd, J = 15.9, 4.0 Hz, 1H), 1.90 (ddd, J = 12.5, 6.6, 3.0 Hz, 1H), 1.81 (qd, J = 10.2, 3.5 






3.35b was recrystallized using the vapor-vapor diffusion method, using benzene to dissolve the 
product in an inner vial, and pentane as the precipitant placed in the outer vial in order for slow 
diffusion to occur into the inner vial. The solution was cooled to 0 °C, whereupon a crystal was 
obtained for X-ray crystallography (Figure S7). The X-ray crystallographic analysis revealed that 
the absolute configuration of 3.35b is (R,R,R,S). 
 








3.6.4.5. Determination of the Absolute Configuration of 3.26d-(R,S) 
The absolute configuration of 3.26d-(R,S) was determined by X-ray crystallographic analysis of 
3.29d-(R,S) (Scheme S11).29 
Scheme S11. Derivatization of 3.26d-(R,S) and Crystal Structure of 3.29d-(R,S) 
 
(S)-4,4,4-Trifluoro-3-((R)-1-(4-methoxyphenyl)pyrrolidin-3-yl)butan-1-ol (3.28d-(R,S)) 
A solution of EtSH (0.51 g, 8.2 mmol, 3.4 equiv) in THF (0.1 M) was cooled to –78 °C and treated 
with n-BuLi (3.8 mL, 6.0 mmol, 1.6 M in hexane, 2.5 equiv). The reaction was allowed to stir at 
0 °C for 30 min. A solution of the 3.26d-(R,S) (1.04 g, 2.4 mmol, 1.0 equiv) in THF (0.060 M) 
was then added dropwise. The reaction was allowed to stir at 0 °C until the consumption of the 
starting material was complete as monitored by TLC (0.5 – 1 h). The reaction was quenched with 
saturated NH4Cl (aq.) and the phases separated. The aqueous layer was extracted with ethyl ether 
(x 3), the combined organic layers were dried over MgSO4, and the solvent removed by rotary 
evaporation. The crude product was then dissolved in ethyl ether (0.10 M) and added to a 
suspension of LiAlH4 (0.29 g, 7.2 mmol, 3.0 equiv) in ethyl ether at 22 °C. The mixture was stirred 
until the consumption of the starting material was monitored by TLC (0.5 – 2 h). The reaction was 
carefully quenched by the addition of water at 0 °C. The aqueous layer was then extracted with 
ethyl ether (x 3) and the combined organic layers were dried over MgSO4 and the solvents removed 
                                                 





to yield the crude product, which was purified by flash silica gel column chromatography.  
1H NMR (500 MHz, CDCl3): δ 6.85 (d, J = 9.0 Hz, 2H), 6.53 (d, J = 9.0 Hz, 2H), 3.82 (dt, J = 
12.0, 6.4 Hz, 1H), 3.79 – 3.71 (m, 4H), 3.42 (t, J = 8.4 Hz, 1H), 3.36 (td, J = 8.7, 1.8 Hz, 1H), 3.26 
(td, J = 9.4, 6.6 Hz, 1H), 3.06 (t, J = 9.1 Hz, 1H), 2.67 – 2.55 (m, 1H), 2.41 (tdd, J = 9.7, 6.5, 2.8 
Hz, 1H), 2.22 (dt, J = 13.0, 6.7 Hz, 1H), 1.96 – 1.75 (m, 3H), 1.43 (s, 1H); 13C NMR (126 MHz, 
CDCl3): δ 151.3, 142.8, 128.4 (q, J = 281.0 Hz), 115.2, 112.7, 60.7, 56.1, 51.6, 48.2, 42.5 (q, J = 
24.9 Hz), 38.0, 30.3, 29.7; 19F NMR (470 MHz, CDCl3): δ -68.24 (d, J = 9.2 Hz); IR (neat): ν 
3385, 2933, 2831, 1514, 1485, 1371, 1239, 1158, 1126, 1039, 812 cm-1; HRMS (DART): Calcd 





To a solution of 3.28d-(R,S) (330 mg, 1.1 mmol, 1.0 equiv.) in toluene (0.035 M) were added p-
bromophenyl isocyanate (416 mg, 3.3 mmol, 3.0 equiv.) and pyridine (434 mg, 5.5 mmol, 5.0 
equiv.). The resulting heterogeneous solution was placed in an oil bath at 100 °C and was allowed 
to stir for 1 hour. The solution was then cooled to 22 °C and filtered through a short plug of Celite 
using DCM. The filtrate was concentrated and the residue was purified by flash silica gel column 
chromatography (EtOAc:hexanes = 1:9) to afford compound 3.29d-(R,S) (406 mg, 74%) as a 
white solid.  
1H NMR (600 MHz, CDCl3): δ 7.41 (dd, J = 8.8, 1.4 Hz, 2H), 7.30 – 7.20 (m, 2H), 6.82 (d, J = 
7.6 Hz, 2H), 6.62 (s, 1H), 6.50 (d, J = 7.6 Hz, 2H), 4.34 (dt, J = 11.8, 6.1 Hz, 1H), 4.27 – 4.16 (m, 





3.05 (t, J = 8.9 Hz, 1H), 2.59 (h, J = 8.0 Hz, 1H), 2.40 – 2.28 (m, 1H), 2.22 (dt, J = 13.4, 6.8 Hz, 
1H), 2.07 – 1.92 (m, 2H), 1.87 (p, J = 10.0 Hz, 1H); 13C NMR (151 MHz, CDCl3): δ 153.1, 151.2, 
142.6, 136.9, 132.1, 128.0 (q, J = 280.8 Hz), 120.4, 115.1, 112.6, 63.3, 56.0, 51.5, 48.0, 42.8 (q, J 
= 25.1 Hz), 37.9, 30.2, 26.5; 19F NMR (564 MHz, CDCl3): δ -68.15 (d, J = 9.4 Hz); IR (neat): ν 
3310, 2924, 2831, 1708, 1592, 1511, 1486, 1396, 1371, 1305, 1233, 1212, 1162, 1129, 1073, 1006, 
890, 810, 764, 735, 700, 650, 626, 592, 521, 503, 458 cm-1; HRMS (DART): Calcd for 
C22H25BrF3N2O3 (MH+): 501.0995; found: 501.0964; Specific Rotation [α]25D = 20.0° (c = 1.0, 
DCM). 
 
3.29d-(R,S) was recrystallized using the vapor-vapor diffusion method, using i-PrOH to dissolve 
the product in an inner vial, and pentane as the precipitant placed in the outer vial in order for slow 
diffusion to occur into the inner vial. The solution was cooled to 0 °C, whereupon a crystal was 
obtained for the X-ray crystallography (Scheme S11). The X-ray crystallographic analysis revealed 






3.6.4.6 Determination of the Absolute Configuration of 3.26e 
The absolute configuration of 3.26e was determined by analogy to 3.26d-major and by 1D 










Figure S8. 1D NOESY spectra of 3.26e 
 






3.6.5. Derivatization of β-Alkylated Amines 
3.6.5.1. Hydrogenation of 3.26f  
 
Diastereoselective hydrogenation of enamine 3.26f was achieved following a previously reported 
literature.19 In a nitrogen filled glove box, Ir[(COD)Cl]2 (3.4 mg, 5.0 mol%), (R)-SIPHOS-PE (11.1 
mg, 22 mol%), and 1.0 mL THF were added to an oven-dried 7.0 mL vial. The mixture was allowed 
to stir at 22 p for 30 min and then transferred to an oven-dried 100 mL Schlenk flask. Then, I2 
(12.7 mg, 0.5 equiv), 3.26f (48.2 mg, 0.10 mmol) and 1.0 mL THF were added to the mixture and 
then the Schlenk flask was taken out of the glove box. The nitrogen atmosphere in the Schlenk 
flask was replaced by hydrogen three times and finally hydrogen gas was charged at −200 p. The 
reaction mixture was slowly warmed up to 22 p and was allowed to stir for 36 hours (under 4.0 
atm H2 pressure). 19F NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was 5.0:1. After purification by flash silica gel column chromatography 
(EtOAc:hexanes = 1:3), 3.30f was obtained as a mixture of diastereomers (40.0 mg, 83% yield). 
Further purification was carried out by PTLC using ethyl ether:hexanes = 2:1 as the eluent to obtain 
3.30f-major. 
 
3.30f-Major. 1H NMR (400 MHz, CDCl3): δ 6.58 (d, J = 3.0 Hz, 1H), 6.45 (d, J = 3.0 Hz, 1H), 
3.74 (s, 3H), 3.23 (dd, J = 17.7, 6.2 Hz, 1H), 3.09 – 2.90 (m, 7H), 2.85 (d, J = 11.3 Hz, 1H), 2.63 





1.61 (m, 2H), 1.31 – 1.26 (m, 7H), 1.04 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3): δ 
175.49, 168.72, 156.49, 142.54, 138.95, 137.91, 128.12 (q, J = 281.1 Hz), 114.22, 113.39, 60.72, 
55.37, 54.13, 50.83, 47.16, 44.07, 41.71 (q, J = 25.1 Hz), 37.44, 32.81, 28.72, 27.05, 25.94, 25.81, 
20.21, 19.66, 12.83; 19F NMR (376 MHz, CDCl3): δ -66.80 (d, J = 10.1 Hz); IR (neat): ν 2930, 
2851, 1745, 1711, 1602, 1485, 1466, 1372, 1309, 1254, 1222, 1189, 1154, 1119, 1067, 990, 855, 
616 cm-1; HRMS (DART): Calcd for C25H37F3N3O3 (MH+): 484.2782; found: 484.2785; Specific 
Rotation [α]25D = -8.0° (c = 0.35, DCM). 
3.30f (major:minor = 1:1.3). 1H NMR (400 MHz, CDCl3, peaks from diastereomers are 
merged): 6.58 (d, J = 3.1 Hz, 1H), 6.45 (d, J = 3.0 Hz, 1H), 3.74 (s, 3H), 3.28 – 3.15 (m, 1H), 3.10 
– 2.92 (m, 7H), 2.89 – 2.80 (m, 1H), 2.67 – 2.51 (m, 2H), 2.29 – 2.21 (m, 6H), 2.11 – 1.99 (m, 
1H), 1.97 – 1.84 (m, 1H), 1.76 – 1.60 (m, 2H), 1.33 – 1.25 (m, 7H), 1.12 – 1.01 (m, 3H); 19F NMR 







3.6.5.1. Fluorocyanation of 3.26f  
 
Fluorocyanation of enamine 3.26f was achieved following a previously reported literature.20 To an 
oven-dried 10 mL round bottom flask was added NFSI (34.7 mg, 1.1 equiv), TMSCN (0.02 mL, 
1.5 equiv) and 0.50 mL of MeCN. After the mixture was cooled to 0 p, pyridine (0.01 mL, 1.2 
equiv) and 3.26f (48.2 mg, 0.10 mmol) were added. The reaction mixture was allowed to stir at 0 
p for 1 hour. Upon completion, the mixture was quenched with saturated aqueous NaHCO3 and 
extracted with ethyl ether three times. The combined organic layer was washed with brine, dried 
with MgSO4 and was concentrated in vacuo. The 19F NMR analysis of the unpurified product 
mixture revealed that the diastereomeric ratio was 4.0:1. After purification by flash silica gel 
column chromatography (EtOAc:hexanes = 1:3), 3.31f was obtained as a mixture of diastereomers 
(46.5 mg, 88% yield). Further purification was carried out by PTLC using EtOAc:hexanes = 1:3 
as the eluent to separate 3.31f-major and 3.31f-minor. 
 
3.31f-Major. 1H NMR (600 MHz, CDCl3): δ 6.56 (d, J = 3.1 Hz, 1H), 6.50 (d, J = 3.1 Hz, 1H), 
4.15 (d, J = 4.9 Hz, 1H), 3.82 – 3.70 (m, 4H), 3.64 (t, J = 11.6 Hz, 1H), 3.47 (ddd, J = 19.1, 6.4, 
2.3 Hz, 1H), 3.16 (dd, J = 19.4, 4.3 Hz, 1H), 3.06 – 2.92 (m, 3H), 2.62 (d, J = 17.3 Hz, 1H), 2.55 
(d, J = 17.3 Hz, 1H), 2.47 (s, 3H), 2.35 – 2.24 (m, 4H), 2.19 – 2.01 (m, 2H), 1.77 – 1.67 (m, 1H), 
1.33 – 1.24 (m, 7H), 1.04 (t, J = 7.1 Hz, 3H); 13C NMR (151 MHz, CDCl3): δ 175.5, 167.7, 157.4, 
139.1, 138.95, 138.86, 126.4 (q, J = 281.9 Hz), 117.1 (d, J = 10.2 Hz), 114.7, 114.3, 92.3 (d, J = 
193.6 Hz), 60.9, 58.8 (d, J = 29.9 Hz), 55.4, 47.5, 47.2, 44.6 (qd, J = 26.1, 21.4 Hz), 43.8, 31.8 





19F NMR (564 MHz, CDCl3): δ -63.97 – -64.00 (m), -161.94; IR (neat): ν 2961, 2839, 1746, 
1711, 1601, 1485, 1466, 1442, 1375, 1304, 1263, 1234, 1216, 1155, 1132, 1094, 1069,992, 975, 
950, 930, 898, 856, 736, 619 cm-1; HRMS (DART): Calcd for C26H35F4N4O3 (MH+): 527.2640; 
found: 527.2640; Specific Rotation [α]25D = +6.9° (c = 1.0, DCM). 
 
3.31f-Minor. 1H NMR (400 MHz, CDCl3): δ 6.58 (d, J = 3.0 Hz, 1H), 6.49 (d, J = 3.0 Hz, 1H), 
4.50 (d, J = 20.3 Hz, 1H), 4.10 (tt, J = 9.8, 5.7 Hz, 1H), 3.74 (s, 3H), 3.45 (dd, J = 17.8, 5.1 Hz, 
1H), 3.27 (ddd, J = 18.0, 6.5, 2.4 Hz, 1H), 3.19 – 3.03 (m, 2H), 3.01 (q, J = 7.1 Hz, 2H), 2.60 (d, 
J = 3.4 Hz, 2H), 2.40 – 2.26 (m, 7H), 2.09 – 1.95 (m, 1H), 1.89 – 1.63 (m, 3H), 1.31 (d, J = 1.7 
Hz, 6H), 1.06 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.77, 166.98, 157.91, 140.77, 
138.35, 138.06, 125.91 (q, J = 280.2 Hz), 114.72 (d, J = 1.9 Hz), 114.48, 113.98, 91.82 (d, J = 
192.2 Hz), 60.72, 59.36 (dd, J = 20.1, 2.5 Hz), 55.28, 49.75, 47.10, 44.89 (p, J = 26.2 Hz), 44.16, 
31.18 (dd, J = 6.7, 2.7 Hz), 29.12, 28.95, 25.87 (d, J = 13.1 Hz), 21.03 (d, J = 2.8 Hz), 19.65, 19.55, 
12.73; 19F NMR (470 MHz, CDCl3): δ -64.16 – -64.69 (m), -159.84; IR (neat): ν 2925, 2851, 
1744, 1712, 1602, 1484, 1465, 1443, 1374, 1302, 1263, 1225, 1196, 1183, 1144, 1113, 1070, 1023, 
992, 949, 855, 835, 796, 769, 734, 619, 458 cm-1; HRMS (DART): Calcd for C26H35F4N4O3 






3.6.6. Mechanistic Studies for β-Amino C−H Alkylation Reaction 
We have demonstrated that cooperative functions of B(C6F5)3 and a chiral Lewis acid co-catalyst 
can promote highly enantioselective union of N-alkylamines and α,β-unsaturated compounds. To 
shed light on the mechanism of this enantioselective process, we embarked on investigations that 
were aimed at determining its turnover-limiting step, understanding the nature of hydride and 
proton transfer processes, and elucidating the origin of chemoselectivity between enamine and N-
alkylamine products. 
Following are the mechanistic studies that were carried out to obtain the necessary data: 
Section 3.6.6.1.1: Determination of the reaction orders involving 3.25e 
Section 3.6.6.1.2: Detection of the catalyst resting state involving 3.25e 
Section 3.6.6.1.3: Kinetic isotope effect studies involving 3.25e 
Section 3.6.6.1.4: Hammett studies 
Section 3.6.6.3: Monitoring the ratios at which different products are formed by the 1H NMR 
studies. 
Section 3.6.6.4.1: Determination of the reaction orders involving 3.25a 
Section 3.6.6.4.2: Detection of the catalyst resting state involving 3.25a 






3.6.6.1 Mechanistic Studies Involving 3.25e 
3.6.6.1.1 Determination of the Reaction Orders 
For the β-C–H alkylation reaction involving 1-(4-methoxyphenyl)pyrrolidine 3.19t and 1-benzyl-
2-cinnamoyl-5,5-dimethylpyrazolidin-3-one 3.25e, the reaction order of each reactant was studied 
through time course reaction monitoring by the 1H NMR spectroscopic analysis. 
3.6.6.1.1.1. Reaction Order of B(C6F5)3 
The reaction between 3.19t and 3.25e was performed using different concentrations of B(C6F5)3 
and the progress of each reaction was monitored by the 1H NMR spectroscopy (Scheme S12).  
Scheme S12. Determination of the Reaction Order of B(C6F5)3 
 
In a nitrogen-filled glove box, L9−Sc(OTf)3 (51.4 mg, 10 mol%), 3.19t (115.1 mg, 0.65 mmol), 
3.25e (326.1 mg, 1.5 equiv) and mesitylene (78.0 mg, 1.0 equiv) were weighed in an oven-dried 
7.0 mL vial and the resulting mixture was dissolved in 3.25 mL of CD2Cl2 (Stock Solution A). In 
another oven-dried 7.0 mL vial, B(C6F5)3 (30.7 mg, 0.060 mmol) was weighed and dissolved in 
1.20 mL of CD2Cl2 (Stock Solution B). To each J-Young tube was added Stock Solution A (0.50 
mL), Stock Solution B (0.05, 0.10, 0.15, 0.20, 0.25, or 0.30 mL) and CD2Cl2 (0.25, 0.20, 0.15, 
0.10, 0.05 or 0 mL) to prepare the reaction samples containing different concentrations of B(C6F5)3. 
After the J-Young tube was tightly capped with the Teflon plug, it was taken out of the glove box 
and the 1H NMR spectra were acquired in the NMR spectrometer preheated at 60 °C using a pre-
acquisition delay in array mode with a spectrum taken every 22 seconds for the length of the 





normalized using mesitylene as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 
600 seconds, showed that there is second-order dependency on B(C6F5)3 concentration in the 
reaction between 3.19t and 3.25e (Figures S9, 10). 
 
 






Figure S10. Log(rate) vs log[B(C6F5)3] is employed to determine the initial reaction order for 






3.6.6.1.1.2. Reaction Order of L9−Sc(OTf)3 
The reaction between 3.19t and 3.25e was performed using different concentrations of 
L9−Sc(OTf)3 and the progress of each reaction was monitored by the 1H NMR spectroscopy 
(Scheme S13).  
Scheme S13. Determination of the Reaction Order of L9−Sc(OTf)3 
 
In a nitrogen-filled glove box, B(C6F5)3 (26.6 mg, 10 mol%), 3.19t (92.0 mg, 0.52 mmol), 3.25e 
(260.8 mg, 1.5 equiv) and mesitylene (26.6 mg, 1.0 equiv) were weighed in an oven-dried 7.0 mL 
vial and the resulting mixture was dissolved in 2.10 mL of CD2Cl2 (Stock Solution A). In another 
oven-dried 7.0 mL vial, L9−Sc(OTf)3 (47.4 mg, 0.060 mmol) was weighed and dissolved in 1.20 
mL of CD2Cl2 (Stock Solution B). To each J-Young tube was added Stock Solution A (0.40 mL), 
Stock Solution B (0.10, 0.20, 0.30 or 0.40 mL) and neat CD2Cl2 (0.30, 0.20, 0.10 or 0 mL) to 
prepare the reaction samples containing different concentrations of L9−Sc(OTf)3. After the J-
Young tube was tightly capped with the Teflon plug, it was taken out of the glove box and 1H NMR 
spectra were acquired in the NMR spectrometer preheated at 60 °C using a pre-acquisition delay 
in array mode with a spectrum taken every 22 seconds for the length of the experiment. The data 
were processed using MestReNova software and peak integrations were normalized using 
mesitylene as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 
1200 seconds, showed that there is zero-order dependency on L9−Sc(OTf)3 concentration in the 














Figure S12. Log(rate) vs log[L9−Sc(OTf)3] is employed to determine the initial reaction order for 







3.6.6.1.1.3. Reaction Order of Amine 
The reaction between 3.19t and 3.25e was performed using different concentrations of 3.19t and 
the progress of each reaction was monitored by the 1H NMR spectroscopy (Scheme S14).  
Scheme S14. Determination of the Reaction Order of 3.19t 
 
 
In a nitrogen-filled glove box, B(C6F5)3 (28.2 mg, 0.055 mmol), L9−Sc(OTf)3 (43.5 mg, 0.055 
mmol), 3.25e (275.9 mg, 0.83 mmol) and mesitylene (66.1 mg, 0.55 mmol) were weighed in an 
oven-dried 7.0 mL vial and the resulting mixture was dissolved in 4.40 mL of CD2Cl2 (Stock 
Solution A). In 5 oven-dried 7.0 mL vials were added 3.19t (4.4 mg, 8.9 mg, 17.7 mg, 26.6 mg or 
35.4 mg). To each oven-dried vial containing 3.19t was added Stock Solution A (0.80 mL) to 
prepare the reaction samples containing different concentrations of 3.19t. The reaction mixture 
was then transferred to a J-Young tube. After the J-Young tube was tightly capped with the Teflon 
plug, it was taken out of the glove box and 1H NMR spectra were acquired in the NMR 
spectrometer preheated at 60 °C using a pre-acquisition delay in array mode with a spectrum taken 
every 22 seconds for the length of the experiment. The data were processed using MestReNova 
software and peak integrations were normalized using mesitylene as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 
600 seconds, showed that there is first-order dependency on amine 3.19t concentration in the 







Figure S13. Monitoring the formation of 3.26k under different concentrations of amine 3.19t 
 
Figure S14. Log(rate) vs log[amine 3.19t] is employed to determine the initial reaction order for 





3.6.6.1.1.4. Reaction Order of α,β-Unsaturated Compound 
The reaction between 3.19t and 3.25e was performed using different concentrations of 3.25e and 
the progress of each reaction was monitored by the 1H NMR spectroscopy (Scheme S15).  
Scheme S15. Determination of the Reaction Order of 3.25e 
 
 
In a nitrogen-filled glove box, L9−Sc(OTf)3 (49.0 mg, 10 mol%), 3.19t (109.7 mg, 0.62 mmol), 
and mesitylene (74.4 mg, 1.0 equiv) were weighed in an oven-dried 7.0 mL vial and the resulting 
mixture was dissolved in 3.10 mL of CD2Cl2 (Stock Solution A). In another oven-dried 7.0 mL 
vial, B(C6F5)3 (35.8mg, 0.70 mmol) was weighed and dissolved in 2.10 mL of CD2Cl2 (Stock 
Solution B). In 4 oven-dried 7.0 mL vials were added 3.25e (33.4 mg, 50.2 mg, 66.9 mg, or 100.3 
mg). To each oven-dried vial containing 3.25e was added Stock Solution A (0.50 mL) and Stock 
Solution B (0.30 mL) to prepare the reaction samples containing different concentrations of 3.25e. 
The reaction mixture was then transferred to a J-Young tube. After the J-Young tube was tightly 
capped with the Teflon plug, it was taken out of the glove box and 1H NMR spectra were acquired 
in the NMR spectrometer preheated at 60 °C using a pre-acquisition delay in array mode with a 
spectrum taken every 22 seconds for the length of the experiment. The data were processed using 
MestReNova software and peak integrations were normalized using mesitylene as the internal 
standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 





concentration in the reaction between 3.19t and 3.25e (Figures S15, 16). 
 
Figure S15. Monitoring the formation of 3.26k under different concentrations of 3.25e 
 
Figure S16. Log(rate) vs log[α,β-unsaturated compound 3.25e] is employed to determine the 






3.6.6.1.2. 19F NMR Experiments for the Detection of the Resting State 
The mechanistic investigations described above (Section 3.6.6.1.1) revealed that the 
(F5C6)3B/L−Sc(OTf)3 co-catalyzed β-amino C−H functionalization has a −1 order dependency 
with respect to the concentration of 1-benzyl-2-cinnamoyl-5,5-dimethylpyrazolidin-3-one 3.25e 
(see Section 3.6.6.1.4). We hypothesized that 3.25e and B(C6F5)3 could form a resting state 
complex and therefore carried out the following 19F NMR experiments to identify the structure of 
the complex (Figures S17, S18). Previously, the group of Piers has reported that B(C6F5)3 and 
benzaldehyde forms an acid−base adduct, which gives characteristic 19F NMR peaks 
at −135.3, −156.3, −164.5 ppm. We acquired the 19F NMR spectrum of a sample containing 1:1 
ratio of B(C6F5)3 and 6g in CD2Cl2 (Figures S17B, S18) and observed new 19F NMR peaks 
at −134.8, −157.7, −164.7 ppm; based on this analysis, our spectrum is in agreement with the 
formation of 3.25e−B(C6F5)3 adduct. The resting state complex was also observed in the reaction 

















3.6.6.1.3. Kinetic Isotope Effect Experiments 
As discussed in Section 3.6.6.1.2, zero-order dependency with respect to concentration of L9–
Sc(OTf)3 suggests that enantioselective C–C bond forming reaction occurs after the turnover-
limiting step. In order to probe whether the turnover-limiting step is the hydride abstraction or the 
deprotonation process, we carried out the following parallel kinetic isotope effect experiments. 
3.6.6.1.3.1. Parallel KIE Measurement for N-Alkylamines Containing α-Amino C−H or C−D 
Bonds  
A parallel kinetic isotope effect study was conducted through time course reaction monitoring by 
the 1H NMR spectroscopy using internal standard to monitor the difference in initial rates of the 
product formation in the reaction of 1-(4-methoxyphenyl)pyrrolidine 3.19t or 1-(4-
methoxyphenyl)pyrrolidine-2,2,5,5-d4 3.19tα-d with 1-benzyl-2-cinnamoyl-5,5-
dimethylpyrazolidin-3-one 3.25e (Scheme S16). In a nitrogen-filled glove box, B(C6F5)3 (20.5 mg, 
0.040 mmol), L9−Sc(OTf)3 (31.6 mg, 0.040 mmol), 6g (200.8 mg, 0.60 mmol) and mesitylene (48 
mg, 0.40 mmol) were weighed in an oven-dried 7.0 mL vial and the resulting mixture was 
dissolved in 2.00 mL of CD2Cl2 (Stock Solution A). In two oven-dried 7.0 mL vials were added 
3.19t (20.5 mg) or 3.19tα-d (20.9 mg). To each oven-dried vial containing 3.19t or 3.19tα-d was 
added CD2Cl2 (0.30 mL) and Stock Solution A (0.50 mL) to prepare the reaction samples 
containing 3.19t or 3.19tα-d. The reaction mixture was then transferred to a J-Young tube. After 
the J-Young tube was tightly capped with the Teflon plug, it was taken out of the glove box and 
1H NMR spectra were acquired in the NMR spectrometer preheated at 60 °C using a pre-
acquisition delay in array mode with a spectrum taken every 22 seconds for the length of the 
experiment. The acquired data were processed using MestReNova software and peak integrations 





From the kinetic analysis based on the initial rates of the product formation (Figure S19), KIE 
value of 1.28 ± 0.07 (average of two experiments) was obtained in the reaction between 3.19t or 
3.19tα-d and 3.25e. This suggests that the hydride abstraction step is not likely the turnover 
limiting process. From the 1H NMR analysis of the isolated and purified 3.26kα-d in CDCl3, it 
was revealed that >95% of d-incorporation level was retained at the α-amino position (Figures 
S20−22). This result suggests that the borohydride reduction step may be irreversible as there was 





Scheme S16. Kinetic Isotope Effect Studies 
3.19tα-d, 0.10 mmol 3.26kα-d
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+
3.19t, 0.10 mmol 3.25e, 0.15 mmol 3.26k


















































































Figure S21. 1H NMR spectrum of 3.26k 
 

















3.6.6.1.3.2. Parallel KIE Measurement for N-Alkylamines Containing β-Amino C−H or 
C−D Bonds 
A parallel kinetic isotope effect study was conducted through time course reaction monitoring by 
the 1H NMR spectroscopy using internal standard to monitor the difference in initial rates of the 
product formation in the reaction of 1-(4-methoxyphenyl)pyrrolidine 3.19t or 1-(4-
methoxyphenyl)pyrrolidine-3,3,4,4-d4 3.19tβ-d with 1-benzyl-2-cinnamoyl-5,5-
dimethylpyrazolidin-3-one 3.25e (Scheme S17). In a nitrogen-filled glove box, B(C6F5)3 (20.5 mg, 
0.040 mmol), L9−Sc(OTf)3 (31.6 mg, 0.040 mmol), 3.25e (200.8 mg, 0.60 mmol) and mesitylene 
(48 mg, 0.40 mmol) were weighed in an oven-dried 7.0 mL vial and the resulting mixture was 
dissolved in 2.00 mL of CD2Cl2 (Stock Solution A). In two oven-dried 7.0 mL vials were added 
3.19t (20.5 mg) or 3.19tβ-d (20.9 mg). To each oven-dried vial containing 3.19t or 3.19tβ-d was 
added CD2Cl2 (0.30 mL) and Stock Solution A (0.50 mL) to prepare the reaction samples 
containing 3.19t or 3.19tβ-d. The reaction mixture was then transferred to a J-Young tube. After 
the J-Young tube was tightly capped with the Teflon plug, it was taken out of the glove box and 
1H NMR spectra were acquired in the NMR spectrometer preheated at 60 °C using a pre-
acquisition delay in array mode with a spectrum taken every 22 seconds for the length of the 
experiment. The data were processed using MestReNova software and peak integrations were 
normalized using mesitylene as the internal standard. 
Kinetic analysis based on the initial rates of the product formation (Figure S23) demonstrates that 
3.19t reacts 2.5 times faster than 3.19tβ-d (kH/kD = 2.50 ± 0.13, average of two experiments) in the 
reaction between 3.19t or 3.19tβ-d and 3.25e. This result suggests that the cleavage of β-amino 
C−H bond is likely involved in the turnover-limiting step. 





incorporation level was determined (Figures S24−28). It was found that there was a d-scrambling 
between the substrates and the products at the β-amino C−H/D bonds and the α-carbonyl C−H/D 







Scheme S17. Kinetic Isotope Effect Studies 
[36%]
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+
3.19t, 0.10 mmol 3.25e, 0.15 mmol 3.26k





































































Figure S24. 1H NMR spectrum of 3.26k (in CDCl3) 
 










































Figure S27. 1H NMR spectrum of 3.26k (in acetone-d6) 
 























3.6.6.1.3.3. Intermolecular Competition KIE Measurement for N-Alkylamines Containing α-
Amino C−H or C−D Bonds 
In order to further probe if the turnover-limiting step is the deprotonation process, we carried out 
the following intermolecular competition kinetic isotope effect experiments. 
An intermolecular competition kinetic isotope effect study between 1-(4-
methoxyphenyl)pyrrolidine 3.19t and 1-(4-methoxyphenyl)pyrrolidine-2,2,5,5-d4 3.19tα-d with 
1-benzyl-2-cinnamoyl-5,5-dimethylpyrazolidin-3-one 3.25e was conducted (Scheme S18). 
Specifically, to a 15 mL oven-dried pressure vessel was added B(C6F5)3 (10.2 mg, 0.020 mmol), 
L9−Sc(OTf)3 (15.8 mg, 0.020 mmol), 3.25e (100.4 mg, 0.30 mmol), 3.19t (17.7 mg, 0.10 mmol), 
3.19tα-d (18.1 mg, 0.10 mmol) and DCM (1.6 mL) under nitrogen atmosphere. The mixture was 
placed in an oil bath at 60 °C and was allowed to stir for 1 hour. Upon completion, the solution 
was cooled to 22 °C and concentrated in vacuo. The 1H NMR analysis of the unpurified product 
mixture using mesitylene as the internal standard revealed that product 3.26kα-d was obtained in 
27% yield (3.5:1 dr). After purification by column chromatography (EtOAc:hexanes = 1:3), 
3.26kα-d was obtained as a light yellow liquid. 
From the 1H NMR analysis of the isolated and purified 3.26kα-d in CDCl3 (Figures S29, S30), 
KIE value of 1.7 was obtained in the reaction between 3.19t and 3.26kα-d with 3.25e. This result 
is in line with the previous independent kinetic isotope effect studies and supports that the hydride 














Figure S29. 1H NMR spectrum of 3.26k 
 

















3.6.6.1.3.4. Intermolecular Competition KIE Measurement for N-Alkylamines Containing β-
Amino C−H or C−D Bonds 
An intermolecular competition kinetic isotope effect study between 1-(4-
methoxyphenyl)pyrrolidine 13.19t and 1-(4-methoxyphenyl)pyrrolidine-3,3,4,4-d4 3.19tβ-d with 
1-benzyl-2-cinnamoyl-5,5-dimethylpyrazolidin-3-one 3.25e was conducted (Scheme S19). 
Specifically, to a 15 mL oven-dried pressure vessel was added B(C6F5)3 (10.2 mg, 0.020 mmol), 
L9−Sc(OTf)3 (15.8 mg, 0.020 mmol), 6g (100.4 mg, 0.30 mmol), 3.19t (17.7 mg, 0.10 mmol), 
3.19tβ-d (18.1 mg, 0.10 mmol) and DCM (1.6 mL) under nitrogen atmosphere. The mixture was 
placed in an oil bath at 60 °C and was allowed to stir for 1 hour. Upon completion, the solution 
was cooled to 22 °C and concentrated in vacuo. The 1H NMR analysis of the unpurified product 
mixture using mesitylene as the internal standard revealed that product 3.26kβ-d was obtained in 
23% yield (2.0:1 dr). After purification by column chromatography (EtOAc:hexanes = 1:3), 
3.26kβ-d was obtained as a light yellow liquid. 
From the 1H NMR analysis of the isolated and purified 3.26kβ-d in CDCl3 (Figures S31, S32), it 
was found that 3.19t reacts 4.3 times faster than 3.19tβ-d (kH/kD = 4.3) in the reaction between 
3.19t or 3.19tβ-d and 3.26kβ-d. This result is in line with the previous independent kinetic isotope 
effect studies and supports that the cleavage of β-amino C−H bond is likely involved in the 
turnover-limiting step. 
It was found that there was a d-scrambling between the substrates and the products at the β-amino 













Figure S31. 1H NMR spectrum of 3.26k (in CDCl3) 
 





3.6.6.1.4. Hammett Studies 
In order to study the effect of varying the substituents on aryl groups of N-alkylamine as well as 
α,β-unsaturated substrates on the rate of C–H alkylation, we carried out the following Hammett 
studies. 
3.6.6.1.4.1 Determination of the Hammett ρ Value for N-Aryl Substituted Pyrrolidines  
A Hammett ρ value for the reaction of N-aryl substituted pyrrolidines (3.19t, 3.19w−3.19y) and 
(E)-1-benzyl-5,5-dimethyl-2-(3-(4-(trifluoromethyl)phenyl)acryloyl)pyrazolidin-3-one 3.25f was 
determined by time course reaction monitoring by the 1H NMR spectroscopy using mesitylene as 
an internal standard. In a nitrogen-filled glove box, L9−Sc(OTf)3 (39.5 mg, 0.050 mmol), 3.25f 
(302 mg, 0.75 mmol), mesitylene (60 mg, 0.50 mmol), and C6F6 (46.5 mg, 0.25 mmol) were 
weighed in an oven-dried 7.0 mL vial and the resulting mixture was dissolved in 2.00 mL of 
CD2Cl2 (Stock Solution A). In another oven-dried 7.0 mL vial, B(C6F5)3 (30.7 mg, 0.060 mmol) 
was weighed and dissolved in 1.20 mL of CD2Cl2 (Stock Solution B). In 4 oven-dried 7.0 mL 
vials, were added 0.10 mmol of each amine. To each oven-dried vial containing amine was added 
Stock Solution A (0.40 mL), Stock Solution B (0.20 mL), and CD2Cl2 (0.20 mL) to prepare the 
reaction samples containing amines 3.19t, 3.19w, 3.19x, or 3.19y. The reaction mixture was then 
transferred to a J-Young tube. After the J-Young tube was tightly capped with the Teflon plug, it 
was taken out of the glove box and the 1H NMR spectra were acquired in the NMR spectrometer 
preheated at 60 °C using a pre-acquisition delay in array mode with a spectrum taken every 22 
seconds for the length of the experiment. The data were processed using MestReNova software 
and peak integrations were normalized using mesitylene as the internal standard. 
The large negative ρ value (−4.9) obtained implies the development of positive charge at the 





supports the proposed mechanism (see section 3.6.6.2) in which B(C6F5)3 abstracts a hydride from 
N-arylpyrrolidine to form an N-aryl iminium cation, and its isomerization into a positively charged 


































3.6.6.1.4.2. Determination of the Hammett ρ Value for Aryl Substituted α,β-Unsaturated 
Compounds 
A Hammett ρ value for the reaction of 1-(4-methoxyphenyl)pyrrolidine (3.19t) and aryl substituted 
α,β-unsaturated compounds (3.25e−3.25h) was determined by time course reaction monitoring by 
the 1H NMR spectroscopy using mesitylene as an internal standard. In a nitrogen-filled glove box, 
L9−Sc(OTf)3 (39.5 mg, 0.050 mmol), 3.19t (88.5 mg, 0.50 mmol), and mesitylene (60 mg, 0.50 
mmol) were weighed in an oven-dried 7.0 mL vial and the resulting mixture was dissolved in 2.00 
mL of CD2Cl2 (Stock Solution A). In another oven-dried 7.0 mL vial, B(C6F5)3 (30.7 mg, 0.060 
mmol) was weighed and dissolved in 1.20 mL of CD2Cl2 (Stock Solution B). In 4 oven-dried 7.0 
mL vials, were added 0.15 mmol of each α,β-unsaturated compounds 3.25. To each oven-dried 
vial containing amine was added Stock Solution A (0.40 mL), Stock Solution B (0.20 mL), and 
CD2Cl2 (0.20 mL) to prepare the reaction samples containing α,β-unsaturated compounds 3.25e, 
3.25f, 3.25g, or 3.25h. The reaction mixture was then transferred to a J-Young tube. After the J-
Young tube was tightly capped with the Teflon plug, it was taken out of the glove box and the 1H 
NMR spectra were acquired in the NMR spectrometer preheated at 60 °C using a pre-acquisition 
delay in array mode with a spectrum taken every 22 seconds for the length of the experiment. The 
data were processed using MestReNova software and peak integrations were normalized using 
mesitylene as the internal standard. 
The σ+ was used in the Hammett plot since the electron-donating ability of the p-OMe substituent 
was enhanced through conjugation in the α,β-unsaturated compound 3.25. The positive ρ value 
(0.92) obtained implies the development of negative charge at the reaction center in the transition 
state at or prior to the turnover-limiting step. This result thereby supports the mechanistic 





negatively charged boron–enolate intermediate, and that this hydride transfer occurs at or prior to 








































3.6.6.2. Catalytic Cycle Consistent with the Results of Mechanistic Studies 
Based on the kinetic studies as described above (Section 3.6.6.1), we propose the following 
catalytic cycle (Figure S35). Zero-order dependency with respect to concentration of L9–Sc(OTf)3 
suggests that enantioselective C–C bond forming reaction between in situ generated enamine and 
[L9–Sc(OTf)3]-activated 3.25e (XXVII → XXVIII, Figure S35) occurs after the turnover-limiting 
step (see Section 3.6.6.1.1.2). –1-Order dependency on the concentration of 3.25e suggests that 
the transformation has a resting state of 3.25e−B(C6F5)3 adduct (XXIII), which was suggested by 
19F NMR studies (see Sections 3.6.6.1.1.4, 3.6.6.1.2). Kinetic isotope effect studies demonstrate 
that cleavage of β-amino C−H bond is likely the turnover-limiting step (see Section 3.6.6.1.3). 
The large negative ρ value (-4.9) obtained from Hammett study of N-aryl substituted pyrrolidines 
supports the proposed mechanism that (F5C6)3B-catalyzed hydride abstraction to generate N-aryl 
iminium cation, and its isomerization into an enammonium species taking place at or prior to the 




















































































































































































































3.6.6.3. Origin of Enamine and N-Alkylamine Products 
In the β-amino C–H alkylation process, the products were obtained either as 3.26-enamine, 3.26-
alkylamine, or a mixture of the two (Figure S35). We questioned if the N-alkylamine products 
were formed through transfer hydrogenation of XXVIII (XXVIII→ 3.26-alkylamine). 
Alternatively, 3.26-alkylamine could be generated through reduction of 3.26-enamine (XXVIII 
→ 3.26-enamine → 3.26-alkylamine). In order to understand the origin of 3.26-enamine and 
3.26-alkylamine products, we conducted the following experiments. 
 
Section 3.6.6.3.1: Kinetic Profile for the β-Alkylation of N-Arylpiperidine 
Section 3.6.6.3.2: Transfer Hydrogenation of Compound 3.21v  
Section 3.6.6.3.3: Dehydrogenation of Compound 3.21i 
 
3.6.6.3.1. Kinetic Profile for the β-Alkylation of N-Arylpiperidine 
As shown in Scheme 3.16 in the manuscript, the reaction of N-arylpiperidine 3.19g and 
diisopropylfumarate 3.20a with 10 mol% B(C6F5)3 in benzene (1.0 M) was found to give N-
alkylamine 3.21i and enamine 3.21v in 57% yield and 29% yield, respectively. Since the products 
were obtained as a mixture of 3.21i and 3.21v, it would be a good platform to study whether the 
N-alkylamine and enamine products are interconvertible. To determine if 3.21i can be generated 
by (F5C6)3B-catalyzed transfer hydrogenation of 3.21v, we monitored the progress of this reaction 
by the 1H NMR spectroscopy (Figure S36). To an oven-dried 7.0 mL vial, amine 3.19g (88 mg, 
0.40 mmol), diisopropyl fumarate 3.25a (120 mg, 0.60 mmol), mesitylene (48 mg, 0.40 mmol), 
B(C6F5)3 (10 mol%) and 0.4 mL C6D6 were added under nitrogen atmosphere. Then, the reaction 





out of the glove box. The 1H NMR spectra were acquired in the NMR spectrometer preheated at 
50 °C using a pre-acquisition delay in array mode with a spectrum taken every 22 seconds for the 
length of the experiment. The data were processed using MestReNova software and peak 
integrations were normalized using m-xylene as the internal standard. 
As shown in Figure S36, it was found that there was minimal transformation of 3.21v into 3.21i, 
evidenced by the mostly unchanged concentration of 3.21v once >85% of amine 3.19g was 














3.6.6.3.2 Transfer Hydrogenation of Compound 3.21v 
As shown in Scheme 3.16 in the manuscript, transfer hydrogenation of compound 3.21v (Figure 
S14, S15) was conducted to further probe whether the enamine product can be reduced to generate 
the N-alkylamine product 3.21i.  
To a 15 mL oven-dried pressure vessel, 3.21v (0.050 mmol), B(C6F5)3 (20 mol%) and benzene 
(0.20 mL) were added under a nitrogen atmosphere (Scheme S20). The reaction mixture was 
placed in an oil bath at 50 °C for 12 hours. Upon completion, the solution was cooled to 22 °C and 
concentrated in vacuo. Through the 1H NMR analysis of the unpurified product mixture using 
mesitylene as the internal standard, it was found that 3.21i was formed in 30% yield, together with 
an ionic complex of [pyridinium]+[C6F5]– (3.33) which was generated in 15% yield. This 
experiment implies that enamine 3.21v can serve as H+/H- source in (F5C6)3B-catalyzed transfer 
hydrogenation of 3.21v to afford N-alkylamine product 3.21i. 
 





1H NMR (600 MHz, CDCl3): δ 8.72 (s, 1H), 8.60 (d, J = 8.2 Hz, 1H), 8.37 (dd, J = 6.0, 1.3 Hz, 
1H), 8.13 – 8.08 (m, 1H), 6.80 (d, J = 4.2 Hz, 2H), 5.06 (dt, J = 12.2, 6.5 Hz, 1H), 4.88 (p, J = 6.7 





17.7, 8.7 Hz, 1H), 1.97 (s, 3H), 1.94 (s, 3H), 1.26 (d, J = 5.1 Hz, 3H), 1.21 (d, J = 5.7 Hz, 3H), 
1.18 (d, J = 6.2 Hz, 3H), 1.14 (d, J = 6.2 Hz, 3H); 19F NMR (564 MHz, CDCl3): δ -137.48 (d, J 
= 23.9 Hz), -160.45 (t, J = 20.1 Hz), -165.00 (t, J = 19.4 Hz); HRMS (DART): Calcd for 
C30H33F5NO5 (MH+): 582.2273; found: 582.2253. 
 
(F5C6)3B-catalyzed transfer hydrogenation of enamines was previously reported by Stephan and 
co-workers; 1-(1-cyclohexen-1-yl)-piperidine was reduced to afford 1-cyclohexylpiperidine in the 
presence of 20 mol% B(C6F5)3 and large excess of (i-Pr)2NH (the mixture was allowed to stir at 
100 °C for 24 hours).30 In our transformation (Figure 2), amine substrate 3.19g may serve as H+/H- 
source in transfer hydrogenation of 3.21v. To determine if this is possible, to a 15 mL oven-dried 
pressure vessel were added enamine 3.21v (0.050 mmol), amine 3.19g-d (0.05 mmol, 1.0 equiv), 
B(C6F5)3 (20 mol%) and benzene (0.20 mL) under a nitrogen atmosphere (Scheme S21). The 
reaction mixture was placed in an oil bath at 50 °C for 12 hours. Upon completion, the solution 
was cooled to 22 °C and concentrated in vacuo. Through the 1H NMR analysis of the unpurified 
product mixture using mesitylene as the internal standard, it was found that 3.21i-d was formed in 
50% yield with <5% of 3.33 formation when 58% of 3.19g-d was recovered. Furthermore, 
deuterium incorporation level was determined after the isolation and purification of 3.21i-d and 
3.19g-d, which revealed that there was d-scrambling at the β-position of 3.19g-d and 3.21i-d (see 
1.6−2.0 ppm in Figures S37, S38) when there was no significant deuterium incorporation at the β-
amino position of recovered 3.21v. These results imply that amine 3.19g-d can serve as D+ and H- 
source in (F5C6)3B-catalyzed transfer hydrogenation of 3.21v to afford N-alkylamine product 
3.21i-d. 
                                                 



















Figure S37. 1H NMR Spectrum of 3.21i 
 







3.6.6.3.3. Dehydrogenation of Compound 3.21i 
As discussed in the Sections 3.6.6.3.1−3.6.6.3.2, under the standard reaction conditions, N-
alkylamine 3.21i is likely generated by transfer hydrogenation of XXVIII (Figure S35) without 
the intermediacy of enamine 3.21v. In order to probe whether enamine 3.21v can be generated 
from N-alkylamine 3.21i through oxidation, dehydrogenation of compound 3.21i (Scheme S22-
23) was conducted.  
To a 15 mL oven-dried pressure vessel was added amine 3.21i (21 mg, 0.050 mmol), B(C6F5)3 (20 
mol%) and benzene (0.20 mL) under a nitrogen atmosphere (Scheme S22). The reaction mixture 
was placed in an oil bath at 50 °C and was allowed to stir for 12 hours. Upon completion, the 
reaction mixture was cooled to 22 °C and concentrated in vacuo. Through the 1H NMR analysis 
of the unpurified product mixture using mesitylene as the internal standard, it was found that 3.21i 
was fully recovered and formation of 3.21v was not observed.  
 







We hypothesized that in order to obtain enamine 3.21v, the presence of diisopropylfumarate 3.20a 
might be necessary to serve as a H+/H- acceptor. Therefore, 3.20a (10 mg, 0.05 mmol, 1.0 equiv.) 
was added to the reaction mixture of amine 3.21i (21 mg, 0.05 mmol), B(C6F5)3 (20 mol%) and 
benzene (0.2 mL) under a nitrogen atmosphere (Scheme S23). The reaction mixture was placed in 
an oil bath at 50 °C and was allowed to stir for 12 hours. Upon completion, the reaction mixture 
was cooled to 22 °C and concentrated in vacuo. However, after 1H NMR analysis of the unpurified 
product mixture using mesitylene as the internal standard, formation of 3.21v was not observed.  
These experiments revealed that 3.21i cannot be readily converted to 3.21v by B(C6F5)3, regardless 
of whether α,β-unsaturated compound 3.20a is present in the reaction mixture or not. This result 
implies that 3.21v is generated from the deprotonation of XXVIII (Figure S35), not through the 
oxidation of 3.21i. Therefore, the interconversion between 3.21i and 3.21v under the standard 
reaction conditions is unlikely to take place. 
 







3.6.6.4 Mechanistic Studies Involving Ester Substituted α,β-Unsaturated Compound 3.25a 
We performed mechanistic investigations on the reaction between N-alkylamine 3.19t and ethyl 
ester-substituted electrophile 3.25a to probe if the mechanism of β-C–H alkylation may be 
different depending on which electrophile is used (vs the processes involving aryl-substituted 
electrophiles in Section 3.6.6.1 to 3.6.6.3). 
3.6.6.4.1. Determination of the Reaction Orders Involving 3.25a 
For the β-C–H alkylation reaction involving 1-(4-methoxyphenyl)pyrrolidine 3.19t and 3.25a, the 
reaction order of each reactant was studied through time course reaction monitoring by the 1H 
NMR spectroscopic analysis. 
3.6.6.4.1.1. Reaction Order of B(C6F5)3 
The reaction between 3.19t and 3.25a was performed using different concentrations of B(C6F5)3 
and the progress of each reaction was monitored by the 1H NMR spectroscopy (Scheme S24).  
Scheme S24. Determination of the Reaction Order of B(C6F5)3 
 
In a nitrogen-filled glove box, L12−Sc(OTf)3 (24.6 mg, 10 mol%), 3.19t (106.2 mg, 0.60 mmol), 
3.25a (241.2 mg, 1.5 equiv) and toluene (55.2 mg, 1.0 equiv) were weighed in an oven-dried 7.0 
mL vial and the resulting mixture was dissolved in 2.40 mL of CD2Cl2 (Stock Solution A). In 
another oven-dried 7.0 mL vial, B(C6F5)3 (35.8 mg, 0.070 mmol) was weighed and dissolved in 
1.40 mL of CD2Cl2 (Stock Solution B). To each J-Young tube was added Stock Solution A (0.40 





to prepare the reaction samples containing different concentrations of B(C6F5)3. After the J-Young 
tube was tightly capped with the Teflon plug, it was taken out of the glove box and the 1H NMR 
spectra were acquired in the NMR spectrometer preheated at 40 °C using a pre-acquisition delay 
in array mode with a spectrum taken every 22 seconds for the length of the experiment. The data 
were processed using MestReNova software and peak integrations were normalized using toluene 
as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 
600 seconds, showed that there is fourth-order dependency on B(C6F5)3 concentration in the 







Figure S39. Monitoring the formation of 3.26a under different concentrations of B(C6F5)3 
 
Figure S40. Log(rate) vs log[B(C6F5)3] is employed to determine the initial reaction order for 





3.6.6.4.1.2. Reaction Order of L12−Sc(OTf)3 
The reaction between 3.19t and 3.25a was performed using different concentrations of 
L12−Sc(OTf)3 and the progress of each reaction was monitored by the 1H NMR spectroscopy 
(Scheme S25).  
Scheme S25. Determination of the Reaction Order of L12−Sc(OTf)3 
 
In a nitrogen-filled glove box, B(C6F5)3 (30.7 mg, 10 mol%), 3.19t (106.2 mg, 0.6 mmol), 3.25a 
(241.2 mg, 1.5 equiv) and toluene (55.2 mg, 1.0 equiv) were weighed in an oven-dried 7.0 mL vial 
and the resulting mixture was dissolved in 2.40 mL of CD2Cl2 (Stock Solution A). In another 
oven-dried 7.0 mL vial, L12−Sc(OTf)3 (57.4 mg, 0.070 mmol) was weighed and dissolved in 1.40 
mL of CD2Cl2 (Stock Solution B). To each J-Young tube was added Stock Solution A (0.40 mL), 
Stock Solution B (0.10, 0.15, 0.20, or 0.25 mL) and CD2Cl2 (0.30, 0.25, 0.20, or 0.15 mL) to 
prepare the reaction samples containing different concentrations of L12−Sc(OTf)3. After the J-
Young tube was tightly capped with the Teflon plug, it was taken out of the glove box and 1H NMR 
spectra were acquired in the NMR spectrometer preheated at 40 °C using a pre-acquisition delay 
in array mode with a spectrum taken every 22 seconds for the length of the experiment. The data 
were processed using MestReNova software and peak integrations were normalized using toluene 
as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 

















Figure S41. Monitoring the formation of 3.26a under different concentrations of L12−Sc(OTf)3 
 
Figure S42. Log(rate) vs log[L12−Sc(OTf)3] is employed to determine the initial reaction order 






3.6.6.4.1.3. Reaction Order of Amine 
The reaction between 3.19t and 3.25a was performed using different concentrations of 3.19t and 
the progress of each reaction was monitored by the 1H NMR spectroscopy (Scheme S26).  
Scheme S26. Determination of the Reaction Order of 3.19t 
 
In a nitrogen-filled glove box, B(C6F5)3 (30.7 mg, 0.060 mmol), L12−Sc(OTf)3 (24.6 mg, 0.030 
mmol), 3.25a (241.2 mg, 0.90 mmol) and toluene (55.2 mg, 0.60 mmol) were weighed in an oven-
dried 7.0 mL vial and the resulting mixture was dissolved in 3.00 mL of CD2Cl2 (Stock Solution 
A). In another oven-dried 7.0 mL vial, 3.19t (177mg, 1.0 mmol) was weighed and dissolved in 
1.00 mL of CD2Cl2 (Stock Solution B). To each J-Young tube was added Stock Solution A (0.50 
mL), Stock Solution B (0.05, 0.07, 0.10, or 0.15 mL) and CD2Cl2 (0.25, 0.23, 0.20, or 0.15 mL) 
to prepare the reaction samples containing different concentrations of 3.19t. The reaction mixture 
was then transferred to a J-Young tube. After the J-Young tube was tightly capped with the Teflon 
plug, it was taken out of the glove box and 1H NMR spectra were acquired in the NMR 
spectrometer preheated at 40 °C using a pre-acquisition delay in array mode with a spectrum taken 
every 22 seconds for the length of the experiment. The data were processed using MestReNova 
software and peak integrations were normalized using toluene as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 
800 seconds, showed that there is first-order dependency on amine 3.19t concentration in the 







Figure S43. Monitoring the formation of 3.26a under different concentrations of amine 3.19t 
 
Figure S44. Log(rate) vs log[amine 3.19t] is employed to determine the initial reaction order for 





3.6.6.4.1.4 Reaction Order of α,β-Unsaturated Compound 
The reaction between 3.19t and 3.25a was performed using different concentrations of 3.25a and 
the progress of each reaction was monitored by the 1H NMR spectroscopy (Scheme S27).  
Scheme S27. Determination of the Reaction Order of 3.25a 
 
In a nitrogen-filled glove box, B(C6F5)3 (30.7 mg, 10 mol%), L12−Sc(OTf)3 (24.6 mg, 5.0 mol%), 
3.19t (106.2 mg, 0.60 mmol), and toluene (55.2 mg, 1.0 equiv) were weighed in an oven-dried 7.0 
mL vial and the resulting mixture was dissolved in 3.00 mL of CD2Cl2 (Stock Solution A). In 
another oven-dried 7.0 mL vial, 3.25a (322mg, 1.20 mmol) was weighed and dissolved in 1.20 mL 
of CD2Cl2 (Stock Solution B). To each J-Young tube was added Stock Solution A (0.50 mL), 
Stock Solution B (0.10, 0.15, 0.20, or 0.25 mL) and CD2Cl2 (0.20, 0.15, 0.10, or 0.05 mL) to 
prepare the reaction samples containing different concentrations of 3.25a. The reaction mixture 
was then transferred to a J-Young tube. After the J-Young tube was tightly capped with the Teflon 
plug, it was taken out of the glove box and 1H NMR spectra were acquired in the NMR 
spectrometer preheated at 40 °C using a pre-acquisition delay in array mode with a spectrum taken 
every 22 seconds for the length of the experiment. The data were processed using MestReNova 
software and peak integrations were normalized using toluene as the internal standard.  
Initial-rate kinetic analysis, which was determined based on the data points acquired in the first 
800 seconds, showed that there is −3-order dependency on α,β-unsaturated compound 3.25a 







Figure S45. Monitoring the formation of 3.26a under different concentrations of 3.25a 
 
Figure S46. Log(rate) vs log[α,β-unsaturated compound 3.25a] is employed to determine the 






3.6.6.4.2. Kinetic Isotope Effect Experiments Involving 3.25a 
In order to probe whether the turnover-limiting step involves the cleavage of α- or β-amino C−H 
bonds, we carried out parallel kinetic isotope effect experiments. 
3.6.6.4.2.1. Parallel KIE Measurement for α-Amino C−H and C−D Bond Cleavage 
A parallel kinetic isotope effect study was conducted through time course reaction monitoring by 
the 1H NMR spectroscopy using internal standard to monitor the difference in initial rates of the 
product formation in the reaction of 1-(4-methoxyphenyl)pyrrolidine 3.19t or 1-(4-
methoxyphenyl)pyrrolidine-2,2,5,5-d4 3.19tα-d with ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-
oxopyrazolidin-1-yl)-4-oxobut-2-enoate 3.25a (Scheme S28).  
In a nitrogen-filled glove box, B(C6F5)3 (20.4 mg, 0.040 mmol), L12−Sc(OTf)3 (16.4 mg, 0.020 
mmol), 3.25a (160.8 mg, 0.60 mmol) and toluene (36.8 mg, 0.40 mmol) were weighed in an oven-
dried 7.0 mL vial and the resulting mixture was dissolved in 2.00 mL of CD2Cl2 (Stock Solution 
A). In two oven-dried 7.0 mL vials were added 3.19t (17.7 mg) or 3.19tα-d (18.1 mg). To each 
oven-dried vial containing 3.19t or 3.19tα-d was added CD2Cl2 (0.30 mL) and Stock Solution A 
(0.50 mL) to prepare the reaction samples containing 3.19t or 3.19tα-d. The reaction mixture was 
then transferred to a J-Young tube. After the J-Young tube was tightly capped with the Teflon plug, 
it was taken out of the glove box and 1H NMR spectra were acquired in the NMR spectrometer 
preheated at 40 °C using a pre-acquisition delay in array mode with a spectrum taken every 22 
seconds for the length of the experiment. The data were processed using MestReNova software 
and peak integrations were normalized using toluene as the internal standard.  
Kinetic analysis based on the initial rates of the product formation (Figure S47) demonstrates that 
3.19t reacts 1.3 times faster than 3.19tα-d (kH/kD = 1.34) in the reaction between 3.19t or 3.19tα-





revealed that 94% of d-incorporation level was retained at the α-amino position (Figures S48−49). 
This result suggests that the borohydride reduction step may be irreversible as there was no H 






Scheme S28. Kinetic Isotope Effect Studies 
 
 






Figure S48. 1H NMR spectrum of 3.26a (CDCl3) 
  





3.6.6.4.2.2. Parallel KIE Measurement for β-Amino C−H and C−D Bond Cleavage 
A parallel kinetic isotope effect study was conducted through time course reaction monitoring by 
the 1H NMR spectroscopy using internal standard to monitor the difference in initial rates of the 
product formation in the reaction of 1-(4-methoxyphenyl)pyrrolidine 3.19t or 1-(4-
methoxyphenyl)pyrrolidine-3,3,4,4-d4 3.19tβ-d with ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-
oxopyrazolidin-1-yl)-4-oxobut-2-enoate 3.25a (Scheme S29). In a nitrogen-filled glove box, 
B(C6F5)3 (20.4 mg, 0.040 mmol), L12−Sc(OTf)3 (16.4 mg, 0.020 mmol), 3.25a (160.8 mg, 0.60 
mmol) and toluene (36.8 mg, 0.40 mmol) were weighed in an oven-dried 7.0 mL vial and the 
resulting mixture was dissolved in 2.00 mL of CD2Cl2 (Stock Solution A). In two oven-dried 7.0 
mL vials were added 3.19t (17.7 mg) or 3.19tβ-d (18.1 mg). To each oven-dried vial containing 
3.19t or 3.19tβ-d was added CD2Cl2 (0.30 mL) and Stock Solution A (0.50 mL) to prepare the 
reaction samples containing 3.19t or 3.19tβ-d. The reaction mixture was then transferred to a J-
Young tube. After the J-Young tube was tightly capped with the Teflon plug, it was taken out of 
the glove box and 1H NMR spectra were acquired in the NMR spectrometer preheated at 40 °C 
using a pre-acquisition delay in array mode with a spectrum taken every 22 seconds for the length 
of the experiment. The data were processed using MestReNova software and peak integrations 
were normalized using toluene as the internal standard.  
Kinetic analysis based on the initial rates of the product formation (Figure S50) demonstrates no 
kinetic isotope effect (kH/kD = 1.00) in the reaction between 3.19t or 3.19tβ-d and 3.25a. From 1H 
NMR analysis of the isolated and purified 3.26aβ-d in CDCl3 and acetone-d6, d-incorporation level 







Scheme S29. Kinetic Isotope Effect Studies 
 
 






Figure S51. 1H NMR spectrum of 3.26a (CDCl3) 
 
Figure S52. 1H NMR spectrum of 3.26aβ-d (CDCl3) 





















Figure S53. 1H NMR spectrum of 3.26aα-d (acetone-d6) 
 
Figure S54. 1H NMR spectrum of 3.26aβ-d (acetone-d6)  




















3.6.6.4.3. The 13C NMR Experiments for Characterization of Resting State Complexes 
The mechanistic investigation revealed that the (F5C6)3B/L12−Sc(OTf)3 co-catalyzed β-amino 
C−H functionalization has a −1 order dependency with respect to the concentration of 
L12−Sc(OTf)3 (see Section 3.6.6.4.1.2) and −3 order dependency with respect to the concentration 
of ethyl (E)-4-(2-ethyl-3,3-dimethyl-5-oxopyrazolidin-1-yl)-4-oxobut-2-enoate 3.25a (see 
Section 3.6.6.4.1.4). We hypothesized that [L12−Sc(OTf)3]−3.25a−B(C6F5)3 adduct could be the 
resting state and carried out the 13C NMR experiments to identify the structure of the resting state 
complex (Figures S55, S56). Previously, the group of Piers has reported that B(C6F5)3 and 
benzaldehyde forms (F5C6)3B−carbonyl compound adduct which showed that 13C NMR peak of 
carbonyl moiety shifted further downfield to 199.4 ppm. We acquired the 13C NMR spectra of a 
sample containing B(C6F5)3 and/or L12−Sc(OTf)3 and 3.25a in CD2Cl2 (Figures S55, S56). 
In the 13C NMR spectrum of a reaction mixture containing 3.25a and 50 mol% B(C6F5)3, it was 
observed that the carbonyl peak of 3.25a at 175.3 ppm has shifted to 178.1 ppm (Figure S55A, 
S51B. See the peak marked with a red arrow). Similar trend was observed in a mixture of 3.25a, 
50 mol% B(C6F5)3, and 25 mol% L12−Sc(OTf)3 showing shifted peak at 178.4 ppm (Figure S55C, 
S56). Furthermore, the peak at 162.5 ppm of 3.25a shifted to 163.5 ppm, which was also detected 
in the solution of 3.25a and 25 mol% L12−Sc(OTf)3 (Figure S55C, S55D, and S56. See the peak 
marked with a blue arrow). 
These results are in agreement with our hypothesis that Lewis acidic B(C6F5)3 and L12−Sc(OTf)3 
coordinate to Lewis basic carbonyl functional groups of 3.25a and form 







Figure S55. 13C NMR experiments for the detection of the resting state 
 





3.6.6.5. Catalytic Cycle for the Enantioselective β-Amino C−H Functionalization Involving 
3.25a 
In Figure S57, we show the catalytic cycles that are consistent with the above-mentioned 
mechanistic investigations (Section 3.6.6.4). The studies discussed in Section 3.6.6.4.3 revealed 
that there is −1 order dependency with respect to the concentration of L12−Sc(OTf)3 (Section 
3.6.6.4.1.2) and −3 order dependency with respect to the concentration of 3.25 (Section 
3.6.6.4.1.4). These results suggest that there is a resting state complex comprised of 
[L12−Sc(OTf)3], 3.25a, and B(C6F5)3 (XXIX) which was verified by the 13C NMR studies 
(Figures S55, S56). B(C6F5)3 released from XXIX abstracts a hydride from 3.19t to form an ion 
pair consisting of iminium ion and borohydride (XXX). The fourth order dependency with respect 
to the concentration of B(C6F5)3 (Section 3.6.6.4.1.1) and the kinetic isotope effect studies 
(Section 3.6.6.4.2) suggest that the borohydride reduction of (F5C6)3B-activated 3.25a is the 
turnover-limiting step (XXX → XXXI). After the protonation of enolate (XXXI → XXXII), 
nucleophilic enamine can undergo enantioselective C−C bond formation with [L12−Sc(OTf)3]-
activated 3.25a to form zwitterionic XXXIV. As discussed in Section 3.6.6.3, we propose that 
3.19t could serve as H+/H- source to reduce XXXIV in order to afford the desired β-alkylation 
product 3.26a.  
The results from the mechanistic investigations involving 3.25a (Section 3.6.6.4) are in similar 
trend with the proposed catalytic cycle that was based on the mechanistic studies involving aryl-
substituted electrophile 3.25e (Figure S35, Section 3.6.6.1−3.6.6.2). However, it was found that 
the turnover-limiting step could be different depending on the electrophile that is used.  When ethyl 
ester-substituted electrophile 3.25a is involved, the borohydride reduction step (turnover-limiting) 
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3.6.7. Analytical Data 
 
Diisopropyl 2-(2-(dibenzylamino)ethyl)succinate (3.21a)  
N,N-Dibenzylethanamine 3.19a was reacted with diisopropyl fumarate 3.20a following the 
General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.80 
mL) as the solvent. After purification by column chromatography (ethyl ether:hexanes = 1:19), 
3.21a was obtained as a colorless liquid (75 mg, 88%).  
 
1H NMR (600 MHz, CDCl3): δ 7.34 (d, J = 7.5 Hz, 4H), 7.29 (t, J = 7.5 Hz, 4H), 7.22 (t, J = 7.3 
Hz, 2H), 4.95 (dp, J = 26.6, 6.2 Hz, 2H), 3.61 (d, J = 13.6 Hz, 2H), 3.46 (d, J = 13.5 Hz, 2H), 2.88 
(dq, J = 12.4, 6.6 Hz, 1H), 2.51 – 2.39 (m, 3H), 2.16 (dd, J = 16.4, 5.1 Hz, 1H), 1.92 (dq, J = 14.4, 
7.3 Hz, 1H), 1.61 (h, J = 7.3 Hz, 1H), 1.20 (d, J = 6.3 Hz, 6H), 1.16 (d, J = 6.3 Hz, 3H), 1.12 (d, J 
= 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3): δ 174.3, 171.3, 139.5, 128.8, 128.2, 126.9, 67.78, 
67.77, 58.3, 50.5, 39.1, 35.9, 29.0, 21.81, 21.78, 21.69, 21.65; IR (neat): ν 2976, 2932, 2796, 
1724, 1452, 1372, 1260, 1168, 1104, 745, 698 cm-1; HRMS (ESI): Calcd for C26H36NO4 (MH+): 
426.2639; found: 426.2643. 
 
 
Tetraisopropyl 5-(dibenzylamino)cyclohexane-1,2,3,4-tetracarboxylate (3.22a)  






1H NMR (500 MHz, CDCl3): δ 7.34 – 7.27 (m, 8H), 7.22 (t, J = 6.6 Hz, 2H), 5.06 (hept, J = 6.4 
Hz, 1H), 5.02 – 4.89 (m, 3H), 3.89 (d, J = 13.6 Hz, 2H), 3.48 (d, J = 13.6 Hz, 2H), 3.38 (t, J = 8.3 
Hz, 1H), 3.30 (t, J = 8.3 Hz, 1H), 2.81 – 2.66 (m, 3H), 2.57 (dd, J = 16.7, 10.1 Hz, 1H), 2.44 (dd, 
J = 16.8, 3.6 Hz, 1H), 1.31 (d, J = 6.3 Hz, 3H), 1.27 (d, J = 6.2 Hz, 3H), 1.21 (td, J = 6.0, 3.7 Hz, 
12H), 1.16 (d, J = 6.2 Hz, 3H), 1.11 (d, J = 6.3 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 172.3, 
172.2, 172.1, 171.1, 139.1, 128.9, 128.4, 127.3, 68.4, 68.3, 67.9, 60.8, 54.8, 45.3, 42.3, 41.2, 39.4, 
34.2, 22.0, 21.91, 21.88, 21.87, 21.78, 21.76, 21.7; IR (neat): ν 2977, 2934, 1725, 1493, 1373, 




Diisopropyl 2-(1-(dibenzylamino)propan-2-yl)succinate (3.21b)  
N,N-Dibenzylpropan-1-amine 3.19b was reacted with diisopropyl fumarate 3.20a following the 
General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.2 mL) 
as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the diastereomeric 
ratio was 1.3:1. After purification by column chromatography (ethyl ether:hexanes = 1:19), 3.21b 
was obtained as a mixture of diastereomers (51 mg, 58%). 3.21c was obtained as a colorless liquid 
(29 mg, 33%). Further purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the 
eluent to separate 3.21b-major and 3.21b-minor. The relative configuration of 3.21b-major was 
assigned in analogy as described in Section 3.6.3. 
3.21b-Major: 1H NMR (600 MHz, CDCl3) δ 7.35 (d, J = 7.1 Hz, 4H), 7.28 (t, J = 7.5 Hz, 4H), 





2.39 – 2.30 (m, 2H), 2.24 (dd, J = 12.8, 9.7 Hz, 1H), 2.14 (dd, J = 12.9, 6.0 Hz, 1H), 1.56 (dd, J = 
16.7, 3.2 Hz, 1H), 1.27 – 1.19 (m, 9H), 1.16 (d, J = 6.2 Hz, 3H), 0.73 (d, J = 6.9 Hz, 3H); 13C 
NMR (151 MHz, CDCl3) δ 174.5, 172.0, 139.5, 129.1, 128.2, 126.9, 67.6, 67.5, 58.7, 56.8, 42.1, 
32.1, 29.8, 21.9, 21.84, 21.83, 21.7, 13.9; IR (neat) ν 2976, 2930, 2799, 1723, 1452, 1372, 1232, 
1172, 1105, 745, 698 cm-1; HRMS (DART) Calcd for C27H38NO4 (MH+): 440.2795; found: 
440.2789.  
 
3.21b-Minor: 1H NMR (600 MHz, CDCl3) δ 7.34 (d, J = 7.5 Hz, 4H), 7.29 (t, J = 7.5 Hz, 4H), 
7.22 (t, J = 7.2 Hz, 2H), 4.96 (dp, J = 22.6, 6.3 Hz, 1H), 3.71 (d, J = 13.6 Hz, 2H), 3.32 (d, J = 
13.6 Hz, 2H), 2.91 (dt, J = 10.7, 4.1 Hz, 1H), 2.62 (dd, J = 16.6, 10.7 Hz, 1H), 2.41 (dd, J = 12.7, 
5.8 Hz, 1H), 2.32 (dd, J = 12.7, 8.8 Hz, 1H), 2.15 (dd, J = 16.6, 4.3 Hz, 1H), 1.98 (ddp, J = 9.8, 
6.4, 3.7, 3.1 Hz, 1H), 1.21 (dd, J = 11.4, 6.2 Hz, 6H), 1.16 (d, J = 6.3 Hz, 3H), 1.06 (d, J = 6.3 Hz, 
3H), 0.88 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.1, 171.8, 139.5, 128.9, 128.1, 
126.8, 107.3, 67.8, 59.0, 58.7, 44.3, 34.2, 33.5, 21.82, 21.79, 21.76, 21.7, 15.2; HRMS (DART) 
Calcd for C27H38NO4 (MH+): 440.2795; found: 440.2780. 
 
 
Diisopropyl 3-(dibenzylamino)-4-methylcyclobutane-1,2-dicarboxylate (3c) 
1H NMR (600 MHz, CDCl3) δ 7.33 (d, J = 7.6 Hz, 4H), 7.28 (t, J = 7.5 Hz, 4H), 7.21 (t, J = 7.3 
Hz, 2H), 5.00 (dp, J = 16.7, 6.3 Hz, 2H), 3.79 (d, J = 14.0 Hz, 2H), 3.63 (d, J = 14.1 Hz, 2H), 3.30 
(t, J = 8.7 Hz, 1H), 3.11 (t, J = 8.4 Hz, 1H), 2.51 – 2.36 (m, 2H), 1.27 (d, J = 6.2 Hz, 3H), 1.24 (d, 





δ 172.7, 172.5, 139.6, 128.4, 128.2, 126.9, 67.91, 67.90, 64.2, 54.7, 43.0, 41.7, 37.3, 21.9, 21.81, 
21.78, 21.76, 18.7; IR (neat) ν 2977, 2927, 1723, 1453, 1373, 1233, 1174, 1107, 746, 698 cm-1; 
HRMS (DART) Calcd for C27H36NO4 (MH+): 438.2639; found: 438.2623. 
 
 
Diisopropyl 3-(dibenzylamino)-4-isopropylcyclobutane-1,2-dicarboxylate (3.21d) 
N,N-Dibenzyl-3-methylbutan-1-amine 3.19c was reacted with diisopropyl fumarate 3.20a 
following the General Procedure D using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
benzene as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was >20:1. After purification by column chromatography (ethyl ether:hexanes 
= 1:33), 3.21d was obtained as a colorless liquid (64 mg, 69%). The relative configuration was 
assigned based on NOESY experiments. 
 
1H NMR (600 MHz, CDCl3) δ 7.34 (d, J = 6.8 Hz, 4H), 7.29 (t, J = 7.6 Hz, 4H), 7.22 (t, J = 7.2 
Hz, 2H), 5.02 (dp, J = 32.2, 6.3 Hz, 2H), 3.92 (d, J = 13.6 Hz, 2H), 3.50 (d, J = 13.6 Hz, 2H), 3.34 
(t, J = 8.6 Hz, 1H), 3.26 (t, J = 8.7 Hz, 1H), 2.55 (t, J = 8.8 Hz, 1H), 2.28 (q, J = 8.7 Hz, 1H), 1.56 
– 1.49 (m, 1H), 1.31 (d, J = 6.3 Hz, 3H), 1.25 (d, J = 6.2 Hz, 3H), 1.21 (dd, J = 9.3, 6.3 Hz, 6H), 
0.86 (d, J = 6.7 Hz, 3H), 0.78 (d, J = 6.7 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.4, 172.8, 
139.6, 128.8, 128.2, 126.9, 68.0, 67.9, 60.9, 54.7, 48.5, 41.0, 39.1, 32.7, 21.9, 21.82, 21.80, 21.6, 
20.2, 19.7; IR (neat) ν 2976, 2931, 1720, 1453, 1372, 1227, 1171, 1105, 747, 698 cm-1; HRMS 









1-Benzyl-4-(((tert-butyldimethylsilyl)oxy)methyl)piperidine 3.19d was reacted with diisopropyl 
fumarate 2.20a following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst and benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 1.1:1. After purification by column chromatography 
(ethyl ether:hexanes = 1:4), 3.21e was obtained as a mixture of diastereomers (77.0 mg, 74%). 
Further purification was carried out by PTLC using ethyl ether:DCM = 1:6 as the eluent to separate 
3.21e-major and 3.21e-minor. The relative configuration for 3.21e-major and 3.21e-minor were 
assigned based on X-ray crystallography data (see Sections 3.6.3). 
 
3.21e-Major: 1H NMR (600 MHz, CDCl3) δ 7.27 (dp, J = 22.0, 7.5 Hz, 5H), 4.98 (dp, J = 16.3, 
6.4 Hz, 2H), 3.71 (dd, J = 10.0, 2.6 Hz, 1H), 3.65 (dd, J = 10.1, 5.1 Hz, 1H), 3.52 (d, J = 13.4 Hz, 
1H), 3.41 (d, J = 13.4 Hz, 1H), 3.09 (dt, J = 11.2, 3.4 Hz, 1H), 2.82 (tt, J = 16.1, 10.8 Hz, 3H), 
2.22 (dd, J = 16.7, 3.7 Hz, 1H), 1.85 (t, J = 11.2 Hz, 1H), 1.82 – 1.77 (m, 1H), 1.76 – 1.63 (m, 
2H), 1.46 (pt, J = 11.9, 6.7 Hz, 2H), 1.21 (dt, J = 12.1, 6.0 Hz, 12H), 0.87 (d, J = 3.2 Hz, 9H), 0.03 
(d, J = 2.9 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 172.7, 171.6, 138.2, 129.1, 129.0, 128.2, 
128.1, 126.9, 67.91, 67.86, 64.6, 63.3, 55.4, 53.3, 40.7, 40.4, 40.0, 35.3, 29.3, 26.0, 25.9, 21.9, 
21.82, 21.80, 21.75, 18.3, -5.4, -5.5; IR (neat) ν 2950, 2854, 1727, 1466, 1372, 1254, 1173, 1104, 






3.21e-Minor: 1H NMR (500 MHz, CDCl3) δ 7.31 – 7.23 (m, 4H), 7.23 – 7.17 (m, 1H), 5.03 – 
4.93 (m, 1H), 4.93 – 4.84 (m, 1H), 3.61 (dd, J = 10.3, 4.1 Hz, 1H), 3.55 (t, J = 5.2 Hz, 1H), 3.50 
(d, J = 13.2 Hz, 1H), 3.36 (d, J = 13.2 Hz, 1H), 3.19 (dt, J = 12.2, 3.6 Hz, 1H), 2.86 (d, J = 11.2 
Hz, 1H), 2.67 – 2.50 (m, 2H), 2.35 – 2.24 (m, 1H), 2.09 (d, J = 11.0 Hz, 1H), 1.95 (t, J = 11.5 Hz, 
1H), 1.70 (dd, J = 21.8, 11.1 Hz, 3H), 1.54 (tt, J = 14.2, 7.1 Hz, 1H), 1.33 (dq, J = 11.0, 5.3 Hz, 
1H), 1.20 (dd, J = 10.0, 6.3 Hz, 6H), 1.13 (d, J = 6.3 Hz, 3H), 1.03 (d, J = 6.3 Hz, 3H), 0.89 (s, 
9H), 0.04 (d, J = 5.8 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 173.7, 172.0, 138.3, 129.0, 128.1, 
126.9, 125.5, 67.9, 67.8, 65.0, 63.3, 54.4, 53.9, 41.3, 39.8, 39.3, 31.0, 29.0, 25.95, 25.94, 21.8, 





3-yl)succinate (3.21f)  
1H NMR analysis of the unpurified product mixture revealed that the diastereomeric ratio of 3.21f 
was 1.4:1. After purification by column chromatography (ethyl ether:hexanes = 1:9), 3.21f was 
obtained as a mixture of diastereomers (26.9 mg, 26%). Further purification was carried out by 
PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.21f-major and 3.21f-minor. The 







3.21f-Major: 1H NMR (600 MHz, CDCl3) δ 7.29 (t, J = 7.4 Hz, 2H), 7.27 – 7.21 (m, 1H), 7.19 
(d, J = 7.5 Hz, 2H), 6.06 (s, 1H), 5.05 – 4.90 (m, 2H), 4.08 – 3.89 (m, 2H), 3.57 (dd, J = 10.1, 4.3 
Hz, 1H), 3.29 (dd, J = 10.0, 5.7 Hz, 1H), 3.21 (t, J = 9.9 Hz, 1H), 2.87 (dd, J = 16.4, 10.1 Hz, 1H), 
2.79 – 2.64 (m, 2H), 2.45 (dd, J = 16.3, 5.7 Hz, 1H), 2.37 (d, J = 7.8 Hz, 1H), 1.95 (dt, J = 13.4, 
2.8 Hz, 1H), 1.65 – 1.46 (m, 1H), 1.32 – 1.11 (m, 12H), 0.86 (s, 9H), 0.06 – -0.08 (m, 6H); 13C 
NMR (151 MHz, CDCl3) δ 173.8, 171.6, 138.4, 135.5, 128.3, 127.8, 127.1, 102.6, 67.73, 67.66, 
65.0, 59.3, 44.3, 41.8, 36.4, 36.3, 26.0, 25.94, 25.90, 23.2, 21.84, 21.82, 21.77, 21.75, 21.7, 18.3, 
-5.2, -5.4; IR (neat) ν 2950, 2854, 1726, 1676, 1466, 1372, 1256, 1172, 1143, 1105, 836 cm-1; 
HRMS (DART) Calcd for C29H48NO5Si (MH+): 518.3296; found: 518.3284. 
3.21f-Minor: 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.20 (m, 3H), 7.20 – 7.14 (m, 2H), 6.09 (s, 
1H), 5.05 – 4.88 (m, 2H), 3.99 (d, J = 3.7 Hz, 2H), 3.78 (dd, J = 10.4, 4.0 Hz, 1H), 3.26 (dd, J = 
10.0, 5.5 Hz, 1H), 3.19 (t, J = 10.1 Hz, 1H), 2.87 – 2.74 (m, 2H), 2.74 – 2.62 (m, 1H), 2.48 (dd, J 
= 16.5, 5.5 Hz, 1H), 2.22 – 2.08 (m, 1H), 1.99 (dd, J = 13.6, 2.9 Hz, 1H), 1.67 – 1.59 (m, 1H), 1.27 
– 1.16 (m, 12H), 0.88 (s, 9H), 0.03 (d, J = 8.5 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 173.4, 
171.6, 138.3, 135.5, 128.3, 127.8, 127.1, 103.0, 67.7, 67.6, 65.3, 59.3, 45.0, 41.6, 38.5, 37.6, 26.0, 








Diisopropyl 2-(2-((4-methoxy-2,6-dimethylphenyl)(methyl)amino)ethyl)succinate (3.21g)  
N-Ethyl-4-methoxy-N,2,6-trimethylaniline 3.19e was reacted with diisopropyl fumarate 2.20a 
following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
benzene (0.2 mL) as the solvent. After purification by column chromatography (ethyl 
ether:hexanes = 1:33) 3.21g was obtained as a colorless liquid (76 mg, 97%).  
 
1H NMR (600 MHz, CDCl3) δ 6.52 (s, 2H), 4.99 (dqd, J = 12.5, 6.3, 1.6 Hz, 2H), 3.74 (d, J = 1.5 
Hz, 3H), 3.05 – 2.96 (m, 2H), 2.93 – 2.85 (m, 1H), 2.71 (s, 2H), 2.63 (ddd, J = 16.4, 9.2, 1.5 Hz, 
1H), 2.37 (dd, J = 16.4, 5.4 Hz, 1H), 2.25 (d, J = 7.6 Hz, 6H), 1.81 (dt, J = 15.4, 7.7 Hz, 1H), 1.62 
(dq, J = 14.9, 8.4, 7.4 Hz, 1H), 1.21 (ddd, J = 7.8, 4.6, 1.5 Hz, 9H), 1.17 (d, J = 6.3 Hz, 3H); 13C 
NMR (151 MHz, CDCl3) δ 174.3, 171.3, 156.3, 142.2, 138.5, 138.4, 113.6, 67.9, 67.79, 67.77, 
67.7, 55.1, 55.1, 53.2, 40.4, 40.3, 39.2, 36.5, 31.4, 21.7, 21.6, 19.4; IR (neat) ν 2976, 2932, 1724, 
1601, 1485, 1372, 1170, 1104, 1062, 854 cm-1; HRMS (DART) Calcd for C22H36NO5 (MH+): 







Diisopropyl 2-(2-(benzyl(4-methoxy-2,6-dimethylphenyl)amino)ethyl)succinate (3.21h)  
N-Benzyl-N-ethyl-4-methoxy-2,6-dimethylaniline 3.19f was reacted with diisopropyl fumarate 
2.20a following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst 
and benzene (0.2 mL) as the solvent. After purification by column chromatography (ethyl 
ether:hexanes = 1:33) 3.21h was obtained as a colorless liquid (82 mg, 87%).  
 
1H NMR (600 MHz, CDCl3) δ 7.31 – 7.19 (m, 5H), 6.53 (s, 2H), 4.93 (dp, J = 12.5, 6.3 Hz, 2H), 
4.09 (s, 2H), 3.74 (s, 3H), 3.00 (ddd, J = 9.6, 6.2, 3.4 Hz, 2H), 2.71 (dq, J = 13.6, 6.1 Hz, 1H), 2.54 
(dd, J = 16.3, 9.4 Hz, 1H), 2.27 – 2.18 (m, 7H), 1.68 (ddd, J = 16.9, 13.9, 7.3 Hz, 1H), 1.50 (ddd, 
J = 13.3, 9.4, 6.5 Hz, 1H), 1.19 – 1.14 (m, 9H), 1.10 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 174.1, 171.2, 156.5, 140.4, 139.9, 138.9, 138.8, 128.8, 128.1, 126.8, 113.87, 113.85, 
113.81, 113.79, 67.8, 58.9, 55.11, 55.05, 50.2, 39.5, 36.4, 31.1, 21.70, 21.67, 21.64, 21.56, 20.0, 
19.9; IR (neat) ν 2976, 2934, 1725, 1601, 1466, 1372, 1312, 1195, 1105, 670 cm-1; HRMS 







Diisopropyl 2-(1-(4-methoxy-2,6-dimethylphenyl)piperidin-3-yl)succinate (3.21i)  
1-(4-Methoxy-2,6-dimethylphenyl)piperidine 3.19g was reacted with diisopropyl fumarate 2.20a 
following the General Procedure C using B(C6F5)3 (5.0 mol%) as the Lewis acid catalyst and 
benzene (0.8 mL) as the solvent. 1H NMR analysis of the unpurified product mixture revealed that 
the diastereomeric ratio was 1.3:1. After purification by column chromatography (ethyl 
ether:hexanes = 1:19) 3.21i was obtained as a mixture of diastereomers (75 mg, 89%). Further 
purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.21i-
major and 3.21i-minor. The relative configuration of 3.21i-major and 3.21i-minor was assigned 
in analogy (see Section 3.6.3). 
 
3.21i-Major: 1H NMR (600 MHz, CDCl3) δ 6.57 (d, J = 3.0 Hz, 1H), 6.46 (d, J = 3.1 Hz, 1H), 
5.04 (hept, J = 5.9 Hz, 1H), 4.96 (hept, J = 12.6, 6.3 Hz, 1H), 3.74 (s, 3H), 3.02 (td, J = 11.2, 2.9 
Hz, 1H), 2.90 (d, J = 7.0 Hz, 2H), 2.85 (dt, J = 11.8, 3.8 Hz, 1H), 2.77 – 2.63 (m, 2H), 2.44 – 2.37 
(m, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 1.96 – 1.85 (m, 1H), 1.78 (dt, J = 13.0, 3.9 Hz, 1H), 1.72 (dt, 
J = 12.7, 3.5 Hz, 1H), 1.68 – 1.55 (m, 2H), 1.25 (t, J = 6.2 Hz, 6H), 1.19 (dd, J = 7.6, 6.2 Hz, 6H); 
13C NMR (126 MHz, CDCl3) δ 173.7, 171.6, 156.3, 142.4, 138.7, 137.9, 114.0, 113.3, 67.9, 67.8, 
55.2, 54.6, 50.7, 44.9, 39.5, 34.5, 28.5, 26.5, 21.9, 21.8, 21.7, 19.9, 19.5; IR (neat) ν 2976, 2932, 
1727, 1485, 1372, 1220, 1173, 1156, 1106, 1067 cm-1; HRMS (DART) Calcd for C24H38NO5 






3.21i-Minor: 1H NMR (600 MHz, CDCl3) δ 6.56 (d, J = 3.0 Hz, 1H), 6.45 (d, J = 3.1 Hz, 1H), 
4.99 (dq, J = 11.8, 6.1 Hz, 2H), 3.74 (s, 3H), 3.02 (td, J = 11.2, 2.6 Hz, 1H), 2.93 – 2.86 (m, 2H), 
2.84 (dt, J = 11.9, 3.9 Hz, 1H), 2.76 – 2.64 (m, 2H), 2.46 (dd, J = 15.7, 3.4 Hz, 1H), 2.26 (s, 3H), 
2.24 (s, 3H), 1.92 (dq, J = 11.6, 6.2 Hz, 1H), 1.84 (dd, J = 13.1, 3.7 Hz, 1H), 1.73 – 1.56 (m, 3H), 
1.25 (t, J = 7.0 Hz, 1H), 1.21 (dd, J = 6.2, 2.6 Hz, 9H), 1.17 (d, J = 6.5 Hz, 3H); 13C NMR (151 
MHz, CDCl3) δ 173.4, 171.7, 156.2, 142.5, 138.7, 137.7, 114.0, 113.2, 67.9, 67.8, 55.2, 54.7, 50.8, 
45.0, 39.5, 34.5, 28.6, 26.6, 21.81, 21.80, 21.76, 20.0, 19.5; HRMS (DART) Calcd for C24H38NO5 









1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpiperidine 3.19h was reacted with diisopropyl 
fumarate 2.20a following the General Procedure D using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst, DCM (0.1 mL) as the solvent, and a second batch of 2.20a in DCM (0.05 mL) was added. 
After purification by column chromatography (ethyl ether:hexanes = 1:33) 3.21j was obtained as 
a colorless liquid (89 mg, 93%).  
 
1H NMR (600 MHz, CDCl3) δ 6.55 (d, J = 13.5 Hz, 2H), 5.82 (s, 1H), 4.96 (dp, J = 17.2, 6.3 Hz, 
2H), 3.75 (s, 3H), 3.41 (dd, J = 10.9, 4.6 Hz, 1H), 3.22 (ddd, J = 12.3, 8.9, 3.7 Hz, 1H), 3.11 (ddd, 
J = 11.9, 6.4, 4.0 Hz, 1H), 2.78 (dd, J = 16.8, 10.9 Hz, 1H), 2.40 (dd, J = 16.7, 4.7 Hz, 1H), 2.18 
(s, 3H), 2.13 (s, 3H), 1.76 (ddd, J = 12.9, 8.9, 4.0 Hz, 1H), 1.70 (ddd, J = 12.9, 6.4, 3.7 Hz, 1H), 
1.23 (d, J = 6.3 Hz, 3H), 1.21 (d, J = 3.5 Hz, 3H), 1.20 (d, J = 3.5 Hz, 3H), 1.19 (s, 3H), 1.17 (d, 
J = 6.3 Hz, 3H), 1.11 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 174.5, 171.8, 157.3, 138.8, 138.3, 
138.2, 132.0, 113.4, 113.3, 108.1, 67.6, 67.3, 55.3, 44.1, 39.9, 39.6, 39.2, 31.6, 29.1, 28.2, 21.9, 
21.82, 21.80, 21.5, 18.4, 18.3; IR (neat) ν 2977, 2933, 1723, 1639, 1466, 1259, 1162, 1102, 1065 







Diisopropyl 2-(2-(benzhydrylamino)ethyl)succinate (3.21k)  
N-Benzhydrylethanamine 3.19i was reacted with diisopropyl fumarate 2.20a following the 
General Procedure D using 10 mol% B(C6F5)3 as the Lewis acid catalyst, benzene as the solvent. 
After purification by column chromatography (EtOAc:hexanes = 1:19) 3.21k was obtained as a 
colorless liquid (77 mg, 93%).  
 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.34 (m, 4H), 7.28 (td, J = 7.5, 1.5 Hz, 4H), 7.22 – 7.16 (m, 
2H), 4.98 (h, J = 6.3 Hz, 2H), 4.78 (s, 1H), 2.91 (ddt, J = 8.9, 7.5, 5.8 Hz, 1H), 2.68 – 2.55 (m, 
3H), 2.37 (dd, J = 16.4, 5.4 Hz, 1H), 1.91 – 1.80 (m, 1H), 1.77 – 1.66 (m, 1H), 1.22 (d, J = 2.5 Hz, 
3H), 1.20 (d, J = 2.5 Hz, 3H), 1.19 (d, J = 6.2 Hz, 3H), 1.14 (d, J = 6.2 Hz, 3H); 13C NMR (151 
MHz, CDCl3) δ 174.2, 171.3, 144.0, 144.0, 128.4, 127.2, 126.4, 67.9, 67.5, 45.4, 39.5, 36.4, 32.2, 
21.8, 21.74, 21.68, 21.6; IR (neat) ν 2977, 2933, 1727, 1452, 1373, 1265, 1173, 1105, 745, 703 






Diisopropyl 2-(1-(benzhydrylamino)propan-2-yl)succinate (3.21l)  
N-Benzhydrylpropan-1-amine 3.19j was reacted with diisopropyl fumarate 2.20a following the 
General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.2 mL) 
as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the diastereomeric 
ratio was 1.1:1. After purification by column chromatography (EtOAc:hexanes = 1:19) 3o was 
obtained as a mixture of diastereomers (56 mg, 66%). Further purification was carried out by PTLC 
using ethyl ether:DCM = 1:49 as the eluent to separate 3.21l-major and 3.21l-minor. The relative 
configuration of 3.21l-major and 3.21l-minor was assigned in analogy, see Section 3.6.3. 
 
3.21l-Major: 1H NMR (600 MHz, CDCl3) δ 7.41 – 7.36 (m, 4H), 7.28 (q, J = 7.8 Hz, 4H), 7.22 – 
7.17 (m, 2H), 5.00 (dq, J = 12.2, 6.2 Hz, 2H), 4.76 (s, 1H), 3.13 (ddd, J = 11.1, 4.7, 3.6 Hz, 1H), 
2.58 (dd, J = 16.6, 11.1 Hz, 1H), 2.49 (dd, J = 11.9, 6.6 Hz, 1H), 2.42 (dd, J = 11.9, 7.4 Hz, 1H), 
2.19 (dd, J = 16.6, 3.6 Hz, 1H), 2.13 (pd, J = 7.0, 4.6 Hz, 1H), 1.25 – 1.20 (m, 9H), 1.17 (d, J = 
6.2 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 174.1, 172.0, 144.2, 144.0, 
128.5, 128.4, 127.3, 127.2, 127.0, 67.8, 67.6, 51.8, 43.6, 35.3, 31.5, 21.83, 21.80, 21.78, 21.7, 14.6; 
IR (neat) ν 2976, 2930, 1725, 1452, 1373, 1260, 1173, 1105, 745, 703 cm-1; HRMS (DART) 
Calcd for C26H36NO4 (MH+): 426.2639; found: 426.2638. 
 
3.21l-Minor: 1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 7.3 Hz, 4H), 7.31 – 7.26 (m, 4H), 7.22 – 
7.16 (m, 2H), 4.98 (pd, J = 6.3, 2.4 Hz, 2H), 4.75 (s, 1H), 2.97 (dt, J = 10.6, 4.3 Hz, 1H), 2.71 (dd, 





J = 16.5, 4.2 Hz, 1H), 2.00 (qd, J = 7.0, 4.6 Hz, 1H), 1.22 (t, J = 6.2 Hz, 6H), 1.19 (d, J = 6.3 Hz, 
3H), 1.13 (d, J = 6.3 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 173.3, 
171.9, 144.2, 144.1, 128.43, 128.41, 127.3, 127.2, 126.96, 126.95, 67.8, 67.7, 51.9, 44.0, 35.8, 







Diisopropyl 2-(2-(benzhydrylamino)-1-phenylethyl)succinate (3.21m)  
N-Benzhydryl-2-phenylethan-1-amine 3.19k was reacted with diisopropyl fumarate 2.20a 
following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified product mixture revealed that 
the diastereomeric ratio was 2.1:1.  After purification by column chromatography (EtOAc:hexanes 
= 1:19) 3.21m was obtained as a mixture of diastereomers (85 mg, 87%). Further purification was 
carried out by PTLC using ethyl ether:DCM = 1:49 as the eluent to separate 3.21m-major and 
3.21m-minor. The relative configuration of 3.21m-major and 3.21m-minor was assigned in 
analogy, see Section 3.6.3. 
 
3.21m-Major: 1H NMR (600 MHz, CDCl3) δ 7.30 (t, J = 7.4 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 
7.25 – 7.19 (m, 6H), 7.19 – 7.12 (m, 4H), 4.89 (dhept, J = 12.5, 6.2 Hz, 2H), 4.71 (s, 1H), 3.06 
(qd, J = 9.5, 8.5, 3.9 Hz, 2H), 2.87 (dd, J = 12.0, 8.5 Hz, 1H), 2.81 (dd, J = 12.0, 4.6 Hz, 1H), 2.47 
(dd, J = 16.8, 10.7 Hz, 1H), 2.08 (dd, J = 16.7, 2.9 Hz, 1H), 1.15 (d, J = 6.2 Hz, 3H), 1.13 (d, J = 
6.3 Hz, 6H), 1.04 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.6, 171.3, 144.0, 143.8, 
140.1, 128.8, 128.40, 128.35, 127.3, 127.18, 127.16, 126.94, 126.88, 68.1, 67.9, 67.2, 50.9, 48.1, 
45.5, 35.3, 21.8, 21.69, 21.66, 21.5; IR (neat) ν 2976, 2931, 1725, 1451, 1372, 1263, 1170, 1105, 
745, 700 cm-1; HRMS (DART) Calcd for C31H38NO4 (MH+): 488.2795; found: 488.2772. 
 
3.21m-Minor: 1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 7.1 Hz, 2H), 7.29 – 7.19 (m, 9H), 7.19 





2H), 2.95 – 2.85 (m, 2H), 2.60 (dd, J = 16.6, 10.4 Hz, 1H), 2.33 (dd, J = 16.6, 3.8 Hz, 1H), 1.18 
(t, J = 6.9 Hz, 6H), 1.08 (d, J = 6.2 Hz, 3H), 0.91 (d, J = 6.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
δ 172.8, 171.4, 143.9, 140.0, 128.6, 128.43, 128.40, 127.3, 127.2, 127.1, 127.0, 126.9, 67.92, 
67.88, 67.4, 49.5, 47.7, 45.5, 34.4, 21.8, 21.7, 21.6, 21.3; HRMS (DART) Calcd for C31H38NO4 








succinate (3.21n)  
(R)-N-Benzyl-2-((tert-butyldimethylsilyl)oxy)-N-ethyl-1-phenylethan-1-amine 3.19l was reacted 
with dibenzyl fumarate 2.20b following the General Procedure C using B(C6F5)3 (10 mol%) as 
the Lewis acid catalyst and benzene (0.8 mL) as the solvent. After purification by column 
chromatography (ethyl ether:hexanes = 1:19) 3.21n was obtained as a mixture of diastereomers 
(93 mg, 69%, dr = 1.5:1). Further purification was carried out by PTLC using ethyl ether:DCM = 
1:49 as the eluent to separate 3.21n-(R,R) and 3.21n-(R,S). The absolute configuration of 3.21n-
(R,R) was assigned in analogy to 3.21o-(R,R) (see Section 3.6.4). 
 
3.21n-(R,R): 1H NMR (600 MHz, CDCl3) δ 7.30 – 7.13 (m, 18H), 7.10 (q, J = 6.9 Hz, 2H), 4.97 
(d, J = 12.4 Hz, 1H), 4.95 – 4.89 (m, 3H), 3.98 (dd, J = 10.5, 6.2 Hz, 1H), 3.87 (dd, J = 10.5, 6.1 
Hz, 1H), 3.75 (t, J = 6.1 Hz, 1H), 3.64 (d, J = 14.0 Hz, 1H), 3.51 (d, J = 14.0 Hz, 1H), 2.89 (dq, J 
= 11.9, 6.4 Hz, 1H), 2.64 (dt, J = 13.5, 6.3 Hz, 1H), 2.43 (dd, J = 16.6, 9.5 Hz, 1H), 2.37 (dt, J = 
13.9, 7.4 Hz, 1H), 2.06 (dd, J = 16.7, 4.7 Hz, 1H), 1.81 (dq, J = 14.1, 7.1 Hz, 1H), 1.46 (dq, J = 
13.8, 6.9 Hz, 1H), 0.76 (s, 9H), -0.10 (d, J = 5.1 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 174.8, 
171.5, 140.5, 140.1, 135.9, 135.8, 128.69, 128.65, 128.5, 128.4, 128.21, 128.17, 128.14, 128.11, 
128.06, 127.90, 126.85, 126.7, 66.33, 66.27, 64.5, 63.2, 55.0, 47.4, 38.6, 35.4, 29.7, 25.8, 18.2, 
1.0, -5.48, -5.50; IR (neat) ν 2925, 2853, 1733, 1453, 1253, 1152, 1106, 835, 746, 697 cm-1; [α]25D 







3.21n-(R,S): 1H NMR (600 MHz, CDCl3) δ 7.36 – 7.20 (m, 19H), 7.16 (t, J = 7.3 Hz, 1H), 5.04 
(d, J = 12.3 Hz, 1H), 5.02 – 4.97 (m, 3H), 4.03 (dd, J = 10.4, 6.3 Hz, 1H), 3.89 (dd, J = 10.5, 6.2 
Hz, 1H), 3.85 – 3.77 (m, 2H), 3.42 (d, J = 14.1 Hz, 1H), 2.96 (dq, J = 12.3, 6.0 Hz, 1H), 2.60 (dt, 
J = 13.4, 7.7 Hz, 1H), 2.52 (dd, J = 16.6, 9.4 Hz, 1H), 2.44 (ddd, J = 13.2, 8.2, 4.8 Hz, 1H), 2.23 
(dd, J = 16.7, 4.8 Hz, 1H), 1.92 (dq, J = 14.1, 7.3 Hz, 1H), 1.57 – 1.48 (m, 1H), 0.81 (s, 9H), -0.06 
(d, J = 5.6 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 174.7, 171.6, 140.6, 139.6, 135.9, 135.8, 
128.7, 128.6, 128.5, 128.4, 128.22, 128.17, 128.13, 128.11, 128.06, 127.9, 127.0, 126.7, 66.32, 
66.29, 65.4, 64.0, 55.1, 47.6, 38.6, 35.3, 30.3, 29.7, 29.4, 25.8, 18.2, -5.51, -5.53; HRMS (DART) 






Dibenzyl 2-(2-(bis((R)-1-phenylethyl)amino)ethyl)succinate (3.21o)  
(R)-N-Ethyl-1-phenyl-N-((R)-1-phenylethyl)ethan-1-amine 3.19m was reacted with dibenzyl 
fumarate 2.20b following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid 
catalyst and benzene (0.8 mL) as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 1.4:1. After purification by column chromatography 
(ethyl ether:hexanes = 1:9), 3.21o-(R,R,R) (3.3 mg, 3% yield), 3.21o-mixture (81 mg, 77%) and 
3.21o-(R,R,S) (2.2 mg, 2% yield) were obtained as colorless oils. The absolute configuration of 
product 3.21o-(R,R,R) was assigned in analogy to a previously synthesized molecule (see Section 
3.74 for details). 
 
3.21o-(R,R,R): 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (m, 18H), 7.20 – 7.14 (m, 2H), 5.03 (d, 
J = 12.4 Hz, 1H), 4.98 (d, J = 12.4 Hz, 1H), 4.94 (s, 2H), 3.93 (q, J = 6.8 Hz, 2H), 2.70 – 2.49 (m, 
3H), 2.40 (ddd, J = 14.0, 10.5, 5.3 Hz, 1H), 2.19 (dd, J = 16.5, 4.9 Hz, 1H), 1.62 – 1.47 (m, 1H), 
1.31 (d, J = 6.8 Hz, 6H), 1.28 – 1.15 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 174.3, 171.5, 144.9, 
135.9, 135.7, 128.5, 128.4, 128.2, 128.1, 128.0, 127.8, 126.6, 66.33, 66.29, 57.9, 44.0, 39.2, 36.0, 
33.1, 18.2; IR (neat) ν 3027, 2965, 1729, 1492, 1452, 1258, 1211, 1150, 971, 736, 696 cm-1; [α]25D 







3.21o-(R,R,S): 1H NMR (600 MHz, CDCl3) δ 7.37 – 7.25 (m, 14H), 7.23 (t, J = 7.5 Hz, 4H), 7.14 
(t, J = 7.2 Hz, 2H), 5.04 – 4.93 (m, 4H), 3.95 (q, J = 7.1 Hz, 2H), 2.75 (dq, J = 11.4, 6.1 Hz, 1H), 
2.59 (ddd, J = 14.2, 8.8, 5.1 Hz, 1H), 2.44 – 2.33 (m, 2H), 1.88 (dd, J = 16.8, 4.7 Hz, 1H), 1.57 – 
1.49 (m, 1H), 1.33 (d, J = 6.9 Hz, 6H), 1.30 – 1.27 (m, 1H); 13C NMR δ 174.8, 171.6, 144.8, 135.9, 
135.8, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 126.6, 66.3, 57.3, 43.0, 38.6, 35.1, 32.3, 







Diisopropyl 2-((4R)-1-benzyl-4-phenylpyrrolidin-3-yl)succinate (3.21p)  
(R)-1-Benzyl-3-phenylpyrrolidine 3.19n was reacted with diisopropyl fumarate 2.20a following 
the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and benzene (0.2 
mL) as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was 1.6:1. After purification by column chromatography (ethyl ether:hexanes 
= 1:4), 3.21p was obtained as a mixture of diastereomers (78.7 mg, 90%). Further purification was 
carried out by PTLC using ethyl ether:DCM:hexanes = 2:8:3 as the eluent to separate 3.21p-
(R,R,R) and 3.21p-minor. The absolute configuration of 3.21p-(R,R,R) was assigned based on 
analogy to 3.21q-(R,R,R) and by NOESY experiments (see Section 3.6.3 for NOE spectra). 
 
3.21p-(R,R,R): 1H NMR (500 MHz, CDCl3) δ 7.29 (ddt, J = 19.6, 15.2, 4.7 Hz, 8H), 7.23 (d, J = 
6.9 Hz, 1H), 7.18 (d, J = 6.9 Hz, 1H), 4.99 – 4.82 (m, 2H), 3.64 (d, J = 12.9 Hz, 1H), 3.57 (d, J = 
12.9 Hz, 1H), 3.17 – 3.10 (m, 1H), 2.96 – 2.88 (m, 2H), 2.85 (t, J = 8.6 Hz, 1H), 2.70 – 2.61 (m, 
1H), 2.61 – 2.55 (m, 2H), 2.55 – 2.48 (m, 1H), 2.40 (dd, J = 16.8, 3.9 Hz, 1H), 1.21 – 1.14 (m, 
9H), 1.02 (d, J = 6.3 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.0, 171.5, 145.0, 139.0, 128.6, 
128.5, 128.2, 127.7, 126.9, 126.3, 68.0, 67.9, 63.3, 60.2, 58.1, 48.7, 47.7, 44.7, 34.9, 21.78, 21.75, 
21.7, 21.5; IR (neat) ν 2975, 2932, 2788, 1725, 1492, 1372, 1261, 1173, 1144, 1105, 754, 699 cm-







3.21p-Minor: 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.22 (m, 8H), 7.17 (q, J = 7.0 Hz, 2H), 4.99 
– 4.91 (m, 1H), 4.82 – 4.70 (m, 1H), 3.61 (d, J = 7.9 Hz, 2H), 3.17 (t, J = 7.0 Hz, 1H), 2.88 (dq, J 
= 24.7, 8.0, 7.6 Hz, 3H), 2.69 – 2.53 (m, 3H), 2.47 (t, J = 8.1 Hz, 1H), 2.37 (dd, J = 16.9, 3.9 Hz, 
1H), 1.21 – 1.16 (m, 6H), 1.12 (d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.3 Hz, 3H); HRMS (DART) Calcd 







yl)succinate (3.21q)  
(R)-1-Benzyl-2-(((tert-butyldimethylsilyl)oxy)diphenylmethyl)pyrrolidine 3.19o was reacted with 
diisopropyl fumarate 2.20a following the General Procedure C using B(C6F5)3 (10 mol%) as the 
Lewis acid catalyst and benzene (0.2 mL) as the solvent. 1H NMR analysis of the unpurified 
product mixture revealed that the diastereomeric ratio was 2.5:1. After purification by column 
chromatography (ethyl ether:hexanes = 1:9) 3.21q was obtained as a mixture of diastereomers (74 
mg, 56%). Further purification was carried out by PTLC using ethyl ether:DCM = 1:49 as the 
eluent to separate 3.21q-(R,R,R) and 3.21q-minor. The absolute configuration of 3.21q-(R,R,R) 
was assigned based on X-ray crystallography data (see Sections 3.6.4). 
 
3.21q-(R,R,R): 1H NMR (600 MHz, CDCl3) δ 7.60 (s, 2H), 7.55 (d, J = 7.3 Hz, 2H), 7.35 – 7.26 
(m, 6H), 7.19 (t, J = 7.4 Hz, 2H), 7.14 (t, J = 7.2 Hz, 1H), 7.04 (d, J = 7.4 Hz, 2H), 4.90 (p, J = 6.2 
Hz, 1H), 4.78 (p, J = 5.9 Hz, 1H), 4.41 (br, 1H), 4.01 (d, J = 10.1 Hz, 1H), 3.35 (d, J = 12.8 Hz, 
1H), 2.46 (t, J = 7.8 Hz, 1H), 2.39 – 2.28 (m, 2H), 2.13 (d, J = 14.4 Hz, 1H), 1.98 (t, J = 10.1 Hz, 
2H), 1.66 (q, J = 11.6 Hz, 2H), 1.15 (t, J = 5.8 Hz, 6H), 1.08 (d, J = 6.4 Hz, 3H), 0.94 (d, J = 6.3 
Hz, 3H), 0.88 (s, 9H), -0.41 (s, 3H), -0.45 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 173.1, 171.3, 
143.4, 140.3, 130.1, 129.9, 128.4, 128.0, 127.4, 127.2, 127.1, 126.4, 70.6, 67.9, 67.5, 61.8, 59.1, 





1727, 1372, 1254, 1173, 1105, 1060, 833, 774, 702 cm-1; [α]25D = 43.1 ° (c = 0.7, EtOH); HRMS 
(DART) Calcd for C40H56NO5Si (MH+): 658.3922; found: 658.3905. 
 
3.21q-Minor: 1H NMR (600 MHz, CDCl3) δ 7.63 – 7.56 (m, 2H), 7.54 (d, J = 6.3 Hz, 2H), 7.37 
– 7.27 (m, 6H), 7.22 (t, J = 7.5 Hz, 2H), 7.16 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 7.6 Hz, 2H), 4.90 (p, 
J = 6.3 Hz, 1H), 4.85 (p, J = 6.3 Hz, 1H), 4.45 (br, 1H), 4.05 (dd, J = 10.2, 2.6 Hz, 1H), 3.36 (d, J 
= 13.1 Hz, 1H), 2.58 (dd, J = 8.8, 6.4 Hz, 1H), 2.35 – 2.25 (m, 2H), 2.10 (s, 1H), 2.00 – 1.89 (m, 
2H), 1.89 – 1.80 (m, 2H), 1.19 (d, J = 6.2 Hz, 3H), 1.15 (d, J = 6.3 Hz, 3H), 1.11 (d, J = 6.2 Hz, 
3H), 1.09 (d, J = 6.2 Hz, 3H), 0.87 (s, 9H), -0.42 (s, 3H), -0.46 (s, 3H); 13C NMR (151 MHz, 
CDCl3) δ 173.1, 171.2, 143.5, 140.4, 130.0, 129.9, 128.2, 128.1, 127.4, 127.2, 127.1, 126.7, 126.4, 
70.8, 67.8, 67.7, 61.8, 59.5, 45.4, 38.4, 35.8, 33.5, 26.3, 21.8, 21.74, 21.70, 21.6, 18.9, -2.9, -3.0; 








fluorophenyl)piperidin-3-yl)succinate (3.21r)  
For 0.2 mmol scale: 
(3S,4R)-3-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-1-benzyl-4-(4-fluorophenyl)piperidine 3.19p 
was reacted with diisopropyl fumarate 2.20a following the General Procedure D using B(C6F5)3 
(10 mol%) as the Lewis acid catalyst and benzene as the solvent.  1H NMR analysis of the 
unpurified product mixture revealed that the diastereomeric ratio of 3.21r was 2.3:1. After 
purification by column chromatography (ethyl ether:hexanes = 3:2), 3.21r was obtained as a 
mixture of diastereomers (48 mg, 39%). The relative configuration of 3.21r-major and 3.21r-
minor was assigned in analogy (see Section 3.6.3). 
 
3.21r-Major: 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.19 (m, 5H), 7.00 (s, 2H), 6.61 (d, J = 8.4 
Hz, 1H), 6.31 (d, J = 2.5 Hz, 1H), 6.09 (dd, J = 8.5, 2.5 Hz, 1H), 5.88 (s, 2H), 4.94 – 4.76 (m, 2H), 
3.64 (d, J = 13.1 Hz, 1H), 3.48 (d, J = 2.6 Hz, 1H), 3.45 (d, J = 13.1 Hz, 1H), 3.41 – 3.33 (m, 1H), 
3.20 – 3.13 (m, 1H), 2.83 – 2.74 (m, 1H), 2.61 – 2.48 (m, 3H), 2.42 (t, J = 11.2 Hz, 1H), 2.29 – 
2.17 (m, 2H), 2.13 (t, J = 11.1 Hz, 1H), 1.84 (t, J = 11.1 Hz, 1H), 1.15 (d, J = 6.2 Hz, 6H), 1.08 (d, 
J = 6.3 Hz, 3H), 1.02 (d, J = 6.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.3, 171.4, 161.8 (d, 
JC−F = 245.3 Hz), 154.2, 148.1, 141.6, 137.9, 136.4, 136.3, 129.1, 128.2, 127.1, 115.8, 107.8, 105.6, 





19F NMR (470 MHz, CDCl3) δ -115.52, -115.53, -115.54, -115.55, -115.56, -115.58; IR (neat) ν 
2978, 2917, 2870, 1724, 1508, 1502, 1486, 1224, 1182, 1104, 1037, 779 cm-1; [α]25D = − 22.1° (c 
= 1.0, EtOH); HRMS (DART) Calcd for C36H43FNO7 (MH+): 620.3018; found: 620.3004. 
 
3.21r-Minor: 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.29 (m, 4H), 7.29 – 7.23 (m, 1H), 7.20 (t, J 
= 7.0 Hz, 2H), 6.98 (s, 2H), 6.60 (dd, J = 8.5, 1.7 Hz, 1H), 6.27 (t, J = 2.1 Hz, 1H), 6.06 (dt, J = 
8.6, 2.1 Hz, 1H), 5.87 (d, J = 1.8 Hz, 2H), 4.97 (td, J = 6.3, 1.7 Hz, 1H), 4.88 (td, J = 6.2, 1.7 Hz, 
1H), 3.58 (q, J = 13.2 Hz, 2H), 3.45 (dt, J = 9.4, 2.2 Hz, 1H), 3.40 – 3.23 (m, 1H), 3.19 – 3.09 (m, 
1H), 3.09 – 2.97 (m, 1H), 2.83 – 2.64 (m, 2H), 2.64 – 2.51 (m, 1H), 2.25 – 2.08 (m, 3H), 2.05 (d, 
J = 11.1 Hz, 1H), 1.83 (t, J = 11.4 Hz, 2H), 1.30 (dd, J = 6.2, 1.7 Hz, 3H), 1.23 (dd, J = 6.3, 1.7 
Hz, 3H), 1.15 (dt, J = 5.6, 2.3 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 172.1, 171.2, 161.7 (d, 
JC−F = 244.8 Hz), 154.3, 148.1, 141.5, 137.8, 137.04, 137.02, 129.0, 128.3, 127.1, 115.5, 107.8, 
105.4, 101.0, 97.8, 69.3, 68.1, 67.9, 63.3, 57.1, 55.6, 46.3, 44.2, 43.1, 40.9, 35.2, 22.0, 21.9, 21.73, 
21.72; 19F NMR (470 MHz, CDCl3) δ -115.96, -115.98, -115.99, -116.00, -116.02; HRMS (DART) 

















1,4,5,6-tetrahydropyridin-3-yl)succinate (3.21s)  
From 0.2 mmol of N-Bn paroxetine (3.21s): 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio of 3.21s was 1.9:1. After purification by column 
chromatography (ethyl ether:hexanes = 1:4), 3.21s was obtained as a mixture of diastereomers (19 
mg, 14%). The relative configuration of 3.21s-major and 3.21s-minor was assigned in analogy 
(see Section 3.6.3). 
 
3.21s-Major: 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.24 (m, 4H), 7.24 – 7.19 (m, 2H), 7.07 (s, 
2H), 6.89 (s, 2H), 6.69 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 2.4 Hz, 1H), 6.35 (s, 1H), 6.27 (dd, J = 8.5, 
2.5 Hz, 1H), 5.91 (s, 2H), 5.00 – 4.83 (m, 2H), 4.17 – 3.99 (m, 2H), 3.78 (d, J = 23.9 Hz, 2H), 3.31 
(s, 1H), 3.22 (dd, J = 10.3, 4.9 Hz, 1H), 2.81 – 2.67 (m, 2H), 2.56 (dd, J = 16.9, 10.3 Hz, 1H), 2.17 
(dd, J = 16.9, 4.9 Hz, 1H), 2.09 – 1.99 (m, 1H), 1.21 (d, J = 6.2 Hz, 3H), 1.19 – 1.12 (m, 9H); 13C 
NMR (151 MHz, CDCl3) δ 173.0, 171.4, 161.5 (d, JC−F = 244.4 Hz), 154.4, 148.2, 141.5 (d, JC−F 
= 2.9 Hz), 137.6, 134.9, 129.9 (d, JC−F = 7.7 Hz), 128.4, 128.1, 127.4, 114.8 (d, JC−F = 21.1 Hz), 
107.9, 105.9, 101.10, 101.07, 98.2, 70.2, 67.9, 67.8, 59.3, 45.9, 42.0, 40.8, 40.4, 37.4, 21.84, 21.78, 
21.75, 21.7, 21.6; 19F NMR (470 MHz, CDCl3) δ -117.23, -117.24, -117.25, -117.26, -117.27, -





1104, 817, 788, 701 cm-1; [α]25D = − 84.8° (c = 1.0, EtOH); HRMS (DART) Calcd for C36H41FNO7 
(MH+): 618.2861; found: 618.2847.  
 
3.21s-Minor: 1H NMR (600 MHz, CDCl3) δ 7.38 – 7.15 (m, 5H), 7.06 (dd, J = 8.3, 5.4 Hz, 2H), 
6.89 (t, J = 8.5 Hz, 2H), 6.68 (d, J = 8.4 Hz, 1H), 6.43 (d, J = 2.4 Hz, 1H), 6.30 (s, 1H), 6.26 (dd, 
J = 8.5, 2.5 Hz, 1H), 5.98 – 5.84 (m, 2H), 4.92 (q, J = 6.3 Hz, 1H), 4.67 (q, J = 6.2 Hz, 1H), 4.09 
(q, J = 14.6 Hz, 2H), 3.82 (dd, J = 9.1, 6.6 Hz, 1H), 3.75 (t, J = 8.3 Hz, 1H), 3.46 (s, 1H), 3.12 (dd, 
J = 10.5, 5.1 Hz, 1H), 2.90 (dd, J = 16.5, 10.6 Hz, 1H), 2.83 – 2.69 (m, 2H), 2.34 (dd, J = 16.5, 
5.1 Hz, 1H), 2.07 (dd, J = 6.9, 3.8 Hz, 1H), 1.17 (d, J = 6.3 Hz, 6H), 1.10 (dd, J = 10.2, 6.3 Hz, 
6H); 13C NMR (151 MHz, CDCl3) δ 173.1, 171.3, 161.5 (d, JC-F = 244.5 Hz), 154.4, 148.2, 141.6, 
140.9 (d, JC-F = 3.1 Hz), 137.6, 134.7, 129.8 (d, JC-F = 7.7 Hz), 128.5, 128.1, 127.5, 114.9 (d, JC-F 
= 21.0 Hz), 107.9, 105.8, 101.8, 101.1, 98.2, 70.2, 68.0, 67.9, 59.5, 44.8, 42.4, 41.4, 40.5, 36.6, 
21.79, 21.75, 21.60, 21.56; 19F NMR (470 MHz, CDCl3) δ -117.14, -117.15, -117.16, -117.17, -











-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone 3.19q (0.20 mmol) was reacted with 
diisopropyl fumarate 2.20a following the General Procedure C using B(C6F5)3 (10 mol%) as the 
Lewis acid catalyst and benzene as the solvent. 1H NMR analysis of the unpurified product mixture 
revealed that the diastereomeric ratio was 2.5:1. After purification by column chromatography 
(ethyl ether:DCM = 1:4), 3.21t was obtained as a mixture of diastereomers (145 mg, 80%). Further 
purification was carried out by PTLC using MeOH:DCM = 1:49 as the eluent to separate 3.21t-
major and 3.21t-minor. The relative configuration of 3.21t-major and 3.21t-minor was assigned 
in analogy (see Section 3.6.3). 
 
3.21t-major. 1H NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.9 Hz, 2H), 7.54 (d, J = 8.8 Hz, 1H), 
7.28 (d, J = 2.2 Hz, 1H), 7.27 – 7.25 (m, 1H), 7.25 – 7.23 (m, 1H), 6.88 (dd, J = 8.8, 2.2 Hz, 1H), 
6.72 (d, J = 8.9 Hz, 2H), 6.66 (d, J = 8.5 Hz, 2H), 4.99 (dp, J = 12.5, 6.3 Hz, 2H), 4.03 (t, J = 6.0 
Hz, 2H), 2.87 (dd, J = 16.7, 9.2 Hz, 2H), 2.80 – 2.62 (m, 4H), 2.46 – 2.32 (m, 1H), 2.06 – 1.82 (m, 
3H), 1.67 (dt, J = 16.5, 12.7 Hz, 2H), 1.54 (q, J = 12.8 Hz, 1H), 1.21 (td, J = 6.0, 1.8 Hz, 12H), 





(126 MHz, CDCl3): δ 193.15, 173.16, 171.57, 162.81, 156.07, 153.48, 143.22, 139.84, 134.49, 
132.28, 130.58, 130.50, 130.29, 126.75, 123.94, 120.24, 119.22, 114.02, 112.06, 67.99, 67.90, 
66.08, 58.32, 57.39, 54.31, 45.06, 44.95, 38.14, 34.00, 27.84, 25.69, 25.62, 25.28, 21.80, 21.79, 
21.74, 18.23, 18.18, -4.38, -4.48. HRMS (DART): Calcd for C50H72NO8SSi2+ (MH+): 902.4512; 
found: 902.4522. 
 
3.21t-minor. 1H NMR (600 MHz, CDCl3): δ 7.73 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.7 Hz, 1H), 
7.28 (t, J = 1.8 Hz, 1H), 7.24 (d, J = 1.3 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 6.76 – 6.69 (m, 2H), 
6.66 (d, J = 8.0 Hz, 2H), 5.06 – 4.93 (m, 2H), 4.03 (s, 2H), 2.93 – 2.81 (m, 2H), 2.79 – 2.66 (m, 
4H), 2.37 (q, J = 10.0 Hz, 1H), 2.00 (t, J = 11.4 Hz, 1H), 1.94 (t, J = 10.9 Hz, 1H), 1.90 – 1.81 (m, 
1H), 1.74 – 1.64 (m, 2H), 1.55 (d, J = 15.3 Hz, 1H), 1.20 (d, J = 1.7 Hz, 12H), 1.10 – 0.99 (m, 
10H), 0.93 (s, 9H), 0.23 (s, 6H), 0.12 (s, 6H). 13C NMR (151 MHz, CDCl3): δ 195.81, 175.86, 
174.19, 165.45, 158.71, 156.13, 145.89, 142.49, 137.14, 134.94, 133.21, 133.15, 132.95, 129.40, 
126.59, 122.90, 121.88, 116.65, 114.72, 70.65, 70.57, 68.74, 60.83, 60.02, 57.02, 47.60, 40.88, 
36.89, 30.44, 28.34, 28.27, 27.81, 24.48, 24.45, 24.40, 20.88, 20.83, 2.63, -1.73, -1.83. HRMS 







4H-pyrido[1,2-a]pyrimidin-3-yl)ethyl)-1,4,5,6-tetrahydropyridin-3-yl)succinate (3.21u)  
3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-
pyrido[1,2-a]pyrimidin-4-one 3.19r (1g, 2.4 mmol) was reacted with diisopropyl fumarate 3.20a 
following the General Procedure C using B(C6F5)3 (10 mol%) as the Lewis acid catalyst and 
DCM as the solvent. 1H NMR analysis of the unpurified product mixture revealed that the 
diastereomeric ratio was 1.7:1. After purification by column chromatography (methanol:DCM = 
1:49), 3.21u was obtained as a mixture of diastereomers (470 mg, 32%). Further purification was 
carried out by PTLC using methanol:DCM = 1:49 as the eluent to separate 3.21u-major. 
 
3.21u-Major. 1H NMR (500 MHz, CDCl3): δ 7.66 (dd, J = 8.8, 5.2 Hz, 1H), 7.21 (dd, J = 8.4, 
2.1 Hz, 1H), 7.06 – 7.00 (m, 1H), 6.15 (s, 1H), 4.95 – 4.81 (m, 1H), 4.81 – 4.68 (m, 1H), 4.08 (d, 
J = 5.1 Hz, 1H), 3.94 (t, J = 6.3 Hz, 2H), 3.22 – 3.12 (m, 3H), 3.10 (s, 2H), 2.89 (d, J = 6.9 Hz, 
3H), 2.74 (d, J = 7.6 Hz, 2H), 2.40 (dd, J = 16.4, 4.8 Hz, 1H), 2.30 (s, 3H), 2.19 – 2.11 (m, 1H), 
2.01 (d, J = 7.3 Hz, 1H), 1.98 (t, J = 6.2 Hz, 2H), 1.93 – 1.83 (m, 2H), 1.20 – 1.09 (m, 12H); 13C 
NMR (151 MHz, CDCl3): δ 173.0, 171.3, 163.9, 163.2, 162.5, 161.3, 158.6, 156.2, 135.7, 135.6, 
122.9, 122.8, 118.2, 118.0, 112.4, 112.2, 99.1, 97.3, 97.1, 67.9, 67.84, 67.80, 67.7, 53.3, 45.7, 44.5, 





21.4, 19.2; 19F NMR (470 MHz, CDCl3): δ -109.99; IR (neat): ν 2975, 2931, 1723, 1649, 1612, 
1533, 1411, 1268, 1167, 1141, 1105, 919, 830 cm-1; HRMS (DART): Calcd for C33H42FN4O6 
(MH+): 609.3083; found: 609.3072. 
 
1H NMR (500 MHz, CDCl3, peaks from diastereomers are merged): δ 7.67 (dd, J = 9.0, 5.1 Hz, 
1H), 7.22 (t, J = 6.8 Hz, 1H), 7.03 (q, J = 9.2 Hz, 1H), 6.24 – 6.10 (m, 1H), 4.88 (dt, J = 12.7, 6.4 
Hz, 1H), 4.81 – 4.71 (m, 1H), 4.09 (dd, J = 5.8, 3.1 Hz, 1H), 3.94 (q, J = 5.0, 4.0 Hz, 2H), 3.27 – 
3.04 (m, 5H), 2.87 (dt, J = 23.5, 9.0 Hz, 3H), 2.74 (t, J = 7.7 Hz, 2H), 2.64 – 2.35 (m, 1H), 2.31 
(d, J = 3.9 Hz, 3H), 2.21 – 2.08 (m, 1H), 2.08 – 2.02 (m, 1H), 2.02 – 1.94 (m, 2H), 1.94 – 1.83 (m, 
2H), 1.20 – 1.06 (m, 12H); 13C NMR (126 MHz, CDCl3): δ 172.9, 172.8, 171.22, 171.16, 164.0 
(d, J = 250.3 Hz), 164.0 (d, J = 250.3 Hz), 163.9, 163.8, 163.7, 162.4, 161.7, 161.2, 158.51, 158.47, 
156.11, 156.07, 135.9, 135.6, 123.4 (d, J = 10.9 Hz), 122.8 (d, J = 11.0 Hz), 118.07, 118.05, 117.9, 
117.6, 112.16 (d, J = 25.2 Hz), 112.22 (d, J = 25.1 Hz), 98.9, 98.5, 97.2 (d, J = 26.7 Hz). 97.1 (d, 
J = 26.7 Hz), 67.8, 67.7, 67.6, 53.2, 53.0, 45.6, 44.4, 42.9, 42.8, 42.6, 37.0, 36.0, 31.6, 31.38, 










To a 15 mL oven-dried pressure vessel was added (R)-1-benzyl-2-(((tert-
butyldimethylsilyl)oxy)diphenylmethyl)pyrrolidine 3.19o (0.10 mmol), (S,E)-4-phenyl-3-(4,4,4-
trifluorobut-2-enoyl)oxazolidin-2-one 3.23b (0.15 mmol), B(C6F5)3 (10 mol%), ZnI2 (10 mol%), 
HBpin (70 mol%) and benzene (0.60 mL) under a nitrogen atmosphere. The reaction mixture was 
allowed to heat for 36 hours at 70 °C. Upon completion, the reaction mixture was concentrated in 
vacuo. After purification by column chromatography (EtOAc:hexanes = 1:6), 3.24b was obtained 
as a white solid (61 mg, 82%). The absolute configuration of 3.24b-(R,R,R,S) was assigned based 
on X-ray crystallography data of 3.35b (see Sections 3.6.4). 
 
1H NMR (600 MHz, CDCl3): δ 7.59 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 6.6 Hz, 2H), 7.37 – 7.27 (m, 
9H), 7.21 (t, J = 7.3 Hz, 4H), 7.15 (t, J = 7.2 Hz, 1H), 7.04 (d, J = 7.4 Hz, 2H), 5.33 (dd, J = 8.8, 
4.1 Hz, 1H), 4.65 (t, J = 8.8 Hz, 1H), 4.46 (br, 1H), 4.25 (dd, J = 9.0, 4.0 Hz, 1H), 4.02 (d, J = 9.8 
Hz, 1H), 3.40 (d, J = 13.3 Hz, 1H), 3.02 (dd, J = 18.4, 6.2 Hz, 1H), 2.80 (dd, J = 18.4, 5.0 Hz, 1H), 
2.63 (t, J = 7.8 Hz, 1H), 2.59 – 2.51 (m, 1H), 1.96 – 1.84 (m, 2H), 1.69 (q, J = 11.7 Hz, 1H), 1.33 
– 1.18 (m, 1H), 0.87 (s, 9H), -0.44 (d, J = 17.4 Hz, 6H); 13C NMR (151 MHz, CDCl3): δ 170.2, 
153.6, 143.2, 140.3, 138.6, 130.2, 130.1, 130.1, 129.4, 129.0, 128.3, 128.2, 128.2, 127.7, 127.4, 
127.2 (q, J = 266.8 Hz), 127.1, 126.6, 125.8, 70.2, 69.8, 61.7, 59.0, 58.1, 40.7 (q, J = 26.3 Hz), 
35.4, 33.1, 29.9, 26.5, 19.1, -2.7, -2.9; 19F NMR (376 MHz, CDCl3): δ -69.82 (d, J = 9.3 Hz); IR 





1120, 1095, 1061, 854, 834, 774, 702 cm-1; HRMS (DART): Calcd for C43H50F3N2O4Si (MH+): 









To a 15 mL oven-dried pressure vessel was added Mg(ClO4)2 (0.010 mmol, 10 mol%), L5 (0.010 
mmol, 10 mol%), Benzene (0.30 mL) under nitrogen atmosphere. The mixture was allowed to stir 
for 20 minutes at 22 °C. Subsequently, 1-(4-methoxy-2,6-dimethylphenyl)pyrrolidine 3.19s (0.10 
mmol), (E)-3-(4,4,4-trifluorobut-2-enoyl)oxazolidin-2-one 3.23c (0.15 mmol), and benzene (0.30 
mL) were added to the vial under nitrogen atmosphere, and the resulting mixture was allowed to 
stir at 22 °C for 12 h. Upon completion, the reaction mixture was concentrated in vacuo. 1H NMR 
and 19F NMR analyses of the unpurified product mixture using mesitylene and perfluorobenzene 
as the internal standard revealed that the diastereomeric ratio was 1.6:1. After purification by 
column chromatography (EtOAc:hexanes = 1:3), 3.24c was obtained as a colorless liquid (28 mg, 
67%). Further purification was carried out by PTLC using ethyl EtOAc:hexanes = 1:2 as the eluent 
to separate 3.24c-anti and 3.24c-syn.  
 
3.24c-anti. 1H NMR (400 MHz, CDCl3): δ 6.55 (s, 2H), 4.41 (t, J = 7.9 Hz, 2H), 4.09 – 3.93 (m, 
2H), 3.73 (s, 3H), 3.41 (dd, J = 18.5, 7.2 Hz, 1H), 3.28 (q, J = 8.7 Hz, 1H), 3.22 – 3.09 (m, 3H), 
3.08 – 2.92 (m, 2H), 2.65 (h, J = 8.3 Hz, 1H), 2.36 – 2.12 (m, 7H), 1.85 (p, J = 10.3 Hz, 1H); 13C 
NMR (101 MHz, CDCl3): δ 170.6, 157.0, 153.6, 139.8, 137.5, 127.8 (q, J = 280.5 Hz), 113.7, 





CDCl3): δ -69.12 (d, J = 9.3 Hz); IR (neat): ν 2921, 2837, 1778, 1701, 1601, 1480, 1387, 1363, 
1319, 1280, 1222, 1194, 1124, 1067, 1040, 956, 856, 709, 671, 626 cm-1; HRMS (DART): Calcd 
for C20H26F3N2O4 (MH+): 415.1839; found: 415.1819; HPLC (CHIRACPAK IA-3; 5%/ 95% 
isopropanol/ hexanes, 0.5 mL/min; tr = 25.7 min (minor), 36.0 min (major); 90:10 er); Specific 

















3.24c-syn. 1H NMR (400 MHz, CDCl3): δ 6.55 (s, 2H), 4.44 (t, J = 8.1 Hz, 2H), 4.09 – 4.00 (m, 
2H), 3.73 (s, 3H), 3.45 – 3.34 (m, 1H), 3.32 – 3.19 (m, 2H), 3.19 – 3.10 (m, 3H), 3.07 (t, J = 8.8 
Hz, 1H), 2.62 (dq, J = 16.7, 7.9 Hz, 1H), 2.21 (s, 6H), 2.10 – 2.01 (m, 1H), 1.79 (p, J = 10.2 Hz, 
1H); 19F NMR (470 MHz, CDCl3): δ -69.62 (d, J = 9.2 Hz); IR (neat): ν 2920, 2852, 1780, 1701, 
1660, 1602, 1480, 1466, 1388, 1364, 1318, 1261, 1223, 1194, 1157, 1126, 1066, 1039 cm-1; 
HRMS (DART): Calcd for C20H26F3N2O4 (MH+): 415.1839; found: 415.1837. HPLC 
(CHIRACPAK IA-3; 5%/ 95% isopropanol/ hexanes, 0.5 mL/min; tr = 22.0 min (major), 30.7 min 









1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 3.19t was reacted with ethyl (E)-4-(2-ethyl-3,3-
dimethyl-5-oxopyrazolidin-1-yl)-4-oxobut-2-enoate 3.25a following the General Procedure E 
for 1 hour using B(C6F5)3 (10 mol%), Sc(OTf)3 (5.0 mol%), L12 (6.0 mol%) and DCM as the 
solvent. 1H NMR analysis of the unpurified product mixture using mesitylene as the internal 
standard revealed that the diastereomeric ratio was 2.0:1. After purification by column 
chromatography (EtOAc:hexanes = 1:2), 3.26a was obtained as a colorless liquid (36 mg, 80%). 
Further purification was carried out by PTLC using ethyl EtOAc:hexanes = 1:2 as the eluent to 
separate 3.26a-(R,S) and 3.26a-(S,S). The absolute configuration for this product was assigned in 
analogy to that determined for product 3.26d (see Section 3.6.4). 
 
3.26a-(R,S). 1H NMR (500 MHz, CDCl3): δ 6.84 (d, J = 9.0 Hz, 2H), 6.51 (d, J = 9.0 Hz, 2H), 
4.22 – 4.08 (m, 2H), 3.75 (s, 3H), 3.46 – 3.37 (m, 2H), 3.33 (td, J = 8.7, 2.7 Hz, 1H), 3.29 – 3.21 
(m, 1H), 3.05 (t, J = 8.7 Hz, 1H), 3.03 – 2.93 (m, 4H), 2.59 (s, 2H), 2.51 (q, J = 8.4 Hz, 1H), 2.14 
– 2.05 (m, 1H), 1.90 (dq, J = 12.2, 8.9 Hz, 1H), 1.31 (d, J = 5.1 Hz, 6H), 1.25 (t, J = 7.1 Hz, 3H), 
1.07 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.5, 174.3, 169.6, 151.1, 142.8, 115.2, 
112.6, 60.88, 60.85, 56.1, 52.3, 48.1, 47.3, 44.3, 43.9, 40.9, 37.9, 29.7, 26.1, 25.8, 14.4, 12.9; IR 
(neat): ν 2968, 2929, 2829, 1727, 1514, 1485, 1465, 1370, 1302, 1238, 1176, 1128, 1095, 1038, 





(CHIRACPAK IA-3; 10%/ 90% isopropanol/ hexanes, 1.0 mL/min; tr = 15.6 min (minor), 21.7 















3.26a-(S,S). 1H NMR (600 MHz, CDCl3): δ 6.82 (d, J = 8.9 Hz, 2H), 6.49 (d, J = 9.0 Hz, 2H), 
4.14 (q, J = 7.1 Hz, 2H), 3.74 (s, 3H), 3.44 – 3.29 (m, 3H), 3.28 – 3.20 (m, 1H), 3.12 (t, J = 8.8 
Hz, 1H), 3.03 (dd, J = 18.0, 3.7 Hz, 1H), 3.02 – 2.90 (m, 3H), 2.58 (s, 2H), 2.56 – 2.48 (m, 1H), 
2.18 (ddd, J = 12.6, 7.7, 5.3 Hz, 1H), 1.83 – 1.71 (m, 1H), 1.30 (d, J = 3.7 Hz, 6H), 1.25 (t, J = 7.1 
Hz, 3H), 1.05 (t, J = 7.1 Hz, 3H); IR (neat): ν 2969, 2924, 2849, 1727, 1513, 1485, 1464, 1371, 
1302, 1238, 1177, 1127, 1095, 1034, 813 cm-1; HRMS (DART): Calcd for C24H36N3O5 (MH+): 
446.2650; found: 446.2643; HPLC (CHIRACPAK IA-3; 10%/ 90% isopropanol/ hexanes, 1.0 
mL/min; tr = 29.0 min (major), 38.5 min (minor); 98:2 er); Specific Rotation [α]25D = -2.0° (c = 
























1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 3.19t was reacted with ethyl (E)-4-(2-benzyl-3,3-
dimethyl-5-oxopyrazolidin-1-yl)-4-oxobut-2-enoate 3.25b following the General Procedure E 
for 1 hour using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L9 (12 mol%) and DCM as the solvent. 
1H NMR analysis of the unpurified product mixture using mesitylene as the internal standard 
revealed that the diastereomeric ratio was 3.0:1. After purification by column chromatography 
(ether:hexanes = 3:2), 3.26b was obtained as a colorless liquid (42 mg, 83%). Further purification 
was carried out by PTLC using ethyl ether:hexanes = 3:2 as the eluent to obtain 3.26b-(R,S). The 
absolute configuration for this product was assigned in analogy to that determined for product 
3.26d (see Section 3.6.4). 
 
3.26b-(R,S). 1H NMR (600 MHz, CDCl3): δ 7.39 (d, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 
7.26 (d, J = 7.3 Hz, 1H), 6.83 (d, J = 8.9 Hz, 2H), 6.49 (d, J = 8.8 Hz, 2H), 4.11 (qd, J = 7.2, 2.0 
Hz, 2H), 4.06 (d, J = 13.6 Hz, 1H), 3.99 (d, J = 13.9 Hz, 1H), 3.75 (s, 3H), 3.38 – 3.26 (m, 2H), 
3.21 (td, J = 8.7, 6.5 Hz, 2H), 2.91 (t, J = 7.0 Hz, 1H), 2.79 (t, J = 10.0 Hz, 1H), 2.70 – 2.47 (m, 
3H), 2.42 (q, J = 8.4 Hz, 1H), 2.06 – 2.01 (m, 1H), 1.81 (p, J = 9.5 Hz, 1H), 1.27 (d, J = 6.5 Hz, 
6H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR (151 MHz, CDCl3): δ 174.6, 174.2, 169.1, 151.1, 142.8, 
137.3, 129.6, 128.6, 127.8, 115.2, 112.6, 61.4, 60.8, 57.0, 56.1, 52.3, 48.1, 44.0, 43.6, 40.8, 37.5, 





1176, 1125, 1038, 812 cm-1; HRMS (DART): Calcd for C29H38N3O5 (MH+): 508.2806; found: 
508.2805; HPLC (CHIRACPAK IA-3; 5%/ 95% isopropanol/ hexanes, 0.45 mL/min; tr = 82.9 
















3.26b ((R,S):(S,S)= 2.3:1). 1H NMR (600 MHz, CDCl3, peaks from diastereomers are merged): 
δ 7.40 (dd, J = 7.4, 2.3 Hz, 2H), 7.35 – 7.29 (m, 2H), 7.29 – 7.23 (m, 1H), 6.89 – 6.79 (m, 2H), 
6.55 – 6.44 (m, 2H), 4.20 – 4.09 (m, 2H), 4.09 – 4.03 (m, 1H), 4.03 – 3.95 (m, 1H), 3.83 – 3.70 
(m, 3H), 3.39 – 3.27 (m, 2H), 3.27 – 3.14 (m, 2H), 3.09 – 2.87 (m, 1H), 2.87 – 2.75 (m, 1H), 2.74 
– 2.36 (m, 4H), 2.13 – 1.98 (m, 1H), 1.86 – 1.63 (m, 1H), 1.31 – 1.25 (m, 6H), 1.25 – 1.19 (m, 
3H); 13C NMR (151 MHz, CDCl3): δ 174.51, 174.47, 174.1, 173.9, 169.0 (overlapped), 151.01, 
151.00, 142.8, 142.7, 137.3, 137.2, 129.5, 129.4, 128.51, 128.48, 127.7, 127.6, 115.0 (overlapped), 
112.5 (overlapped), 61.3, 61.2, 60.72, 60.70, 56.84, 56.80, 56.00, 55.99, 52.15, 52.13, 48.0, 47.9, 
44.0, 43.9, 43.5, 43.4, 40.6, 40.4, 37.4, 37.0, 29.8, 29.6, 26.4 (overlapped), 25.9 (overlapped), 
14.30, 14.26; HPLC (CHIRACPAK IA-3; 5%/ 95% isopropanol/ hexanes, 0.45 mL/min; tr = 























1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 3.19t was reacted with (E)-1-(2-benzyl-3,3-
dimethyl-5-oxopyrazolidin-1-yl)-4-phenylbut-2-ene-1,4-dione 3.25c following the General 
Procedure E for 12 hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L9 (12 mol%) and 
DCM as the solvent. 1H NMR analysis of the unpurified product mixture using mesitylene as the 
internal standard revealed that the diastereomeric ratio was 3.5:1. After purification by column 
chromatography (ethyl ether:hexanes = 3:2), 3.26c was obtained as a colorless liquid (42 mg, 
78%). Further purification was carried out by PTLC using ethyl ether:hexanes = 3:2 as the eluent 
to separate 3.26c-(R,S) and 3.26c-(S,S). The absolute configuration for this product was assigned 
in analogy to that determined for product 3.26d (see Section 3.6.4). 
 
3.26c-(R,S). 1H NMR (600 MHz, CDCl3): δ 7.97 (d, J = 7.7 Hz, 2H), 7.52 (t, J = 7.4 Hz, 1H), 
7.42 (t, J = 7.6 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 7.29 – 7.22 (m, 1H), 
6.83 (d, J = 8.6 Hz, 2H), 6.45 (d, J = 8.7 Hz, 2H), 4.04 (d, J = 13.3 Hz, 1H), 3.94 (d, J = 13.6 Hz, 
1H), 3.91 – 3.82 (m, 1H), 3.75 (s, 3H), 3.57 – 3.40 (m, 1H), 3.32 – 3.23 (m, 1H), 3.20 (td, J = 8.6, 
2.3 Hz, 1H), 3.11 (q, J = 8.6 Hz, 1H), 2.97 – 2.87 (m, 1H), 2.59 (d, J = 17.1 Hz, 1H), 2.49 (d, J = 
17.2 Hz, 1H), 2.47 – 2.37 (m, 1H), 1.86 – 1.77 (m, 1H), 1.62 – 1.53 (m, 2H), 1.31 – 1.23 (m, 7H); 
13C NMR (151 MHz, CDCl3): δ 203.3, 174.6, 169.7, 151.1, 142.7, 138.1, 137.1, 133.0, 129.8, 





26.7, 25.8; IR (neat) ν 2924, 2850, 1742,1674, 1511, 1464, 1446, 1359, 1300, 1234, 1178, 1001, 
957, 811, 729, 700, 595, 564 cm-1; HRMS (DART): Calcd for C33H38N3O4 (MH+): 540.2857; 
found: 540.2856; HPLC (CHIRACPAK IA-3; 10%/ 90% isopropanol/ hexanes, 1.0 mL/min; tr = 














3.26c-(S,S). 1H NMR (600 MHz, CDCl3): δ 7.96 (d, J = 6.7 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 
7.43 (t, J = 7.7 Hz, 2H), 7.34 (d, J = 7.1 Hz, 2H), 7.28 (d, J = 7.3 Hz, 2H), 7.22 (t, J = 7.1 Hz, 1H), 
6.77 (d, J = 9.0 Hz, 2H), 6.35 (d, J = 9.0 Hz, 2H), 4.02 (d, J = 13.4 Hz, 1H), 3.99 – 3.90 (m, 2H), 
3.72 (s, 3H), 3.53 – 3.38 (m, 1H), 3.27 (td, J = 8.7, 2.8 Hz, 1H), 3.17 (q, J = 8.8 Hz, 1H), 3.13 (t, 
J = 8.3 Hz, 1H), 2.83 (t, J = 8.6 Hz, 1H), 2.57 (d, J = 17.0 Hz, 1H), 2.54 – 2.45 (m, 2H), 2.08 – 
1.99 (m, 1H), 1.75 – 1.62 (m, 1H), 1.31 – 1.23 (m, 7H); 13C NMR (151 MHz, CDCl3): δ 202.9, 
182.3, 174.6, 151.1, 142.7, 137.6, 137.1, 133.1, 129.7, 128.75, 128.67, 128.6, 127.8, 115.1, 112.6, 
61.4, 57.0, 56.1, 52.2, 47.9, 44.3, 43.5, 41.1, 37.4, 29.5, 26.6, 25.9; IR (neat): ν 2922, 2850, 
1744,1676, 1513, 1484, 1447, 1364, 1301, 1237, 1179, 1038, 812, 699 cm-1; HRMS (DART): 
Calcd for C33H38N3O4 (MH+): 540.2857; found: 540.2828; HPLC (CHIRACPAK IA-3; 10%/ 90% 
isopropanol/ hexanes, 1.0 mL/min; tr = 26.2 min (minor), 47.0 min (major); 95:5 er); Specific 






















1-(4-Methoxy-2,6-dimethylphenyl)pyrrolidine 3.19t was reacted with (E)-1-ethyl-5,5-dimethyl-2-
(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General Procedure E for 3 
hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L12 (12 mol%) and DCM as the solvent. 
1H NMR and 19F NMR analyses of the unpurified product mixture using mesitylene and 
perfluorobenzene as the internal standard revealed that the diastereomeric ratio was 6.7:1.  After 
purification by column chromatography (EtOAc:hexanes = 1:2), 3.26d was obtained as a colorless 
liquid (27 mg, 62%). Further purification was carried out by PTLC using EtOAc:hexanes = 1:2 as 
the eluent to separate 3.26d-(R,S) and 3.26d-(S,S). The absolute configuration of product was 
assigned based on X-ray crystallography data of 3.29d (see SI-Sections 4 and 10). 
 
3.26d-(R,S). 1H NMR (500 MHz, CDCl3): δ 6.83 (d, J = 8.9 Hz, 2H), 6.50 (d, J = 9.0 Hz, 2H), 
3.75 (s, 3H), 3.41 (dd, J = 18.3, 6.9 Hz, 1H), 3.38 – 3.32 (m, 2H), 3.31 – 3.22 (m, 2H), 3.09 (t, J 
= 9.1 Hz, 1H), 3.02 (qd, J = 6.9, 2.7 Hz, 2H), 2.89 (dd, J = 18.4, 4.3 Hz, 1H), 2.69 – 2.54 (m, 3H), 
2.23 (dt, J = 13.0, 7.3 Hz, 1H), 1.83 (p, J = 10.3 Hz, 1H), 1.32 (s, 6H), 1.09 (t, J = 7.1 Hz, 3H); 
13C NMR (101 MHz, CDCl3): δ 175.5, 168.4, 151.3, 142.6, 127.8 (q, J = 280.4 Hz), 115.1, 112.7, 
60.8, 56.1, 51.3, 48.1, 47.2, 44.0, 40.9 (q, J = 26.0 Hz), 37.8, 33.2, 30.2, 26.1, 25.7, 12.9; 19F NMR 
(470 MHz, CDCl3): δ -69.19 (d, J = 9.5 Hz); IR (neat): ν 2974, 2934, 2853, 2833, 1745, 1709, 
1514, 1373, 1303, 1260, 1238, 1159, 1125, 1038, 813, 690 cm-1; HRMS (DART): Calcd for 





isopropanol/ hexanes, 1.0 mL/min; tr = 15.8 min (major), 31.5 min (minor); 96:4 er); Specific 




















3.26d ((R,S):(S,S)= 1:4.7). 1H NMR (600 MHz, CDCl3, peaks from diastereomers are merged): 
δ 6.86 – 6.81 (m, 2H), 6.53 – 6.48 (m, 2H), 3.77 – 3.73 (m, 3H), 3.50 – 3.39 (m, 1H), 3.39 – 3.30 
(m, 2H), 3.30 – 3.20 (m, 2H), 3.11 – 2.86 (m, 4H), 2.67 – 2.54 (m, 3H), 2.27 – 2.06 (m, 1H), 1.84 
(p, J = 10.4 Hz, 1H), 1.33 – 1.28 (m, 6H), 1.11 – 1.05 (m, 3H); 19F NMR (470 MHz, CDCl3): δ -
69.18 (d, J = 9.6 Hz, 7f-(S,S)), -69.48 (d, J = 9.2 Hz, 3.26d-(R,S)); HRMS (DART) Calcd for 
C22H31F3N3O3 (MH+): 442.2312; found: 442.2305; HPLC (CHIRACPAK IA-3; 5%/ 95% 






























N-Ethyl-4-methoxy-N,2,6-trimethylaniline 3.19e was reacted with (E)-1-ethyl-5,5-dimethyl-2-
(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General Procedure E for 24 
hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (20 mol%), L12 (24 mol%) and DCM as the solvent. 
After purification by column chromatography (Et3N:ethyl ether:hexanes = 1:50:50), 3.26e was 
obtained as a single diastereomer and as colorless liquid (31 mg, 67%). The absolute configuration 
for this product was assigned in analogy to that determined for product 3.26d (see Section 3.6.4).  
 
1H NMR (600 MHz, CDCl3): δ 6.61 (d, J = 3.0 Hz, 1H), 6.46 (d, J = 3.0 Hz, 1H), 4.38 – 4.23 (m, 
1H), 3.74 (s, 3H), 3.24 (td, J = 12.1, 2.6 Hz, 1H), 3.19 (d, J = 7.3 Hz, 2H), 3.07 (dq, J = 14.2, 7.2 
Hz, 1H), 3.04 – 2.93 (m, 2H), 2.91 (dq, J = 13.8, 7.1 Hz, 1H), 2.62 (d, J = 17.3 Hz, 1H), 2.54 (d, 
J = 17.3 Hz, 1H), 2.37 (s, 3H), 2.25 (s, 3H), 1.98 (dd, J = 12.8, 4.3 Hz, 1H), 1.82 (qd, J = 12.4, 4.6 
Hz, 1H), 1.29 (s, 6H), 1.03 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.3, 169.9, 
157.0, 141.3, 139.5, 138.1, 127.5 (q, J = 280.2 Hz), 114.2, 113.5, 60.2, 55.4, 53.4, 48.9, 46.9, 44.4, 
41.9, 41.1 (q, J = 26.0 Hz), 26.4, 25.3, 25.1, 20.0, 19.7, 12.7; 19F NMR (376 MHz, CDCl3): δ -
70.88 (d, J = 7.7 Hz); IR (neat): ν 2960, 2836, 1742,1701, 1601, 1485, 1467, 1443, 1388, 1373, 
1303, 1227, 1191, 1151, 1130, 1085, 1034, 999, 855, 731, 619 cm-1; HRMS (DART): Calcd for 





isopropanol/ hexanes, 0.5 mL/min; tr = 12.5 min (minor), 16.0 min (major); 95:5 er); Specific 




















1-(4-Methoxy-2,6-dimethylphenyl)piperidine 3.19g was reacted with (E)-1-ethyl-5,5-dimethyl-2-
(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General Procedure E for 12 
hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L12 (12 mol%) and DCM as the solvent. 
After purification by column chromatography (ethyl ether:hexane = 1:1), 3.26f was obtained as a 
colorless liquid (46 mg, 95%). The absolute configuration for this product was assigned in analogy 
to that determined for product 3.26d (see Section 3.6.4).  
 
1H NMR (400 MHz, CDCl3): δ 6.55 (s, 2H), 5.91 (s, 1H), 3.75 (s, 3H), 3.43 – 3.29 (m, 2H), 3.20 
– 3.07 (m, 3H), 2.96 (q, J = 7.0 Hz, 2H), 2.57 (s, 2H), 2.29 – 2.10 (m, 8H), 2.05 – 1.83 (m, 2H), 
1.29 (s, 6H), 1.06 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.3, 168.2, 157.5, 138.8, 
138.38, 138.37, 135.6, 127.7 (q, J = 280.9 Hz), 113.53, 113.50, 95.9, 60.6, 55.4, 47.3, 47.2, 44.8 
(q, J = 27.0 Hz), 44.0, 34.32, 34.30, 25.9, 25.8, 23.2, 22.7, 18.44, 18.41, 13.0; 19F NMR (376 MHz, 
CDCl3): δ -70.18 (d, J = 9.3 Hz); IR (neat): ν 2925, 2840, 1743, 1708, 1654, 1602, 1487, 1467, 
1442, 1374, 1319, 1301, 1274, 1152, 1099, 1068, 999, 857, 616 cm-1; HRMS (DART): 
C25H35F3N3O3 (MH+): 482.2625; found: 482.2617; HPLC (CHIRACPAK IA-3; 2.5%/ 97.5% 
isopropanol/ hexanes, 0.5 mL/min; tr = 15.4 min (minor), 38.7 min (major); 95:5 er); Specific 























1-(4-Methoxy-2,6-dimethylphenyl)piperidine-3,3,5,5-d4 3.19g-d was reacted with (E)-1-ethyl-
5,5-dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General 
Procedure E for 12 hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L12 (12 mol%) and 
DCM as the solvent. After purification by column chromatography (ethyl ether:hexanes = 1:1), 
3.26f-d was obtained as a colorless liquid (41 mg, 84%). The absolute configuration for this 
product was assigned in analogy to that determined for product 3.26d(see Section 3.6.4).  
 
1H NMR (500 MHz, CDCl3): δ 6.55 (s, 2H), 5.91 (s, 1H), 3.75 (s, 3H), 3.42 – 3.30 (m, 1.78H, 
11%D), 3.22 – 3.08 (m, 3H), 2.97 (q, J = 7.2 Hz, 2H), 2.60 – 2.50 (m, 1.53H, 23%D), 2.20 – 2.08 
(m, 8H), 1.98 – 1.87 (m, 0.32H, 81%D), 1.29 (s, 6H), 1.06 (t, J = 7.1 Hz, 3H); 13C NMR (126 
MHz, CDCl3): δ 175.3, 168.2, 157.5, 138.8, 138.41, 138.40, 135.6, 127.7 (q, J = 281.0 Hz), 
113.55, 113.52, 96.0, 60.63, 60.56, 55.4, 47.3, 47.22, 47.20, 44.8 (q, J = 27.0 Hz), 44.0, 34.3, 25.9, 
23.0, 18.5, 18.4, 13.0; 19F NMR (564 MHz, CDCl3): δ -70.18 (d, J = 8.6 Hz); IR (neat): ν 2971, 
2934, 2840, 1744, 1707, 1655, 1601, 1486, 1467, 1374, 1319, 1155, 1102, 856, 616 cm-1; HRMS 
(DART) Calcd for C25H33D2F3N3O3 (MH+): 484.5804; found: 484.2746; HPLC (CHIRACPAK 
IA-3; 2.5%/ 97.5% isopropanol/ hexanes, 0.5 mL/min; tr = 12.8 min (minor), 33.6 min (major); 



























1-(4-Methoxy-2,6-dimethylphenyl)-4,4-dimethylpiperidine 3.19h was reacted with (E)-1-ethyl-
5,5-dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General 
Procedure E for 36 hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L12 (12 mol%) and 
DCM as the solvent at 80 p. After purification by column chromatography (EtOAc:DCM = 1:16), 
3.26g was obtained as a colorless liquid (38 mg, 74%). The absolute configuration for this product 
was assigned in analogy to that determined for product 3.26d (see Section 3.6.4). 
 
1H NMR (500 MHz, CDCl3): δ 6.58 (s, 2H), 5.97 (s, 1H), 3.76 (s, 3H), 3.70 (dt, J = 9.8, 6.7 Hz, 
1H), 3.34 (dd, J = 17.4, 6.2 Hz, 1H), 3.25 – 3.08 (m, 3H), 2.97 (q, J = 7.1 Hz, 2H), 2.60 – 2.48 (m, 
2H), 2.17 (d, J = 9.7 Hz, 6H), 1.72 (t, J = 5.8 Hz, 2H), 1.29 (s, 6H), 1.14 (d, J = 9.1 Hz, 6H), 1.05 
(t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.2, 168.4, 157.6, 138.80, 138.75, 138.1, 
134.2, 127.7 (q, J = 280.1 Hz), 113.63, 113.56, 104.9, 60.6, 55.4, 47.2, 44.3, 44.1, 39.2, 38.5, 37.6 
(q, J = 26.9 Hz), 31.5, 29.0, 28.7, 26.0, 25.7, 18.4, 18.3, 12.9; 19F NMR (376 MHz, CDCl3): δ -
69.40 (d, J = 9.5 Hz); IR (neat): ν 2959, 2927, 2842, 1744, 1711, 1637, 1466, 1442, 1374, 1302, 
1250, 1228, 1150, 1123, 1096, 856, 670 cm-1; HRMS (DART): Calcd for C27H39F3N3O3 (MH+): 
510.2938; found: 510.2922; HPLC (CHIRACPAK IA-3; 2.5%/ 97.5% isopropanol/ hexanes, 0.2 























1-(4-Methoxy-2,6-dimethylphenyl)azepane 3.19u was reacted with (E)-1-ethyl-5,5-dimethyl-2-
(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General Procedure E for 24 
hours using B(C6F5)3 (10 mol%), Sc(OTf)3 (10 mol%), L12 (12 mol%) and DCM as the solvent. 
After purification by column chromatography (ethyl ether:hexanes = 1:1) 3.26h was obtained as a 
colorless liquid (39 mg, 78%). The absolute configuration for this product was assigned in analogy 
to that determined for product 3.26d (see Section 3.6.4). 
 
1H NMR (600 MHz, CDCl3): δ 6.55 (s, 2H), 5.84 (s, 1H), 3.75 (s, 3H), 3.40 – 3.22 (m, 4H), 3.15 
(d, J = 12.8 Hz, 1H), 3.01 – 2.90 (m, 2H), 2.61 – 2.50 (m, 2H), 2.41 – 2.25 (m, 2H), 2.20 (d, J = 
4.3 Hz, 6H), 1.84 – 1.70 (m, 4H), 1.28 (d, J = 3.6 Hz, 6H), 1.04 (t, J = 7.1 Hz, 3H); 13C NMR (151 
MHz, CDCl3): δ 175.4, 168.1, 157.4, 141.8, 140.5, 138.1, 137.9, 127.7 (q, J = 280.8 Hz), 113.6, 
113.5, 104.1, 60.6, 55.4, 54.7, 47.2, 46.7 (q, J = 26.7 Hz), 44.0, 34.5, 30.5, 29.3, 26.8, 25.9, 18.9, 
18.8, 13.0; 19F NMR (470 MHz, CDCl3): δ -70.17 (d, J = 9.1 Hz); IR (neat): ν 2925, 2849, 1744, 
1709, 1648, 1602, 1485, 1466, 1442, 1374, 1308, 1261, 1207, 1152, 1104, 1066, 1031, 895, 732, 
701, 618 cm-1; HRMS (DART): Calcd for C26H37F3N3O3 (MH+): 496.2782; found: 496.2774; 
HPLC (CHIRACPAK IA-3; 5%/ 95% isopropanol/ hexanes, 1.0 mL/min; tr = 4.2 min (minor), 






















1-(2-((4-Chlorophenyl)(phenyl)methoxy)ethyl)piperidine 3.19v was reacted with (E)-1-ethyl-5,5-
dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General 
Procedure General Procedure E for 24 hours using B(C6F5)3 (20 mol%), Sc(OTf)3 (10 mol%), 
L10 (12 mol%) and DCM as the solvent at 80 p. 1H NMR and 19F NMR analysis of the unpurified 
product mixture using mesitylene and perfluorobenzene as the internal standard revealed that the 
diastereomeric ratio was 1.0:1. After purification by column chromatography (EtOAc:hexanes = 
1:4), 3.26i was obtained as an inseparable mixture of diastereomers (31 mg, 53%). The absolute 
configuration for this product was assigned in analogy to that determined for product 3.26d (see 
Section 3.6.4). 
 
1H NMR (400 MHz, CDCl3, peaks from diastereomers are merged): δ 7.33 – 7.20 (m, 8H), 5.96 
(s, 1H), 5.27 (s, 1H), 3.48 – 3.40 (m, 2H), 3.39 – 3.27 (m, 2H), 3.14 – 2.83 (m, 7H), 2.61 – 2.48 
(m, 2H), 2.03 (t, J = 6.2 Hz, 2H), 1.83 – 1.67 (m, 2H), 1.25 (d, J = 9.6 Hz, 6H), 1.01 (t, J = 7.1 Hz, 
3H); 13C NMR (126 MHz, CDCl3): δ 175.3, 168.3, 141.88, 141.87, 141.0, 136.9, 133.3, 128.7, 
128.6, 128.34, 128.31, 127.8, 127.6 (q, J = 281.3 Hz), 127.00, 126.96, 97.8, 83.4, 67.55, 67.53, 
60.6, 55.0, 47.2, 47.0, 45.0 (q, J = 27.1 Hz), 44.1, 34.2, 26.0, 25.7, 22.8, 22.6, 12.9; 19F NMR (470 
MHz, CDCl3): δ -69.70 – -69.87 (m); IR (neat): ν 2919, 2849, 1742, 1710, 1654, 1513, 1488, 





HRMS (DART): Calcd for C31H38ClF3N3O3 (MH+): 592.2548; found: 592.2542; HPLC 
(CHIRACPAK AD-H; 5%/ 95% isopropanol/ hexanes, 0.2 mL/min; tr = 49.2 min (major1), 53.6 
min (major2), 61.7 min (minor1), 65.5 min (minor2); 90:10 er); Specific Rotation [α]25D = +2.0° 







































-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone 3.19q was reacted with (E)-1-ethyl-5,5-
dimethyl-2-(4,4,4-trifluorobut-2-enoyl)pyrazolidin-3-one 3.25d following the General 
Procedure General Procedure E for 24 hours using B(C6F5)3 (20 mol%), Sc(OTf)3 (10 mol%), 
L10 (12 mol%) and DCM as the solvent at 80 p. After purification by column chromatography 
(EtOAc:hexanes = 1:4), 3.26j was obtained as a white solid (55 mg, 57%). The absolute 
configuration for this product was assigned in analogy to that determined for product 3.26d (see 
Section 3.6.4). 
 
1H NMR (500 MHz, CDCl3): δ 7.72 (d, J = 8.9 Hz, 2H), 7.54 (d, J = 8.7 Hz, 1H), 7.29 – 7.22 (m, 
3H), 6.87 (dd, J = 8.8, 2.3 Hz, 1H), 6.70 (d, J = 9.0 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 5.95 (s, 1H), 
3.93 (t, J = 5.6 Hz, 2H), 3.40 – 3.30 (m, 2H), 3.22 – 3.12 (m, 2H), 3.11 – 3.03 (m, 1H), 3.00 – 2.93 
(m, 2H), 2.91 (q, J = 7.1 Hz, 2H), 2.59 – 2.48 (m, 2H), 2.01 (t, J = 6.3 Hz, 2H), 1.85 – 1.69 (m, 
2H), 1.25 (d, J = 10.2 Hz, 6H), 1.02 – 0.98 (m, 12H), 0.92 (s, 9H), 0.22 (s, 6H), 0.11 (s, 6H); 13C 
NMR (101 MHz, CDCl3): δ 193.3, 175.3, 168.3, 162.8, 156.2, 153.6, 143.4, 140.0, 136.5, 134.6, 





66.6, 60.6, 54.1, 47.2, 47.1, 44.9 (q, J = 27.2 Hz), 43.9, 34.2, 30.4, 29.8, 25.8, 25.7, 22.7, 22.5, 
18.4, 18.3, 12.9, -4.2, -4.4; 19F NMR (376 MHz, CDCl3): δ -69.86 (d, J = 9.2 Hz); IR (neat): ν 
2952, 2927, 2856, 1744, 1710, 1655, 1597, 1530, 1465, 1304, 1255, 1165, 1137, 1038, 942, 909, 
838, 642 cm-1; HRMS (DART): Calcd for C51H69F3N3O6SSi2 (MH+): 964.4392; found: 964.4392; 
HPLC (CHIRACPAK IA-3; 5%/ 95% isopropanol/ hexanes, 1.0 mL/min; tr = 11.8 min (minor), 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.6.9. X-Ray Crystallography Data 
3.6.9.1. X-Ray Crystallography Data of 3.21e-major 
 
 





Table S7.  Crystal data and structure refinement for C23H36NO5+Cl-. 
Identification code  C23H36NO5+Cl- 
Empirical formula  C23 H37 Cl N O5.50 
Formula weight  450.98 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 15.0369(10) Å α= 90°. 
 b = 15.1361(9) Å β= 109.486(2)°. 
 c = 11.4130(7) Å γ = 90°. 
Volume 2448.8(3) Å3 
Z 4 
Density (calculated) 1.223 Mg/m3 
Absorption coefficient 1.662 mm-1 
F(000) 972 
Crystal size 0.570 x 0.250 x 0.220 mm3 
Theta range for data collection 4.273 to 66.688°. 
Index ranges -17<=h<=17, -17<=k<=18, -13<=l<=13 
Reflections collected 26897 
Independent reflections 4324 [R(int) = 0.0346] 
Completeness to theta = 66.688° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5887 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4324 / 4 / 296 
Goodness-of-fit on F2 1.145 
Final R indices [I>2sigma(I)] R1 = 0.0506, wR2 = 0.1303 
R indices (all data) R1 = 0.0511, wR2 = 0.1306 
Extinction coefficient n/a 











Table S8. Crystal data and structure refinement for C23H36NO5+Cl-. 
Identification code  (C23H36NO5)+Cl- 
Empirical formula  C27 H46 Cl N O6 
Formula weight  516.10 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 12.7945(13) Å a= 90°. 
 b = 16.9523(16) Å b= 90.019(5)°. 
 c = 13.6116(13) Å g = 90°. 
Volume 2952.3(5) Å3 
Z 4 
Density (calculated) 1.161 Mg/m3 
Absorption coefficient 1.449 mm-1 
F(000) 1120 
Crystal size 0.600 x 0.280 x 0.220 mm3 
Theta range for data collection 3.454 to 66.915°. 
Index ranges -15<=h<=15, -20<=k<=0, -16<=l<=16 
Reflections collected 9581 
Independent reflections 5139 [R(int) = 0.0569] 
Completeness to theta = 66.915° 97.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5470 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5139 / 1 / 335 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0789, wR2 = 0.2343 
R indices (all data) R1 = 0.0836, wR2 = 0.2389 
Extinction coefficient n/a 












Table S9. Crystal data and structure refinement for C23H29NO4. 
Identification code  C23H29NO4 
Empirical formula  C23 H29 N O4 
Formula weight  383.47 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 10.2867(8) Å α= 90°. 
 b = 7.8024(7) Å β= 94.248(4)°. 
 c = 13.1792(10) Å γ = 90°. 
Volume 1054.87(15) Å3 
Z 2 
Density (calculated) 1.207 Mg/m3 
Absorption coefficient 0.659 mm-1 
F(000) 412 
Crystal size 0.600 x 0.320 x 0.220 mm3 
Theta range for data collection 3.363 to 66.626°. 
Index ranges -9<=h<=12, -9<=k<=7, -15<=l<=15 
Reflections collected 6116 
Independent reflections 2950 [R(int) = 0.0250] 
Completeness to theta = 66.626° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5979 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2950 / 1 / 255 
Goodness-of-fit on F2 1.076 
Final R indices [I>2sigma(I)] R1 = 0.0275, wR2 = 0.0732 
R indices (all data) R1 = 0.0276, wR2 = 0.0734 
Extinction coefficient n/a 











Table S10. Crystal data and structure refinement for (C40H56NO5Si)+Cl- 
Identification code  (C40H56NO5Si)+Cl- 
Empirical formula  C44 H66 Cl N O6 Si 
Formula weight  768.51 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 13.8219(7) Å α= 90°. 
 b = 25.0250(14) Å β= 90°. 
 c = 26.0978(14) Å γ = 90°. 
Volume 9027.0(8) Å3 
Z 8 
Density (calculated) 1.131 Mg/m3 
Absorption coefficient 1.348 mm-1 
F(000) 3328 
Crystal size 0.540 x 0.100 x 0.080 mm3 
Theta range for data collection 2.446 to 66.712°. 
Index ranges -15<=h<=16, -29<=k<=29, -31<=l<=25 
Reflections collected 46423 
Independent reflections 15586 [R(int) = 0.0733] 
Completeness to theta = 66.712° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.5629 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15586 / 793 / 965 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0642, wR2 = 0.1605 
R indices (all data) R1 = 0.0698, wR2 = 0.1646 
Absolute structure parameter 0.037(7) 
Extinction coefficient n/a 











Table S11. Crystal data and structure refinement for C36H37F3N2O3(C6H6)2. 
Identification code  C36H37F3N2O3(C6H6)2 
Empirical formula  C48 H49 F3 N2 O3 
Formula weight  758.89 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 13.7584(15) Å α= 90°. 
 b = 6.1841(7) Å β= 100.009(6)°. 
 c = 24.281(3) Å γ = 90°. 
Volume 2034.4(4) Å3 
Z 2 
Density (calculated) 1.239 Mg/m3 
Absorption coefficient 0.698 mm-1 
F(000) 804 
Crystal size 0.360 x 0.180 x 0.120 mm3 
Theta range for data collection 1.848 to 67.096°. 
Index ranges -16<=h<=16, -7<=k<=7, -28<=l<=28 
Reflections collected 52023 
Independent reflections 7082 [R(int) = 0.0633] 
Completeness to theta = 67.096° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6627 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7082 / 33 / 514 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0399, wR2 = 0.0896 
R indices (all data) R1 = 0.0503, wR2 = 0.0949 
Absolute structure parameter -0.06(8) 
Extinction coefficient n/a 











Table S12. Crystal data and structure refinement for C22H24BrF3N2O3. 
Identification code  C22H24BrF3N2O3 
Empirical formula  C22 H24 Br F3 N2 O3 
Formula weight  501.34 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 46.369(4) Å α= 90°. 
 b = 5.7157(5) Å β= 91.434(2)°. 
 c = 7.9867(7) Å γ = 90°. 
Volume 2116.0(3) Å3 
Z 4 
Density (calculated) 1.574 Mg/m3 
Absorption coefficient 3.128 mm-1 
F(000) 1024 
Crystal size 0.560 x 0.380 x 0.160 mm3 
Theta range for data collection 3.814 to 66.565°. 
Index ranges -54<=h<=54, -6<=k<=6, -9<=l<=9 
Reflections collected 32823 
Independent reflections 3675 [R(int) = 0.0304] 
Completeness to theta = 66.565° 98.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.4622 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3675 / 1 / 280 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0218, wR2 = 0.0587 
R indices (all data) R1 = 0.0218, wR2 = 0.0587 
Absolute structure parameter -0.007(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.388 and -0.506 e.Å-3 
 
 
 
 
